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Abstract  
Background: Postpartum haemorrhage (PPH) remains a major cause of 
maternal mortality and morbidity, and in recent years there has been a temporal 
increase in the incidence of PPH and associated morbidities in resource rich 
countries. Individual risk factors for PPH have long been identified but the relative 
importance of each has been under explored and thus the potential for 
preventative strategies is unknown.  
Aim: The aim of this study was to, i) ascertain the incidence of PPH at various 
thresholds in a South of England population, ii) identify the relative importance of 
predictor variables associated with PPH at different blood loss thresholds and iii) 
identify the independent and cumulative association of prepregnancy, pregnancy 
acquired and intrapartum variables on estimated blood loss following birth.   
Methodology: A prospective observational study was undertaken in two 
maternity services. Estimated blood loss data for all women (n=10,213) were 
imported from NHS electronic summary records. A representative sample of cases 
(n=1897) was selected for review, using a weighted sampling strategy. 
Univariate analysis identified variables associated with mean estimated blood loss 
and PPH at various thresholds. Multivariate regression modelling assessed the 
association of sequentially acquired variables with PPH ≥500 ml, ≥1000 ml, and 
≥1500 ml.                                                                                             
Results: The incidence of PPH ≥500 ml, ≥1000 ml ≥1500 ml ≥2000 ml and 
≥2500 ml was 33.9% (95%CI 31.4 to 36.5), 9.4% (95%CI 8.5 to 10.4), 4.0% 
(95%CI 3.4 to 4.6), 2.0% (95%CI 1.6 to 2.4) and 0.8% (95%CI 0.7 to 1.0) 
respectively. Incidence of PPH ≥1000 ml was investigated by mode of birth. The 
incidence for spontaneous vaginal birth (SVD) was 4.75% (95%CI0.37 to 3.7) 
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and instrumental vaginal birth, 12.1% (95%CI 9.3 to 14.6).  The incidence 
following abdominal birth was 18.2% (95%CI 15.8 to 20.7); elective CS 11.8% 
(95%CI8.9 to 14.5), emergency CS 22% (95%CI18.6 to 25.4). Multiple 
regression analyses identified different independent variables associated with 
overall PPH at different thresholds. Novel independent variables resulting from 
this study associated with PPH at varying levels, were Black African ethnicity 
(≥500 ml and ≥1000 ml) OR 1.68 (95%CI 1.23 to 2.28) and OR 1.50 
(95%CI1.13to 1.98), assisted conception (≥500 ml) OR 3.80 (95%CI1.69 to 
8.57), antenatal attendance feeling ‘generally unwell’ (≥500 ml) OR 2.03 
(95%CI1.18 to 3.49), antenatal steroid administration for fetal reasons (≥1500 
ml) OR 2.00 (95%CI 1.17 to 3.41). In addition some previously known variables 
were confirmed. These were the impact per unit of BMI (Kg/m2) OR 1.04 (95%CI 
1.01 to 1.04); previous PPH (≥500, ≥1000, ≥1500) 2.75 (95%CI1.40 to 5.44) 
1.88 (96%CI 1.13 to 3.11) 2.39 (95%CI1.33 to4.28) multiple pregnancy (≥1000, 
≥1500) 2.33 (95%CI1.23 to 4.41) 2.60(95%CI1.27 o 5.38) retained placenta 
(≥1000) 7.51 (4.08 to 13.8), interval to suturing (≥1000 ml) 1.74 (95%CI1.46 to 
2.08). There was also a liner association with maternal temperature in labour and 
level of PPH.  
Conclusion: This study found higher rates of PPH at all thresholds and, with 
all modes of birth. Which is not fully explained by rising Caesarean section rates. 
Prepregnancy and pregnancy acquired variables are commonly mediated through 
intrapartum events, and previous pregnancy management can impact on blood 
loss in subsequent pregnancies. Novel variables found in this study require 
further investigation, particularly the impact of Black African ethnicity, assisted 
conception techniques, antenatal steroid administration, and, feeling “generally 
unwell”. Modifiable risk factors include preconceptual weight loss, expedient 
suturing of genital tract trauma and regular recording of maternal temperature in 
labour, which may alert staff to higher risk of PPH.  
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Pregnancy and birth are major life events and, in high resource countries, are 
rarely considered “risky”, especially for the mother. In the UK maternal deaths 
have been reported since 1928 (Drife, 1997; RCOG, 1992). The system of 
confidential investigation into factors surrounding each maternal death has been 
admired and replicated in other high resource settings (Biaggi et al., 2004; 
Chichakli et al., 1999; Schuitemaker et al., 1998). There was a sharp decline in 
maternal deaths between 1935 and 1985 (RCOG, 1992), attributed to 
improvements in public health, the introduction of antibiotics and blood 
transfusion regimes and legislative changes, notably the Abortion Act (1967) 
(Drife, 1997). However the number of these untimely deaths has remained 
remarkably stable in recent years (Lewis, 2007). Causes and frequency vary in 
each triennium, but obstetric haemorrhage has been among the top 4 causes in 
every report. 
 
With maternal death being a rare event in high income countries, severe adverse 
maternal morbidities have been identified as indicators of reproductive health, 
and a useful adjunct to maternal death statistics (Mantel et al., 1998; Waterstone 
et al., 2001; Hall, 2001; Pattinson and Hall, 2003; Brace et al., 2004; Say et al., 
2004; Ronsmans and Filippi, 2004; Wen et al., 2005; Baskett and O’Connell, 
2005; Brace et al., 2007; Callaghan et al., 2008). Moreover, maternal deaths are 
not representative of the major problems encountered every day in maternity 
services. In high resource settings postpartum Haemorrhage (PPH) seldom 
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results in maternal death, but is a major cause of serious morbidity (Lewis, 2007; 
Knight, 2007).  
 
The UK has pioneered improvements in obstetric care, including maternal 
mortality statistics, clinical audit and the introduction of the United Kingdom 
Obstetric Surveillance System (UKOSS) to describe the epidemiology of 
uncommon disorders of pregnancy (Knight et al., 2005). Yet, with the exception 
of the Confidential Scottish Audit (Brace et al., 2004), there are no local, regional 
or national systems to record adverse events, identify exemplar or substandard 
care, and address issues contemporaneously. The UKOSS methodology, whilst 
effective for rare conditions, is not transferrable to common events, like PPH 
(Knight et al., 2005). This is due not only to the increased burden for clinical staff 
that data collection would incur, but also the anonymised, minimal data used. 
Whilst maintaining confidentiality, identification of specific areas of good or poor 
practice cannot be achieved.  
 
The consequences of failing to prevent excessive blood loss following childbirth 
have been documented through the ages. Around 1500BC the Ebers Papyrus 
advocated the use of fly excrement, juniper berries, celery in milk or hemp in 
honey to stop bleeding (Nunn, 1996). Discovery of the original uterotonic drug, 
ergot, is attributed to herbalist Adam Lonicer in 1582. It was introduced into 
obstetrics in the 19th century to expedite labour, but caused fetal hypoxia and 
demise. However its effectiveness at preventing PPH when administered 
immediately post birth was noted (Stearns, 1822). By the late 19th and early 20th 
centuries numerous scientists were developing more sophisticated products, 
facilitating dose titration and reducing side effects. Initial clinical trials were 
undertaken in 1932 (Moir, 1962). But the identification of the structure of 
oxytocin and production of it in synthetic form in the 1950s revolutionised 
potential prophylaxis and treatment of PPH (Du Vingneaud et al., 1954).  
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Mechanical interventions have also been devised to prevent and treat PPH. These 
include uterine massage, bimanual compression and uterine packing.  
 
Uterine massage has been advocated as an effective method of reducing blood 
loss and advocated in resource poor settings (WHO, 2006). A systematic review 
assessed the its’ effectiveness following birth and before or after placental 
delivery to reduce blood loss and associated morbidities and mortalities (Hofmeyr 
et al., 2008). This review included one trial where 200 women were randomised 
to uterine massage or no uterine massage following active management of the 
third stage of labour (Abdel-Haleem et al., 2006). Blood loss exceeding 500 ml 
was rare, with wide confidence intervals (Relative Risk 0.52 95%CI 0.16 to 1.67), 
so interpretation is not possible. Whilst mean blood loss was less in the uterine 
massage group, as was the requirement for additional uterotonic drugs, the size 
of the study was a significant limitation, from which it was not possible to make 
recommendations.  
 
Since completion of my study a further systematic review has included an 
additional RCT involving almost 2000 women (Hofmeyr et al., 2013). This study 
demonstrated disparity in the results by Centre, attributed to procedural 
differences, but concluded that uterine massage was less effective than 
intramuscular oxytocin with or without uterine massage (Abdel-Haleem et al., 
2013). The Cochrane Review concluded there should be no revision of 
recommendations and highlighted the need for more trials as, if proved effective, 
uterine massage could be a simple inexpensive intervention that would save lives 
(Hofmeyr et al., 2013). 
 
 
Bimanual compression has been advocated as an effective first-line treatment for 
PPH, despite no published data confirming its’ efficacy (Winter et al., 2007) there 
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remains general professional consensus supporting its use (RCOG, 2009). The 
widely used training algorithm ‘HAEMOSTASIS’ includes bimanual compression, 
as shown in Figure 1 (Chandraharan and Arulkumaran, 2005). 
 
 




No additional work regarding the efficacy of bimanual compression has been 
published since undertaking the current study, but the HAEMOSTASIS mnemonic, 
shown in Figure 1.1, is advocated as a logical progression through procedures 
and has been associated with fewer blood transfusions, peripartum 
hysterectomies and maternal mortality (Varatharajan et al., 2011).  
 
Uterine packing, most commonly with gauze, was described in early obstetric 
textbooks (Cosgrove, 1936). By the 1950s this technique became less popular 
due to concerns about the pack inhibiting uterine contraction and potential 
infection, despite no evidence of either (Hester, 1975). Balloon tamponade, 
initially with a Foley catheter, preceded the development of the Bakri balloon (in 
2001) and similar devices, which when inflated (to a maximum of 500ml) 
provides pressure but has a tip that enables drainage, therefore negating the 
possibility of a concealed Haemorrhage (Bakri et al., 2001).  
 
 19 
Since undertaking the work for this thesis developments in military medicine have 
led to the availability of locally applied haemostatic agents, for example Chitosan, 
the effectiveness of these have been reported in cases of severe PPH (Schmid et 
al., 2013). These interventions appear promising as packing with a haemostatic 
agent may reduce bleeding locally whilst simultaneously providing time for 
uterotonic drugs to take effect (Schmid et al., 2012). Additionally a retrospective 
case series investigating the utility of transabdominal uterine packing with gauze 
in cases of central placenta praevia, reported avoiding hysterectomy in 93% of 
cases (Ge et al., 2012), compared with the 84% overall success rate reported in 
the literature (Douchmouchtsis et al., 2007). These rates in a single Centre may 
be attributable to operator competence, unit protocols and other interventions to 
reduce blood loss, which are not described in the paper (Ge et al., 2012).  
However with reported increasing rates of abnormal placentation these findings 
require further investigation. 
 
 
Uterine compression sutures were first described in a small series of 5 cases in 
1997  (B-Lynch et al., 1997). Since that time various modifications of this 
technique have been described, but similarly these have been relatively small 
case series (Cho et al., 2000; Hayman et al., 2002) A review suggested that 
compression sutures were a simple treatment for intractable bleeding less 
mutilating to the woman than hysterectomy (El-Hamamy and B-Lynch, 2005)  
Reduction of pulse pressure to that of venous flow, enabling haemostasis through 
clot formation is the rational behind internal iliac artery ligation, which was 
developed in the early part of the 20th century to control PPH. Although success 
rates were not specified, the procedure was described as “effective” or “very 
effective”(Clark et al., 1985). In the 1980s a case series reported efficacy ranging 
from 25-40% (Clark et al., 1985). More recently a series of 117 cases in a single 
centre over a 15 year period reported a 100% success rate, but only 37 were 
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obstetric cases and uterine conservation was achieved in only 13 of these (Papp 
et al., 2006). There are currently no randomized controlled trials comparing 
internal iliac artery ligation with any other techniques to arrest bleeding (Shah 
and Wright, 2009). 
 
 
Uterine artery ligation was fist described to arrest PPPH in 1966 (O’Leary and 
O’Leary, 1966). By ligating the uterine arteries at the level of the cervical os the 
blood flowing to the uterus was dramatically reduced, rendering this particularly 
useful when treating PPH caused by atony or abnormal placentation. Initial fears 
that future pregnancies may be compromised by this treatment have proved 
unfounded, but complications identified in a recent systematic review included 
arterial injury, haematomas and nerve ischaemia have been reported 
(Doumouchtsis et al., 2007).  
 
 
Arterial embolisation as a treatment to control PPH was first used in two cases 
and published in 1980 (Pais et al., 1980). Since that time it has used successfully 
to control PPH (Doumouchtsis et al., 2007). It is particularly useful when 
excessive bleeding is anticipated (in cases of abnormal placentation for example) 
and the intra-arterial catheters can be placed in situ prior to delivery. The 
unpredictable nature of PPH and the necessity for the patient to be stable for 
transfer to a radiology suite is a limiting factor for this treatment, although a 
recent report using national data reported a dramatic increase in the use of 
arterial embolization in Korea (Cho et al., 2013)  
 
Peripartum hysterectomy remains the ultimate treatment for uncontrollable 
Haemorrhage. The incidence of this is variably reported, as indicated in Tables 
1.1a and 1.1b, although this not an exclusive list, and definition variations are 
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highlighted in the table footnote.  Of those reviewing emergency peripartum 
hysterectomy rates over time, several report increased incidence in more recent 
years (Parazzini et al., 2013; Bodelon et al., 2009; Flood et al., 2009). A recent 
review article reported the incidence of emergency peripartum hysterectomy 
(EPH) as 0.24 to 8.9 per 1000 births (Machado, 2011). 
 
 
Table 1.1a: Incidence of emergency peripartum hysterectomy as 
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UK 2005-2006 0.4 











Ireland 1990-1999 0.03 












Saudi Arabia 1991-2002 0.5 
 
*Bodelon et al., included CS performed up to 30 days post birth 
**Chestnut et al., 73/117 PEH were considered “elective” 
***Choi et al., only reported EPH associated with placenta praevia 






















Table 1.1b: Incidence of emergency peripartum Haemorrhage as 

































Australia 1999-2008 0.85 





Nigeria 2004-2011 0.23 















China 2000-2010 0.02 










case study (15) 
Greece 1994-2009 0.92 





Turkey 2008-2009 0.37 
Gurtani et al., 
2013 
Case series (41) Iran 2004-2009 1.39 





UK (London) 2000-2011 0.85 
Kara, 2012 Retrospective 
case review 
(54) 






Germany 2003-2008 0.63 





Pakistan 2000-2010 10.5 
Jin et al., 2014 Case control 
study (21) 
China 2005-2013 0.024 
Lee et al., 2012 Retrospective 
case review 
(46) 
South Korea 2008-2010 2.28 





Italy 1996-2010 0.70 







Netherlands 2004-2006 0.3 
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Prior to setting up the current study several reviews had shown distinct variation 
in the policies and practices regarding the prevention and treatment of PPH 
(Winter et al., 2007; Knight, 2007). A more recent review also demonstrated 
persistent differences in management prior to peripartum hysterectomy (Rossi et 
al., 2013).   
 
 
Throughout the literature, the importance of recognising and accurately assessing 
blood loss following the birth of the baby has been identified as problematic and 
contributory to adverse outcomes (Drife, 1997; Lewis, 2003; Brace et al., 2004).  
 
 
Following the birth of the baby and placenta there is a normal blood loss from the 
internal surface of the uterus that settles as uterine contraction and involution 
occur. The volume constituting normal blood loss has long been the subject of 
debate (Gyte, 1992). Excessive blood loss following delivery, or postpartum 
Haemorrhage (PPH), is a common obstetric complication, reportedly affecting 1 in 
10-100 women worldwide (Carroli et al., 2008). Most PPHs occur within the first 
24 hours following childbirth and are referred to as primary postpartum 
haemorrhage. Whilst uterine atony is acknowledged as a major cause of primary 
PPH (RCOG, 2009), it is estimated that 40% of women who experience PPH have 
identifiable risk factors (Ramanathan and Srulkumaran, 2006); therefore the 
majority of PPHs still occur unexpectedly. Many risk factors for PPH have been 
identified and variably reported. The current study aims to identify risk factors in 
a contemporaneous cohort with adequate resources to deal with PPH and to 




Secondary postpartum haemorrhage is defined as excessive bleeding from the 
genital tract 24 hours to 12 weeks following childbirth (Arulkumaran et al., 2009). 
The causes of secondary PPH are different to those for a primary PPH, and are 
most commonly due to sub-involution leading to failure to obliterate the large 
vessels caused by infection or retained products of conception (Neill et al, 2002). 
Secondary PPH has also been linked with genital tract infection, which remains a 
cause of maternal death in the UK (Lewis, 2007a). The incidence of secondary 
PPH is reportedly 2% in resource rich countries, but remains unknown in low 
income settings (Alexander, 2002). 
 
 
The majority of available evidence regarding PPH relates to the incidence, 
management and outcomes associated with primary PPH.  
 
 
This thesis focuses on primary PPH, investigating and improving methods of 
recording and reporting estimated blood loss, and the prediction of those at risk 
of PPH ≥500 ml, ≥1000 ml and ≥1500 ml.  
 
 Outline of the thesis 
 
Chapter 2 Outlines the background leading up to the STOP study.  
 
Chapter 3 highlights the methodological considerations involved in the design of 
the STOP study. While methods are described in the following chapter, the 
rationale for these is provided in detail here.  
 
Chapter 4 describes methods used to undertake the STOP study and the aspects 
of it covered by this thesis 
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Chapter 5 describes the missing data and reporting errors between summary 
data on NHS electronic databases and documented in handheld maternity notes 
and other NHS reporting systems. 
 
Chapter 6 describes the study population and the risk factors associated with 
mean estimated blood loss and estimated blood loss thresholds. 
 
Chapter 7 describes the selection of variables to be used in regression models to 
identify risk factors for PPH.  
 
Chapter 8 describes the construction of models to identify predictive variables 
for PPH ≥500, ≥1000 and ≥1500 ml. 
 
Chapter 9 contains a general discussion of the findings, in light of other more 
recent findings. It also describes the limitations of the current study, and 
identifies implications for practice and areas for future research.  
 
 
Having described the nature and size of the problem Chapter 2 describes the 




Chapter 2: Background  
2.1 Introduction 
 
As identified previously there is controversy around many aspects of PPH, from 
definition to estimation and assessment to of blood loss.  
 
The aim of a literature review is to objectively present the current 
evidence/knowledge on a topic, and produce a summary based on previously 
published research (Bowling, 2009). 
 
In recent years systematic literature reviews are advocated as the ‘gold standard’ 
used for close examination of specific topics, or to answer clearly formulated 
questions (White and Schmidt, 2005). By employing rigorous, explicit protocols at 
each step of the review process, reviewer bias is reduced and the process is 
replicable (Higgins and Green, 2008). However, this systematic approach is not 
without limitations, including: 1) ensuring the reviewers’ methodological rigour 
and strength of the findings, prior to application to patient care; 2) systematic 
reviews are time consuming so it is possible for the conclusions to be superseded 
by new evidence prior to, or shortly after completion; 3) it is possible that a large 
well conducted randomised controlled trial provides more compelling evidence 
than a systematic review of small, underpowered trials.   
 
In contrast narrative reviews utilise a variety of forms of evidence that may not 
conform to the rigid protocols employed in systematic reviews, for example they 
may be evidence based, but may not be research (Green, 2001; Bowling, 2009). 
These reviews critique and summarise a body of literature around a topic, and 
therefore have been advocated as more useful when investigating more broad 
literature around a subject as opposed to a specific, focused question or area of 
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investigation and potentially more appropriate for thesis  (Griffiths and  Norman, 
2005; Cronin et al., 2008).  
 
The differences between systematic and narrative reviews are summarised in 
Table 2.1 (Cipriani and Geddes, 2003). 
 
Table 2.1 Summary differences between systematic and narrative 
reviews (adapted from Cipriani and Geddes, 2003). 
 
Systematic Reviews Narrative Reviews 
 
Investigate a clearly defined topic or 
question 
 
Provide an overview of an area 
 
Explicit, pre-specified search protocols 
are used to find literature 
 
Explicit, pre-specified systematic 
literature search protocols are not used  
 
Inclusion and exclusion criteria are 
specified in studies selected for review 
 
Studies to support the reviewers’ 
recommendations are not selected 
according to an explicit predetermined 
protocol 
 
Data from a primary source may be 
synthesised in meta-analysis, individual 
studies may be “graded” for quality of 
evidence. 
 
May use a grading system to assess the 
quality of individual studies. 
 
Authors recommend further research in 
areas where evidence is lacking 
 
Authors make recommendations based 
on opinions and experience when 
evidence is lacking. These 
recommendations may be graded 






Due to the extensive range of the literature around PPH, the abundance of 
literature in some aspects and paucity in others, combined with the lack of RCTs 




2.2 Literature search strategy 
 
Initially electronic databases were searched:  
AGRIS 1999 to 2004; Maternity and infant Care 1971 to March 2010; Medline In-
Process & Other Non-Indexed Citations and Ovid Medline 1946 to present; 
Cochrane Library to present; PubMed; Web of Science; CINAHL; Embase Classic+ 
Embase 1947 to 2010 May 1; Global Health 1973 to 2010 Week 15. These dates 
were later extended to May 2014 to inform the discussion and include studies and 
reviews undertaken during and post this work. 
 
 
International organisations websites and publications were reviewed, as they are 
all concerned with maternal morbidity and mortality. These included: World 
Health Organisation (WHO) (www.who.org), UNICEF (www.unicef.org), Save the 
Children (www.savethechildren.org.uk) and Maternity Worldwide 
(www.maternityworldwide.org.uk). 
National and international professional and guideline groups were also 
investigated, these included: 
Royal College of Midwives (RCM); International Confederation of Midwives (ICM); 
Royal College of Obstetricians (RCOG); Royal College of Anaesthetists (RCOA); 
Confidential Enquiry in to Maternal Deaths and Child Health (CEMACH); National 
Institute of Clinical Health and Excellence (NICE); United Kingdom Obstetric 
Surveillance Service (UKOSS); American College of Obstetricians and 
Gynecologists (ACOG); The Australian and New Zealand College of Obstetricians 
and Gynaecologists (ANZCOG); Institute of Medicine (IOM); Federation of 
Gynecologists and Obstetricians (FIGO); Scottish Confidential Audit of Severe 
maternal Morbidity; Cochrane Database of Systematic Reviews.  
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Other databases were searched for guidelines: UK, www.eGuidelines.co.uk; New 
Zealand www.cdhb.health.nz; USA www.cmqcc.org (California Maternal Quality 
Care Collaborative); Australia www.clinicalguidelines.gov.au, 
www.health.qld.gov .au (Queensland), www.sahealth.sa.gov.au (South Australia), 
www.thewomens.org.au (Melbourne); Europe www.  
 
 
Initial key words were: postpartum haemorrhage, postpartum hemorrhage, 
obstetric haemorrhage and obstetric hemorrhage.  
 
 
Non-English publications were excluded. When randomised controlled trials were 
reviewed, papers where the population, intervention, comparison group or 
outcome (PICO) was not clearly described were also excluded. 
Review data were selected to investigate PPH in high, middle and low resource 
countries, and some combinations of mixed resource settings. Similarly review 




Following the basic search for PPH other search terms were added to identify and 
investigate a range of literature around this common obstetric complication. In all 
cases haemorrhage was spelt with and without the ‘a’.  
 
 
To investigate definitions, key words included: minor PPH; severe PPH; major 
PPH; massive obstetric haemorrhage; major obstetric haemorrhage; MOH; 
definitions; classification; life threatening. 
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To investigate measurement, key words included: blood loss; childbirth; 
measure; measurement; assess; assessment; estimate; estimation; gravimetric; 
visual; drapes; biochemical; weigh; weight.  
 
 
To investigate pre-existing risk factors, key words added included; ethnicity; 
ethnic minority; BME; Hispanic; Black; Caucasian; Chinese; immigration; 
immigrant; social exclusion; access to care; index of multiple deprivation; age; 
old; older; teenage; young; younger; obesity; overweight; lean; underweight; 
heavy; Body Mass Index; BMI; parity; previous C(a)esarean section; previous 
PPH; fibroids; endometriosis, assisted conception techniques; IVF; GIFT; ovarian 
stimulation; endometriosis; polycystic ovary syndrome; PCOS; metabolic 
syndrome; late booker; late booking; diabetes; diabetes AND treatment; 
epilepsy; epilepsy AND treatment; lupus; depression; depression AND treatment.  
 
 
To investigate pregnancy acquired risk factors, key words added included: 
multiple pregnancy; twins; triplets; quadruplets; higher order multiple 
pregnancies; planned pregnancy; unplanned pregnancy; short inter-pregnancy 
gap; long inter-pregnancy gap; gestational diabetes; diabetes in pregnancy; 
antenatal depression; antenatal depression AND treatment; pre-eclampsia; 
toxaemia; obstetric cholestasis; OC; antenatal day unit attendance; prelabour 
rupture of membranes; threatened preterm birth; preterm birth; gestation at 
birth; inpatient admissions; placenta praevia; low-lying placenta; abnormal 
placentation; placenta percreta; placenta accrete; placenta increta; antepartum 








The literature reviewed in relation to data collection and electronic summary data 
were searched for on the same databases in addition the: European Clinical 
Research Infrastructures (ECRIN); US Food and Drug Administration (FDA); Data 
Protection Act; Principles AND Data Protection Act; NHS National Programme for 
Information Technology; Caldicott Guardian; Caldicott Guardianship; Principles 




2.2.1.1 Postpartum Haemorrhage (PPH) 
The contemporary definition of PPH is still debated.  Some favour the traditional 
definition of: “blood loss of 500 ml or more from the genital tract following 
childbirth”.  This definition was devised by a technical working group, with global 
representation, co-ordinated by the World Health Organisation more than 20 
years ago (WHO, 1990a; WHO, 1990b). Whilst concurring with this volume for 
vaginal birth, the International Classification of Diseases (ICD 10-072) further 
defined haemorrhage following Caesarean birth as blood loss exceeding 750 ml 
(WHO, 2007a). Conversely, others state average blood loss at Caesarean section 
(CS) is 1000 ml (Pritchard et al., 1962; Stafford et al., 2008). 
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The American College of Obstetricians and Gynecologists (ACOG) have adopted 
this definition (ACOG, 2006), and subsequently it has been suggested that blood 
loss should only be classified as excessive, and termed “haemorrhage” when 
1000 ml is exceeded following abdominal birth (Wise and Clark, 2008).  The 
selection of this volume is justified by early seminal works which, by employing 
radiolabelled red blood cells (51Cr) to accurately measure blood loss, reported 
7% of women bled 1000 ml following vaginal birth and 23% lost 1000-1500 ml 
following CS (Pritchard J.A., 1962). Using the same technique, Read and 
Anderton (1977) reported blood loss (mean +/-Standard Deviation) in primary CS 
as 1290 +/-240 ml and for repeat CS as 1012 +/-380 ml. However this study was 
small (n=30) and undertaken in elective CS. Therefore the impact of labour prior 




Another proposed definition has been “excessive bleeding causing symptoms in 
the patient” However this is criticised because many women will have lost a 
significant amount (10-15% of their circulating blood volume) before becoming 
symptomatic (Devine, 2009). Another proposed, more objective, definition of PPH 
is a 10% decrease in haemoglobin or haematocrit levels from late pregnancy 
value. However the utility of this definition relies heavily on the time taken to 
obtain results if delay in diagnosis and treatment is to be avoided. Therefore the 
more clinical definition of  “need for blood transfusion” has also been proposed 
(Combs et al, 1991). It could be argued, however, that any definition reliant on 
requirement for a specific treatment, might demonstrate evidence of provider 
practice, and resource availability, rather than the clinical condition of a patient.  
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Indeed, a review reported postpartum anaemia requiring transfusion occurred in 
less then 1% of vaginal births and 1-7% of CS, admitting that this range may be 
due to inconsistencies in definitions and thresholds for treatment (Jansen et al., 
2005). Furthermore, transfusion guidelines have significantly changed in the 
twenty years since the definition was originally proposed.  
 
General consensus in current practice is that PPH occurs at 500 ml, regardless of 
mode of delivery (NICE, 2007). 
 
2.2.1.2 Classification of postpartum haemorrhage  
 
Severe PPH is even less well defined, either using a blood loss volume (anything 
between 1000 ml and 2500 ml) or the need for blood products, and is dependent 
on resource availability (Brace and Penney, 2004; Knight, 2007; Carroli et al., 
2008). The Health Care Commission (2008) (now the Care Quality Commission) 
adopted different terminology defining “significant” PPH as ≥1000 ml and “major 
obstetric haemorrhage” as ≥2500 ml. The current RCOG Green-Top guideline 
classifies PPH as: minor when estimated blood loss is 500-1000 ml; moderate 
when estimated blood loss is between 1000 and 2000 ml; and severe, when 
estimated blood loss exceeds 2000 ml (Arulkumaran et al., 2009).  
 
 
Others advocate the number of units of blood required as definitive of massive 
haemorrhage. In Scotland, the definition of massive obstetric haemorrhage 
(MOH) is a blood loss volume of ≥2500 ml or a haemorrhage requiring ≥5 unit 
blood transfusion or treatment for a coagulopathy (Penney and Adamson, 2007a). 
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Elsewhere, 4, 6 and 10 unit transfusions fulfill the definition (Shevell and Malone, 
2003; Macphail and Fitzgerald, 2001; Burke and Duignan, 1991).  
 
 
Using blood loss volumes and blood product requirement to fulfill definitions 
whilst incorporating the slow blood loss attributable to surgery, does not 
encompass the rapidity of blood loss often seen in PPH, which requires urgent 
recognition and treatment. The rate of blood loss should be considered when 
assessing PPH, as this influences the woman’s capacity to compensate, 
physiologically, for the blood loss  (Macphail and Fitzgerald, 2001), and urgency 
of treatment response required. In a review document a working definition of the 
loss of 50% of blood volume in 3 hours was proposed, equating to a blood loss 
rate of 150 ml/min (Macphail and Fitzgerald, 2001). The WHO disagrees, 
evidence from a systematic review showed that exsanguination from undiagnosed 
or untreated postpartum haemorrhage, in a “well” woman, leads to death within 
2 hours (Khan et al, 2006).  
 
 
In real terms, the rate of 150 ml/min would result in a PPH of 1500- 2500 ml 
within 10-17 minutes in a woman of average weight (50- 70kg) with a circulating 
blood volume of approximately 5 litres, at term. Therefore, if associated 
morbidities are to be avoided, prompt recognition of the severity of the situation 
is essential when estimated blood loss reaches 1000-1500 ml, which could occur 




There are inherent difficulties with all the “absolute” amounts fulfilling definitions 
of PPH, as each woman’s response to a loss of a certain volume of blood may be 
different from that of another. The ability to “cope” physiologically following 
haemorrhage is determined by a woman’s general health and nutritional status, 
and associations with lifestyle choices, socio-economic status and poverty are 
recognised (UNICEF, 2008; WHO, 2008; WHO, 2006a). Women with complex 
health and social issues are likely to be less able to tolerate and compensate for 
blood loss following birth (Lewis, 2007b).  
 
 
The changes in nutritional status, lifestyle choices and demography of women 
giving birth today may mean that the seminal work, some undertaken more than 
40 years ago, regarding blood loss and ability to compensate are different today 
(Pritchard et al., 1962; WHO, 1990; Combs, 1991). 
 
 
Furthermore, because circulating index blood volume (INBV), and total 
intravascular blood volume decrease in a non-linear manner in obese and 
morbidly obese people (Lemmens et al., 2006), women with high body mass 
indexes (BMI) are  potentially more vulnerable to blood loss, being compromised 
when losing lower blood volumes than their lean counterparts. Given the 
increasing number of women embarking on pregnancy with a high body mass 
index (BMI) (Heselhurst, 2010) this is especially important, and may necessitate 
further clarification of the definition of severe PPH. To date this has not been 
addressed in the literature, however, whilst not acknowledging associated 
comorbidities, or assigning causality, the latest CEMACH Report stated 50% of 
the women who died were overweight or obese (BMI >25Kg/m2)  (Lewis, 2007b). 
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2.2.2 The size of the problem 
 
Globally, it is estimated more than 14 million women a year experience PPH at or 
shortly after giving birth (WHO, 2007b). This common obstetric complication 
causes more than 24% of all maternal deaths worldwide, equating to more than 
132,000 women dying as a result of uncontrolled bleeding following childbirth 
(WHO, 2004). There is wide regional variation, but PPH is particularly problematic 
in parts of Asia and Africa, where it accounts for up to 30% of maternal deaths 
(Khan et al., 2006). Deaths in low resource countries can be attributed, at least 
in part, to inherent complex social, infrastructural and health care issues. But 
even in Europe, every year, between 335 and 1000 women die during or shortly 
after giving birth. At the time of commencing this work, 13.2% of these maternal 
deaths were attributed to PPH according to a European survey aimed to describe 
mortality and morbidity across the member States (EUROPERISTAT, 2008). In 
the UK, whilst not the main cause of maternal death, 14 of the 132 (10.6%) 
women who died as a direct result of pregnancy in the last triennial report, were 




In addition to PPH related mortality, it is estimated that more than 10 million 
women worldwide live with the short and long term consequences of PPH 
(UNICEF, 2004). As outlined in chapter 1, in the UK it is reported, using the 
UKOSS methodology, that for each woman who dies, 15 undergo peripartum 
hysterectomy (Knight, 2007). This equates to an incidence of 0.45 per 1000 
births, comparable to the Netherlands (0.47 per 1000 births) (Kwee et al., 2006), 
and lower than the rate reported in Canada (0.8 per 1000 births) (Glaze et al., 
2008) and parts of the USA (1.4 and 2.7 per 1000 births) (Kastner et al., 2002; 
Bakshi and Meyer, 2000). The variation in incidence, before and after this current 
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work, is shown in Tables 1.1a and 1.1b. Most are calculated using retrospective 
case review, and differences may be attributable to practice variation with earlier 
resort to peripartum hysterectomy, or increased associated maternal morbidities 
including previous CS.  
 
 
The impact of PPH on other morbidities (such as collapse, heart failure, intensive 
care admissions, prolongation of hospital stay, anaemia, blood transfusion, 
fatigue or mental ill health) is difficult to assess due to reporting inconsistencies, 
and the amalgamation of data for all severe morbidities. However an audit of 
intensive care admissions (ITU) suggested that of those women admitted during 
pregnancy or shortly afterwards, 72% were for haemorrhage (IRNARC, 2009). 
This figure must be viewed with caution because antepartum, intrapartum and 
postpartum bleeding are not differentiated, and this audit refers to females aged 
16-50 years admitted to general ITU facilities. Women over 50 or under 16 years 
of age or treated in maternity high dependency units are not included. 
 
 
2.2.3 Trends over time 
 
In the UK, maternal death was relatively common at the start of the 20th century. 
Scientific breakthroughs, including the understanding of the integral role of 
oxytocin in uterine contractility (1906) and subsequent development of synthetic 
oxytocic’s (Du Vingneaud et al., 1953), made a significant impact on the maternal 
death rate. Alongside the discovery of antibiotics, improved surgical techniques, 
anaesthetic advances and the development of haematological sciences and blood 
banks, maternal deaths rapidly declined from 50/1000 maternities in 1900 to 
8/1000 in 1950  (Chamberlain, 2006). However at the time of initiation of this 
research, in 2008, the total numbers of maternal deaths had remained 
remarkably constant throughout the previous 20 years (see Figure 2.1). 
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Figure 2.1: Maternal deaths (rate per 1000 births) in the UK between 1985-2005. 
(Lewis, 2007; p 5) 
Line with error bars indicated direct death rates with 95% confidence intervals. 
Chi Square =5.48, 6 df, p=0.48; Chi square for linear trend =0.48, p=0.49 (Lewis, 2007 
b, page 5). 
During this 20 year period a total of 130 women bled to death during childbirth 
despite improved surgical techniques, interventional radiology, arterial 
embolisation, novel drug development and autologous blood transfusion (Walfish 
et al., 2009; Wise and Clark, 2008). Of these 130 deaths, 55 were simply 
attributed to PPH and the contribution of these deaths in each triennium is shown 
in Figure 2.2. Of the remaining haemorrhage related deaths, 27 were due to 
placental abruption, 22 caused by placenta praevia and 24 by genital tract 




                     Confidential Enquiry Triennial Reports 
Figure 2.2: Contribution of PPH to UK maternal deaths 1985-2008 according to 
the Confidential Enquiry Reports (adapted from Fleming et al., 2012) 
 
 
The first report into maternal deaths was produced by local governments in 
England and Wales in 1915, largely comprising of data from birth and death 
certificates to ascertain and investigate causes of death and geographical 
variations. During the intervening years, the system for recording and monitoring 
maternal deaths was developed, and the Confidential Enquiry into Maternal 
Deaths was introduced, in its current format, in the 1950s. PPH has been cited as 
a cause of death in every report as shown in Figure 2.2.  
 
 
The incidence of PPH has always been difficult to assess reliably, with a 
consensus incidence of 1-10% generally reported in the literature (Carroli et al., 
2008; Henry et al., 2005). This difficulty is attributed to variation in definitions 
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temporal rise in the incidence of PPH in industrialised countries (Knight et al., 
2009; Ford et al., 2007a; Cameron et al., 2006; Wen et al., 2005). These 
retrospective studies relied on analyses of routinely collected clinical data, some 
of which was coded, and variable definitions, dependent on local practice, 
therefore the results should be considered with caution. Conversely, the incidence 
of PPH has been reported as low as 1-2%, with little associated morbidity, in 13 
European countries; probably because this cluster randomised trial used a 
composite measure of severe PPH (one or more: blood transfusion, IV plasma 
expansion, arterial embolism, surgical procedure, ITU admission, treatment with 
recombinant factor VII or death), any of which are reserved only for the most 
severe cases (Zhang et al., 2010).  Despite this seemingly deflated PPH rate wide 
variation in incidence of PPH in participating countries was apparent (Winter et 
al., 2007). Furthermore, in this work, data were collected from a single region in 
each country and this may further limit the generalisability of findings.   
 
 
Others have sought to investigate the incidence globally, which has proved 
difficult due to absence of and variation in reporting mechanisms even in resource 
rich countries  (Knight et al., 2009). Heterogeneity of definition, practice 
variation, as well as reporting differences are cited as being likely contributors, 
concurring with earlier findings in Europe (Zhang et al., 2005) and data from the 




An international collaboration that investigated trends in PPH in several high 
resource settings further concluded that PPH was increasing in Australia, Canada, 
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USA and the UK (Knight et al., 2009). This increase was attributed solely to 
uterine atony in the USA, Canada and Australia. The rise in PPH was also directly 
associated with increasing rates of other serious adverse events in Australia, 
Canada, USA and the UK (Knight et al., 2009). Knight and colleagues (2009), 
used routinely collected and categorised data in accordance with local definitions 
and classifications. Difficulties due to administrative differences in interpretation 
of International Classification of Disease Codes (ICD) and definition variability 
were reported. One country reported the proportion of women receiving a blood 
transfusion within 24 hours following birth as a surrogate indicator of PPH. Where 
ICD categorisation was not available, information was obtained from local 
sources, such as the United Kingdom Obstetric Surveillance System (UKOSS) 
survey of peripartum hysterectomy, and the Scottish Audit of Severe Maternal 
Morbidity. The majority of these systems rely on local reporting mechanisms and 
therefore potential omission of cases and questionable consistency and quality of 
information may limit any conclusions that can be drawn. For example, these 
data demonstrated an increase in PPH from 3.4 to 5.5 per 1000 deliveries 
between 2003 and 2007, but given the inconsistencies in definition and reporting 
and coding of PPH, in addition to changes in policies and practice during the study 
period, it is very difficult to ascertain the accuracy of this trend. Additionally these 
authors excluded “postnatal blood transfusion for low haemoglobin” from their 
analyses due to uncertainty that low Hb was caused by PPH.  Therefore it is likely 
that PPH rates are under-reported in high resource countries.   
 
 
A population-based study in New South Wales, Australia, using linked hospital 
discharge and birth records to assess incidence of PPH an increase from 4.7% to 
6.0% between 1994 and 2002 was reported (Ford et al., 2007a). In singleton 
pregnancies an increase was reported regardless of mode of birth. There was no 
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difference in PPH rates over time in multiple pregnancies, but this may be 
because the numbers of multiple pregnancies in this cohort was small. Ford and 
colleagues concluded that the increase was not attributable to the changing 
demography of childbearing women, although they reported increased numbers 
of women aged >35 years, immigrants, nulliparous women, placental 
abnormalities, post dates births and babies with birth weights ≥3500 g. Nor was 
the rise in PPH attributable to increased obstetric procedures, although there 
were increased numbers of CS, epidurals and induced labours. The authors 
identify variation and evolution of midwifery practice and components of active 
and expectant management of the third stage of labour over the course of the 
study. Unusually, in this study CS was reported as protective against PPH with 
both spontaneous vaginal and instrument vaginal birth conferring greater risk 
(Figure 2.3). (Ford et al., 2007a). However this was probably due, at least in 
part, to the variation in management of third stage, which tends to be more 
diverse following vaginal birth and the adoption of higher rates of blood loss to 






Figure 2.3: Incidence of postpartum haemorrhage (PPH) (defined as >500 ml 
following vaginal birth and >750 ml following Caesarean delivery) by mode of 
delivery for singleton pregnancies between 1994-2004 (taken from discharge 
summaries for women delivering in New South Wales, Australia) Instrumental and 




The Scottish Audit of Severe Maternal Morbidity (2010) using case review by local 
clinicians of data from 2008, acknowledged major obstetric haemorrhage (defined 
as ≥2500 ml or requiring ≥5 unit blood transfusion) as the most common cause 
of morbidity (4.3 per 1000 live births) and reported a halt in the upward trend 
seen in the preceding five consecutive audits (shown in Table 2.2, Lennox and 









Table 2.2: Numbers and rates of women delivering in Scotland with major 
obstetric haemorrhage (defined as blood loss ≥2500 ml or requiring ≥ 
 5 unit blood transfusion), 2003-2008 (Lennox and Marr, 2010). 
















*Women with major obstetric haemorrhage per 1000 live birth each year 
 
 
Scotland is the only region of the UK to systematically collect data regarding 
maternal morbidity (Brace et al., 2004). In all other areas limited data are 
available, primarily collected in accordance with Clinical Negligence Scheme for 
Trusts (CNST) requirements. Data are not circulated regionally or nationally and 
therefore comparisons cannot be made. The lack of routine and consistent data 
collection is surprising given that in countries where maternal death is rare, 
“near-miss” audit has long been advocated as a useful adjunct to mortality 
reports to examine adverse events and investigate substandard care (Mantel et 
al., 1998; Mantel and Moodley, 2002; Pattinson et al., 2003). Despite limitations 
of collection methods and reliance on local reporting and assessment of issues 
around severe adverse events most commonly by a risk midwife or manager in 
each health Board, and funding uncertainties for this system, the Scottish Severe 
Morbidity Audit has reported a year on year reduction in associated substandard 








2.2.4 Risk factors and causes  
 
Causes of PPH have been identified in the literature for many years, with many 
striving to identify those most at risk and therefore provide the opportunity to 
predict and prevent these events.  Traditionally the causes of PPH have been 
referred to as the “4 Ts”: Tone, Tissue, Trauma, and Thrombin, which are 
summarised in Table 2.3. 
 
 
Table 2.3: Summary of risk factors for PPH (adapted from Devine and Wright, 2009). 




Over distended uterus 
 
Multiple gestation, 
polyhydramnios & macrosomia. 
 Uterine muscle fatigue Prolonged or augmentation of 
labour & previous PPH 
 Chorioamnionitis Prolonged ROM 
Spontaneous preterm birth 
Cervical insufficiency 
 Uterine distortion/ 
abnormality 
Fibroids & placenta praevia 
 Uterine-relaxing drugs Beta mimetics, Magnesium 
Sulphate & anaesthetic drugs 
TISSUE 










Lacerations to the:  
Cervix, vagina and/or 
perineum 
Precipitous labour, macrosomia,  
shoulder dystocia, operative 
delivery & episiotomy 
(especially mediolateral) 
 Extension/laceration at 
Caesarean section 
Deep engagement, malposition 
& malpresentation 
 Uterine rupture Previous uterine surgery. 
 Uterine inversion Fundal placenta, grand 
multiparity, excessive traction 









History of coagulopathy or liver 
disease 
 Acquired in pregnancy Sepsis 
 Disseminated intravascular 
coagulation (DIC) 
Intrauterine fetal demise 
 HELLP syndrome Haemorrhage 
Pre-eclampsia 
 Anticoagulation  
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The impact of traditional and newly identified factors have been explored and 





2.2.4.1 Causes of increases in PPH 
 
Using birth records and discharge data Ford and colleagues (2007) identified 
associations between the upward trend (1994 to 2002) with abnormal 
placentation, macrosomia, and oxytocin (Syntocinon®) use. But concluded that 
changes in practice during the study period were more likely to be causative of 
increased PPH rates. Specific changes highlighted were, increased use of 
physiological third stage, more choice for health care professionals regarding 
uterotonic agents, reduction in the clinical time midwives spent during training 
and decreasing number of practicing midwives. Again, variation of definitions and 
local coding inconsistencies make comparison and conclusions difficult. In 
addition, several previously identified risk factors were excluded from modeling 
due to small numbers reported, these included, anaemia, pyrexia in labour, 
amnionitis, high maternal weight gain. But potentially more importantly 
datapoints not available for the duration of the project were also excluded and 
these included: placenta accreta, previous CS and vaginal birth after CS (VBAC). 
Therefore it is possible that maternal characteristics may have more impact on 
rising PPH rates than reported by these authors.  
 
 
Using coded data from an anonymised patient record census Cameron and 
colleagues (2006) attributed the increased rates of PPH, from 4.9% in 1994 to 
6.3% in 2002, which after adjustment for under reporting increased from 8.3% to 
10.7% over the same time frame, to differences in maternal characteristics 
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(notably maternal age and BMI), variations in obstetric practices (increased use 
of physiological third stage) and improved ascertainment and reporting of PPH 
(registry records) (Cameron et al., 2006). Whilst these data represented a State 
wide population, and therefore truly represented women giving birth in the time 
frame, there were concerns regarding data quality within this dataset, particularly 
under-reporting, which was identified as up too 41% in key items, when a sample 
set of cases were reviewed in detail  (Taylor et al., 2005).  
 
 
Whilst improved ascertainment of cases is desirable, apportioning causality to 
maternal characteristics and variation in practice would appear to present 
opportunities to revert the trend, especially in resource rich countries. These 
authors used retrospective coded data, and without further details of clinical 
scenarios the implications may be difficult to interpret.  
 
 
In contrast, Wen and colleagues (2005), using coded data, but with broader 
admission and treatment categories, compiled by the Canadian Institute for 
Health Information, identified increased numbers of women embarking on 
pregnancy with pre-existing conditions, repeat CS births, and changing 
transfusion policies as contributory to the upward trend in Canada (Wen et al., 
2005). In the UK, using the UKOSS reporting methodology Knight (2007) 
reported increased incidence of placenta accreta, increta and percreta, ruptured 
uterus and infection as contributory to incidence of peripartum hysterectomy to 
control bleeding (Knight, 2007). Yoong et al (2006), used retrospective case 
review to investigate peripartum hysterectomy over 20 years in a multi-ethnic UK 
population, reported maternal ethnicity as contributory, in addition to previous 
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and current CS, abnormal placentation and morbidly adherent placentas (Yoong 
et al., 2006).   
Thus the reasons for the increasing trend of PPH is likely to be multifactorial and 
may not be simply attributable to increased CS rates as might be anticipated 
(Cameron et al., 2006; Ford et al., 2007a; Brace et al., 2007).  
 
The clinical risk factors identified here are by no means inclusive. 
 
2.2.4.3 Pre-existing or pre-pregnancy risk factors 
A range of pre-existing or pre-pregnancy risk factors for PPH have been identified 
in the literature: 
 
1) Maternal ethnicity, particularly Hispanic and Asian (Combs et al., 1991) and 
non-White women, reported as “women of colour” (Guendelman et al., 2006) 
have been noted as at increased risk of PPH. Although ethnicity is variably 
reported, and comparisons not uniform, therefore confounding the impact of 
ethnicity. Additionally immigration patterns have changed considerably since 
Combs early case control study, and Guendelman and colleagues used data from 
the California Office of State Health Planning and Development, and excluded the 
smallest minority ethnic groups. In common with other reports using similar data 
sources, it is not clear whether ethnicity is self reported or by what criteria it is 
assigned.   
 
 
African American women were also described as at increased risk of pregnancy 
related death, because they have more existing co-morbidities, including lower 
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haemoglobin (Hb) concentrations prior to PPH (Harper et al., 2007) and uterine 
leiomyomas (Laughlin et al., 2009, Wise et al., 2007). Also in USA, using national 
datasets Black women have been described as 5 times more likely to die than 
White women due to pregnancy associated conditions, with the exception of PPH  
(OR 0.80 [95%CI 0.5 to 1.0]). Even so, those Black women who did experience 
PPH were 3 times more likely to die (Tucker et al., 2007). Using routinely 
collected State wide data to identify ethnic disparities in relation to specific 
outcomes, including PPH, in an area with universal health care provision, it has 
been suggested that all women in minority ethnic groups are at increased risk of 
adverse health outcomes due to discrimination and inability or reluctance to 
engage with services (Sundararajan et al., 2007).  A retrospective follow up study 
showed ethnic minority groups were also over represented in women requiring 
intensive care following childbirth (Keizer et al., 2006). However Keizer and 
colleagues  (2006) reported 18.3% (26/142) of all intensive care (ITU) 
admissions were for PPH, of whom 77% (20 women) were white. Although the 
impact of specific ethnicities could not be assessed, it could be suggested that 
massive PPH requiring ITU admission, unlike other morbidities, is less problematic 
in non-white women. Additionally women receiving high level care, but not 
admitted to general ITU, were excluded from this analysis, and there was no 
adjustment for changing admission criteria during the 12 year study period. Such 
adjustment and the inclusion of cases treated in Obstetric High Dependency Units 
might have altered these findings. 
  
 
It could be argued that appropriately targeted preconceptual and antenatal care 
to reduce associated morbidity, for example, weight management, treatment of 
hypertension and routes of access to care, could, in part, ameliorate the impact 
of ethnicity.  However these data should be considered cautiously as ethnicity is 
variably defined. Guendalman and colleagues (2006) compared broad categories 
 51 
of Latina, non-Latina and Asian women; Harper and colleagues (2007) 
categorised women as African-Americans and White-Americans; whereas Tucker 
et al., (2007) simply used Black or White. Thus, no consideration was given to 
the areas in Africa or geographical differentiation between a Black or White 
person. Neither was duration of immigration considered. Sundararajan et al. 
(2007), whilst advocating areas of universal health provision as appropriate to 
assess the influence of epidemiological factors, acknowledged limitations in 
reporting ethnicity within their population. Combs et al. (1991) categorised 
ethnicity as Black, White, Hispanic, Asian or other and more recently, Keizer and 
colleagues (2006) used Caucasian, Surinam, Moroccan, Turkish, sub-Saharan 
African and Asian. Uniformity of definition, and categories used, would facilitate 
easier understanding of the impact of ethnicity on blood loss (Keizer et al., 2006). 
When investigating risk factors associated with PPH >1000 ml following vaginal 
birth Asian ethnicity increased risk OR 1.8 (95%CI 1.4 to 2.2) (Magann et al., 
2005). Using the same database this was not apparent in women delivering by 
emergency or elective CS, but this could be due to differences in the ethnicities 
and smaller numbers of women delivering abdominally (Magann et al., 2006). 
 
 
2) Older maternal age has been identified as a risk factor for many adverse 
pregnancy outcomes in a review document using the National Swedish Dataset, 
which is renown for complete and accurate data  (Montan, 2007).  Although the 
association between maternal age and PPH has been variably reported with no 
increased risk reported in a cross sectional study  (Roberts et al., 1994) and 
increased risk of severe haemorrhage incrementally increasing with age ≥30 in 
data from the Norwegian National Register (Al-Zirqi et al., 2008). The 
independent effect of age is difficult to ascertain as the higher incidence and 
impact of co-morbidities with older age is not always described or adjusted for 
(Al-Zirqi et al., 2008; Montan, 2007). Roberts et al. (1994) concluded that PPH 
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was not influenced by maternal age, however this cross sectional cohort analysis 
was undertaken when the proportion of women giving birth aged ≥35 years was 
smaller than currently, and therefore these conclusions may be less relevant 
today. Uterine fibroids are also associated with increasing maternal age. One self  
report survey of Black women, with diagnoses confirmed by ultrasound or surgery 
evidence, reported highest incidence in women aged 40-45 years (Wise et al., 
2005). Earlier work, also in the USA, reported a linear relationship with age and 
incidence of fibroids in Black and White women aged between 35 and 49 (Baird et 
al., 2003). This study population was randomly selected from a health insurance 
company, and therefore the influence of healthcare provision cannot be ignored.  
 
 
Additionally these authors concluded that potential adverse events could easily be 
managed within the context of modern obstetric services, contradicting more 
recent reports of increasing maternal morbidities associated with medical 
interventions (Al-Zirqi et al., 2008), but potentially contributing to rising CS rates 
seen in older women (Smith et al., 2008).  
 
 
Geller and colleagues (2004) reported the highest levels of mortality and 
morbidity in women aged between 20 and 34 years old, but this may be reflected 
by three times fewer women aged ≥35 years in all aspects of the mortality to 
morbidity continuum (Geller et al., 2004).  Whilst teenage pregnancies have been 
associated with some adverse pregnancy outcomes, there is no reported 
association with PPH (Al-Zirqi et al., 2008). This may be attributable to more 
efficient uterine contractility, smoking habits or higher rates of spontaneous 




3) Obesity, expressed as high BMI (≥30 kg/m2), has been variably associated 
with PPH. A retrospective cohort study using data from the Aberdeen Maternity 
and Neonatal Databank where early pregnancy measurements of maternal height 
and weight calculated BMI, showed that although blood loss increased in a linear 
relationship with increasing BMI, PPH was statistically significant in obese women  
(Bhattacharya et al., 2007). Conversely data from the Nova Scotia Atlee Perinatal 
Database reported no relationship between obesity and PPH, although these 
authors, rather than using BMI, defined obesity as a pre-pregnancy weight of ≥90 
kg. Women weighing > 75 kg but <90 kg were excluded, as were women 
weighing <50 kg, and those weighing 50-75 kg were the referent range 
(Robinson et al., 2005). Whilst women weighing > 90 Kg are likely to be obese, 
despite the limitations of BMI, the degree of obesity is not apparent and this 
limits the generalisability of these authors findings. If indeed, these women were 
morbidly obese, these findings would concur with those Bhattacharya.  
 
 
In retrospective case review studies in different areas of the UK, obesity has also 
been linked with poor uterine contractility leading to increased rates of induction, 
augmentation and CS (Zhang et al., 2007) and prolonged third stage of labour 
(Usha Kiran et al., 2005). A further UK database reported that, conversely, being 
underweight (BMI<19 kg/m2) was protective against PPH (Sebire et al., 2007a), 
this was confirmed using a slightly different definition (BMI<20 kg/m2) (Denison 
et al., 2008). Many of the studies investigating the effects of obesity have relied 
on epidemiological or clinical databases (Bhattacharya et al., 2007; Robinson et 
al., 2005) and are, therefore, reliant on the accuracy of blood loss assessment 
and entered or coded data, with no recourse to medical records to confirm details. 
One such study, employing the highly regarded Swedish National Register, 
reported a linear increase in incidence of PPH with increasing BMI (Denison et al., 
2008) contradicting the findings of others, who have suggested that those at 
 54 
greatest risk were the obese, but not the severely obese (Robinson et al., 2005). 
However the definition of severe obesity in this latter cohort was ‘weight 
exceeding 120 kg’, making comparison difficult, as weight alone does not 
discriminate level of obesity. BMI, although widely utilised, has been identified as 
a crude measurement of obesity and indicator of health status (Cawley and 
Burkhauser, 2006). Despite these limitations the overall evidence suggests that 
obesity is linked to PPH, although with these data there is seldom any adjustment 
for confounding factors associated with obesity.  
 
 
4) Social deprivation and poverty are complicated to measure, but poverty has 
been associated with maternal obesity, risky health behaviours, low educational 
attainment and lack of engagement with services, leading to adverse pregnancy 
outcomes (Nagahawaite and Goldenberg, 2008; Lalonde et al., 2006; Vais and 
Bewley, 2006). Waterstone et al., (2001) employed a complex strategy to assign 
social exclusion. This included: social categories according to the UK Registrar 
General, extended to include information regarding marital situation and male 
partner’s employment status; social exclusion was further considered to be 
present when notes review revealed one or more of: concealed pregnancy; age 
<16 years; poor housing; low income (on “income support” documented); 
previous child in local authority/state care (current or previously); in trouble with 
the law (currently or previously); living alone (partner abroad or “unsupported” 
documented in notes); unbooked; unwanted pregnancy; currently or previously 
in foster care; care order being considered for unborn child; social worker 
involvement or alcohol dependency. This would appear to be cumbersome and 
not necessarily generalisable or applicable as social norms evolve. Even so, their 
comprehensive case control study reported social exclusion, in accordance with 
this definition, reported OR 2.91 (95%CI 1.76 to 4.82) for severe PPH (1500 ml) 
(Waterstone et al., 2001).   
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Others have suggested poor maternal nutrition, food insecurity, and associated 
psychosocial factors may be more contributory of adverse pregnancy outcomes. 
Certainly links between such socioeconomic indicators and preterm birth and 
perinatal infections have been identified in a prospective cohort study (Laraia et 
al., 2006), but the impact on PPH has not been assessed. Multi-level health care 
provision, dependent on ability to pay, influences women attending for care, 
further complicating comparison (Nagahawaite and Goldenberg, 2008; Costello et 
al., 2004). 
 
A universal health care system, as provided by the NHS, and other areas such as 
Victoria, Australia, should eliminate such differences. However the Health Survey 
for England 1998, 1999, 2000, showed systemic inequalities in healthcare use in 
relation to income, ethnicity, employment and low educational achievement 
(Morris et al., 2005). Higher formal educational attainment was associated with 
fewer GP and outpatient appointments and certain ethnicities attend for primary 
care but are not proportionally referred for specialist care (Morris et al., 2005). 
However these findings referred to general health and predated NHS reforms, 
therefore extrapolation to pregnancy may be inappropriate to maternity services, 
and also to postdating the reforms. Earlier work to develop a theoretical 
framework to assess inequities in health care in the UK also concluded these 
existed in some domains (Goddard and Smith, 2001). But similarly maternity 
services were not included. A qualitative study, nested in a larger survey, of 
Somali women who were refugees and asylum seekers reported communication 
as the major barrier preventing access to maternity care, compounded by specific 
health needs, namely the high prevalence of female genital mutilation (Harper 
Bulman and McCourt, 2002).  A cross-sectional postal survey using a stratified 
clustered random sampling strategy concluded that women were more likely to 
book late for antenatal care if they were born outside the UK or non-cohabiting; 
there was no difference according to social economic classification or age at 
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completion of full time education (Rowe et al., 2008). It could be argued that 
completion of a postal questionnaire demands a level of education, and therefore 
these data may exclude a relevant group. Although an earlier systematic review 
investigating social and ethnic disparities in antenatal screening tests reported 
inconsistent uptake with different screening tests, with South Asian women least 
likely to receive prenatal screening this was potentially because fewer of these 
women were offered the tests (Rowe et al., 2004). As screening has become 
more universal, it could be hoped that this is no longer the case.   
 
 
Others have suggested that social support determines health in mothers and 
babies, rather than class (Oakley et al., 1994), which could concur with the 
finings of Rowe et al., (2008) regarding single women tending to delay initiation 
of antenatal care. Conversely, it would contradict associations between ethnicity 
and poor outcomes as many cultures form supportive communities. 
 
 
A joint WHO/FIGO statement (2006) described PPH as an ‘equal-opportunity 
incident’ due to its unpredictability. This suggests that it is the existence and 
ability of health systems to deal with PPH that makes poorer people more likely to 
suffer associated morbidities (Lalonde et al., 2006). This might be particularly 
applicable in countries with multi-level health care based on the ability to pay, 
but would appear less relevant in a universal system like the NHS. 
 
 
5) Maternal smoking at first antenatal appointment has long been associated with 
preterm birth, intrauterine growth restriction, and fetal demise (Meyer and 
Tonascia, 1977), in addition to placental abruption and placenta praevia (Ananth 
et al., 1996). Both these epidemiological studies used perinatal registers that 
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captured data regarding smoking at first antenatal contact. The information was 
self reported, the accuracy of which is variously described (Stevens and Munoz, 
2004). Additionally there was no account of changing habits throughout 
pregnancy.  The effects of smoking on uteroplacental blood supply are therefore 
controversial, both appearing to be inadequate, leading to reduced fetal growth 
but also associated with bleeding due to abnormal placentation and premature 
placental separation. In a case control study Waterstone and colleagues (2001) 
reported a protective effect of smoking at booking with subsequent severe PPH 
(≥ 1500 ml) OR o.65 995%CI 0.44 to 0.96). Maternal smoking has also been 
associated with lower antenatal haemoglobin concentrations (Bodnar et al., 2004), 
which have also been associated with PPH (NICE, 2007).  These data were 
obtained from a randomised control trial of iron supplementation in a low 
socioeconomic population, and adjustment for other confounders and compliance 
data were not included. There are no published data on the impact of paternal or 




6) Primiparity and multiparity have been variably associated with risk of PPH 
(Sheiner et al., 2005; Williams et al., 1998). Primiparity was reportedly a major 
risk factor for massive PPH, defined as blood loss >1500 ml, in a UK study (Hazra 
et al., 2004). However this study reported an incidence of 0.5%, investigating 
just 145 cases, and using retrospective computerised data to identify cases and 
clinically assessed blood loss volumes, the method of assessment was not 
clarified. Furthermore identification was achieved through electronic summary 
data no evidence of clarification for erroneous data. This may have influenced 
these findings, as potential under reported volumes in summary data were not 
investigated. The authors propose inappropriate management of women not 
traditionally considered at risk as the rationale for their finding. No report of 
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management of the third stage is included and it is therefore difficult to assess 
this conclusion. However, the identification of primiparity as a risk factor was not 
novel, although the earlier study investigated PPH >500 ml using retrospective 
coded records for a discreet geographical area (Hall et al., 1985). 
 
 
Grand multiparity has been historically associated with increased risk (Babinszki 
et al., 1999), despite definition difference of ≥4 (Bibi et al., 2007) or ≥5 
(Humphrey, 2003) previous births after 20 weeks’ gestation. However more 
recently several authors have reported grand multiparity as negatively associated 
with PPH (Hazra et al., 2004; Mousa and Walkinshaw, 2001). These observational 
studies, both historical and more recent, whilst reporting on index pregnancy 
outcomes, commonly did not account for other confounding factors, such as 
previous obstetric history. Babinszki and colleagues (1991) reported all grand (n= 
314) and great-grand (n= 133) multiparas were all aged over 35 years and 
therefore used this criterion to select the comparison group. Great-grand 
multiparity, defined as >9 previous births, whilst increasingly rare in high-income 
countries, was not associated with PPH (Babinski et al., 1999). As the average 
family size has decreased in recent years, this may be a less important risk factor 
than previously considered (Glinianaia et al., 2008) and active management 




Long inter-pregnancy spacing has also been proposed as increasing labour 
dystocia and incurring subsequent adverse effects, including PPH  (Conde-
Agudelo et al., 2007), contradicting the findings of earlier authors (Orji et al., 
2004). But these findings may be more relevant than previously, due to societal 
trends of serial monogamy. Others have reported short inter-pregnancy spacing 
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in women who delay initiation of childbearing (Nabukera et al., 2009). This 
retrospective cohort study, using regional linked registration data, merely focused 
on pregnancy booking interval data and therefore the impact of short inter-
pregnancy spacing on PPH (and other pregnancy outcomes) could not be 
assessed.    
 
 
7) Assisted conception techniques result in around 12,000 UK births each year 
(http//:www.hfea.gov.uk) and birth registry data have shown they are associated 
with various pregnancy complications (Shevell et al., 2005) including abnormal 
placentation (Romundstat et al., 2006) and PPH (Breheny et al., 2009). Although 
many of these studies are large, the majority of women conceived spontaneously 
and the numbers achieving pregnancy with specific assisted reproduction 
techniques (ART) were small. Therefore caution should be exercised when 
interpreting these results (Shevell et al., 2005). Despite guidelines advocating 
single embryo transfer (RCOG, 2007), ARTs are also associated with increased 
numbers of multiple pregnancies, which are also associated with PPH, but this 
was not the explanation in the studies cited, as only singleton pregnancies were 
included (Romundstat et al., 2006; Shevell et al., 2005).   
 
 
Similarly women achieving pregnancy as a result of ART are more likely to be 
older than women conceiving spontaneously (Breheny et al., 2009), but rarely is 
maternal age adjusted for when investigating the impact of these technologies. It 
has also been suggested that underlying reasons for infertility, for example 
endometriosis, or specific treatment regimens, such as in-vitro fertilization, may 
be causative of excessive bleeding following birth (Kallen, 2008). Further 
investigation may inform women and health service providers regarding place of 
birth, mode of delivery and third stage management.  
 60 
8) Previous PPH has long been identified as a risk factor in subsequent 
pregnancies  (Ford et al., 2007b; Kominiarek and Kilpatrick, 2007; Newton et al., 
1961). However history often relies on maternal report, especially when previous 
maternity notes are unavailable. Inaccuracies in information are possible due to 
varying definitions and limited maternal understanding. Advances in technology 
facilitate the emergence of large regional and national databases with the 
potential to gather and link information, as achieved by some authors, but 
reporting consistency needs to be assured. Earlier work, undertaken in smaller 
networks, without computerised systems, although more labour intensive, may 
have provided more accurate data (Doran et al., 1955).  
 
 
One of the earliest studies investigating repeated PPH using data State University 
of Iowa Hospitals from 1936-1945 with a PPH definition of blood loss exceeding 
600 ml, reported a PPH rate of 5.2% following spontaneous vaginal birth, but the 
recurrence rate was 8.1% Doran et al., (1955). Of these 68% (21/31) were 
attributed to the same cause as the initial haemorrhage. This suggests recurring 
risk factors may be contributory. However these authors excluded caesarean 
births (1.7% of all deliveries) and counted multiple births as one, which may 
have influenced their findings. However, Dewhurst and colleagues (1957) 
reported a 23% recurrence rate, which increased to 28% with ≥2 previous PPH. 
This study, however, was considerably smaller involving 132 women. In 1991 
Comb and colleagues reported previous PPH had OR of 3.55 (95%CI 1.24 to 
10.19) for recurrence (defined as a fall in haematocrit by 10 or more points from 
pre delivery result or blood transfusion). These authors constructed a logistic 
regression model and previous PPH was one of the strongest predictors of the 17 
factors included (Combs et al., 1991). Similar findings were reported in a single 
centre review of 19,476 births. Defining PPH as >1000 ml or need for blood 
transfusion, the PPH rate following vaginal delivery was 5.15%, and prior PPH had 
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an OR of 2.2 (95%CI 1.7-2.9) (Magann et al., 2005). In the UK a case control 
study investigating severe maternal morbidities, defining PPH as, estimated blood 
loss exceeding 1500 ml or fall in haemoglobin concentration of ≥40 g/l or ≥ 4 
unit transfusion, previous PPH was associated with OR 2.74 (95%CI 1.69 to 4.44) 
(Waterstone et al., 2001). 
 
 
The risk of recurrence in women who required bilateral hypogastric artery ligation 
to arrest bleeding in a previous pregnancy has been reported in a small case 
review study, of 13 pregnancies. Three women had PPH; 2 following vaginal 
births and reported as “easily managed…” and another successfully treated with 
prostaglandins at caesarean birth. This is the largest reported follow up study of 
pregnancies following hypogastric artery ligation, and despite the limitations of 
small numbers the recurrence rate of 27% is significant (Nizard et al., 2003). 
 
 
Recurrence of PPH in women with previous uterine artery embolization to treat 
PPH has been investigated in a cohort study (n=28), of the 4 women who 
subsequently gave birth, all experienced PPH, 2 of whom required hysterectomy 
(Salomon et al., 2003).  
 
 
Case reports of outcomes of subsequent pregnancies following B-Lynch and other 
compression sutures alone or in combination with other treatments are few and 
therefore it is difficult to interpret the impact of these on recurrence of PPH (B-
Lynch et al., 1997; Api et al., 2005). 
 
Retained placenta and associated PPH has been identified as recurrent events. A 
Norwegian collaboration identified women with retained placenta from medical 
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records of 24,750 births over 5 years. Retained placentas, requiring manual 
removal, occurred in 0.66% of cases (n=165) and 10% of these had a PPH; 
although blood volume is not described, but PPH attributed to decrease in pre and 
post delivery haemaglobin. Seventy-four of the 165 women with retained 
placenta were parous and of these, 12 (16%) had a retained placenta in their 
previous pregnancy (Tandberg et al., 1999). The overall incidence of retained 
placenta in this study is low, although the authors used multiple data sources to 
identify women requiring manual removal of placenta. Even so, previous retained 
placenta was similarly identified as a risk factor in subsequent pregnancies in a 
case control study of 113 women with retained placenta, logistic regression 
analysis showed OR 9.8 (95%CI 1.1 to 85.5) (Titiz et al., 2001). The wide 
confidence intervals seen in this study is due to the small sample size and 
therefore means the results should be viewed with caution. Furthermore a large 
Australian study identified prior retained placenta as a risk factor for PPH 
>1000ml and >1500 ml at subsequent non-elective CS (Magann et al., 2006).    
 
 
Uterine inversion is associated with PPH, but is a rare event, estimated to occur in 
1: 2500 births (Kominiarek and Kilpatrick, 2007). PPH reportedly occurs in 94% 
of cases (Platt and Druzin, 1981). An early study suggested uterine inversion 
occurred in 33% of subsequent deliveries, however a more recent case review of 
40 cases where 65% has associated PPH and 47.5% required blood transfusion, 
found no recurrence in 26 subsequent pregnancies (Baskett, 2002). This case 
series took more than 24 years to complete, and therefore changes in practices 
and policies during this time may have influenced the results.  
 
The impact of previous PPH can be difficult to assess as guidelines dictate women 
with a history of PPH are actively managed in the third stage of subsequent 




9) Previous CS has been associated with subsequent adverse pregnancy 
outcomes, including repeat CS and abnormal placentation leading to excessive 
bleeding and associated morbidities (Magann et al., 2006; Kwee et al., 2006). In 
a prospective cohort study the incidence of placenta praevia has been reported as 
5 times higher in women with a scarred uterus than multiparous women without 
a uterine scar (Chattopadhyay et al., 1993). Furthermore, placenta praevia was 
complicated by accreta in 10% of cases with one previous CS and 59.2% after 
two or more abdominal births. In this study 4.5% of women embarking on 
pregnancy had previously delivered by CS. With increasing numbers of primary 
CS in the intervening years (Jarman, 2004) it is likely many more women embark 
on pregnancy following CS, and therefore these findings may be even more 
relevant.  It is possible that women requesting CS may not consider the impact of 
this decision on subsequent fertility and pregnancy outcomes (Postnote, 2002). 
 
 
A population based study in Australia of over 136,000 women showed that when 
compared with those having a previous vaginal birth, those previously delivered 
by CS and planned a vaginal birth subsequently had an OR 1.6 (95%CI 1.4 to 
1.7; p<0.0001) for PPH, but were also at increased risk of uterine rupture in 
labour, peripartum hysterectomy and manual removal of placenta: all of which 
are associated with increased blood loss. Amongst those who were delivered by 
elective CS subsequently the risk of PPH was lower (OR 0.6 [95%CI 0.5 to 0.7]; 
p<0.0001) (Taylor et al., 2005). This study used Health Department and Births, 
Deaths and Marriages Registry data regarding first and second singleton births in 
New South Wales, Australia 1994-2002. This excluded multiple pregnancies and 
higher multiparous women, which may have influenced the results, as both have 
been associated with higher rates of PPH. 
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Ascertainment of the effect of previous CS on PPH could provide valuable 
information regarding risk of excessive blood loss in the future, with inherent 
value for women and health care providers.  
 
 
10) Associations with maternal medical history and pre-existing medical 
conditions and PPH are variably reported. Given the variation in incidence of pre-
existing diseases in the population, different risk profiles are inferred. 
 
 
Epilepsy is variably reported as 0.2-0.4% and 0.7% of the antenatal population 
(Tomson and Hiilesmaa, 2007). Sonneveld and Correy (1990) reported increased 
rates of PPH in women who suffered epilepsy. However, no consideration was 
given to the drug regimes employed to prevent or minimize seizures, and issues 
of compliance were not addressed. Others report non-compliance with drug 
therapies as common, due to fears of teratogenicity, which Registry data show 
are largely dose dependent and less common with the new generations of 
medication available (Tomson and Hillesmaa, 2007). A case control study 
reported antiepileptic medication at antenatal booking being associated with 
several severe maternal morbidities, however the confidence intervals in all cases 
were wide, for example for severe PPH OR 5.75 (95%CI 1.20 to 25.72) 
(Waterstone et al., 2001). Therefore caution should be used in applying these 
findings, but the consistent increased OR may be indicative of clinical significance 
and therefore relevant to health care providers.   
With anti-seizure medications increasingly prescribed for other psychiatric and 
neuropathic pain disorders, further investigation of associations with specific 
medications and management of pregnancies complicated by epilepsy is required.  
The incidence of diabetes is increasing worldwide and the age at onset decreasing 
(Boyle et al., 2001). Combined with the trend for women to delay motherhood, 
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many more women are at risk of pregnancy complicated by diabetes (Shand et 
al., 2008). Whilst acknowledging the impact particularly of pre-existing diabetes 
on maternal and perinatal morbidity Shand and colleagues (2008) in their cross-
sectional study using linked databases in Australia, reported no significant 
association with PPH or severe PPH (Shand et al., 2008), concurring with earlier 
findings (Doran et al., 1955), although this case review study used a different 
definition of PPH (≥ 600 ml as opposed to ≥ 500 ml). Similarly Waterstone and 
colleagues in a south of England case control study reported non-significant 
association with diabetes and PPH >1500 ml (Waterstone et al., 2001). 
Conversely in a small (n=182) regional database review it has been suggest that 
Type 2 diabetes is associated with a six times increased risk of PPH (Dunne et al., 
2003; Dunne, 2005;). Shand and colleagues (2008) used validated datasets and 
case notes to confirm diagnoses of both Type 1 and Type 2 diabetes. Using 
similar methodology, Dunne and colleagues (2003) investigated outcomes for 
women with Type 2 diabetes. This may contribute to the difference in findings.  
 
 
A retrospective case control study investigating women with and without pre-
gestational diabetes showed that women with either Type 1 or Type 2 diabetes 
were twice as likely to have PPH > 1000 ml than non-diabetic women (12% 
versus 6%) and estimated blood loss was also higher in the effected group 
(781+/-27 ml versus 642+/-0.2 ml) (Takoudes et al., 2004).   In another 
Register study the Canadian Perinatal Surveillance System reported pre-existing 
diabetes mellitus complicated 1.29 per 1000 births and 2 of the 13 women who 
died with a pre-existing condition had diabetes (Wen et al., 2005). It is estimated 
that of those pregnancies complicated by diabetes 7.5% are Type 1 and 5% are 
Type 2 (NICE, 2008b). Given projected rates of diabetes for the coming years, 
the impact of diabetes demands extensive evaluation.  
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Inherited bleeding disorders, such as Von Willebrand Disease and haemophilia are 
known to be associated with PPH (James, 2006; Lee et al., 2006). The incidence 
of Von Willebrand disease is reported as 1.3% (James, 2006). Most of the 
evidence regarding von Willebrand disease and association with PPH are case 
reports of less than 100 women and report incidences of 12.5% (Ramsahoye et 
al., 1995) to 80% (Chediak et al., 1986) in 24 and 6 women restively. In a rare 
case control study of 102 women with von Willebrand’s disease and 88 controls, 
59% of women with the disease compared with 21% of the controls experienced 
PPH (Kirtava et al., 2003).  The controls in this study were identified by the cases 
and PPH is described as “excessive blood loss”. The high rate of PPH in this 
control group is curious and may be due, in part, to self report through telephone 
interviews and questionnaires.   
 
 
Whilst haemophilia is sex linked, affecting males, female carriers have a 50% 
incidence of passing the defect to their sons, and the reported incidence of 
primary PPH in these women is 16%  (24% for secondary PPH) (Lee et al., 2006). 
Guidelines exist for antenatal, intrapartum and postnatal care for these women, 
with unanimous agreement that women with such conditions should receive 
active management of the third stage of labour (Arulkumaran et al., 2009; NICE, 
2007: Lee et al., 2006).  
 
Women with connective tissue disorders are more at risk of PPH than the general 
population (Kominiarek and Kilpatrick, 2007), although the incidence varies 
according to disease, for example PPH in women with Ehlers-Danlos syndrome is 
19% (Volkov et al., 2007), Gaucher 21-77% (Rosnes et al., 1996), Oesteogenesis 
Imperfecta 11% (Young and Gorstein, 1968), and Marfans syndrome 8-21% 
Rahman et al., 2004). All these conditions are relatively rare and therefore there 
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is a paucity of evidence around cases, suffice that health care professionals 
remain vigilant when managing labour and delivery in these women.  
 
 
Until recently there was a paucity of evidence regarding the impact of female 
genital mutilation (FGM) on obstetric outcomes. A WHO study recently addressed 
this, and identified several adverse pregnancy outcomes, including PPH were 
increased in women who had experienced FGM (WHO, 2006; Johansen and 
Bathija, 2008). With the more extensive procedures conferring the greatest risk 
(Banks et al., 2006). Whilst this large prospective observational study rigorously 
assessed the impact of FGM, the practice of antenatal defibulation in the UK, may 
lessen the impact of these procedures on PPH and other obstetric outcomes. 
Midwives working in multi-ethnic communities should be aware of the population 
at risk (RCN, 2006).  
 
 
Uterine fibroids are likely to increase in size in pregnancy and are associated with 
increased risk of PPH (Jolley, 2009). One cross sectional study reported PPH in 
10.3% of women with fibroids, but this study also reported high rates of 
dysfunctional labour and malpresentations, with no adjustments made for these 
potential confounding variables (Noor et al., 2009). Additionally this study was 
undertaken in Pakistan and therefore transferability to a UK population may be 
limited. Using a large obstetric database with extensive information regarding 
18,705 women giving birth between 1998 and 2002, and defining PPH >1000 ml 
and >1500 ml, Magann and colleagues identified fibroids as a cause of PPH 
(Magann et al., 2006), they reported OR 3.53 (95%CI 0.92 to 10.64) for blood 
loss >1000 ml, and OR 11 (95%CI 3.01 to 40.0) for blood loss exceeding 1500 
ml. Despite not being statistically significant for >1000 ml, and with wide 
confidence intervals for >1500 ml, these OR are likely to be clinically significant 
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(Coggan, 2003). These authors proposed the distortion of the normal uterine 
architecture by leiomyomata preventing contraction of the uterine musculature as 
the rationale for PPH at both elective and emergency CS (Magann et al., 2006). 
 
 
The odds ratio (OR) for PPH in women with asthma has been reported as 1.38 
(95%CI 1.21 to 1.57) (Tata et al., 2007). Using a well validated, primary care 
database these authors adjusted for maternal age, BMI and smoking status, and 
compared women with asthma with the general population. Severity of asthma 
was identified via codes for asthma diagnosis, medication prescriptions and 
exacerbation during the year preceding pregnancy. Unlike many complications, 
PPH was reportedly more common in women with mild asthma and no 
exacerbations, rather than more severe disease (Tata et al., 2007). Given the 
reported increase in incidence of asthma in women of childbearing age (3-8%) 
the association with certain obstetric complications, including PPH, needs further 
investigation in a contemporaneous population. Examination and comparison of 
treatment regimes may also prove valuable to ensure women receive optimal 
treatment for asthma, whilst reducing the risk of obstetric complications, 
including PPH.  
 
 
2.2.4.4 Current pregnancy acquired risk factors 
 
1) Multiple pregnancies have long been associated with many pregnancy 
complications, including excessive blood loss following birth (Sebire et al., 2001b; 
Waterstone et al., 2001), and attributed to the larger placental site, exaggerated 
maternal physiological responses to pregnancy and increased uterine stretch to 
accommodate more than one baby (Walker et al., 2004). Magann and colleagues 
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(2005) investigating risk factors for PPH >1000 ml and/or need for transfusion 
following vaginal birth, reported OR 2.2 (95%CI 1.5 to 3.2) for multiple 
pregnancy. This was further increased to OR 5.1 (95%CI 1.5 to 15.7) when 
multiple pregnancy was complicated by twin to twin transfusion syndrome, 
although these were rare (0.8% of study population) so caution should be 
exercised interpreting this result. Increased incidence of multiple pregnancies has 
been attributed to increasing maternal age and ARTs (Practice Committee, 2004; 
Eriksson and Fellman, 2007), both have increased in recent years, and therefore 
are potentially responsible, at least in part, for the temporal rise in PPH. 
 
 
2) Pre-eclampsia has been well documented as associated with abnormal 
bleeding, both placental abruption and PPH (Combs et al., 1991). This could be 
due both to the endothelial dysfunction responsible for the atherosclerosis 
apparent in placental vessels, and the failure of spiral artery adaptation in 
pregnancy, which cause problems with placental adherence and vascular 
constriction following delivery of the placenta (Roberts and Cooper, 2001).  
Furthermore the haematological disruption (haemolysis, elevated liver enzymes 
and low platelets) associated with pre-eclampsia may be contributory to the 
increased rates of PPH (Young et al., 2010), and clarifies the importance of 
differentiating between pre-eclampsia and gestational hypertension.  Miller and 
colleagues (2007) reported an odds ratio of 1.49 (95%CI 0.99 to 2.23; p=0.05) 
for PPH in women with pre-eclampsia or gestational hypertension. Failure to 
differentiate between gestational hypertension and pre-eclampsia, the inclusion of 
vaginal deliveries alone and the additional impact of pregnancy at high altitude 
(Tibet, >3100 m above sea level) may limit the generalisability of their findings 




3) Obstetric cholestasis (OC), whilst relatively rare (affecting <1% of the 
antenatal population), has been associated with adverse fetal outcomes and PPH 
(RCOG, 2006). The aetiology of abnormal liver enzymes and pruritus in OC 
remains uncertain, and the association with PPH equally unclear. One case control 
study reported PPH rates of 14.9% versus 1.38% in women with and without OC 
(Kenyon et al., 2002). In this study controls were selected as the next delivered 
woman, matched for age, ethnicity and parity, but given the definition for PPH 
used (>500 ml), the incidence appears very low in this arm, and inclusion of 
matching for mode of delivery may have been more appropriate, given the 
increased number of women with OC requiring emergency CS (14 versus 8). It is 
unclear as to whether prophylactic vitamin K was administered to women with OC 
despite PPH being identified as particularly problematic when this is not given. 
Mechanistically it is not entirely clear how vitamin K reduces PPH rates in women 
with OC (Kenyon et al., 2002). 
 
 
4) Placenta praevia, particularly major and anterior, is known to increase blood 
loss following delivery (Chattopadhyay et al., 1993). A large database study 
investigating PPH associated with elective and emergency CS, reported the OR for 
EBL > 1000 ml (and/or transfusion) with placenta praevia as 6.65 (95%CI 3.24 
to 13.09) and for > 1500 ml (and/or transfusion) OR 8.06 (95%CI 2.98 to 21.81) 
(Magann et al., 2006).   
 
Factors associated with increased risk of placenta praevia include smoking 
(Ananth et al., 1996), older maternal age (Montan, 2007) and previous CS 
(Coulter-Smith et al., 1996). Therefore the impact of the changing demography 





5) Morbidly adherent placenta is a major risk factor for severe PPH and has been 
identified as commonly, but not exclusively, associated with placenta praevia 
(Chattopahdyay et al., 1993). In this study, accreta was diagnosed according to 
difficulty in delivering the placenta, resulting in piecemeal delivery. It could be 
argued that this is moderated by operator competence (Chattopahdyay et al., 
1993). A more recent review, investigating the impact of abnormal placentation, 
reported an absence of randomised controlled trials, and therefore the level of 
available evidence remains limited (Oyelese and Smullian, 2006). Given the 
increasing incidence of placenta accreta, increta and percreta due to other 
demographic and pregnancy management changes, attending clinicians are 
advised to identify those at risk due to a previous history of uterine surgery. 
Indeed it has been suggested that morbidly adherent placentas are the 
“unintended consequences” of rising CS rates (Scott, 2008).  
 
 
6) Other antenatal complications, events and illnesses associated with PPH 
include; antepartum haemorrhage (Bibi et al., 2007), PPH > 1000 ml OR 2.92 
(95%CI 1.90 to 4.45) PPH > 1500 ml 3.64 (95%CI 2.00 to 6.60) (Magann et al., 
2006), antenatal anaemia, although haemoglobin levels of concern are variably 
reported (Kavle et al., 2008; Singh et al., 1998), antenatal blood transfusion PPH 
>1000 ml OR 4.80 (95%CI 1.02 to 20.67), > 1500 ml OR 9.01 (95%CI 1.94 to 
41.94) (Magann et al., 2006) and acute fatty liver of pregnancy (Bonnar, 2000). 
A tenuous link with urinary tract infection may be due to other factors, such as 





2.2.4.5 Intrapartum acquired risk factors 
 
1) Gestation at onset of labour has been variably reported as influencing blood 
loss following birth. Preterm birth has been associated with PPH, potentially due 
to infection (Shennan et al., 2006). However blood loss was a secondary outcome 
in this study. Preterm birth, <37 completed weeks of pregnancy, resulting in 
either elective or emergency CS has been reported as increasing risk of PPH 
>1000 ml and >1500 ml (OR 2.23 [95%CI 1.27 to 2.82] and OR 
2.79[95%CI1.22 to 6.37] respectively) (Magann et al., 2006). Administration of 
corticosteroids, for fetal lung maturation, whilst undoubtedly beneficial for the 
neonate, confers no maternal benefit (RCOG, 2004), and has been associated 
with increased rates of PPH (Pattanittum et al., 2008). However these authors 
concluded that women receiving antenatal corticosteroids were more likely to 
have labour induced, and was twice as likely to have a CS. It could therefore be 
suggested that these cases were managed more actively, and other factors could 
contribute to PPH. Seminal work suggested that singleton, vaginal, preterm birth 
was significantly associated with prolonged third stage and retained placenta, 
which led to PPH (Combs and Laros, 1991). The relevance of this work is 
questionable, as prophylactic oxytocin was rarely used, and although some 
clinicians used controlled cord traction, others used techniques not currently in 
practice, such as the Credo manoeuvre and fundal pressure to expel the placenta 
(Combs and Laros, 1991). Prolonged gestation has been variably associated with 
PPH rates. It is difficult to determine the independent influence of gestation, as 
this is often associated with other factors, such as older maternal age (Zhang et 
al., 2005), obesity  (Sebire et al., 2001c) baby birth weight (Sosa et al., 2009) 




2) Fetal macrosomia has been associated with PPH (Gregory et al., 1998), 
although the impact is difficult to assess due to its association with other factors, 
such as maternal obesity (Jolly et al., 2003; Sebire et al., 2001c) and both pre-
existing and gestational diabetes (Mathew et al., 2005). Conversely, Siggelkow 
and colleagues (2008) reported a direct correlation between birth weight and 
mode of delivery, but no increase in perineal trauma or PPH with infants weighing  
more than or less than 4000 g (Siggelkow et al., 2008). This study involved 215 
women whose infants weighed >4000 g, focusing on the influence of maternal 
gestational weight gain. These findings may be due to intrapartum management 
and other issues in this relatively small heterogeneous cohort. In a single centre 
observational study Hazra and colleagues (2004) reported no association with 
birth weight and severe PPH (defined as blood loss ≥1500 ml). However this 
study was relatively small, with 145 babies of which 26 (17.9% weighed more 
than 4 kg (Hazra et al., 2004). Conversely a large population based cohort 
investigating risk of PPH associated with elective and emergency CS showed an 
OR 2.45 (95%CI 1.60 to 3.71) for PPH >1000 ml and OR 2.26 (95%CI 1.16 to 
4.41) for PPH >1500 ml (Magann et al., 2006) 
 
 
3) Induction and augmentation of labour are both associated with greater 
estimated blood loss using several methodologies including case control (Sheiner 
et al., 2005) and retrospective database review (Duff and Sinclair, 2000; Hall et 
al., 1985). Despite various investigations of induction techniques, (e.g. oxytocin 
versus misoprostol and dinoprostane) and mode of administration (orally, per 
vagina or intravenously) none has proved more effective at limiting primary blood 
loss  (NICE, 2008a; Calder et al., 2008; Bugg et al., 2006; Majoko et al., 2002; 
Hofmeyr, 2001; Stones et al., 1993). Duration of oxytocin administration has not 
been investigated, but augmentation in the first or second stages of labour has 
been associated with both increased blood loss (Bugg et al., 2006) and as having 
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no impact on blood loss (Hinshaw et al., 2008). Conversely in a retrospective 
cohort study others report less postpartum blood loss following induction with 
prostaglandins, except where oxytocin is also required, unless this is continued 
until after the birth of the baby (Philip et al., 2004). This suggests that oxytocin 
in the first and second stages of labour may lead to excessive blood loss in the 
third stage. Mechanistically, this could be due to the down regulation of 
myometrial oxytocin receptors in the presence of pharmacological concentrations 
infused during induction/augmentation  (Phaneuf et al., 2000). Combined with 
the myometrial lactic acidosis that occurs in dysfunctional labour, this leads to 
failure of the uterine contractility required to ameliorate bleeding after placental 
separation (Quenby et al., 2004).  
 
Other studies such as Magann and colleagues, do not whilst reporting labour 
dystocia as a risk factor for PPH > 1000 ml, but not > 1500 ml following 
emergency CS, do not give details regarding the methods of augmentation 
adopted (Magann et al., 2006). In an earlier investigation using the same 
extensive obstetric database these authors reported induction of labour resulting 
in vaginal birth as having OR1.5 (95%CI 1.2 to 1.7)  (Magann et al., 2005). 
Prolonged first stage (defined as: latent phase exceeding 20 h for nulliparous and 
> 14 h in multiparous women; active phase < 1.2 cm per hour in nulliparous and 
<1.4 cm per hour in multiparous women) OR 1.6 (95%CI 1 to 1.6), and 
prolonged second stage of labour (defined as: > 2h with epidural; analgesia; >3 
h without epidural) OR 1.6 (95%CI 1.1 to 2.1). 
 
4) Duration of labour has been shown to influence blood loss. Precipitate labour, 
although variably defined (Thevakumar et al., 2008), has long been associated 
with PPH (Brincat et al., 1984). Similarly, the association of PPH with prolonged 
first and second stages of labour are well known (Magann et al., 2006; Hayash, 
1990; Gilbert et al., 1987). A literature review suggested that second stage of 
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labour duration ≥4 hours, whilst potentially associated with PPH, conferred no 
detriment for the infant but disempowers women (Williams, 2007). Little of the 
literature reviewed used electronic fetal monitoring and heterogeneity of the 
studies used compounded findings. Once labour is prolonged, prompt or delayed 
oxytocin administration has been shown to have no effect on blood loss (Hinshaw 
et al., 2008). Reasons for dystocia and resultant slow progress are manifold, 
including advanced maternal age (Montan, 2007), obesity (Sebire et al., 2001c), 
fetal macrosomia (Jolly et al., 2003), fetal malpresentation or malposition 
(Chapman, 2004), ineffective uterine activity (Zhang et al., 2007) and epidural 
analgesia (Roberts et al., 2004). Prolonged third stage of labour has also been 
associated with increased blood loss (Bias et al., 2004) and reasons cited for 
elongated third stage include maternal age ≥35 years, prolonged second stage of 




In a Dutch regional study using an obstetric database third stage of labour 
exceeding 30 minutes was identified as a risk factor for PPH (Bias et al., 2004). 
Magann and colleagues investigated the optimal time to remove retained 
placentas to prevent PPH in a randomised controlled trial which was not 
completed because 99.5% of placentas were delivered within 20 minutes (89% 
less than 10 minutes post birth) and therefore the sample size required to answer 
this question was unattainable (Magann et al., 2006b). A previous prospective 
observational study by the same authors had identified increased risk of PPH 
when delivery of the placenta did not occur within 10 minutes (OR 2.1[95%CI 1.6 
to 2.6]), risk of PPH increased further at 20 minutes (OR 4.3 [95%CI 3.3 to 5.5]) 
and still further at 30 minutes (OR 6.2 [95%CI 4.6 to 8.2]). Concluding that the 
best predictor for PPH using receiver operating characteristic (ROC) curves was 
18 minutes (Magann et al., 2005b). Earlier work had also identified rapid 
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placental delivery, with the majority delivered within 15 minutes in a variety of 




5) Epidural analgesia has been associated with PPH  (Gilbert et al., 1987), but as 
this tends to be the preferred pain relief option for women undergoing induction 
or long labours (Roberts et al., 2004; Duff and Sinclair, 2000), it is difficult to 
ascertain the independent contribution to PPH. Additionally epidural is associated 
with longer duration of the second stage of labour and instrumental vaginal birth 
(NICE, 2007), both of which have been associated with increased blood loss. 
Although one literature review, whilst reporting increased duration of the second 
stage of labour with epidural analgesia, concluded there was no consensus 
regarding optimal length and, furthermore, identified a reduction in mid cavity/ 
rotational forceps deliveries in women with epidurals (Odiho, 2007). Incidence of 
perineal trauma and PPH have been reported as similar in women with and 
without epidurals and with early versus delayed pushing in several RCTs (Rogers 
et al., 1999; Fraser et al., 2000; Fitzpatrick et al., 2002) 
 
 
6) Raised maternal temperature in labour has been reported in women with 
epidural analgesia (Lieberman et al., 1997; Odiho, 2007) and is a cardinal sign of 
chorioamnionitis (Bailey and Steer, 2007), both of which have been implicated as 
increasing blood loss. Others have described a “normal” physiological 0.3°C 
increase in temperature during labour (Schouten et al., 2008). Raised maternal 
temperature may therefore be associated with other intrapartum factors that 
contribute to PPH. These observational studies and guidelines focused on 
maternal pyrexia leading to neonatal sepsis, and incidence of PPH was not 
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reported, despite the known association between chorioamnionitis and PPH, 
especially at term (Cooke, 2008).  
 
 
7) Mode of birth has been cited as a key predictor of blood loss. Spontaneous 
vaginal delivery is associated with the least blood loss, except where mediolateral 
episiotomies have expedited delivery and soft tissue damage has been sustained 
(Combs et al., 1991). Instrumental vaginal births are also associated with 
increased blood loss (Henry et al., 2005;). Elective and emergency CS have 
variably reported associations with PPH (Waterstone et al., 2001; Ford et al., 
2007b) with the temporal rise in PPH reported as not being wholly attributable to 
increased CS rates  (Wen et al., 2005). 
 
 
Labouring and birthing in water has been associated with less blood loss at 
delivery (Garland and Jones, 1994), but difficulties in assessing blood volume lost 
in water means this is impossible to confirm, without undertaking pre and 
postnatal haemoglobin (Hb) assessment. Despite inherent problems in this 
approach, one study utlising this methodology reported no benefit of water birth 
in terms of improving postnatal Hb (Bodner et al., 2002)   concluding that giving 
birth in water had no impact on blood loss. 
 
 
8) Management of the third stage of labour is the term used to describe how the 
placenta and membranes are delivered and bleeding is controlled. Active 
management of the third stage of labour (AMTSL) is described as a combination 
of interlocking interventions, most commonly prophylactic administration of a 
uterotonic drug, early cord clamping and controlled cord traction (Prendeville et 
al., 2000). Others have included uterine massage and are less prescriptive 
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regarding timing of cord clamping (WHO, 2000). Several clinical trials have 
convincingly demonstrated that AMTSL prevents PPH (Prendiville et al., 1998; 
Rogers et al., 1998; Prendiville et al., 2000) and it is recommended for all women 
(RCOG, 2002). Due to differences in some aspects of the management in earlier 
trials, for example dose, route, timing and choice of uterotonic, and ‘early’ versus 
‘delayed’ cord clamping, there remains less consensus regarding the impact of 
individual components (Gulmezoglu and Souza, 2003) and insufficient evidence to 
recommend an optimal uterotonic drug (NICE, 2007).  
 
 
The origins of ‘early’ cord clamping are unclear (Weeks, 2007), but it was integral 
to the protocol for a cohort study investigating controlled cord traction in 1962 
(Spencer, 1962). Early cord clamping is not universally adopted (Winter et al., 
2007). The benefits of delayed cord clamping have long been advocated for 
preterm infants (Kinwood et al., 1993) and more recently a systematic review 
and meta-analysis in term babies reported delayed cord clamping improved 
haematologic status in the children when aged 2-6 months (Hutton and Hassan, 
2007).  Although early cord clamping has been advocated to prevent PPH, a 
Cochrane Review reported no increased risk of excessive bleeding when cord 
clamping is delayed by 2-3 minutes (McDonald and Middleton, 2008). 
 
 
Controlled cord traction (CCT), first introduced in the 1930s, has long been 
advocated to reduce both PPH and retained placenta (Quadir Khan et al., 1997). 
However this large RCT compared early administration of uterotonic and CCT with 
no cord traction and administration of uterotonic following delivery of the 
placenta. The impact of CCT alone cannot therefore be ascertained. More recently 
a pilot randomized superiority trial where women received intramuscular 
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uterotonic with birth of the anterior shoulder, regardless of allocation to CCT or 
hands-off technique,  
 
 
Similarly, although administration of a uterotonic is considered pivotal in the 
prevention of PPH, the choice of uterotonic remains controversial. A Cochrane 
Review concluded that prophylactic oxytocin, as opposed to no uterotonic, 
reduced blood loss but there was little evidence of any difference in blood loss 
when oxytocin was compared with ergot alkaloids. However, these were 
associated with more manual removals of placenta and there was a suggestion of 
increased hypertension (Cotter et al., 2001). Comparison between ergometrine-
oxytocin (Syntometrine®) and oxytocin showed that whilst there was a small 
statistically significant reduction in the risk of PPH with the ergometrine-oxytocin 
compound this was associated maternal side effects (raised BP nausea and 
vomiting) (McDonald et al., 2004). Ergot alkaloids (Ergometrine®) administered 
intramuscularly or intravenously were found effective at reducing blood loss but 
were associated with elevated blood pressure and severe pain (Liabsuetrakul et 
al., 2007).  Whist confirming the effectiveness of a prophylactic oxytocin and 
ergometrine compound (Syntometrine®) with associated side-effects (most 
notably hypertension), a further review concluded there was no evidence that 
intravenous administration of a long acting oxytocin agonist (Carbetocin®) was 
more effective than oxytocin at reducing PPH (Su et al., 2007).  Other potential 
prophylactic uterotonics investigated include oral prostaglandins (Misoprostol®) 
that have the advantage of requiring minimal storage requirements, but was not 
more effective than other uterotonics in preventing PPH and was frequently 
associated with side effects (raised basal temperature, nausea and shivering) 
(Gulmezoglu et al., 2007). More recently tranexamic acid has been proposed as a 
useful alternative or adjunct to current prophylactic uterotonic drugs having been 
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shown to reduce blood loss in trauma and surgery. Tranexamic acid is not a 
uterotonic but an antifibrinolytic and therefore could be particularly useful when 
PPH is due to placenta praevia or genital tract trauma and has already been 
shown to reduce blood loss following CS in a randomised controlled trial of 
primiparous women (Gai et al., 2004). A Cochrane Review found that, whilst 
potentially effective at reducing blood loss, further research is required before it 
could be recommended in practice (Novikova and Hofmeyr, 2010)  
 
 
Conversely, proponents of physiological management of the third stage state it is 
the natural conclusion of a normal labour (Davis-Floyd, 2003) with no resultant 
adverse consequences, in terms of need for transfusion or increased inpatient 
nights when used appropriately (Begley, 1990). Although evidence from a 
randomised controlled trial concedes incidence of PPH> 500 ml is higher and 
haemoglobin concentration is lower in women who have expectant third stage 
management (Begley, 1990). Confirming the results from two seminal 
randomised controlled trials, the Bristol third stage trial (Prendiville et al., 1988) 
and the Hinchingbrooke trial (Rogers et al., 1998). The latter acknowledged the 
importance of staff remaining competent in both management strategies for 
delivery of the placenta, and also identified the importance women and their 
health providers place on blood loss following a physiological birth (Rogers et al., 
1998). These findings were subsequently confirmed in systematic reviews 
(Prendiville et al., 2000; Prendiville et al., 2003). But this meta-analysis also 
concluded that physiological management of the third stage of labour may be 
appropriate in domiciliary environments (Prendiville et al., 2003).  
More recently, and in the face of irrefutable evidence for the effectiveness of 
active management, proponents of physiological management have attributed 
biomedical domination as underpinning the universal adoption of interventionist 
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obstetrics, leading to a risk-entrenched approach that has replaced physiological 
management with comprehensive active management (Fry, 2007). Factors to 
enhance physiological delivery of the placenta have been identified and include 
reducing fear, cold and bright lights (Gyte, 2006; Odent, 2003), uninterrupted 
skin to skin contact and suckling to promote a surge of oxytocin required for 
placental separation (Page, 2007), no cord clamping as free drainage of placental 
blood causes the placenta to ‘shrink”, promotes the effective uterine contractions 
required and reduced retroplacental blood loss (Lucas, 2006). However none of 
these processes have been formally tested in randomized controlled trials. 
 
 
Guidelines state that midwives should remain competent in both methods of 
placental delivery and control of bleeding (Jokinen and Munroe, 2008; NICE, 
2007). Lack of expertise and confidence in either management technique, has 
been associated with increased blood loss (Rogers et al., 1998), with resultant 
“piecemeal” management cited as additionally causative of retained placenta and 
uterine inversion (Inch, 1988). An investigation of European policies for third 
stage management found wide variation in practice (uterotonic agents used, 
timing of administration, draining of placenta, timing of cord clamping and 
application of controlled cord traction) and differences in practice and policy 
documents (Winter et al., 2007). This study used postal questionnaires, with wide 
variation in numbers of both invited respondents (22 - 719 in each country) and 
response rates (29=100% in each country).  The diversity of practice identified in 
this study, given the documented limitations of postal surveys, in terms of 
response rates and self selection, could imply even more variation in practice 
than reported here.  
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9) Retained placenta has long been identified as a cause of PPH (Al-Zirqi et al., 
2008; Stones et al., 1993). Partial accreta is particularly problematic and 
associated with the greatest blood loss (Weeks, 2008). Some report manual 
removal of retained placenta as causative of severe PPH following spontaneous 
vaginal birth (Hazra et al., 2004). The treatment of retained placenta varies 
dependent on the cause, but delay can lead to severe morbidity (Chhabra and 
Dhorey, 2002).  
 
 
Duration of the third stage was identified as a risk factor for PPH> 1000 ml in a 
large observational study of women following vaginal birth, with the optimal time 
to avoid PPH being 18 minutes (Magann et al., 2005). This single Centre study 
employed AMTSL in all women (IM oxytocin with delivery of the anterior 
shoulder), and manually removed undelivered placentas after 30 minutes. These 
policies remove maternal choice regarding both physiological management of the 
third stage, and delaying manual removal of placenta in the absence of bleeding. 
It was also undertaken in a single Centre which may not be replicated elsewhere. 
However it is a large study employing meticulous blood loss data. But information 
regarding the impact of vaginal operative deliveries, although included (incidence 
17%), was not reported, neither was the impact of previous history in 
multiparous women who constituted 55.2% of the study population.  
 
 
10) Episiotomy has been shown to be a major cause of severe PPH following 
instrumental vaginal birth, with second and third degree tears more frequently 
causative following spontaneous vaginal birth (Hazra et al., 2004). Although 
historically undertaken to expedite birth and prevent vaginal tears, research 
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emerging in the 1990s showed episiotomy did not reduce perineal trauma or birth 
asphyxia and was associated with PPH (Cleary-Goldman and Robinson, 2003). A 
randomised controlled trial of routine (all cases) versus restrictive (only 
performed with evidence of tearing) episiotomy, reported a moderate increase in 
PPH (>500 ml) in the routine episiotomy group (Murphy et al., 2008). Given the 
decreasing incidence of episiotomy, at a time of increasing PPH, the impact of this 
surgical procedure could be considered less important than when it was 
undertaken more routinely.  
 
 
This survey of the available evidence the complexity of risk factors is apparent 
and concurs with the National Institute of Health and Clinical Excellence (NICE), 
which also reported widely varying degrees of evidence for risk factors for PPH, 
and concluded that production of an exhaustive list was not possible  (NICE, 
2007). The factors identified by NICE are shown in Figure 2.4. NICE 
recommendations included counseling regarding place of birth and an identified 
documented care plan for women with identified risk factors. No comment 
regarding the cumulative impact of multiple risk factors was made and risk 
factors were not ranked depending on impact. Most risk factors have been 
identified though retrospective coded data, cross sectional, cohort and 
observational studies. This means most of these findings lack a control or 








 Antenatal risk factors:  
º Previous retained placenta or postpartum haemorrhage  
º Maternal haemoglobin level below 8.5 g/dl at onset of labour  
º Body mass index greater than 35 kg/m²  
º Grand multiparity (parity 4 or more)  
º Antepartum haemorrhage  
º Overdistention of the uterus (for example, multiple pregnancy, 
polyhydramnios or macrosomia)  
º Existing uterine abnormalities  
º Low-lying placenta  
º Maternal age 35 years or older.  
 
 Risk factors in labour:  
º Induction  
º Prolonged first, second or third stage of labour  
º Oxytocin use  
º Precipitate labour  
º Operative birth or caesarean section.  
 




2.2.5 The Impact of PPH 
2.2.5.1 Mortality versus morbidity  
 
Whilst PPH is responsible for an estimated 125,000 maternal deaths worldwide 
each year, as previously described such deaths are rare in resource rich countries 
(Khan et al., 2006). In the UK, whilst not always the main cause of maternal 
deaths, PPH has been consistently cited in the triennial Confidential Enquiry into 
Maternal Deaths since its inception (Lewis, 2003).  
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Maternal morbidity is traditionally defined as “morbidity in a woman who has 
been pregnant (regardless of site or duration of pregnancy), from any cause 
related to, or aggravated by, the pregnancy or its management, but not by 
accidental or incidental causes” (WHO, 1990a). Limitations of this definition 
include consideration of ongoing pregnancies and the lack of clarity regarding 
duration of the postnatal period. It also lacks the differentiation and classification 
as described by direct and indirect causes of maternal deaths, outlined in the 
Confidential Enquiry (Lewis, 2007b).  
 
 
Although there are wide variations in estimates, it is acknowledged that globally 
up to 10,000,000 women live with the short and long term health and social 
consequences of pregnancy complications (UNICEF, 2008) with severe PPH a 
major cause of these morbidities (Khan et al., 2006). Figure 2.5 depicts the 
continuum between health and death (adapted from Minkauskiene, 2003). It 
graphically represents that women can experience an uncomplicated pregnancy 
and remain well throughout. Others develop a complication that can deteriorate 
further, from which they either recover completely, or survive with an associated 
short or long term morbidity. Conversely the complication can deteriorate further 
and become life threatening, from which the woman may die or will survive but 
almost certainly sustain a short or long term morbidity. Maternal morbidities 
associated with PPH include, adult respiratory distress syndrome, coagulopathy, 
loss of fertility and pituitary necrosis (Abalos, 2009), with their inherent short and 




Figure 2.5: Graphic representation of continuum between health and death 
(adapted from Minkauskienne, 2003) 
 
 
The impact of morbidities associated with PPH is difficult to establish in the 
literature. A European Union (EU) collaboration was established in an attempt to 
monitor and evaluate maternal morbidity using consensus indicators as a 
composite measure of severe obstetric morbidity. This was considered effective in 
accounting for virtually all the factors that constitute severe maternal morbidity, 
regardless of individual member States’ maternity service provision (PERISTAT, 
2003). One, or more, of the following fulfilled the criteria for the composite 
measure: eclamptic fit; surgery (except tubal ligation or CS); embolisation; blood 
transfusion; and intensive care unit admission exceeding 24 hours (Buitendijk et 
al., 2003).  However, evidence should be considered with caution, as the 2008 
report referred to data collected in 2003, during the intervening years the EU 
population increased and evolved, with changing patterns of migration within the 






The impact of PPH as a severe maternal morbidity has been investigated and 
confirmed; a study in high-income countries concluded that rates of severe 
maternal morbidity vary between 3.8 and 12 per 1000 births, PPH being the most 
common cause (van Roosmalen and Zworst, 2009). Disparity in definition and 
recording and coding issues made data comparison difficult (for example, in 
Scotland haemorrhage ranked first, compared to 4th in the Netherlands where, 
intensive care unit admission was first). The potential for under-reporting, due to 
differences in health systems, variation in definitions and a tendency to 
underestimate blood loss in particular, for fear of recriminations and accusations 
of poor practice, was highlighted (van Roosmalen and Zworst, 2009). 
 
 
A UK population based study of all 229 consultant-led maternity units, found that 
for every women who died following peripartum hysterectomy (most commonly 
undertaken to control postpartum haemorrhage) 150 survived with associated 
consequences (Knight, 2007). These findings confirm the contribution of PPH to 
the severest acute maternal morbidity in high resource settings. Furthermore it 
highlights the importance of data consistency and the accuracy of information 
regarding short and long term effects and subsequent health.  
 
 
Post-traumatic stress disorder (PTSD) has been associated with childbirth, 
especially following an adverse event, and investigation of short and long term 
mental health issues, in addition to social functionality and adaptation to 




2.2.5.2 Near-miss audit  
 
The term “near-miss” was adopted from the aviation industry, where it describes 
a near accident, without casualties or material damage (Mantel et al., 1998). It 
therefore does not readily translate to the context of maternal health, where 
there has already been an “accident” with a “casualty” and the prospect of short 
and long-term consequences, “material damage”. Furthermore the definition of 
“near-miss” depends on local facilities and maternal health parameters, but the 
originator of the term, defined a “near-miss” event as: “ a very ill woman who 
would have died, had it not been that luck and good care were on her side”  
(Mantel et al., 1998; Bewley and Creighton, 1997). The inclusion of “good luck” 
before “good care” in this definition, as requisite to survive such an event is 
curious. The term “near-miss” effectively evokes emotions regarding the 
seriousness of the situation, but the term severe acute maternal morbidity 
(SAMM) is preferred by others, avoiding the inherent ambiguity caused by 
translation from the original context (Zwart et al., 2008).  
 
 
The ten-fold reduction in the UK maternal death rate between 1952 and 2002 
(530 to 53 per million maternities) indicates that death is too rare an event to be 
a sensitive marker of quality of care.  Other high-income countries have also 
achieved dramatic reductions in maternal deaths and therefore severe acute 
maternal morbidity (SAMM), or “near-miss” audits, have been advocated as 
useful mechanisms to examine practice and improve patient care, providing a 
valuable quality indicator for obstetric services and a useful adjunct to the 
Confidential Enquiries into Maternal Deaths (Hill et al., 2007; Lewis, 2007a; Drife, 
1993). The impact of examining critical incident audit in maternity and perinatal 
health has not been evaluated in randomised controlled trials (Pattinson et al., 
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2005), but review of observational data relating to near-miss events around PPH, 
concluded that despite diverse approaches, and varying inclusion criteria (Penney 
and Brace, 2007; Baskett and O’Connell, 2005; Mantel et al., 1998; Stones et al., 
1991), this form of analysis was effective in identifying suboptimal care and 
should be accepted as complementary to maternal mortality reports (Penney and 
Adamson, 2007a). Objective assessment of severity of morbidity remains 
challenging with incidence dependent on definition, and management dependent 
on availability of health care resources, in addition to maternal health status prior 
to the insult.  
 
 
Despite reported advantages in critical incident analyses to identify and address 
suboptimal care, the effectiveness of this type of investigation is dependent on 
standardisation of frameworks used, identification of robust “triggers” for action 
and acknowledgement of the influence of human error in these events, with 
supportive and non-punitive treatment of those involved  (Kershaw, 2007;Iedema 
et al., 2006; Ahluwia and Marriott, 2005). In qualitative studies doctors have 
been identified as particularly reluctant to report critical incidents, believing that 
errors are “inevitable”, fearing retribution or failure and investigation by “non-
medical” professionals. All further compounded by anti-bureaucratic sentiment 
and desired avoidance of excessive administrative work (Waring, 2005; Lawton 
and Parker, 2002). This may be due, in part, to the lack of reflexivity in their 
training and perceived lack of support (Vincent et al., 1999). Nurses, on the other 
hand, have been identified as more likely to report such incidents  (Throckmorton 
and Etchegaray, 2007; Meurier 2000). Although the largest of these studies was 
undertaken in USA and organisational differences in health delivery may mean 
the findings are not transferable (Throckmorton and Etchegaray, 2007).  
Investigations in other clinical areas have used different critical analyses 
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techniques, and have advocated their implementation in other areas of medicine 
(Tighe et al., 2006) but with different models employed it is difficult to draw 
conclusions as to which might be most effective in any given area. Indeed, in the 
UK, Woloshynowych and colleagues identified the further potential for 
development of novel techniques and transfer of others from high risk industries 
to better utilise critical incident analysis to improve patient care; but cautioned 
the need for these implementation of recommendations to be formally evaluated 




Table 2.4 shows several epidemiological and register studies have reported 
marked increases in maternal morbidity in high income countries, regardless of 




Table 2.4: Summary of epidemiological and register data demonstrating 
increased maternal morbidity in high income countries over time (Zwart 2009, 
p167).  
 
Country Time period Rate of SAMM 
per 1000 births 
Increase 
Canada  








































Footnote: SAMM: Severe Acute Maternal Morbidity. NSW: New South Wales. 
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Wen and colleagues (2005) demonstrated how PPH and uterine rupture were 
more common than other severe acute maternal morbidities in Canada between 
1991 and 2000, shown in Figure 2.6. The apparent reduction in PPH rates is 
misleading, as the definition relied on receipt of blood products, and the threshold 
for transfusion changed significantly during this decade (Wen et al., 2005).  
 
 
Figure 2.6: Data illustrating severe postpartum haemorrhage (requiring 
transfusion), and uterine rupture as major causes of severe acute maternal 
morbidity SAMM (Wen, 2005 p Online-4). 
 
 
Consecutive Scottish Audits of Maternal Morbidity have consistently reported 
massive obstetric haemorrhage (MOH) as the major cause of severe morbidity. In 
the 2005 report this accounted for 75% of all “near-miss” events (Lennox and 
Marr, 2007) and 74% in the 2008 audit (Lennox and Marr, 2010). This is depicted 
in Figure 2.7, visually demonstrating the impact of obstetric haemorrhage.  
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A large Irish cohort reported incidence of severe acute maternal morbidity in 
2003-2004 as 3.2/1000 maternities. Vascular dysfunction following major 
obstetric haemorrhage was the most common cause (36%) (Murphy et al., 
2009). These data confirm the impact of PPH on maternal morbidity in many high 
income countries, with abundant resources to deal with severe bleeding.   
 
 
Figure 2.7: Severe acute maternal morbidity, displayed cumulatively year on year 
between 2003-2008 to compare contribution of major obstetric haemorrhage 
(MOH) with all other severe acute maternal morbidities (SAMM) (adapted from 
Lennox and Marr, 2010). 
 
 
In addition to the consequences for the women, there is an inherent demand on 
resources in dealing with PPH. The UK Intensive Care National Audit and Research 
Centre reported PPH was the most common cause of admissions of  “recently 
pregnant” women (ICNARC, 2009) accounting for 34% of admissions. This refers 
to seriously ill women admitted to adult general intensive care units (ITU). 
Therefore it is likely to be an underestimate of the impact of PPH, as many 
maternity units now have high dependency areas where recently delivered ill 
women are cared for within maternity services.  In the Scottish Confidential 
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Audit, 42 of the 90 women (46%) admitted to ITU experienced PPH (Lennox and 
Marr, 2010). Similarly this is likely to be an underestimation, as not all maternity 
units in Scotland have access to ITU, further demonstrating that any definitions 
or management strategies may be more representative of resource availability 
and clinician preference than severity of maternal condition.  
 
 
These data confirm that PPH remains a major complication of childbirth in high-
income countries, despite heterogeneity of definition, differences and limitations 
of documentation, resource differences and advances in clinical practice. It also 
shows the benefit of audit in ascertaining practice, identifying and promoting 
good care, whilst identifying and addressing substandard care. PPH has inherent 
personal, medical and societal impacts in terms of health and wellbeing, as well 
as concomitant financial and other resource implications to the NHS, social care, 




2.2.6 Assessment of blood loss 
 
Ambiguity around assessment of blood loss at birth has long been contentious 
being regularly criticised as unreliable and ineffective (Bose et al., 2006; 
Prasertcharoensuk et al., 2000; Newton et al., 1961). Early textbooks typically 
advised postpartum blood loss was recorded as “small/minimal”, 
“average/moderate” and “large/heavy/excessive” (Luegenbiehl et al., 1990). 
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Blood loss at birth, and in the early postnatal period, is most commonly assessed 
visually, by attending clinicians facilitating the birth and providing early postnatal 
care. Training tends to be minimal and most commonly undertaken at the 
bedside (Stafford et al., 2008). Visual assessment has been associated with both 
under- and over-estimation (Bose et al., 2006; Dildy et al., 2004; Higgins, 1982) 
and variably associated with mode of birth (Larsson et al., 2006). The proportion 
of underestimation has been reported as 33-50% when compared to 
photospectrometry and colorimetric measurement of alkaline hematin in blood, 
which are considered the “gold standard” for blood loss assessment (Patel, 
2006a). Using simulator training, similar levels of under-estimation have been 
reported in Australia (Glover, 2006), USA (Dildy et al., 2004) and the UK (Bose et 
al., 2006). Prasertcharoensuk and colleagues (2000) reported visual assessment 
leading to underestimation of PPH (>1000 ml) by 88.9% when compared with 
direct measurement. An additional meta-analysis also discovered that when blood 
loss was measured the incidence of PPH was 10.5% compared with 7.2% when 
blood loss was assessed visually (Carroli et al., 2008). This considerable 
underestimation of blood loss artificially reduces the reported incidence of PPH.  
 
 
Others have applied complex formulae to calculate blood loss volume  (calculated 
pregnancy volume [0.75 x maternal height in inches x 50] +[maternal weight in 
pounds x 25] x % blood volume lost [predelivery haematocrit - postdelivery 
haematocrit/predelivery haematocrit]) and compared this with visually estimated 
blood loss (Stafford et al., 2008).  These authors concluded that when visual 
assessment alone is used blood loss is significantly underestimated and that 
further adjustment was required depending on perineal trauma sustained. 
Implementation of this calculation is less burdensome, yet provides comparable 
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results to those of more robust laboratory investigations reported in early seminal 
papers (Pritchard, 1965). 
 
 
The ability of attending clinicians to accurately assess blood loss in obstetrics and 
emergency medicine has been variably reported in the literature. Some suggest 
that estimation of blood loss is so poor that patient management should be 
dictated by vital signs, symptoms of shock, mechanism of injury and associated 
comorbidities rather than estimated blood loss (Tall et al., 2003; Patton et al., 
2001). Direct comparison with emergency medicine may not be appropriate as 
major blood loss is commonly associated with multiple injuries, requiring 
independent and targeted treatments. Additionally physiological adaptations to 
pregnancy mean that early postnatal women compensate for blood loss 
differently to trauma victims.  
 
 
Kavle and colleagues (2006) compared visually estimated blood loss with 
quantified methods using alkaline hematiin and reported midwives assessment as 
within 5 ml of the more robust assessment (Kavle et al., 2006). Greater 
differences were seen when visual assessment exceeded 200 ml, concurring with 
others that lower levels of blood loss are more accurately assessed than larger 
volumes (Schorn, 2008). Kavle’s study is preliminary work in an affluent area of a 
developing country and may have been influenced by the provision of free safe 
birth kits and local sociodemographic factors, therefore potentially of questionable 
generalisability. All blood loss was significantly lower than that reported in an 
early US cohort utilising a similar method, despite no prophylactic uterotonic, 
other than early breast feeding (Newton et al., 1961).  
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It has been suggested that historically a documented PPH ≥500 ml was 
considered problematic, prompting rapid response (Myles, 1985). The increase in 
estimated and documented blood volume lost following birth has been attributed 
to raised awareness caused by the introduction of obstetric emergency training, 
with staff are inclined to document higher levels of blood loss (Buckland and 
Homer, 2007; Black and Brocklehurst, 2003). Classic early studies using robust 
measurement techniques concluded that, regardless of visually estimated 
volumes, average post birth blood loss was 500 ml and 7% of women lost ≥1000 
ml (Pritchard, 1961). Thus, it could be argued that historically health care 
practitioners were more likely to underestimate blood loss, a situation that is, to 
some degree, less apparent today. Unfortunately, it is difficult to ascertain the 
contribution of this practice change to the increasing reported trend on PPH.  
 
 
Whist visual estimation remains acceptable for smaller volumes of blood loss, 
once excessive bleeding is recognised weighing of swabs and drapes (gravimetric 
methods) in addition to frequent biochemical assessment to monitor and inform 
treatment is required (RCOG, 2009; Brace et al., 2007; Stainsby et al., 2006).  
Failure to accurate record blood loss has been associated with substandard care 
identified in maternal mortality and morbidity reports (Lewis, 2007; Brace 2007). 
 
 
The collection of blood directly into receptacles was also advocated, but was only 
achievable when women gave birth in a static supine position (Newton et al., 
1961). Other gravimetric techniques, such as drape estimation and the use of 
calibrated and non-calibrated plastic collector bags are alternative measurement 
approaches, which demonstrate greater accuracy. However, to date, these have 
 97 
failed to be widely adopted (Patel et al., 2006b; Alexander et al., 2005) outside 
the domain of operative birth  (Stafford et al., 2008). This may be due to 
criticism that these tools fail to discriminate between blood and other body fluids 
and inhibit maternal mobility during labour (Alexander et al., 2005). Furthermore, 
some have suggested that the specific construction materials used, and the 
presence of clots, may affect the accuracy of blood loss measurement with these 
tools (Patel, 2006a).  
 
 
Photometric methods and radioactive chromium-tagged red blood cell techniques 
have long been advocated as more accurately assessing blood loss (Chua et al., 
1998; Gahres et al., 1962). Unfortunately, these are not practical in the clinical 
situation, due to the time taken causing treatment delay in addition to cost 
constraints. There are also limitations to comparing antenatal and postnatal 
haematocrit, which additionally has been shown to correlate poorly with visual 
estimation of blood loss. When blood loss is normal (<500 ml) haematocrit levels 
commonly remain unchanged, or even elevated (Gharoro and Enabudoso, 2009), 
thus rendering this clinically unusable for several reasons. 
 
 
2.2.6.1 Strategies to improve estimation of lost blood 
volume  
Staff training in obstetric emergencies, including PPH has been strongly 
advocated (Crofts et al., 2007). The Confidential Enquiry into Maternal and Child 
Deaths and the Confidential Enquiry into Stillbirths and Deaths in Infancy have 
long recommended training drills to reduce substandard care and enhance staff 
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confidence  (Lewis and Drife, 1998; Lewis 2003). Additionally, the Clinical 
Negligence Scheme for Trusts (CNST) insists that ‘all relevant staff annually 
participate in skills drills’ training to qualify for Level 2 status (Clinical Negligence 
Scheme for Trusts, 2003), further confirming the belief that skills and drills 
training is an essential requirement to reduce morbidity and develop and 
maintain staff competence.  However evidence exists that, whilst some training 
courses are effective at increasing staff knowledge, there is no resultant 
improvement in patient care  (Black and Brocklehurst, 2003).  
 
 
Clinical reconstructions, implementation of guidelines and staff education have 
been promoted to improve visual estimation of blood loss and prompt recognition 
of excessive bleeding (Bose et al., 2006; Rizvi et al., 2004). Practical simulations 
(drills and skills) have been shown to be more effective in increasing and 
retaining knowledge than didactic lectures or a combination of lectures and 
practical sessions (Buckland and Homer, 2007). Potentially because simulation-
based learning exposes learners to events, in a safe, controlled environment. This 
is consistent with the constructivist learning principles that promote retention, 
understanding and active use of skills (Lathrop et al., 2007).  
 
 
The pivotal role of effective teamwork, and resultant importance of 
multidisciplinary training in obstetric emergencies is acknowledged  (Neilsen et al., 
2007). Additionally the reflective techniques widely used in midwifery and 
medical education maximise the effect of this type of learning but, with reflexivity 
being an integral part of simulation-based learning post training support must be 




Common errors occur repeatedly around obstetric emergencies, in PPH these are 
identified as: 1) failure to transfer bleeding patients to operating theatres, 2) 
unfamiliarity with drug regimes to correct uterine atony, and 3) poor 
cardiopulmonary resuscitation techniques (Maslovitz et al., 2007). This seems to 
reiterate the importance of promptly recognising excessive bleeding, dealing with 
it in an appropriate setting and being confident and competent in all aspects of 
resuscitation. Disappointingly, the evidence suggests that whilst various 
techniques to improve estimation of blood loss, and emergency training have 
emerged and been adopted, the outcomes of PPH remain unchanged (Bose et al., 
2006; Black and Brocklehurst, 2003). It has been reported that where awareness 
of PPH is high and consequent training and management standardised, it is still 
difficult to correlate individual training directly with outcome (Zhang et al., 2010). 
Suggesting that improved estimation and assessment of blood loss does not 




2.2.7 The impact on those involved  
2.2.7.1 Women, birth partners and staff 
 
There is an emerging literature regarding the development of post traumatic 
stress disorder (PTSD) in those who have experienced traumatic birth events 
(Beck, 2004; Bailham and Joseph, 2003). The subjectivity of trauma perception is 
noted, as is the impact of support during such events  (Seng et al., 2001), and 
the effect on birth partners and couples who experience near miss events 
(Nicholls, 2007). The requirement for future research in this area and 
construction of diagnostic and conceptual frameworks is identified (Ayers et al., 
2008). Increased stress levels in men witnessing traumatic birth events have 
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been reported (Somers-Smith, 1999) and further corroborated by a healthcare 
professional who stated normal birth can lead to paternal depression.  This 
phenomenon is reportedly multiplied when men witness adverse events (Odent, 
2008; Schumacher et al., 2008). Whilst uncertainty exists around the 
manifestations, longevity, effects and management of this condition, there is 
unanimous agreement that women and their birth partners can experience PTSD 
following near-miss events and this adversely impacts on their health and 
confidence in parenting, with concomitant longer term health and social issues for 
the family (Gamble et al., 2000; Axe, 2000; Alexander, 1999).   
 
 
The importance of early contact and bonding between parents and child is 
acknowledged as fundamental for successful long term parenting. Parent-child 
bonding can be reduced when mothers suffer ill health around giving birth, 
subjecting the child to adverse psychological  affects throughout life (UNICEF, 
2004). Exclusive breast feeding is the optimal infant diet for the first six months 
of life  (WHO, 2009a). Initiation and establishment of lactation is more difficult 
following adverse intrapartum events, and crucially women requiring emergency 
treatment may be separated from their baby for prolonged periods in the first day 
of life further impairing the initiation of breast feeding (UNICEF, 2004). Postnatal 
low haemoglobin levels are associated with maternal symptoms of fatigue, 
fainting, dizziness (Glazener et al., 1993) slower recovery from childbirth 
(Waterstone et al., 2003) and the introduction of infant formula feed due to 
inadequate lactation (UNICEF, 2004). Babies given formula feeds in the early 
postnatal period are less likely to subsequently succeed at breast feeding (WHO, 
2009a). Consequently experiencing PPH with concomitant issues inhibits 
adaptation to life as a new, or larger, family. 
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The Care Quality Commission (formally the Health Care Commission) reported a 
high level of complaints from women and their families relating to emotional as 
well as physical suffering following PPH (Sue Eardley, RCM Conference 
presentation, Brighton, 2008).   
 
 
At the time of embarking on this work, there was a paucity of evidence regarding 
the effect on staff of dealing with obstetric emergencies, the most common of 
which is PPH, although there was growing evidence of the impact of vicarious 
trauma on other health care professionals (Jonsson and Halabi, 2006; Sluiter et 
al., 2003). Given the unique and distinct close woman-midwife relationship it is 
hypothesised that midwives may be at particular risk of suffering emotional 





2.2.7.2 Economic impact of PPH 
 
No formal evaluation of the health care resource costs have been undertaken in 
relation to PPH, potentially due to difficulties in attributing ongoing health and 
social care needs to PPH, as opposed to other aspects of childbirth.  
According to the Department of Health (DOH) website, inpatient hospital bed 
days cost £400 (www.doh.gov.uk/stats downloaded 6th May 2010); a medical 
consultation £250-400; a standard unit of packed cells £130.52, rising to  
£213.79 for platelets (www.nbt.nhs.uk/recruitment/documents downloaded 6th 
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May 2010). Other costs are difficult to acquire, but even this simple example 
shows PPH confers considerable financial burden on the NHS. 
 
 
Financial implications for the family are not inconsiderable when considering loss 
of earnings due to prolonged care requirements or delay in return to work and 
additional transport or childcare costs. It is difficult to envisage how these costs 
could be accurately assessed in a local, regional or national level, although they 






2.2.8 Management debate including prevention 
 
2.2.8.1 Evolution of the management of the third stage of 
labour  
As outlined in Chapter 1, arresting excessive bleeding following birth has been 
documented through the ages. According to the Ebers Papyrus (1500BC) the 
Ancient Egyptians used fly excrement, juniper berries, celery in milk or hemp in 
honey, to ameliorate blood loss (Nunn, 1996). They also tied weights to the 
umbilical cord and encouraged women to sneeze to expedite placenta delivery 




By the 18th century the association between haemorrhage, uterine atony, 
hypovolemic shock and maternal death was well described in a case notes of a 
leading obstetrician (Smellie, 1752).  
 
 
The original modern oxytocic drug was a fungus called ergot. There were 
epidemics of ergotism, a condition caused by eating rye bread contaminated with 
the fungus, and related to wet seasons and damp crops when the fungus 
flourished. It was noted that during these epidemics women miscarried and 
midwives therefore concluded that ergot caused uterine contractions. Adam 
Lonicer first reported the effectiveness of ergot in inducing uterine contractions in 
his herbal book published in 1582. It was more than 200 years later that the 
effects of ergot were first reported in a medical journal (Paulitsky, 1787 cited by 
Nunn, 1996). Early case reports appeared in the literature advocating the use of 
ergot to expedite labour and control postpartum bleeding (Stearns, 1808). 
However by 1822 the association of premature ergot use and fetal or neonatal 
demise were reported (Stearns, 1822) and as a result the role of ergot was 
promoted solely for treatment of PPH . By the late 19th and early 20th century 
numerous scientists were developing increasingly sophisticated products to 
enable dose titration and therefore increase safety (Hart, 1912). The first clinical 
trial of Ergotine versus breast feeding to cause uterine contractions was 
undertaken in 1932 (Moir, 1934).  
 
 
In 1953 Vincent Du Vigneaud identified the structure of oxytocin and synthesized 
the hormone, revolutionising the active management of the third stage of labour  




Early studies prospectively evaluating the benefits of components of the third 
stage of labour versus physiological or expectant management were undertaken 
in the 1980s and 1990s  advocated AMTSL as reducing blood loss and shortening 
the duration of the third stage, although resultant reduced neonatal packed cell 




Other studies investigated the impact of oxytocin and oxytocin and ergometrine 
(Mitchell and Elbourne, 1993); this RCT concluded that, whilst there was no 
difference in duration of third stage or manual removal of placenta, combined 
oxytocin and ergometrine (Syntometrine®) led to less PPH >500 ml, but was 
associated with hypertension, nausea and vomiting.  
A Cochrane review in 2000 stated conclusively that AMTSL was associated with 
less blood loss and fewer postpartum complications than physiological 
management, however the prophylactic uterotonics varied and therefore no 




 A later prospective study in Japan suggested that intramuscular oxytocin caused 
less mean blood loss than intramuscular ergometrine, and halved the risk of PPH 
≥500 ml (Saito et al., 2007). Women were allocated temporally to treatment 
allocation, which would appear less rigorous than randomization and indeed there 
were disproportionate numbers in each arm. Additionally blood loss was only 
assessed up to 12 hours post delivery, thus not conforming to the WHO definition 
of PPH, which includes all blood loss in the first 24 hours following birth (WHO, 
1989).  
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Other components of the package of interventions constituting active 
management of the third stage of labour have been previously outlined in 
Chapter 1, and discussed in Management of the third stage earlier in this chapter 
(p73). Following review of an historical medical textbook series Aflaifel and Weeks 
(2012) developed a timeline of the evolution of medical education regarding third 




Figure 2.8: Routine management of the third stage of labour. Intramuscular IM, 
intravenous IV (Aflaifel and Weeks, 2012) 
 
 
Figure 2.8 clearly shows that the administration of uterotonic drugs has been 
consistently recommended, but controlled cord traction and early cord clamping 
are relatively new innovations.  
 
 
Despite PPH being long identified as problematic and the discovery of medicines 
and evolution of care, much uncertainty exists around the impact of individual 
components and it is widely acknowledged that many women receive “piecemeal” 
management of varying quality.  
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2.2.8.1 Identification of those at risk 
 
Despite many identified associated risk factors PPH is frequently an unexpected 
event (Walfish et al., 2009). Conversely positive risk assessment does not always 
correctly predict haemorrhage (Devine and Wright, 2009). Despite this 
unpredictability many protocols state that women with identified risk factors 
should be aware of the potential for PPH and an appropriate care pathway be 
designed and adjusted in response to the emergence of risk factors (Arulkumaran 






The introduction of guidelines and protocols is advocated as essential to 
standardise and improve patient care. Standardisation of definitions used in 
obstetrics has been recommended (Thevakumar et al., 2008) and minimum 
standards of care have been created (Whittle, 2007). The value of clinical care 
guidelines have been outlined and developed in various aspects of pregnancy 
related care (NICE, 2008a; NICE, 2007; RCOG, 2004; RCOG, 2002) including the 
intrapartum period (RCOG, 2009; NICE 2008b; NICE, 2007). Early midwifery 
textbooks commonly advocated categorisation of blood loss was reported 
(minimal, average/moderate or large) (Neeson and May, 1986; Myles, 1985). 
Subsequently the value of quantified volumes was acknowledged (Luegenbiehl et 
al., 1990) but despite several attempts standardisation, or reproducible, accurate 
assessment, has not yet been achieved  (McConnell et al., 2007; Kodkany and 
Derman, 2006; Kavle et al., 2006).  
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In accordance with guidelines (Arulkumaran et al., 2009) maternity services have 
protocols for the prevention and management of PPH. Approaches introduced to 
standardise care include guidelines implementation (RCOG, 2009) and evidence 
based multi-methods training packages incorporated into mandatory training for 
all clinical staff (Johanson et al., 2002).  
 
 
Increased awareness of PPH in developed countries has reportedly resulted in 
routine approaches to care (WHO, 2006b; ACOG). Despite this, and the 
implementation of evidence based protocols for the prevention and treatment of 
PPH, there remains lack of consensus and local, regional and national variations 
in practice (Knight et al., 2009; Winter et al., 2007 Cameron et al., 2007; Mousa 
and Alfirevic, 2002).  
 
 
The evidence base for some practices incorporated into guidelines appears 
unclear. For example, a Cochrane review concluded that whilst uterine massage 
reduced blood loss after placental delivery, the value of sustained uterine 
massage, with and without uterotonics, could not be assessed (Hofmeyr et al., 
2008). Conversely, there is good quality evidence that active management of the 
third stage of labour reduces blood loss, but most units have protocols for 
physiological management of the third stage (Prendiville et al., 2000), 
Additionally there is variation regarding components of active management, 
particularly around the uterotonic of choice, timing of uterotonic administration 
(with birth of the anterior shoulder/following expulsion of the child), timing of 
cord clamping and inclusion of placental drainage. This variation was highlighted 
in a European wide study and is summarised in Table 2.5 (Winter et al., 2007). 
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Table 2.5: Policies for the management of the third stage of labour following 
vaginal birth in maternity units from 14 countries  
(Winter et al., 2007 p 848)  
 
*some units had more than one ‘usual’ policy or had a policy of cutting the cord ‘at another time’ 
**Usually cut the cord immediately after birth or after the cord stops pulsating, perform 




The WHO recommend all women are offered oxytocin 10 IU either IM or IV as the 
uterotonic of choice, in preference to ergot alkaloids or misoprostol because of 
lower associated adverse reactions (Gulmezoglu and Souza, 2009). UK guidelines 
concur with the use of oxytocin but the dose (5 to 10 IU) and administration 
route are variable (IM, IV, bolus, slow infusion) and other uterotonics are not 
excluded (Arulkumaran et al., 2009; NICE, 2007). 
 
Therefore whilst active management of the third stage is advocated to reduce 
blood loss following childbirth (NICE, 2007; WHO, 1990; Prendiville et al., 1988; 
Rogers et al., 1988), the individual contribution of each component and variation 
of components remains debated (Winter et al., 2007). 
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2.2.8.3 Treatment of PPH 
In principle strategies for the management of PPH remain consistent (RCOG, 
2009; NICE, 2007): Immediate treatment– summoning help, uterine massage 
and IV fluids. The choice of crystalloid or colloid remains contentious (Wise and 
Clark, 2008) but rapid hydration is essential to maintain maternal circulation. 
Support refers to allocating a team member to maintain constant communication 
and support for the woman and her partner throughout the event (NICE, 2007). 
 
 
Available treatments include: uterotonic options- repeat oxytocin (IV), 
ergometrine (IM or IV cautiously), or Ergometrine Maleate/Oxytocin 
(Syntometrine®) (IM). Oxytocin infusion (Syntocinon®), Carboprost (IM) and 
Misoprostol® (per rectum) (Arulkumaran et al., 2009). Misoprostol is advocated 
sublingually in resource poor settings, where other uterotonics may not be 
available  (Vaid et al., 2009) but is not licensed for this indication in the UK and 
therefore may only be given in accordance with local protocol (NICE, 2007).  
 
 
Additional less widely used treatments include Tranexamic acid® (IV) which has 
been identified as potentially effective in arresting bleeding in trauma patients, 
but requires further validation in PPH (The CRASH-2 Trial Collaborators, 2006). 
Haematologists may advise and administer other treatments such as recombinant 




Mechanical interventions for the immediate treatment of PPH have been long 
advocated (Myles, 1985). These include uterine massage, urinary catheterisation 
and bimanual compression of the uterus. Wide variation in policies for each of 
these exist across Europe (Winter et al., 2007). Uterine massage is widely 
advocated. Urinary catheterisation policies exist as an immediate response to PPH 
in 80% of maternity units in Austria, France, Hungary, Ireland, the Netherlands 
and the UK, but only 39% of Danish maternity services and 27% of those in 
Finland.  Policies exist regarding implementation of bimanual compression of the 
uterus to treat PPH in 34-68% of maternity services in EU countries, the 
exception being the Netherlands (15%) and Italy (21%). Bimanual compression 
is viewed as effective and easily taught with evidence of knowledge retention in 
developed and developing countries (Andratta et al., 2011). Consequently 
bimanual compression of the uterus saves lives. The operator places one hand in 
the uterus and the other on the fundus, compressing it against the hand in the 




Figure 2.9: Bimanual compression 
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Surgical treatments include repair of genital tract trauma, compression sutures, 
brace sutures, balloon tamponade, uterine packing and interventional radiology.  
The NICE guidelines concluded there is insufficient evidence to recommend any 
particular uterotonic or surgical procedure (NICE, 2007).  
The United Kingdom Obstetric Surveillance System (UKOSS) studied the 
management of severe PPH resulting in peripartum haemorrhage, and reported 
wide variation in treatment strategies, such as brace sutures, rFactor VIIa 
therapy and intra arterial embolism, prior to these procedures (Knight, 2007; 
Vais and Bewley, 2006). This provides further evidence of the non-uniform 
approach to treating PPH and the potentially premature resort to hysterectomy 
with inherent morbidity. Additionally, a European consortium investigating 
prevention and immediate management of PPH reported wide variation in 





In summary, what is known includes:  
 PPH is common and remains a major cause of mortality and morbidity 
despite being easily treatable with available resources. 
 The incidence appears to be rising.  
 The ‘true” incidence remains unknown, due to inconsistences in data 
collection, coding and definition variation. 
 Severe maternal morbidity reports are useful adjuncts to mortality reports 
to identify and reduce substandard care in countries where maternal 
deaths are rare. 
 There are many strategies available and widely utilised to treat PPH, 
although the effectiveness of these is variably reported. 
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 PPH has a major impact on women and their families. 
 
Despite being the focus of many studies and reports, uncertainty and gaps in 
knowledge exist. These include:  
 Why, with the availability of multiple resources to treat PPH does it remain 
a major cause of maternal morbidity and mortality?  
 Why have there been several reports of increased incidence of PPH? 
 Are existing known risk factors relevant to a contemporaneous population?  
 Are novel risk factors responsible for the increasing rates of PPH? 
 Would incidence be more accurately recorded and both exemplars in 
practice and substandard care be identified and addressed with the 
introduction of an audit system, as apparent in Scotland? 
 Despite longstanding and more recently discovered medical, surgical and 
radiological techniques, which are all readily available, why is PPH, 
increasing in resource rich countries? 
 
 
PPH is preventable and treatable, but unlike some other medical emergencies, 
such as cardiac arrest, management tends to be variable and success difficult to 
assess. A situation further compounded by the varying definitions, policies and 
practices employed regionally, nationally and globally. Risk factors for PPH have 
been identified and yet it remains unpredictable and common even in resource 
rich countries. The impact on women and their families is considerable, and not 
entirely understood. Additionally there are financial and resource implications for 
the NHS, which given the increasing reported incidence, are not inconsiderable, 
and need addressing urgently. This rise is despite the implementation of risk 
management strategies and CNST training requirements leading to mandatory 
updates for staff.  
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The true picture in England and Wales is unclear, as there is no national or 
regional reporting mechanism. UKOSS only collects data on rare events due to its 
methodology and resources available. Thus it can only examine most serious 
morbidities, which are by definition rare in the UK. The Scottish Confidential Audit 
into Maternal Morbidity has reported year on year increases in the incidence of 
PPH, with a corresponding year on year reduction in substandard care, despite 
the absence of any additional training programmes (Lennox and Marr, 2010). This 
confirms the value of audit at identifying both good and bad practice in order to 
promote better care and rectify substandard care. In addition the use of PPH as a 




2.2.10 Research question 
 
The overarching research goal of this study is to contribute to the improvement in 
the prediction, prevention, identification and treatment of PPH. The research 
approach included mixed methodology, focused on gaining insight into this 
complex clinical problem through quantitative analysis of blood loss and 
management of the situation in an inner London teaching hospital and a suburban 
district general hospital in England.  
 
 
The research question addressed in this thesis is: What is the incidence of PPH in 
a contemporaneous UK population, is there any improvement in blood loss 
assessment, and can statistical modelling be employed to predict blood loss at 
different thresholds?   
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2.2.10.1 Aims and objectives of this research  
 
Aim: to inform the evidence base to improve the prediction and prevention of 
PPH.  
Objectives employed to achieve this: 
 
Objectives:  
1. Devise an effective data collection system to facilitate contemporaneous 
data retrieval which will not incur additional work for clinical staff 
2. To ascertain the current incidence of blood loss, at various levels, in 2 
maternity care service providers in England. 
3. To compare current PPH rates with historical data for the same maternity 
services. 
4. To identify the contemporaneous risk factors for PPH ≥500ml 
5. To identify contemporaneous risk factors for progression to PPH ≥1000 ml 
and ≥1500 ml).  
 
A methodology was developed to address these omissions in the literature, in an 
attempt to quantify the incidence of PPH and identify risk factors in a 
contemporaneous population. This methodology and the rationale for component 
parts are described in Chapter 3. 
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Chapter 3: Methodology 
3.1 Introduction 
The need for high quality evidence to inform policy makers, health care providers, 
clinicians and users is undisputed (Tunis et al., 2003) 
 
 
Research is a systematic and rigorous investigative process that describes 
phenomena as well as developing and testing concepts and theories, with the 
ultimate ambition of adding to scientific knowledge (Bowling, 2009). 
 
 
In any health related investigation the ultimate aim of research is to improve 
health outcomes and health care provision. Employing the most appropriate 
research methodology is integral to ensuring rigour in the work undertaken 
(Cresswell, 2002).  
 
 
Whilst randomised controlled trials (RCTs) are often considered the ‘gold standard’ 
research methodology, they are not appropriate for all investigations. RCTs 
reliably determine treatment effects when the design and conduct of the trial 
minimise potential sources of bias (internal validity), whilst being appropriate and 
relevant for a defined group of patients and therefore generalisable  (external 
validity) (Rothwell, 2005).   
 
 
Whilst a treatment effect is commonly investigated in a controlled trial, some 
research questions are better addressed using alternative methodologies.  For 
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example, when there is no intervention, and the researcher observes the 
prevalence, incidence, cause or prognosis, or undertakes a cross-sectional, case 
control or cohort study, often collectively referred to as “observational studies”, 
(Mann, 2003).  
 
 
Cross-sectional studies determine the number of cases in a population at one 
point in time (Bowling, 2009).  They are effective at determining prevalence for 
single or multiple outcomes. Due to the single time point for data collection, they 
are quicker to complete than other research methodologies, and therefore incur 
less cost. However, they do not differentiate between cause and effect, although 
they can be used to infer causation and generate future hypotheses for testing. A 
drawback is that this type of study often uses questionnaires for data collection 
and this can lead to low response rates and bias caused by differences in 
responders and non-responders (Mann, 2003). 
 
 
Case-control studies tend to be retrospective, in that participants with the 
condition of interest are selected and matched to those who do not (control 
group).  Case control studies determine the significance of predictor variables in 
relation to a condition, but due to their retrospective nature cannot be used to 
calculate risk, however, they can generate odds ratio (OR) which usually 
approximate relative risk (Bowling, 2009). Case control studies are particularly 
useful when there is a time delay from exposure and disease development and 
when investigating rare conditions, as they generate lots of information on a 
limited number of subjects. However, case control studies are subject to sampling 




Cohort studies are used to determine the incidence of a condition, either 
prospectively or retrospectively, in a particular population and one cohort can be 
compared with another (Hackshaw, 2009). Cohort studies are often undertaken 
when an RCT would be unethical, for example, withholding uterotonic medication 
for the third stage of labour, irrespective of risk of PPH.  Cohort studies identify 
potential causes prior to the outcome occurring and the effect of each variable on 
developing the outcome can be calculated. Loss to follow up can be problematic 
in prospective cohort studies, if they are conducted over many years, which can 
affect results and inferences, especially when investigating rare conditions.  
 
 
Retrospective cohort studies have the advantage that the data are collected for 
another purpose and therefore this study design minimises bias but the trade off 
is that clinical practice may have already changed compared to the time when the 
cohort study was conducted. Other disadvantages of this study design include the 
data quality of the variables and outcome of interest may be less rigorously 
collected because the cohort was formed for another purpose (Mann, 2003), and 
the inability to control for confounding variables (Bowling, 2009).  
 
 
Secondary data analyses using pre-exiting databases have the advantage of 
being convenient and enable the inclusion of large numbers of people with data 
entered prospectively and retrospectively. Thus facilitating a) the identification of 
people with and without certain conditions or outcomes for a case controlled 
study, b) a sample for cross sectional investigation and c) the construction of a 
cohort. This methodology commonly employs routinely collected data, which has 
the disadvantage of potential data entry errors and omissions, but the advantage 
of diminished bias as it is collected independently of specific hypotheses 
(Cresswell, 2002). 
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3.2 Philosophical framework for research 
  
Each branch of scientific enquiry is rooted in theoretical perspectives, known as 
paradigms. These are important because these overarching philosophical or 
ideological standpoints form a framework for generating and interpreting 
knowledge. Paradigms consist of a set of assumptions, or way of viewing the 
world, and it from these perspectives that research questions are formulated 
(Bowling, 2009). Research is not value-free, therefore it is important for 
researchers to identify and acknowledge personal theoretical perspectives and 
reflect and report these when designing studies and analysing data. 
  
The overarching philosophical or ideological framework and the investigators 
assumptions about the nature of knowledge or epistemiological standpoint inform 
the design and method of investigation used. For example, the interpretivist 
paradigm maintains that knowledge is socially constructed and therefore reality is 
subjective. In health care research this paradigm underpins qualitative research 
methodologies.  Conversely a positivist paradigm maintains that reality is 
established and knowledge can be produced through rigorous quantitative 
methodologies. Positivism assumes a single objective reality, ascertainable by the 
senses, and able to be tested in accordance with laws of scientific method 
(Bowling, 2009). In reality, this is often an artificial dichotomy with many 
research designs using mixed methods to provide complementary components of 
a research project. 
 
Investigators can undertake research from two perspectives. They can begin with 
general ideas from which theories and hypotheses are developed, which are then 
tested by collecting and analysing data, this is known as deductive reasoning. 
Conversely the researcher can start with observations from which they 
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accumulate and develop general statements and hypotheses that are tested, this 
is inductive reasoning (May, 1993). 
  
In the current study, the positivist paradigm with deductive reasoning was used. 
This was the appropriate philosophical paradigm because the aim of the study 
was to identify and investigate causal relationships between risk factors and 
postpartum blood loss. The starting point was the observed increase in PPH, seen 
both anecdotally in the participating units and reported in the literature (Wen et 
al., 2005; Ford et al., 2009; Knight et al., 2009). The general ideas from which 
the hypothesis was developed were based on the notion that better prediction of 
PPH can contribute to improved outcomes.  Data were then collected and 
analysed using multilevel modelling to ascertain which independent risk factors 
were associated with estimated blood loss, at different levels and adjust for 
confounding factors.  
 
Whilst acknowledging the potential for bias in all research methodologies, most 
readily addressed by randomised controlled trials, in the current study this was 
addressed in several wys. 1) the weighted sampling strategy described in Section 
3.4, 2) minimising the number of staff members reviewing case notes and 
entering data, and ensuring ongoing inter-user comparison, 3) independent 
review in 10% of all cases, as described in the Chapter 3 (Methods).  
 
 
3.3 Ethical framework for research 
All research within the NHS must conform to an ethical framework to ensure the 
wellbeing of participants and researchers as well as ensuring high quality data are 
obtained. The origins of this framework date back to the Nuremberg Trials (1947) 
which exposed the medical experiments carried out by doctors in Nazi Germany 
on concentration camp victims. Following this the Nuremberg Code of ethics 
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emerged outlining the ‘standards to which physicians must conform when 
carrying out experiments on human subjects’. A draft code of ethics on human 
experimentation was first published in the BMJ on 27th October 1962  (BMJ, 1962).  
 
 
A revised version was developed and accepted at a meeting of the World Medical 
Association in Helsinki, together with the edict that this would be known as the 
‘Declaration of Helsinki’ (BMJ, 1964). Although its’ roots were firmly in the 
Nuremberg Code, the initial Helsinki agreement changed ‘the consent of the 
human subject is absolutely essential’ to include provision for a ‘legal guardian’ to 
give consent in cases of ‘legal incapacity’. The other omission was the statement 
‘during the course of the experiment the human subject should be at liberty to 
bring the experiment to an end if he has reached the physical or mental state 
where continuation of the experiment seems to him to be impossible’. Which was 
replaced with ‘the investigator or investigating team should discontinue the 
research if in his or their judgement it may, if continued, be harmful to the 
individual’. The first revision (1975) was extensive and introduced the 
requirement of independent committees to review protocols to ensure the 
conduct of medical research, in addition to significant elaboration around the 
requirements for informed consent (Flanigan, 1997). Nothing was removed from 
the earlier version and considerable information was added, additionally the 
sexist language utilized in the 1964 version was updated, for example the phrase 
‘fully qualified medical man’ was changed to ‘medically qualified person’.  
 
 
Further minimal revisions took place in Venice in 1983 and Hong Kong in 1989. In 
South Africa, 1996 whilst the text changed little there was, for the first time, 
specific reference to placebos, and is fundamental to the USA Food and Drug 
Administrations referral to the 1989 version in its regulations (Temple, 2003). In 
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Edinburgh, 2000 the document was restructured. Prior to this version the 
Declaration dichotomised research into therapeutic (potentially benefitting the 
subject) and non-therapeutic (no direct benefit to the subject) the new category 
of ‘Medical Research Combined with Medical Care’ was introduced as a subset of 
‘all medical research involving human subjects’. ’Non-therapeutic’ research 
considered synonymous with ‘healthy volunteers’ was removed as a distinct 
category, and an explicit statement permitting participation of healthy volunteers 
included. This more logical categorisation has been advocated as removing 
previous ambiguity (Levine, 2000). 
 
3.3.1 Regulatory Approvals 
MHRA approval 
 
MHRA approval was not required for the current observational study as there was 
no investigative medicinal (IMP) product being tested.  
 
Ethics approval 
In the current study because information was obtained from NHS databases and 
other data sources ethical approval from the National Research Ethics Committee 
was required.  
 
 
Whilst no single framework exists to ensure ethical research (Soobrayan et al., 
2003) there are key ethical theories that are integral to all aspects of it. The 
mechanisms employed to regulate research practices are derived from utilitarian 
and deontological theories. They query what should be done to achieve the 
greatest good and to maintain obligations inherent in human interaction. 
Utilitarian theories are concerned with purposes and consequences (“teleologocal” 
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or “consequentialist” theories). Deontalogical theories can be further subdivided 
into those based on “duties” and those based on “rights” (Kimmel, 1998). 
 
Subdivisions of theory are common, Miles and Huberman (1994) identify seven 
potential frameworks but explain four- utilitarian, deontological, relational and 
ecological, each of which bring differing priorities to each part of the research 
process. For example utilitarianism prioritises informed consent, the deontological 
– reciprocity, the relational collaboration and the ecological prioritising cultural 
sensitivity (Miles and Huberman, 1994). The evolution of ethical theory within the 
operationalised principles employed today is hard to trace. Recently research into 
informed consent has demonstrated its complexity (Sin, 2005; Wiles et al., 2005). 
Others have identified further difficulties with the concept of informed consent 
especially pertaining to health, when research designs are too complex for a 
person normally considered to have capacity to give consent, to fully comprehend 




The first Research Ethics Committee (REC) was established in the UK in 1966. 
The primary function of RECs is to save guard and protect patients and the 
general public from harm caused by unethical research but also to encourage and 
promote research that improves health and healthcare (Alberti, 2000). In addition 
to reviewing clinical trials, the REC reviews other research protocols for both 
clinical and social researchers in Health, as approval is required in the majority of 
cases prior to research being undertaken involving NHS patients, staff or 
premises.    Some exceptions to this rule exist and the Health Research Authority 
has a web based tool to ascertain whether a study requires full approval 
(www.hra-decisiontools.org.uk). In accordance with the EU Directive and Clinical 
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Trials Regulations a REC must given an opinion within 60 days of receipt of a 
valid application.  
 
Research and Development (R and D) approval  
In addition to REC approval all research projects on NHS premises, or with NHS 
patients or staff need to be reviewed and approved by the Research and 
Development department in each participating centre. NHS England states that 
research and research evidence is integral to the day to day business of the NHS.  
The Department of Health invests in research to support government objectives 
for public health, health services and social care, in addition to contributing to the 
government science strategy, within the NHS, R and D ensures: 
1) Policies for health, health care and social care are based on reliable 
evidence of need and of what works best to meet those needs. 
2) Improved interventions are developed to promote health, treat ill health 
and provide social care. 
3) Information is available to those responsible for health and social care 
services on what works and does not, and on proven ways of improving 
quality, access and efficiency. 
 
Best Research for Best Health (DoH, 2006) outlined a 5 year Research and 
Development Strategy for NHS England, which included the establishment of 
phased funding that ensured by 2009 all Research and Development (R and D) 
would be funded through the National Institute for Health Research (NIHR). R and 
D Committees in each Trust have overall responsibility for the strategic direction, 
decision-making and alignment of research themes with local, regional and 
national priorities.  
R and D Directors have executive responsibility for the R and D functions, 
chairing R and D committees and reporting R and D output to the Trust Board.  
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The management of R and D within the Trusts is the responsibility of the R and D 
Directors, Assistant Director and the R and D office. R and D offices are 
responsible for ensuring the core functions of R and D are fulfilled, ensuring that 
all research is of high quality, ethically sound and of benefit to the patient.  
Functions of the R and D office include: 
o The collection and collation of essential information about all research 
within the Trust that involves Trust patients or uses Trust resources 
directly or indirectly. 
o Registers all projects on the R and D database. 
o Costs registered projects. 
o Administers Clinical Projects Peer Review Groups. 
o Ensure research governance procedures are undertaken. 
 
 
A high priority for R and D offices is to ensure researchers and potential 
researchers comprehend the research process when commencing a project. To 
facilitate this many departments offer support and advice at various stages, 
including protocol development and peer review, identification of potential 
funding opportunities, advice regarding ethical review submission, budgeting for 
the project and ongoing advice and support to enable the researcher to undertake 




3.4 Sampling strategy 
 
The design for the study presented in this thesis was carefully considered prior to 
initiation. The benefit of extracting a large volume of contemporaneous data from 
NHS electronic patient records had to be counterbalanced with the widely 
acknowledged error rates inherent in clinical data. The ideal would have been to 
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check all the electronic data against the handheld notes and other medical 
records for accuracy. However, for a study with data from more than 10,000 
women and over 12 month period, this was not feasible due to resource 




Looking at a range of approaches to deal with this it was apparent that many 
fields of biological and medical research, when the population of interest is large, 
employ a sampling strategy. There are several approaches that could be used but 
all are based on statistical probability which has its roots in the investigation of 
patterns from gaming tables using dice and cards, this theory of statistics 
underpins medical statistics as it is extrapolated to a sample of the community, or 
group of patients with a disease, to represent the population, all people in one 
area or all patients with a certain disease (Peacock and Peacock, 2011). 
 
 
Random sampling gives everyone in the target population an equal, and non-zero, 
chance of selection. Unrestricted random sampling means members of the 
population are numbered and some of them are selected using random numbers. 
Those selected are then replaced in the population prior to the next selection. 
Whilst each population member has an equal chance of selection, it is possible 
that each unit/person could be selected more than once. 
 
 
Simple random sampling refers to members of the population being numbered 
and selected as above, but those selected are not replaced in the population, thus 
all members of the population have an equal chance of selection and can only be 
selected once.  This method of sampling without replacement undermines the 
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underlying statistical assumption of independence of the sample and therefore a 
correction adjustment to the formula would be required (Blalock, 1972). Both 
these techniques would be unsuitable for the current study because the sample 
could fail to be representative of blood loss at all levels, as the random sampling 
could mean over or under representation at all or any level. 
 
 
Truly random sampling is rare as often lists are organised in alphabetical order, 
for example, therefore systematic random sampling is achieved. This fails to give 
the whole population an equal chance of inclusion, rather, the chance of selection 
is dependent on the previous unit/person selected (Bowling, 2009). A random 
sample will be representative of the population from which it is drawn because 
the characteristics of individuals are not considered when selection is made 
(Peacock and Peacock, 2013). As with random sampling this technique would not 
be useful in the current study, as it may not provide information regarding all 
levels of blood loss. 
 
 
A stratified sample is used when fixed numbers are required from particular 
sections of the population in order to balance across the sample. This method of 
sampling provides the best overall estimate where it is weighted in accordance 
with the incidence of each stratum (Pocock and Pocock, 2011). Disproportionate 
or weighted sampling is an extension of this, Adoption of a pre-specified sampling 
frame would enable contemporaneous selection of a random sample stratified 
according to blood loss at all levels but focusing on those of greatest interest i.e., 




Quota sampling is where the numbers selected for the sample are proportionate 
to the incidence in the population being investigated, for example people in a 
certain age range. This sampling is commonly used in market research. It has the 
disadvantage that those included may differ from those not selected (Peacock and 
Peacock, 2011). This would not be appropriate for the current study as the 
majority of women would have lower levels of blood loss and therefore the 
sample would provide more information about lesser blood loss.  
 
 
Cluster sampling involves selected those who naturally fall into groups, however 
this sampling strategy is less precise than random sampling and therefore 
corrections need to be made later in the analyses (the standard error is likely to 
be higher) (Bowling, 2009). Similarly in the current study sampling could have 
been undertaken according to blood loss categories, but the proportions 






The specific approaches for data analysis in my study are further described in 
detail in Chapter 4 methods.  
 
 
Initially data were summarised to facilitate data monitoring and cleaning to 
ensure the accuracy of recorded data. Descriptive statistics were used to provide 
information about the sample, facilitating identification of the group and 
comparison with the general population from which it was drawn, but also to 
assess generalisability with other communities (Peacock and Peacock, 2011). 
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Additionally these basic statistics provided the foundation upon which further 
analytical processes could be produced.  
 
Continuous variables, such as blood loss and birthweight, were classified in 
groups to ease handling and reporting, for example: PPH > 500 ml; 500-999 ml; 
1000-1499 ml; ≥ 1500 ml. This avoids the problems of excluded data and loss of 
statistical power caused by dichotomizing data, that is putting all data into 2 
categories. Placing, for example, PPH or no PPH, or birthweight <4 kg or ≥ 4kg. 
 
 
Continuous data were summarised using means (simple average of all data), 
most commonly the arithmetic mean, when the data distribution was reasonably 
symmetrical.  But when the distribution of the data was non-normal, most 
commonly with a positive skew (that is the tail on the right side of the 
distribution curve is longer) geometric mean was calculated. This involves 
replacing each value with the logarithm of its base, and using this to calculate the 
arithmetic mean. This is then back transformed, producing a mean that is in the 
same units as the original data (Peacock and Peacock, 2011). 
 
 
For all means, standard deviations were calculated, indicating the dispersion of 
the data that is the average difference between the mean and each data point. 
This was used in preference to the variance because standard deviation is in the 
same units as the mean, and is easier to interpret (Peacock and Peacock, 2011) 
 
 
Interquartile ranges were calculated for certain data points, for example the 
Index of Multiple Deprivation (IMD), which are commonly reported in this way. 
The interquartile range includes the middle 50% of values and is bounded by the 
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upper and lower quartiles. The data are ranked, as for calculating the median, 
and the lower quartile includes those values below the point at which 25% of the 
data sit. The upper quartile is similarly calculated as the data above the top 25% 
(Peacock and Peacock, 2011). 
 
 
As in any medical statistics in my study it was important to ascertain the 
independence of variables. Incorrect assignment of independence leads to wrong 
conclusions. Peacock and Peacock (2011) state the “theory of statistics” 
underpins medical statistics but the theory of probability facilitates investigation. 
Probability is the number of times an event occurs, which is estimated from a 
proportion calculated in a sample (Peacock and Peacock, 2011). Probability 




There are several versions of data distribution, for example Binomial and Poisson, 
which are appropriate when using discrete variables within limited sets of values, 
but given the nature of PPH, and number of variables used in the current study, 
would be inappropriate. Continuous probability variables were used because these 
distributions use any values within given limits. In this situation probabilities are 
determined by the area under the curve between two values. The most common 
form of continuous probability is Normal distribution, with its’ characteristic bell 
shaped curve. Variations in Normal distribution are manifold, depending on 
individual mean and standard variations, but these can be converted into a 
standard format, which has mean=0 and standard deviation =1  (Coggan, 2009). 
As a sample size increases the sampling distribution of any estimated quantity is 
Normal in accordance with the central limit theorem (Peacock and Peacock, 2011) 
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and therefore, given the size of the current project Normal distribution was 
achieved.  
 
When undertaking statistical analyses there is always uncertainty and various 
statistical tests can be undertaken to identify and account for these. The mean of 
multiple samples produce the sampling distribution of the mean and the precision 
of the sample mean can be estimated by calculating the standard deviation from 
the mean (Bland, 2000). 
 
 
I chose to calculate confidence intervals (CI) to quantify the certainty of findings. 
Although other percentages could have been used, most commonly 95% CI are 
recommended when the sample size is large (>100). Therefore, in common with 
most other studies, a 95% CI was the margin of error around the estimate 




Another form of expressing probability is the P value, which is expressed as a 
value between 0 and 1. It is derived from a statistical test and expresses the 
weight of evidence for or against the stated null hypothesis (Bland, 2000) with 
the cut off for statistical significance commonly 0.05 (5%). However p values are 
less informative than 95% confidence intervals and are given as an addition 
rather than the main route to determine how important study results are.  
 
 
Univariate analysis, looking at the impact of each single variable on the outcome 
variable, for example body mass index (BMI) on PPH, would initially be 
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undertaken to refute or identify variables associated with the outcome variable of 
interest.  
 
Due to the large number of variables being assessed some would advocate the 
use of a statistical correction for multiple comparisons, such as Bonferroni 
(Peacock and Peacock, 2011). However others have suggested use of such 
adjustment is not appropriate in epidemiological studies and clinical trials as this 
leads to over adjustment because of the assumption that all null hypotheses are 
simultaneously true, which is rarely the case. Additionally using such an 
adjustment involves undertaking numerous tests, therefore interpretation of the 
findings can be influenced by the number of tests performed, increasing the 
likelihood of a type II statistical error (where important differences are rendered 
non-significant) (Perneger, 1998). Following statistical consultation it was decided 
not to make such an adjustment in the current study because of the multiple 




Multiple regression analysis would be undertaken, should the associations seen in 
simple linear regression reveal inconsistent results. This was anticipated in light 




3.6 Clinical Study Regulations in Europe 
3.6.1 EU Directive and GCP 
When planning my study the myriad of regulation relating to clinical studies were 
considered and appropriate approvals obtained, specific details are described in 
Chapter 4. The complexity of regulatory framework for human research is 
detailed below. 
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In May 2004 The European Clinical Trial Directive 2001/20/EC for clinical trials 
was adopted across EU Member States (Directive 2001/20/EC, 2001). These 
regulations relate to the implementation of Good Clinical Practice (GCP), in the 
conduct of clinical trials of investigational medicinal products (IMPs). GCP was 
developed by the regulatory authorities in Europe, USA and Japan at the 
International Conference of Harmonisation in 1997, but was not embedded in law 
until The Medicines for Human Use (Clinical Trials) Regulations 2004 (Medicines 
for Human Use (Clinical Trials) Regulations, 2004). The main principle of GCP is 
that ‘the rights, safety and wellbeing of trial participants are of paramount 
importance and should prevail over the interests of society’. Anyone designing or 
conducting a clinical trial employing an IMP must comply with these regulations.  
 
 
The Medicines and Healthcare Regulatory Agency (MHRA) provide guidance as to 
what constitutes an IMP (MHRA, 2007). Whilst investigations not involving an IMP 
are exempt from these regulations, the expectations of stakeholders is that all 
trials will be conducted to the same robust standard, thus ensuring patient safety 
and scientific credibility in all trials (Bollapragarda et al., 2007). All personnel 
involved with clinical research therefore need to be trained in GCP, in addition to 
being relevantly qualified (UKCRN, 2007). 
 
 
3.6.2 Data Protection Act (1998) 
The UK Data Protection Act 1998 exists to protect the privacy and confidentiality 
of individuals, including those accessing health and social care and the principles 




Table 3.1: Principles of the Data protection Act, 1998 
 
 
It is the law around obtaining, storing and anonymising personal data, but has 
caused confusion in its’ interpretation and implementation (Metcalfe et al., 2008). 
The Data Protection Act defines and limits patient identifiable data (Data 
Protection Act, 1998). Patient identifiable data is defined as all personal 
information from which a person can be directly or indirectly identified, for 
example name and postcode. It also includes encrypted data, if the solution for 
decryption remains in use, for example hospital or NHS number. Whilst many 
authorities recommend informed consent is obtained for all participants, whether 
it involves direct contact or access to medical records, this is not an obligation 
under the law and the Data Protection Act envisages circumstances when 
personal health records may be accessed and used in medical research without 
consent or complete anonymisation (Falconer, 2000). It has been suggested that 
 1. Personal data shall be processed fairly and lawfully. 
  
 2. Personal data shall be obtained only for one or more specified and lawful purposes, and shall not 
be further processed in any manner incompatible with that purpose or those purposes.    
 
 3. Personal data shall be adequate, relevant and not excessive in relation to the purpose or purposes 
for which they are processed. 
 
 4. Personal data shall be accurate and, where necessary, kept up to date.    
 
 5. Personal data processed for any purpose or purposes shall not be kept for longer than is necessary 
for that purpose or those purposes. 
 
 6. Personal data shall be processed in accordance with the rights of data subjects under this Act. 
 
 7. Appropriate technical and organisational measures shall be taken against unauthorised or unlawful 
processing of personal data and against accidental loss or destruction of, or damage to, personal 
data. 
 
   8. Personal data shall not be transferred to a country or territory outside the European Economic 
Area unless that country or territory ensures an adequate level of protection for the rights and 
freedoms of data subjects in relation to the processing of personal data. 
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NHS data controllers have been over-zealous in their interpretation of the Data 
Protection Act, namely ignoring Section 33, which permits the further processing 
of previously collected personal data for research purposes (Data Protection Act 
1998; Iveson et al., 2006; Walley, 2006). Further confusion has arisen due to 
misinterpretation of the common law of confidentiality, established in case law, 
and therefore is open to interpretation, states that patient identifiable data should 
not be disclosed to third parties, regardless of compliance with the Data 
Protection Act. This contradicts section 60 of the Health and Social Care Act 2001, 
which states that collection of patient identifiable data without patient consent is 
lawful, despite the duty of confidentiality (Department of Health, 2003). 
Additionally the Human Rights Act 1998 assumes compliance with the Data 
Protection Act and the common law duty of confidentiality, in Article 8 (1) it 
states ‘Everyone has the right to respect for his private and family life, his home 
and his correspondence’ and that ‘the protection of personal data, not least 
medical data, is of fundamental importance to a person’s enjoyment of his or her 






3.6.3 Caldicott Guardianship 
Although informed consent was not required for the aspect of the STOP study 
covered in my thesis, confidentiality had to be ensured, as it is integral to the 
relationship between patients, healthcare providers and researchers. In 1997 the 
Chief Medical Officer for England, in response to concerns about patient 
confidentiality in light of widespread information technology, commissioned a 
review of data handling and the development of principles to underpin the 
approach of NHS Organisations when protecting and using patient identifiable 
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data. This Committee, chaired by Dame Fiona Caldicott, cited six principles (Gill, 
1997): 
1. Justify the purposes) for using patient identifiable information 
2. Only use patient identifiable information when absolutely necessary 
3. Use the minimum identifiable data required 
4. Access to patient identifiable data should be on a strict need-to-know 
basis. 
5. Everyone must understand their responsibilities regarding patient 
identifiable information 
6. Understand and comply with the law regarding patient identifiable 
information.  
 
In the current study all data collected had minimal identifiers, achieved with a 
link-anonymised system that generated a unique study identification number (ID) 
this ensured compliance with the Caldicott principles and good clinical practice 
(GCP). Demographic information, date of birth and maternal initials, were 
collected to enable the researcher to identify all medical records and facilitate 
communication with participants (for the qualitative aspect of the larger STOP 
study). These data were stored separately from clinical data.  
 
 
3.6.4.Electronic data collection and ECRIN guidance  
Since my study was extracting electronic patient records from NHS systems and 
storing information on an Internet database it was important to review the 
literature and guidance surrounding the use of electronic data capture and 
storage.  Electronic data collection (EDC) has been advocated as effective for 
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recording research and clinical data, and its introduction and evolution has been 
expedited by technological developments in recent years.  
 
 
EDC was first introduced in clinical trials in the 1970s, when the Institute for 
Biological Research and Development (IBRD) provided study specific computers 
for direct data entry by members of a clinical collaboration onto the IBRD 
mainframe. Data were cleaned and reports provided for Abbott Pharmaceuticals. 
These early systems used “thick-client” software, necessitating a modem and 
periodic transmission of information through analogue telephone lines, which was 
slow and the delay between data receipt and query generation apparent. Study 
specific computers were installed in clinical areas, coupled with cumbersome 
programming and slow speed machines initial trials employing these methods 
were unpopular with clinicians (Handelsman, 2010).  
 
 
In the 1990s accessibility of the internet, combined with the development of high 
speed machines and secure servers meant that EDC became a reliable form of 
gathering contemporaneous accurate information, with many web-based software 
solutions available, both in customised and “off the shelf” formats.  
 
 
Electronic patient records have been widely introduced in all aspects of clinical 
health provision (Bewley et al, 2010; Mutic et al, 2010; Raynor, 2010) and have 
been cited as improving care (Scopelliti, 2010). The introduction of electronic 
patient records is widely advocated (Protti, 2007) with slow progress attributed to 
political and contractual issues (Robertson et al, 2010).  
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Whilst the term ‘electronic data management system’ has been broadly used to 
describe a variety of systems, from stand alone data entry ports to complex 
programmes underpinning international multicentre studies, these have long 
been advocated for clinical trials (Litchfield et al., 2005; Kush et al., 2003; Kiuchi 
and Kaihara, 1997; McFadden et al., 1995).  
 
 
Combining clinical and research records within compatible electronic databases 
could further improve the overall quality of data and care. Organisations such as 
the Clinical Data Interchange Standards Consortium (CDISC) and Health Level 
Seven (HL7) exist to ensure quality whilst pursuing interoperability of such 
systems (de Montjoie, 2009; HL7 International, 2010). 
 
 
The proportion of trials fully utilising EDC is unclear. A survey of practice 
regarding data management for 947 Canadian studies (2006- 2007) concluded 
that 41% relied on internet data collection, and these were more likely to be 
industry rather than academically funded studies. Overall the sophistication of the 
systems used was similar regardless of funding source, but the sample size 
tended to be larger in the industry funded studies (El Emam et al., 2009). 
 
 
The European Clinical Research Infrastructure Network (ECRIN) established in 
2004 to connect academic clinical research throughout Europe. Whilst identifying 
fundamental differences and discrepancies between regions, their 2007 survey 
found that of those trials using EDC systems 48% were commercially available 
and 38% employed proprietary systems. Additionally some centres used open 
source solutions, for example “Open Clinica”, but these tended to be small studies 
(ECRIN, 2007).  ECRIN have also devised a list of requirements to ensure data 
management meets GCP standards, these are shown in Table 3.2.  
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Table 3.2: ECRIN requirements for GCP compliance with regard to EDC 
 
 Summary EDC requirements for GCP 
1 Software must be validated 
2 Restricted access 
3 Audit trail to data 
4 Traceability- changes to data recorded 
5 Written instructions for GCP compliance 
6 Check of data quality 
7 Encryption of ID 
8 Automatic back up of data 





In the US the Food and Drug Administration (FDA) issued regulations regarding 
electronic signatures and records in 1997 (21 CFR 11) followed in 1999 by further 
regulations regarding computerised systems to create, modify, maintain, archive 
retrieve or transmit clinical data (Department of Health and Human Services, 
1997; FDA, 1999). The aim of these regulations was to ensure the integrity of 
data from computerized systems. Further guidance regarding electronic 
signatures and software validations were issued in 2001 and 2002 (Food and 
Drug (FDA, 2001; FDA, 2002). 
 
 
Traditional methods of data collection have been associated with delays in data 
review and transcription errors (Mitchel et al., 2003). The Maternal and Fetal 
Research Unit have employed electronic data management for several single and 
multicentre clinical trials (Poston et al., 2006; Baker et al., 2009) and have a 
partnership with a commercial company who specialise in developing web based 
solutions for clinical trials and registers (MedSciNetAB). Discussions with their 
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representative and the Information Technologists for participating Trusts 
importation form NHS databases onto a secure Internet platform appeared 
technically possible. Confirmation that the MedSciNetAB system adhered to FDA 
regulations as well as the Data Protection Act, Caldicott Guardianship and ECRIN 





3.7.1 The Protocol 
This is a document containing a full description of the background, aims, 
objectives and methods of a clinical trial, including dissemination of findings. The 
protocol is an essential document for Research and Ethics Committee (REC) and 
local Research and Development (R and D) approval prior to starting the study. 
Regulations dictate that adherence to the protocol is mandatory when 
undertaking a clinical trial, this is especially the case when undertaking an 
interventional study, but GCP dictates adherence to a protocol is the accepted 
standard for clinical research. Therefore in the current study the protocol was 
developed and all study processes were followed. The STOP study protocol, which 
includes the work presented in this thesis is shown in Appendix 1. Variations to 
the protocol need to be notified to the sponsor, the MHRA (in trials using an IMP) 
the REC and R and D department at all participating sites.  
 
 
3.7.2 The Sponsor 
The Sponsor is defined as an individual, company, institution or organisation 
which takes responsibility for the initiation, management and/or financing of a 
clinical trial (Clinical trials tool kit, 2007). In an industry funded study the 
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Sponsor is invariably a drug company, but for studies funded by public bodies or 
charities often the employer of the Chief Investigator will be the Sponsor. Since 
the EU Directive 2004 it has been illegal to commence as study without 





 3.8 Summary 
 
Despite randomised controlled trials being advocated as the “gold standard” for 
clinical research, due to its capacity to compare an intervention with no 
intervention, or placebo with random allocation and controlling for confounding 
variables, it would not be appropriate for the current investigation. It would not 
be ethical to assign women to no treatment, given the evidence of reported 
effectiveness of active management of the third stage of labour.  
Additionally the aim of the current study was to ascertain the incidence of PPH in 
a contemporaneous population and to develop prediction models to identify those 
at risk of PPH at various levels. It was therefore appropriate to use an 
observational methodology.  
 
 
A cross sectional study would inform us of incidence at a single time point, but a 
more comprehensive view was required, therefore identifying incidence over the 
course of a year was deemed advantageous, which would take into account 
seasonal fluctuations. A case control study was considered but whilst providing 
information regarding the cases of greatest interest (largest blood loss), it would 




A cohort study was therefore the methodology of choice as it would provide 
information about the whole cohort, and comparison with the earlier cohort would 
be possible. However given the anticipated size of the cohort (around 9500 
women) resources were insufficient for scrutiny of all medical records to be 
undertaken. The weighted sampling strategy, whilst novel in medical research, is 
commonly used in epidemiology and accountancy would enable scrutiny of a 
realistic and manageable sample within the available resources of the project and 
enable observations and investigation of all levels of blood loss.  
 
 
Electronic data management facilitated importation of summary data from NHS 
databases without being burdensome for clinical staff, and with the reassurances 
of a secure system would facilitate data entry being accessible on both sites and 
all geographical areas. Previous experience with electronic data management 
further confirmed this as desirable for the current study.  
Having outlined the theories and methodologies considered prior to development 
of the current work. Chapter 4 outlines the methods employed to undertake this 
work and address the research questions posed.
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Chapter 4: Methods 
4.1 Introduction 
 
The work included in this PhD thesis was undertaken in tandem and as part of the 




4.2 The STOP study 
The STOP study was funded by the Guys and St Thomas’ Charity (registered 
charity 251983; Chief Investigator (CI) Susan Bewley; Co-Investigators Annette 
Briley, Jane Sandall and Mark Waterstone). The main goal of the study was to 
ascertain whether the prediction, prevention, identification and treatment of 
postpartum haemorrhage could be improved.  
 
 
4.2.1. My role in the STOP study 
I was the STOP study manager and co-ordinator. I was jointly responsible for 
developing the idea, preparing and submitting the funding application, developing 
the protocol, patient information sheets and consent forms (for the qualitative 
aspect of the study), obtaining regulatory approvals, database development, 
random case generation, review of the notes, discussion and decisions regarding 
ambiguous cases, facilitation of study advisory group, undertaking qualitative 
interviews with women, their birth partners and the staff involved in the 
emergency and analyses of all data.  Additional support for recruitment, and data 
collection and entry was provided as part of the main study by Mrs Henrietta 
Ballard  (research midwife).  
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Mr Paul Seed, study statistician, provided support and supervision for the main 
study analysis and for this thesis. A formal Trial Steering Committee was not 
required as STOP was an observational study, however a Study Advisory Group 
was formed to provide advice and support during the initial set up and throughout 
the duration of the study.  
 
 
The specific objectives of this PhD in relation to the STOP study are outlined in 
Table 4.1. The main study design is described below, followed by the 
methodology for the specific objectives undertaken as part of this PhD, which 

























Table 4.1: Objectives and activities for the main STOP study and those 
undertaken within this PhD. 
 




1  Investigate current guidelines regarding the management of 
PPH in different units. 

2. Devise a data collection system that facilitates 
contemporaneous data retrieval but is not onerous for 
clinical staff.  
√
3. 1) Investigate the professional, personal and team factors 
that influence the management of haemorrhage. 
2) Ascertain and examine multidisciplinary staff attitudes to 
the management of this complication. 
3) Explore the experience of haemorrhage from the 
sufferer’s perspective. This will include their views of the 
professionals’ response to the emergency and the impact on 
them and their families. 
 
 
5. Ascertain the current incidence of PPH at various levels of 
blood loss in 2 maternity service providers. 
√ 
6. Identify contemporaneous risk factors for PPH and in 2 units √ 
7. Identify risk factors for progression to moderate and severe 
PPH in 2 units 
√ 
8. Compare trends in PPH over time in 2 maternity services 
providers in addition to comparing PPH rates in these two 
Centres with a contemporaneous data set 
 
√ 
9 To compare the evidence of actions taken from maternity 
records with the protocols in 2 maternity services providers 
√ 
10. Develop a single unified protocol for the management of PPH 
in the participating Centres. 
 
11. Establish an internet-based data collection system to 
continuously monitor all haemorrhage and the quality of care 
in analysis of cases of severe haemorrhage. This will 
facilitate effective monitoring and auditing in participating 
units. 

12. If deemed appropriate establish a support group for women 





A detailed literature review identifying those at risk of PPH, trends in PPH and the 
current management and treatment of the condition enabled the establishment of 
feasible research questions.  
 
 
For the main STOP study a mixed methods approach was adopted: quantitative 
methods to achieve the precision, scientific and statistical tools required to 
answer specific questions regarding risk factors and current practice (Cresswell, 
2009); qualitative methodologies were used to facilitate in-depth exploration of 
the experience of PPH for women, their birth partners and the health care 
professionals involved in this common emergency. It was anticipated that these 
data would focus on the management of the PPH and therefore this aspect of the 
STOP study was excluded form the PhD thesis that concentrated on predication. 
 
 
This approach enabled the STOP study to provide a complete, contemporaneous 
account of PPH events including identification of the incidence, current risk factors 
for PPH and for progression from minor to major haemorrhage, it’s management 
and impact. This triangulation would also confirm the validity of the findings and 
ultimately improve the rigour of the data (Brannen, 1992). 
 
 
This thesis, whilst acknowledging the added value of the qualitative methodology, 
will focus on the quantitative aspects of the work. The interview and management 
data will be analysed and reported separately. The creation of the database, data 
collection and univariate and multivariate regression models for the prediction of 
PPH at different levels were considered a discreet project within STOP, with the 
potential to contribute to the evidence base and influence practice. 
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4.2 Site selection 
Initially the STOP study was conceived as a single Centre project to investigate 
the PPH in the unit where the idea was developed (Centre 1). However it became 
apparent that, an additional Centre was required to increase generalisability. This 
was considered essential because the initial Centre is a tertiary referral unit 
serving a high-risk inner city population; consequently PPH rates in that Centre 
may be unrepresentative of the general population. It is estimated that 30% of 
UK babies are born in large teaching hospitals (Birthchoice, 2010) 
(www.birthchoice.co.uk). Therefore a District General Hospital (DGH) would be 
desirable, both in terms of being where the majority of babies are born, but also 
potentially because it could provide a more realistic incidence of PPH. Additionally, 
staff retention and recruitment in inner city units has historically been 
problematic (RCM, 2008; Davis, 2005) with reports of increased employment 
longevity in more rural locations (www.rcm.org.uk). It was anticipated that staff 
experience and knowledge could also impact on the management of PPH and 
therefore inclusion of a district general hospital provided diversity in this area too. 
 
 
Pragmatically, involvement of a unit that was easily accessible was desirable. 
Student midwives training through a different university could provide further 
educational diversity regarding this common obstetric complication. The second 
site was additionally selected to enable comparison with a seminal study on 
severe maternal morbidity, including PPH (Waterstone et al., 2003). The second 
unit was a DGH 20 miles south of the tertiary referral unit with an annual birth 
rate of approximately 3000, with similar protocols, and similar service 
configuration to Centre 1, being a consultant led obstetric unit with an alongside 
midwife led unit. The project was presented to the Department of Obstetrics and 
Gynaecology and the Research and Development department at the Centre and 
they agreed to collaborate with us for this study. 
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4.3 Population and sample size 
The sample size was determined based on the incidence of the primary outcome, 
PPH, in the two participating Centres. The combined annual birth rate in the year 
preceding the study was 9,515 (6,540 and 2,975). With rising birth rates in both 
Centres, it was anticipated that data would be available for around 10,000 
women in the index year of 2008/2009. As the study was observational by design, 
with no single intervention or risk factor whose influence was to be assessed, a 
conventional power calculation was not undertaken (Rothman, 1990).  
Collection of a full 12 months of data (01/08/2008- 31/07/2009) was considered 
necessary to eliminate possible seasonal fluctuations and population diversity was 




4.4 Weighted sampling strategy and selection of 
notes for review 
Since review of all maternity records was not feasible within available resources, 
a random weighted sample of maternity records was selected to provide a 
representative sample set for detailed review. The prospective weighting strategy 
was calculated following discussion with the study statistician using the incidence 
of blood loss at various levels in a clinical dataset available in Centre 1 for 2000-
2005 in conjunction with regional data for PPH >1500ml from the earlier COSMO 
study (1997-1998) (Waterstone et al., 2003).  
 
 
The use of a weighted sample design, known as disproportionate stratified 
sampling, whilst novel in obstetrics, is a method commonly employed in 
epidemiological and observational studies (Korn and Graubard, 1999) and non-
clinical contexts (Malgarini, 2005). Women who had a PPH were selected on the 
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basis of blood loss category, together with a random selection of unaffected 
women, to achieve high statistical power. Standard errors were adjusted for the 
sampling strategy using the Huber-White estimator (Huber, 1967).  
 
 
This statistical methodology is well established for all types of summary and 
analysis (Kish, 1965) with suitable software widely available (Kreuter and Valliant, 
2007). The main advantage of a weighted sample is similar to that of a case-
control design: by selecting all the most interesting subjects and only a 
representative sample of the controls (as determined by a pre-specified sampling 
frame), high power is maintained whilst greatly reducing the workload.  However, 
common problems with case-control studies are avoided: data-collection is 
identical for all subjects, and re-allocation between groups is possible. 
 
 
Within one week of delivery, one in twelve women were randomly selected from 
those with imported estimated blood loss recorded on the electronic patient 
record as 25-499 ml and one in six women with recorded estimated blood loss of 
500-999 ml. All available medical records were scrutinised for these women and 
for all those who had electronically reported estimated blood loss of ≥1000 ml, no 
electronically documented blood loss or where electronically reported estimated 
blood loss was <25 ml and for all women for whom blood or blood products were 
ordered. Random selection was achieved by witnessed and recorded paired dice 
throws. Testing for any systematic bias towards any particular number validated 
the process of random selection, using fair dice.  The frequencies were 371 (for 
1), 372 (for 2), 396 (for 3), 369 (for 4), 383 (for 5), 384 (for 6) for a sample of 
the first 2275 throws; Chi-sq = 1.432, p = 0.921 (5 degrees of freedom). 
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4.5 Protocol development 
In accordance with Good Clinical Practice (GCP) (MRC, 2004a; MRC, 2004b; NIHR, 
2004) a protocol for the STOP study was developed by the investigators (Annette 
Briley, Susan Bewley, Mark Waterstone and Jane Sandall) and further refined in 
collaboration with the STOP Study Advisory Group, the aspects of the protocol to 
be used for this thesis were identified and approved.  
 
 
The final STOP study protocol (version 4) (see Appendix 1) was submitted during 
the funding application process and subsequently reviewed by the ethics 




4.6 Regulatory approvals 
4.6.1 Ethics Approval 
The National Research Ethics centralised system was used to apply for ethical 
committee review. It was anticipated that informed consent would not be 
required from participants included in the quantitative study but that consent 
would be required form women, their birth partners and the staff involved in the 
qualitative aspect of the study and not reported here. Ethical review was 
considered invaluable in terms of identifiers required to permit location of 
maternity records, and facilitation of access to medical records.   The South East 
Coast Strategic Research Ethics Committee reviewed and approved the study 




4.6.2 Research and Development (R and D) approval 
Despite data collection not directly involving contact with women, because those 
data are held within NHS systems, local R and D approval was required prior to 
commencement of the STOP study. Approval was granted at each participating 
Centre (see Appendix 2). 
 
 
4.6.3 Compliance with the Data Protection Act and 
information approvals 
All access to and processes of data storage and use adhered to the Data 
Protection Act (HMSO, 1998) and Framework of handling identifiable patient 
information (Report of the Caldicott Committee, 1997) (www.dh.gov.uk).  
Discussions with the Caldicott Guardians for King’s College London, and the two 
participating NHS Trusts, ensured imported data contained minimal identifiers to 
enable researchers to locate maternity records and obtain additional information 
to review and validate information entered electronically 
 
 
4.7 Data collection  
Prior to commencement of the study there was careful consideration for the 
methods and source of data collection to be undertaken.  The majority of 
evidence regarding PPH is based on audit of routinely collected or summary 
clinical data (Zwart, 2009) or retrospectively collected data (Callaghan et al., 
2010; Knight et al., 2009). Both approaches are associated with inherent 
limitations; it is commonly reported that routinely collected data, especially 
documented in emergency situations, are of variable formats, detail and quality. 
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Retrospectively collected data is associated with recall bias (Knight et al., 2009; 
Claudius et al., 2008). 
 
 
It was decided that contemporaneous, expedient data collection was required to 
optimise data quality, facilitating prompt identification and investigation of 
omissions and inconsistencies in the information recorded. In both Centres 
maternity records comprised of a combination of paper and electronically 
recorded data. It was therefore necessary to expediently interrogate multiple 
sources of information, from handheld maternity records to specific databases 
used within the NHS, such as Results Reporting Service (RRS, for biochemical and 
haematological results), ultrasound and radiology reports (ASTRIA™) and blood 
transfusion records (electronic and paper) in addition to the electronic summary 
data in each unit (Healthware™ and EuroKing™). 
 
 
The method used by the annual Scottish Confidential Audit of Severe Maternal 
Morbidity was considered. This is a paper based reporting system where 
predefined events are investigated locally by designated staff members in each 
participating Centre (most commonly Risk Managers). Requisite data collection 
forms are completed and sent, by post, to the Audit Management Centre in 
Aberdeen. Data are then entered onto a central database, and any 
inconsistencies or missing data queried and investigated prior to analyses. 
However, it was decided that this process was too slow and labour intensive, 
potentially prone to inputting errors and now superseded by internet based 
solutions (Feied et al., 2004).  
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The availability of internet, high speed machines and secure servers made 
electronic data capture a more attractive and reliable method of gathering 
contemporaneous accurate information.  The emergence of electronic patient 
records in all aspects of clinical health care and the potential for the sharing of 
contemporaneous and historical data to improve clinical care, providing data 
quality and consistency was assured  (Hammond et al., 2003; Boyle and 
Cunningham, 2002) also informed the study design. Electronic patient records are 
advocated in numerous countries, including England (Protti, 2007) where the 
slow progress in introduction is due to political and contractual issues, rather 
than commitment to this mode of record keeping (Robertson et al., 2010). 
Furthermore the experience of the Division of Women’s Health, Kings College 
London and King’s Health Partners of using electronic data management for all 
clinical trials since 2003 (Baker et al., 2009; Poston et al., 2006) further 




Negotiations with MedSciNetAB, a leading provider of Internet based web solutions 
for clinical registers and trials, confirmed that anonymised data importation would 
be possible from most existing system formats, including the commonly used 
maternity specific data systems employed within the NHS e.g. Healthware 
(Terranova)™ (used at Centre 1) and HSS EuroKing™ (used at Centre 2). 
Discussions with the NHS managers responsible for the information technology in 
participating Centres, confirmed that importation of clinical data with minimal 
identifiers to maintain confidentiality was possible. This involved processing the 
information through a series of filtration silos, with different levels of access, to 
maintain confidentiality and security. This approach still provided sufficient 
information for research midwives to identify the maternity notes. A secure 
 153 
internet based data management system was developed with the address 
www.medscinet.net/stop. Figure 4.2 shows the public front page was created for 






Figure 4.1: Public page of STOP study website.  
 
 
4.7.1 Database access 
Authorised users had variable degrees of access in order to maintain 
confidentiality. Each access required a user name and individual password that 
needed updating every 3 months. This enabled unit users to view and enter data 
for a single site. Global access allowed all data to be viewed and summary data to 
be extracted, and the global administrator was allowed the same access rights as 
global user, but additionally could add data options as required (for example 
conditions added to drop down boxes). All database activity was recorded in an 
 154 
audit trail. A further user status, “view all” enabled those granted this access to 
see all data but no ability to enter or edit it.  Members of the advisory group 




4.7.2 Importation of data from NHS systems 
The first level of access is “Unit User”. After entering an individual login and 
password, this allows authorised individuals to view the imported summary data 
for all women giving birth in one Centre. Separate passwords are required for 
each Centre.  
 
 
An additional password was required to view more detailed summary information 
for those women randomly selected according to the weighting strategy.  
Imported data were not entirely consistent, due to variance in routinely collected 
information in each Centre, and the format of information entered onto 
EuroKingTM and Healthware™; for example, pain relief in labour was collected in 
Centre 1 but not available for import in Centre 2. Where erroneous imported data 
were discovered, corrections were made in accordance with reviewed case notes 
and other available data. All analyses were undertaken according to re-
catagorised estimated blood loss.  
 
 
Figure 4.3 shows the mechanisms employed to import select and review 
maternity records to ascertain documented blood loss, and the processes 
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Figure 4.2: Flow diagram of note selection and review processes 
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4.8 Data variables 
 
4.8.1 Selection of data variables to be imported from NHS 
electronic patient records 
Relevant data variables were selected for importation into the research database 
are shown in Appendix 3. These were selected to 1) facilitate identification 
sufficient to enable location and review of all relevant patient notes, or 2) on the 
basis of previously reported risk factors.  
 
 
4.8.2 Selection of outcome variables to be reviewed in 
weighted sample 
Outcome variables accessed from data sources for reviewed cases were selected 
following review of the available literature and discussion with the STOP study 
advisory group. Many were identified as relevant to the changing demography of 
childbirth, and therefore potential contributors to the temporal rise in PPH (Knight 
et al., 2009; Ford et al., 2007). 
 
 
Primary outcome variables related to estimated blood loss and information 
regarding this was collected in multiple ways to maximise accuracy. However, 
only documented blood loss volumes were included, as arbitrary application of a 
specified blood loss volume, for example when lochia was recorded as “heavy”, or 
“clots” would make accurately quantifying total volume impossible, and 
potentially introduce ascertainment bias, However this policy could potentially 
mean that all volumes are underestimated. 
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It was anticipated that blood volumes lost would be both over and 
underestimated (Larsson et al., 2006; Glover, 2006). Therefore factors associated 
with estimation were selected in an attempt to investigate the true incidence of 
PPH, to ascertain frequency and scenarios for measuring blood loss and identify 
recording errors. Irrespective of documented blood loss, these factors included 
actions taken in response to PPH, date and time of documentation of PPH in 
maternity records, receiving of blood or blood products and the number of units 
given, admission to higher levels of postnatal care (high dependency unit or 
intensive care unit, due to differing facilities in participating Centres) and, 
antenatal haemoglobin (Hb) level preceding birth and postnatally. In women with 
an available antenatal Hb within 6 weeks prior to giving birth, a fall of 4 grams 
per litre (g/l) between this and the third day postnatal result, in women not in 
receipt of blood or blood products, was defined as “probably PPH”. Although 
difficult to locate evidence for, anecdotally and clinically, a fall of 2 g/l is 
commonly considered indicative of a 500 ml blood loss. We therefore estimated 4 
g/l indicated at least 1000 ml loss and therefore constituted “probably PPH”. 
Other outcome variables were selected on the basis that they may increase or 





4.8.3 Ordering of variables: determination of risk factors 
for PPH 
Variables were ordered sequentially and chronologically.  It was assumed that 
earlier events could affect those occurring later, but the reverse was not possible. 




Previously identified and de novo risk factors were assessed in three categories: 
a)  Pre-pregnancy: socio-demographic (maternal age and ethnicity); local    
deprivation (The Index of Multiple Deprivation 2007 combines a number of 
indicators, chosen to cover a range of economic, social and housing issues, 
into a single deprivation score for each small area in England.  It covers 
seven aspects of deprivation, [i) income, ii) employment, iii) health 
deprivation and disability, iv) education, skills and training v) barriers to 
housing and services, vi) crime, vii) living environment], to produce a 
single deprivation score for each small area of England. 
www.gov.uk/government/collections/english-indices-of-deprivation); 
general and medical risk factors (BMI, pre-exiting medical conditions); 
obstetric history (previous PPH, previous CS, parity). 
b) Pregnancy acquired/ developed: first antenatal appointment data 
(gestation at booking, BP, smoking status); antenatal day unit 
attendances (number and reasons); placenta praevia  (diagnosis and 
location); urinary tract infection (gestation, number and treatment); 
gestational hypertension, pre-eclampsia, polyhydramnios and anaemia; 
medications pre-birth. 
a) Birth and the third stage of labour: gestation at birth, birth weight, onset 
of labour; intrapartum (duration of ruptured membranes, Prostaglandin E2  
dinoprostane (Prostin®) use); maximum maternal temperature in labour, 
evidence of chorioamnionitis, oxytocin (Syntocinon®) use, spinal/epidural 
anaesthesia/analgesia; delivery (mode); management of third stage of 
labour; retained placenta; interval to suturing. 
 
 
A complete list of the imported data variables and outcome variables, definitions 
of categories, variables and terms, outcomes, exposures, risk factors, potential 
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confounders, effect modifiers and the diagnostic criteria selected are listed, in 
alphabetical order, in Appendix 3. 
4.8.4 Non-specified, descriptive and repeated variable 
data entry 
It was decided that to enable additional data entry on three occasions (extraction 
comments, pre-existing maternal medical conditions and pregnancy acquired 
conditions) a limited number (ECRIN, 2007) of free text boxes were necessary to 
capture additional relevant clinical information.  
 
 
Ease of abstraction of relevant data was paramount, therefore any repeated 
variables, for example antenatal admissions, were entered in chronological order, 
with the gestational age at admission recorded. For each admission duration of 
stay was not recorded, as this was considered subjective in terms of management 
and social situation, and not necessarily attributable to severity of maternal 
condition. The exception, due to association with abnormal placentation and 
prediction of postpartum haemorrhage, was admissions for antepartum 
haemorrhage (APH). However, as minor vaginal bleeds during pregnancy are 
common, the degree of bleeding was captured using a selection of drop down box 
options which included:  spotting, light, like a period, heavy/clots, 
heavy/transfusion required. Further drop down options regarding the cause of 
bleeding were: unknown, placenta abruption, placenta praevia, local genital tract, 




Drop down lists were used where appropriate to expedite data entry but also 
reduce the typographical errors, which complicate data cleaning prior to analyses. 
These included reasons for induction of labour, CS and causes of PPH.  
 
 
As documentation in emergency situations has been criticised in terms of 
accuracy of timings (Knight et al., 2009; Claudius et al., 2009; Winter et al., 
2007), it was decided to record actions undertaken in the order they were 
executed and not record the time of administration. All actions were entered via 
drop down boxes as described above.  
 
 
Blood test information pages were generated by clicking the “additional blood info” 
icon on the navigation tree, thus as many as were required could be generated, 
with no upper limit applied. The date and time of each test was entered initially 
and the results sorted into chronological sequence by the computer programme, 
thus providing an accurate time/result continuum, regardless of the order of test 
entry. This was considered important, as results are not always filed sequentially 
in medical records. 
 
 
Experience of attending clinicians has been cited as important in various reports 
(Lewis, 2007b), therefore the database was designed to capture the grade of staff 
involved in managing any PPH. Due to the observational nature of the study and 
the importance of a no-blame culture it was decided that tick boxes noting all 
personnel involved would be the most appropriate method to collect these data. 
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4.9 Database Piloting 
The process of data importation, whilst theoretically possible, had to be tested, to 
ensure regular downloads from NHS computer systems, completeness of 
imported data and the employment of appropriate, but minimal, identifiers to 
enable location of the handheld maternity notes for selected cases. Therefore 
data were imported, from one Centre, for two months (01/06/2008 to 
31/07/2008) and all processes of data review piloted. During this time the list of 
options for numerous drop down boxes were altered and increased to reflect the 
data recorded in the handheld maternity notes. The chronological ordering 
facilitated data entry, the system of identifying missing and incomplete data 
further aiding data completeness. 
 
 
4.10 Data entry processes to ensure data 
consistency and quality/data cleaning 
Each database page contained a “save draft” and “save” function, this enabled 
data to be checked, and pages commenced where certain points required 
verification, using the NHS results database for example. In the patient overview 
window pages with no information entered appeared as white, those with some 
data entered, but requiring additional information or confirmation, were yellow, 
and completed data pages appeared as green. This facilitated identification of 
missing data. Additionally an “alert” system identified missing and incomplete 
data, which could be accessed via the “alerts” tab on the database. 
 
 
Due to the limited number of people entering data the potential for erroneous 
data entry was low. Ongoing contemporaneous inter-user assessments were 
undertaken throughout the period of data collection. All ambiguous data and 
discrepancies, and 10% of all notes, were further reviewed independently (by Dr 
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Graham Tydeman, NHS Fife). Where assessment of total volume lost varied 
between researchers by >5%, the researchers undertook further review and 
discussion led to a consensus decision. Had this not been achievable, Professor 




4.11 Data analysis  
All analyses were undertaken using revised data and Stata version 11.2 (Stata 
Corp, College Station, Texas USA). Summaries, estimates and comparisons were 
calculated using proportional weighting to adjust for the sampling plan. The 
variables were analysed in sequential order grouped in 3 broad categories: a) 
pre-pregnancy, b) pregnancy acquired and c) labour, intrapartum and third stage 
management.  Throughout the results, both the number of women involved (n), 
and the number represented (nw) are shown. 
  
4.11.1 Grouping of estimated blood loss into categories: 
assessment of incidence of PPH 
Mean millilitres (ml) of blood volume loss may be less important than thresholds, 
which are triggers or prompts for actions in terms of monitoring, reporting and 
treatment. In order to calculate the incidence of PPH at various thresholds, and 
compare with other historical and contemporaneous data, imported and total 
estimated blood loss for each woman was therefore categorised as: 
i) Missing 
ii) 0- 24 ml 
iii) 25-499 ml- no PPH 
iv) 500-999 ml- minor PPH 
v) 1000-1499 ml- moderate PPH 
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vi) ≥1500 ml- severe PPH, further divided: 1500-1999 ml;  
2000-2499 ml; ≥2000 ml; ≥2500 ml  
 
 
4.11.2 Initial statistical methods 
Descriptive statistics were used to summarise the data and presented as 
proportions for estimated blood loss error rates (Chapter 6), population 
demographic characteristics, days of the week and time of delivery and blood loss 
at different thresholds (Chapter 6). Time of delivery was grouped in 3 hour 
segments (00.00- 02.59; 03.00- 05.59; 06.00-08.59; 09.00-11.59; 12.00-14.59; 
15.00-17.59; 18.00-20.59; 21.00-23.59), as this was considered discrete enough 
to identify differences that could be missed with both smaller and larger time 
frames. These also meant that staff ‘change-over’ did not occur on the cusp in 
either Centre for midwives, ancillary or medical personnel. Confidence intervals 
were included for incidence of estimated blood loss at different thresholds (as 
described above). Geometric mean and medians were calculated for estimated 
blood loss categories to investigate differences by Centre. Geometric mean was 
calculated because of the positive skew apparent in non-symmetrical data. The 
inclusion of a small number of high values means the distribution tail is longer on 
the right hand side, leading to inflation of the arithmetic mean. Geometric mean 
is calculated using log-transformed data; the arithmetic mean is then calculated 
using the created log transformed scale, which can then be back-transformed to 
give a mean in the same units as the original data (Peacock and Peacock, 2011).  
 
 
The arithmetic mean is appropriate whenever the total is an important concept, 
for example total wages bill, total cost total number of employees. The total blood 
loss across many different pregnancies carries no meaning. For a log-normal 
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distribution the geometric mean is more stable and being close to the median is a 
better representation of the typical woman's experience.  Mean estimated blood 
loss and Odds Ratios were calculated for mean change in estimated blood loss 
and PPH≥500 ml in all women and ≥1000 ml and ≥1500 ml in women who bled 




4.12. Development of regression models  
Multiple regression analyses were used to investigate the predictors of blood loss. 
Logistic regression analyses were required to investigate PPH and progression to 
severe PPH where the outcome variables are categorical (as opposed to linear) 
and therefore simple linear regression models would be inaccurate (Field, 2009).  
Logarithmic transformation of the data enables a non-linear relationship to be 
expressed in a linear way overcoming the problem of violating the assumption of 
linearity (Field, 2009). 
 
 
Three series of hierarchical regression models were developed to investigate:  
1) mean estimated blood loss, 2) estimated blood loss ≥500 ml, 3) estimated 
blood loss ≥1500 ml. Variables were included chronologically, with those failing to 
reach statistical significance at each stage dropping out of the model (see 
explanation below). Whilst it could be argued that all variables should remain, 
models work best with reduced numbers of cells and therefore inclusion of non-
significant variables would inhibit the performance of the prediction model. 
Consequently a trade off is required between inclusion of all possible variables 
and minimising the number of cells within the model to enhance the predictive 




The initial model used linear regression, with the outcome estimated total blood 
loss in ml, and undertaken using the representative sample. Secondly, logistic 
regression analysis investigating estimated blood loss ≥500 ml (all PPH) using the 
representative sample. Thirdly, logistic regression with the outcome, estimated 
blood loss ≥1500 ml, using a reduced data set comprising of those women with 
estimated blood loss ≥500 ml (all those with no PPH, EBL<500 ml were excluded 




In each case, a series of models were fitted: firstly estimating the role of 
variables in category 1 (pre-pregnancy); then category 2 (pregnancy and labour) 
adjusting for group 1; then category 3 (birth and third stage) adjusting for 
groups 1 and 2 and iteratively for all 15 subgroups. The lists were reduced in size 
at each stage by fitting new variables singly and removing non-contributory 
variables shown not be related to outcome. In this way, adjustment was made for 
potential confounders at each stage (Herman et al., 2002). 
 
 
Three variables required alternative models to be fitted to determine the most 
appropriate method of characterising them. These were: temperature, measured 
in degrees centigrade above 37, with normal characterised as 0; placenta praevia, 
characterised as anterior, posterior, major and minor, was considered as a 
potential predictor of PPH; antepartum haemorrhage, characterised as APH or 





No formal adjustment was made for multiple testing or colinearity (Perneger, 
1998; Rothman, 1990) as a single primary endpoint was not relied upon; the 
totality of the evidence from a number of related sources was considered with the 
most weight put on the most significant results. Adjustments focus on a number 
of null hypotheses being simultaneously true and interpretation relies on the 
cumulative results of multiple tests. Problems with tests have been explored in 
detail in the literature and deemed not suitable for epidemiological studies 
(Perneger, 1998). All principal conclusions were supported by a number of related 




4.13 Comparison with previous and contemporary 
datasets 
Comparison with historical data obtained 1997-1998 from the same hospital 
Trusts for the two STOP study sites (Waterstone et al., 2001) was undertaken to 
identify changes in severe PPH rates with time, using an identical definition. An 
additional comparison of major haemorrhage rates (≥2500 ml) was made 
between study data and a contemporary cohort from the 2009 Scottish Audit of 









The impact of duplication of data caused by transcribing from paper records to 
NHS summary data has not been identified previously. The current study 
facilitates error rates to be calculated for estimated blood loss and other routinely 




The investigation of known and propose variables and their relationship with 




The introduction of variables chronologically, acknowledging that earlier factors 
may influence subsequent events, but the reverse is unlikely, means that each 
variable and its association with PPH is considered in a logical sequence.  
 
 
Prior to investigating the impact of variables on blood loss, it was necessary to 















Chapter 5: Missing data, 
estimation and reporting errors 




5.1 Missing Data 
No blood loss or EBL 0-24 ml was recorded on NHS summary data (Healthware™ 
or EuroKing™) for 133 (7%) women. Two women were excluded from analyses 
because there was no mention of blood loss in maternity records. Of the 
remaining 131 women, all but two, one with blood loss 0 ml documented in 
handheld notes, and the other had documented blood loss of 20 ml, were 
recategorised into higher blood loss categories following review of handheld 
maternity notes and NHS databases. Table 5.1 shows the distribution of these 
through the categories. Of these women with no reported blood loss in maternity 






Table 5.1: Recoding for 133 women where EPR stated no imported blood loss or 
volume 0-24 ml imported after review of the maternity notes. 
 
Blood loss recorded 
in notes (ml) 
Missing 1-24 ml % of volumes 
represented 
missing 2 0 0.77% 
0-24 ml  2 0 0.77% 
25-499 ml 98 1 75.8% 
500-999 ml 19 0 14.62% 
1000-1499 ml 6 0 4.62% 
1500+ 3 2 3.85% 
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5.1.1 Waterbirths  
Water births proved difficult to classify, with acknowledged challenges of 
estimating blood loss in water (Garland and Jones, 1994). This was further 
confounded by Centre 2 where, in accordance with unit protocol, estimated blood 
loss at water birth was recorded as < 500 ml or > 500 ml. There were 101 
recorded pool births (22 at Centre 1; 79 at Centre 2).   
 
 
In 61 cases total blood loss could only be estimated within broad categories 
(<500 ml/>500 ml). These included 8 homebirths. The remainder were in 
alongside midwife led units (4 in Centre 1, 49 in Centre 2). Women were assigned 
to no PPH if EBL was documented as “normal”, “<500 ml”, or any volume <500 
ml where there was no documented subsequent blood loss. Women who had 
initial and subsequent EBL totaling >500 ml were recatagorised accordingly. (57 




5.2 Differences between imported and notes 
review of estimated blood loss according to 
category 
 
Table 5.2 shows the number of cases imported from electronic patient records 
(EPR) including 35 identified via blood transfusion services, according to category 
and recategorisation after review. Of the 4 ‘missing/<25ml’, 2 were excluded 
from analyses, due to the absence of any documented estimated blood loss data 
(1 unattended birth; 1 attended by paramedics), and two were included because 
the attending midwives had documented “no blood loss”, and it was considered 
this was as valid as any other volume estimated by attending clinicians.  
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Estimated blood loss was correctly recorded according to category 82% when EBL 
25-499 ml; 87% when EBL 500-999 ml; 94% when 1000-1400 ml; 88% when 





Table 5.2: Data imported from NHS electronic patient records, or blood 
transfusion services, according to estimated blood loss category for the selected 
weighted sample. 
 




Missing/<25 25-499 500-999 1000-
1499 
 1500+ Total 
Missing 2 98 19 6 3 128 
0-24  0 1 0 0 2 3 
25-499 0 537 12 0 3 552 
500-999 0 5 372 13 4 394 
1000-1499 0 1 5 453 22 481 


















In summary, following review of the complete maternity records (handheld ‘paper’ 
and all electronic databases) relating to each woman, recoding was required in 
>12% of the cases reviewed. Table 5.3 shows the number and % of cases 
recoded into a different blood loss category that almost four times as many 
women in the sample group were recoded up compared to the number recoded 
down. This concurs with the findings of others investigating measured blood loss, 
that whilst overestimation can occur, underestimation is more common (Larsson 
et al., 2006; Bose et al., 2006). Thus suggesting such errors are evident in both 










Frequency Percentage (%) Cumulative 
Recoded down 50 2.64 2.64 
Unchanged 1662 87.70 90.34 






5.3 Validation of reviewed data 
All randomly selected notes were reviewed independently by one of two members 
of the research team (Annette Briley/ Henrietta Ballard). Any ambiguous cases 
were discussed, and where agreement could not be reached, were reviewed 
independently by a member of the Study Advisory Group (Graham Tydeman). 
Additionally every 10th set of notes was further scrutinised by the reviewers to 
ensure inter-observer validity (Uebersax, 1989). Where there was >10% 
difference in the volumes documented, discussion between the reviewers led to 
consensus agreement of volume lost. Total number of notes discussed by 2 or 3 
researchers was 213. A sample of this process can be seen in Figure 5.1. Final 














Figure 5.1: An example of the spreadsheet indicating validation process. 
Minimal identifiers, (study ID maternal initials), estimated blood loss as imported into study specific database from NHS electronic patient records, the 
next column indicated the volume as independently assessed (GT) the next column indicated EBL as calculated following review of medical records 
(AB/HB) if the estimated blood was revised the reasons are noted, and where consensus was difficult due to documentation a range was also noted, 
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When extrapolated to the population studied, after adjustment for documented 
estimated blood loss, >95% women remained in the same estimated blood loss 
category. Table 5.3a shows the percentage of women represented for whom 
these adjustments meant estimated blood loss category changed. The prevalence 
of under reporting remained, with 4.30% coded into a higher estimated blood 











Recoded down 75 0.76 
Unchanged 9435 94.94 
Recoded up 427 4.30 




When investigating errors by Centre, Table 5.4 shows Centre 2 more accurately 
estimated lower volumes of blood loss (00-499 ml) but Centre 1 more accurately 
recorded blood loss 1000-1499 ml. For blood loss ≥ 1500 ml, error rates in both 
Centres exceeded 40%. 
 
Table 5.4: Represented sample (n) and percentage (%) requiring 




Centre 1  
n represented                 % 
Centre 2  
n represented                 % 
00-499 ml 480/4261 11.26 121/2324 5.21 
500-999 ml 302/1783 16.94 112/636 17.61 
1000-1499 ml 92/403 22.83 54/139 38.85 









5.4 Data quality and error rates 
 
Handheld paper records are legally considered to be the “gold standard”; a 
concise, accurate, legible account of all symptoms, actions and treatments are 
clearly documented by attending clinicians (NMC, 2012). But from a research 
perspective have inherent issues regarding accuracy.  Additionally summary data 
are often entered retrospectively onto NHS databases (Fawdry et al., 2011; Boyle 
and Cunningham, 2002). Due to data variance and limitation, comparison 
between paper and electronic records was limited. Table 5.5 shows the error 
rates where available, and highlights discrepancies in data collected in different 
units. Centre 2 had far fewer obligatory summary data points than Centre 1. 
Similar errors were recorded for maternal date of birth (0.21% versus 0.19%). 
Maternal age had an error rate in Centre 1 (0.46%), but not in Centre 2; 
investigation revealed this was due to the system used in Centre 1 not 
automatically updating age following birthdays. There were no errors in baby’s 
date of birth, however time of birth had an error rate of 0.2%-0.3%. Most 
commonly these were due to errors in recording the 24hour clock. Sex of baby 
could only be assessed in singletons due to confusion regarding birth order in 
multiple pregnancies, and the error rate was 0.41%. Mode of birth was incorrect 
in 1.97% of cases and birth weight in 2.03%. It was not possible to ascertain 
error rates in ethnicity due to the diversity of terminology used and data entered. 








Item Imported  
Centre 1 
n sampled= 1308 
n represented= 6731 
Centre 2 
n sampled= 588 
n represented= 3207 
n n (w) % % (w) n n (w) % % (w) 
Maternal age 10 31 0.76 0.46 0 0 0 0 
Maternal DOB 3 14 0.23 0.21 1 6 0.20 0.19 
Ethnicity * * * * * * * * 
Date of 
delivery 
0 0 0 0 0 0 0 0 
Time of 
delivery 
6 28 0.3 0.42 1 6 0.17 0.19 








male on PM 




34/1259 129/6561 2.70 1.97 ** ** ** ** 
Birth weight 
(singletons) 
32/1259 133/6561 2.54 2.03 ** ** ** ** 
Blood loss*** 254 1003 19.4 14.9 178 393 30.4 12.3 
*ethnicity was reported too diversely to assess error rates. 
**these data were not imported directly to the database from NHS systems  
Date of birth, DOB.  
*** These are the numbers of women and women represented who had blood loss 
volumes corrected, but did not necessarily change blood loss category. Of the 1895 
(representing 9937) women described, 431 (1395) changed blood loss category, while 
1464 (8542) did not. 
 
5.5 Errors & typology of those errors: digit 
preference, threshold avoidance, threshold 
preference 
Apparent in both electronic summary data and maternity notes tables 5.6 a, b, c, 
d and e show that a preference for recording estimated blood loss volumes 
ending in 10 and 50 ml was prevalent in all blood loss ranges in both Centres. 
This is particularly apparent in Centre 2 where no volumes were recorded 




Table 5.6a. Digit preference and threshold avoidance for no postpartum 
haemorrhage. 





















0 0 316 
(10.04%) 




Estimated blood loss, EBL. 
 
A disproportionate number of women have EBL at the thresholds 500 ml, 1000 ml, 
1500 ml and 2000 ml see Tables 5.5b, c, d and e. This was also demonstrated at 
2500 ml, but all numbers were small at this volume. Threshold preference is 
important because these thresholds are commonly described as “triggers” for 
further action in guidelines and protocols, which in turn have been advocated to 
improve patient care (Lyndon et al., 2010; Arulkumaran et al., 2009; Alfirevic et 
al., 2004). At these larger volumes, where blood loss should have been 
accurately recorded in accordance with national guidelines and local protocols 
(RCOG, 2009; Brace et al., 2007; Stainsby et al., 2006), the majority of 
documented blood loss volumes ended in 0 or 5, which may be acceptable due to 
the precision achievable in measurement. However there was a disproportionate   
percentage at both 2000 ml and 2500 ml thresholds. In both Centres, volumes 
under a threshold were favoured over those above, although this was inconsistent 
across all thresholds.  
 
 
Table 5.6b: Digit and threshold preference and avoidance around 500 ml 
estimated blood loss (EBL). 
 


























Table 5.6c: Digit and threshold preference and avoidance around 1000 ml 
estimated blood loss (EBL). 
 











0 0 1 
(0.01%) 
Centre2 0 0 6 
(0.19) 












Table 5.6d: Digit and threshold preference and avoidance around 1500 ml 
estimated blood loss (EBL). 
 


























Table 5.6e: Digit and threshold preference and avoidance around 2000 ml 
estimated blood loss (EBL). 
  
EBL ml 1850 1870 1887 1900 1955 2000 2015 2050 2065 
Centre1 3 
(0.04%) 

























 5.5.1 Threshold preference 
Table 5.7, shows the effect of threshold preference, looking at the incidence of 
PPH at various thresholds using the definition “equal to or more than” (Table 
3.7a), compared with “more than” (Table 3.7b), in each Centre and combined in 
uploaded electronic data and in reviewed data.  
 
 
Overall, when using the definition ≥, the incidence increased disproportionately 
for the additional 1 ml of estimated blood loss. In the imported data the incidence 
was significantly more when using this definition (≥), 32.3% versus 23.9% at 
500 ml and 33.9% versus 25.6% in reviewed data. This was repeated at all 
thresholds (1000 ml: imported 8.0% versus 5.9%, reviewed 9.4% versus 7.3; 
1500 ml imported 3.1% versus 2.3%, reviewed 4.0% versus 3.1%; 2000 ml 
imported 1.0% versus 1.3%, reviewed 2.0% versus 1.3%; 2500 ml imported 
0.7% versus 0.6%, reviewed 0.8% versus 0.6%).  
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Table 5.7: Incidence of estimated blood loss at different thresholds, using the 
definition “equal to or more than (≥)” at each threshold (data entered by clinical 
staff, and following review). 
 
 Centre 1 Centre 2 All 
As imported 
Geometric mean 375 (392 to 359) 299 (321 to 278) 349 (363 to 336) 
Median (Quartiles) 400 
(IQR 250 to 550) 
300 
(IQR  200 to 500) 
350 
(200 to 500) 
Normal estimated 




(62.3 to 68.4) 
72.8% 
(68.5 to 76.6) 
67.7% 
(65.2 to 70.1) 
≥ 500 ml 34.6% 
(31.6 to 37.7) 
27.2% 
(23.4 to 31.5) 
32.3% 
(29.9 to 34.8) 
≥ 1000 ml 8.7% 
(7.8to 9.7) 
6.4% 
(5.4 to 7.6) 
8.0% 
(7.3 to 8.7) 
≥ 1500 ml 3.2% 
(2.8 to 3.7) 
2.8% 
(2.2 to 3.5) 
3.1% 
(2.7 to 3.5) 
≥ 2000 ml 1.5% 
(1.2 to 1.9) 
1.4% 
(1.0 to 1.9) 
1.5% 
(1.2 to 1.7) 
≥ 2500 ml 0.7% 
(0.5 to 0.9) 
0.8% 
(0.6 to 1.2%) 
0.7% 
(0.6 to 0.9) 
As validated 
Geometric mean 395 (414 to 377) 305 (328 to 284) 349 (363 to 336) 
Median (Quartiles) 400  
(IQR 250 to 600) 
300 
(IQR 200 to 500) 
350 
(IQR 200 to 545) 
Normal blood loss 63.3%  
(60.1 to 66.4) 
72.1%  
(67.8 to 76.0) 
66.1% 
(63.5 to 68.6) 
≥ 500 ml 36.7 % 
(33.6 to 39.9) 
27.9%  
(24 to 32.2) 
33.9 
(31.4to 36.5) 
≥ 1000 ml 10.2%  
(9.0 to 11.4) 
7.8% 
(6.4 to 9.4) 
9.4%  
(8.5 to 10.4) 
≥ 1500 ml 4.3% 
(3.5 to 5.2) 
3.3%  
(2.6 to 4.3) 
4.0% 
(3.4 to 4.6) 
≥ 2000 ml 2.2% 
(1.7 to 2.9) 
1.4% 
(1.0 to 1.9) 
2.0% 
(1.6 to 2.4) 
≥ 2500 ml 0.8% 
(0.6 to 1.1) 
0.8% 
(0.6 to 1.2) 
0.8% 
(0.7 to 1.0) 
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Table 5.7a: Incidence of estimated blood loss at different thresholds, using the 
definition “more than (>)” at each threshold (data entered by clinical staff, and 
following review). 
 
 Centre 1 Centre 2 All 
As imported  mean (Standard Deviation) 
Geometric mean 375 (392 to 359)  299 (321 to 278)              349 (363 to 336) 
 
Median (Quartiles) 400  
(IQR* 250 to 550)  
300  
(IQR 200 to 500) 
350  
(IQR 200 to 500) 
 
% (95%CI) % (95%CI) % (95%CI) 
Normal estimated 
blood loss (no 
PPH) 
74.0%  
(71.3 to 76.5)  
80.7%  
(77.1 to 83.8) 
76.1%  
(74.0 to 78.1) 
>500 ml 26.0%  
(23.5 to 28.7)  
19.3%  
(16.2 to 22.9) 
23.9%  
(21.9 to 26.0) 
> 1000 ml 6.4% (5.7 to 7.1)  4.8% (4.0 to 5.8)              5.9% (5.3 to 6.5) 
> 1500 ml 2.4% (2.0 to 2.9)  2.2% (1.7 to 2.8)              2.3% (2.0 to 2.7) 
> 2000 ml 0.9% (0.7 to 1.2)  1.1% (0.7 to 1.5)              1.0% (0.8 to 1.2) 
> 2500 ml 0.5% (0.3 to 0.7)  0.7% (0.4 to 1.0)              0.5% (0.4 to 0.7) 
Following review 
Geometric mean 395 (414 to 377)  305 (328 to 284)               349 (363 to 336) 
Median (Quartiles) 400  
(IQR 250 to 600)  
300  
(IQR 200 to 500) 
350  
(IQR 200 to 545) 
Normal estimated 
blood loss (no 
PPH) 
72.2%  
(69.3 to 74.8)  
79.3%  
(75.7 to 82.6) 
74.4%  
(72.2 to 76.6) 
> 500 ml 27.8%  
(25.2 to 30.7)  
20.7%  
(17.4 to 24.3) 
25.6%  
(23.4 to 27.8) 
> 1000 ml 7.9% (6.9 to 9.0)  6.1% (4.9 to 7.5)              7.3% (6.5 to 8.2) 
> 1500 ml 3.3% (2.6 to 4.1)  2.6% (2.0 to 3.4)              3.1% (2.6 to 3.7) 
> 2000 ml 1.4% (1.0 to 2.0)  1.0% (0.7 to 1.5)              1.3% (1.0 to 1.7) 
> 2500 ml 0.6% (0.4 to 0.8)  0.7% (0.4 to 1.0)              0.6% (0.5 to 0.8) 
*IQR interquartile range 
 
 
5.6 Place of birth 
 
To further investigate influences on estimated blood loss and in the light of a 
recent report, analyses were undertaken investigating influence of place of birth 
(Birthplace in England Collaborative Group, 2011). However intended place of 
birth was not recorded, so direct comparison was hampered.  
 
 
The majority of women (78.6%) gave birth in obstetric units 5348/6732 (79.4% 
Centre 1) 2461/3205 (77.8% in Centre 2).  Alongside midwife led units (MLU) 
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existed in both Centres and 18% of women delivered there (16.6% in Centre 1; 
21% in Centre 2), concurring with recent estimates that around 1:20 women give 
birth in these along side or freestanding units (www.health.org.uk).  
 
 
The homebirth rate was 2.5% (245/9936) comparable to the average for England 
(2.49%) (Birthchoice, 2010), although there were significantly more in Centre 1 
(198/6731 2.9%) than Centre 2 (47/3205, 1.4%), a reflection of typical variance 
across England (0.1% to 11.4%) (Birthchoice, 2010, www.birthchoiceuk.com). 
 
 
Women delivering at home or in the MLUs were not at increased risk of  
PPH≥500 ml, concurring with the findings of others (Birthplace in England 
Collaborative Group, 2011) and shown in Table 5.8. There was also no increased 
risk of PPH ≥1500 ml, in either Centre 1 [OR 0.48, 95% Confidence Intervals (CI) 





Table 5.8: Postpartum haemorrhage (PPH) ≥500 ml in women giving birth at 
home or in midwife led units, by Centre and combined 
 
Place of birth PPH≥500 ml 
Odds Ratio 
95% CI P 
Home birth 0.38 0.11 to 1.26 0.114 
MidLed Unit  (1) 0.80 0.49 to 1.30 0.37 
MidLed Unit (2) 1.03 0.58 to 3.02 0.51 
AMU* 0.90 0.60 to 1.37 0.64 
Midwifery led, MidLed 




This was not the case for PPH ≥1000 ml, which was more likely in MLU Centre 1, 
(OR 3.15 [95%CI 1.38 to 7.17, p=0.006]) compared to MLU Centre 2, (OR 0.38 
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[95%CI 0.12 to 1.20, p= 0.101]). Despite the prevalence of African ethnicity in 





One hundred and thirty one women had no information regarding blood loss 
entered onto NHS electronic data summary. Robust review of the notes showed 
that all but 2 women had estimated blood loss documented in the handheld 
maternity notes.  Review of handheld maternity records and other information 
sources available regarding intrapartum care and blood loss, revealed visual 
assessment remains commonly the method of choice. In the current study no 
attempt was made to assess the accuracy of estimation of blood loss, but review 
of the data available showed further errors in the addition of documented 
volumes and failure to upload or edit estimated blood loss volumes onto 
electronic data systems. This study therefore has identified a further source of 
error, hitherto unreported or quantified. Whilst error rates for other routinely 
collected summary data range from 0.0-2.70%, those for estimated blood loss 
were much higher (12.3-19.4%). 
The phenomena of digit preference and threshold avoidance previously described 
in relation to BP measurement are apparent when estimating blood loss. 
Recording volume ≥ a threshold, under estimates blood loss <500 ml and inflates 
estimated blood loss at all other thesholds.  
 
 
With additional sources of errors identified the robust review system was required 
to ensure the completeness and quality of the available data within the 
constraints of visual assessment. Once the data were confirmed as complete as 
accurate as possible statistical analyses could be undertaken to investigate the 
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variables associated with mean estimated blood loss and PPH. These results are 














  183 
Chapter 6: Results 1; Risk 
factors associated with mean 
estimated blood loss 
thresholds. 
Sample selection is outlined with details of those excluded from analyses, and the 
handling of ambiguous data. Population characteristics in terms of incidence in 
the total population and relationship with PPH versus no PPH will be examined.  
Comparison with historical data in the same geographical locations and impact of 
place of birth, day of the week and time of birth will be presented.  
 
 
6.1 Cohort and weighted sample details 
 
The total number of deliveries in the participating Centres during the study period, 
01st August 2008 to 31st July 2009, was 10,213 (Centre 1: 6721; Centre 2: 3492), 
which was within the 95% CI of the estimated annual deliveries represented by 





Following detailed review of the maternity records selected by weighting (n= 
1897) two women were excluded from analysis, as there was no documentation 
regarding blood loss (1 unattended home birth; 1 attended by paramedics).  
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Review of the notes for women randomly selected according to the weighting 
strategy revealed a further woman (with reported estimated blood loss of 800ml) 
experienced an antenatal cardiac arrest and underwent emergency CS prior to 
maternal resuscitation, which was unsuccessful. It was decided to include her 
data regarding risk factors and incidence of PPH. 
 
 
6.3 Sample size 
 
Figure 6.1 shows 99.4% of sample (9,936/9,938) had sufficient data to assess 
estimated blood loss. The proportion of notes randomly selected according to 
imported estimated blood loss and those identified through blood transfusion 
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Figure 6.1:  STROBE diagram. Identification and classification of cases according 
to imported electronic patient records, recategorisation by estimated blood loss 





















Shaded boxes demonstrate additional cases not identified through electronic patient 
records. EPR; electronic patient record; EBL, estimated blood loss; nw; number of women 
represented by the reviewed notes allowing for the weighted sampling. *Weighted 
sampling strategy represented population total of 9,937 (95%CI 9,532 to 10,340). 
Imported EBL 
Missing / <25ml 












n = 6,624 
 
Total reviewed 
n = 552 
 
Total reviewed 






n = 783 
 
 
Identified only via 
blood transfusion 
(25-999 ml)  n = 35 
 
Total reviewed 






Imported EBL from EPR for all deliveries 
1 August 2008 – 31 July 2009 
n= 10,213 
Total in study 
n = 1895 
nw = 9937* 
EBL 500-999 ml 
n = 427 
nw = 2,419 
 
 
EBL <500 ml 
n= 653 
nw = 6,585 
 
 
 EBL >1500 ml 
n = 338 
nw = 391 
EBL >1000 ml 
n = 815 
nw = 933 
EBL 1000-1499 ml 
n = 477 










n = 2 
nw = 2 
1 unattended birth 
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6.4 Demographic characteristics of the sample 
 
Risk factors according to PPH category are shown as a percentage of the 
representative sample. Due to the weighted sampling strategy and proportional 
representation for differing estimated blood loss categories, combined with 
recoding, the number of women (n) in each category is not provided. 
 
 
6.4.1 Pre-pregnancy factors and incidence of PPH  
Table 6.1 shows the demographic characteristics and outcomes in women with 
and without PPH. In the whole cohort, 55% were aged ≥30 with 26% ≥35 years, 
indicating that this population was older than the general UK pregnant population 
at the time, reported as 47% aged over 30 years  (ONS, 2010). Almost 60% 
were White, with Black African the largest minority ethnic group (17%). Whilst 
the percentage of White people is significantly less than the general population of 
England and Wales (>80%) the lower proportion is likely to be influenced by the 
proximity to London of the two participating Centres, where 45% of the resident 
population are White (ONS, 2011).  
 
 
The Asian minority group is comparable to elsewhere in the UK (2.7%) (KSO6, 
2009). Conversely the population in north Kent comprises 91.6% White, 3.5% 
South Asian, 2.0% Black, 1.7% Mixed race and 1.2% Chinese or other 
(www.dartford.gov.uk). Overall the study population was representative of the 
communities from which it was drawn. Thirty nine percent lived in areas of 
highest deprivation, influenced by the locality served by Centre 1 which is in the 
top 10% of most deprived London Boroughs (Trust for London, 2010). Conversely 
deprivation levels were lower than average around Centre 2 (www.apho.org.uk). 
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Just over half the women (51%) were primiparous, which is higher than reported 
in other datasets (www.birthchoiceuk.com) and may reflect the impact of Centre 
1 as an inner city tertiary referral Centre. 
 
 
More than 50% of women had a healthy BMI (defined as 19.0 to 24.9 kg/m2), 
despite rising levels of obesity reported in the whole population 
(www.apho.org.uk; www.webarchive.selondonsector.nhs.uk). Over 22% were 
overweight (BMI 25- 29.9 kg/m2) and >15% were obese (BMI≥30.0 kg/m2). 
Twelve percent were cigarette smokers at first antenatal contact, less than in the 
general antenatal population (14%) (ONS, 2010). 
 
 
Factors associated with PPH ≥500 ml were: maternal age 30-34, 35-39 and over 
40 years, Black African ethnicity, Chinese ethnicity and primiparity. Conversely 
women aged <20 and 20-24 years, White ethnicity, BMI <19 kg/m2 and cigarette 
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Table 6.1: Characteristics of the study population by postpartum haemorrhage 
(PPH) (estimated blood loss ≥500 ml) or no PPH, following correction of errors, 
categorisation and weighting. 
 
Demography No PPH PPH ≥500 ml All 
No. of women/notes reviewed 653 1242 1895 
No. of women represented (nw) 6585 3352 9937 
Age (years) % of population 
<20  5.0 2.8 4.2 
20-24 15.9 8.9 13.5 
25-29 22.4 22.0 22.2 
30-34 32.0 36.6 33.6 
35-39 19.8 22.6 20.7 
40+ 5.0 7.2 5.7 
Ethnicity 
White 61.2 55.3 59.2 
Black British 2.4 1.0 2.0 
Black Caribbean 4.4 4.2 4.3 
Black African 14.2 22.3 16.9 
Bangladeshi 2.0 1.1 1.7 
Indian 3.0 3.8 3.3 
Pakistani 3.7 3.9 3.7 
Other Asian 0.7 0.9 0.8 
Chinese 0.6 1.3 0.8 
Mixed 3.0 1.6 2.6 
Unknown 4.8 4.5 4.7 
Body Mass Index (BMI) (kg/m2) 
<19 6.3 4.8 5.8 
19-24.9 50.8 51.2 50.9 
25-29.9 22.3 22.3 22.3 
30-34.9 10.3 11.9 10.8 
35+ 4.1 4.8 4.4 
Index of multiple deprivation 
Quintile 1 (least deprived) 7.3 6.6 7.1 
Quintile 2 9.8 10.1 9.9 
Quintile 3 14.1 15.2 14.5 
Quintile 4 29.5 28.0 29.0 
Quniltile 5 (Most deprived) 38.8 39.3 39.0 
Parity    
Primiparity 47.0 58.8 51.0 
Smoking     
At booking 13.2 10.2 12.2 
Previous obstetric history (includes primiparous women) 
No previous PPH 96.5 94.7 95.9 
1 x previous PPH 3.5 4.8 3.9 
>1 previous PPH 0 0.3 0.1 
Previous Caesarean section 9.2 22.6 13.7 
Pre-existing medical conditions 
Diabetes 0.9 1.2 1.0 
Epilepsy (on medication) 0.4 0.7 0.5 
Depression (on medication) 2.8 2.2 2.6 
Hypertension 0.7 1.6 1.0 
Fibroids 3.8 6.1 4.5 
Female genital mutilation 2.8 3.3 2.9 
Clotting or thromboembolic 
disorder 
0.6 1.8 1.0 
Uterine abnormality 0.2 0.3 0.2 
Assisted conception  1.3 4.8  2.5 
Current pregnancy 
Multiple pregnancy 1.8 4.0 2.6 
Antenatal admissions 14.3 19.1 15.9 
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Any antenatal day unit 
attendance 
47.3 53.6 49.5 
Abdominal pain 15.7 17.2 16.3 
Itching 2.0 2.3 2.1 
External cephalic version 1.3 1.8 1.5 
Pre-eclampsia screen 6.8 10.7 8.1 
Reduced fetal movements 12.8 14.4 13.3 
Possible spontaneous ROM 13.8 15.3 14.3 
Generally unwell 3.1 3.8 3.3 
Possible UTI 0.0 0.4 0.1 
Vaginal bleed (no admission) 3.9 3.8 3.8 
Placenta praevia 0.2 1.4 0.6 
APH requiring admission 3.4 4.6 3.8 
UTI (confirmed) 9.0 9.9 9.3 
Gestational hypertension 2.1 4.6 2.9 
Pre-eclampsia 0.9 4.3 2.1 
Anaemia (Hb<10.5 g/ml) 12.4 14.1 12.9 
Intrapartum 
Spontaneous onset of labour 74.7 51.3 66.8 
Induced onset of labour 14.2 19.3 15.9 
Augmented onset of labour 5.0 6.9 5.6 
No labour elective Caesarean# 6.2 22.5 11.7 
Temperature (>37.2°C) 12.3 27.8 17.3 
Ruptured membranes >48 h 2.7 4.1 3.2 
Dinoprostone 13.1 18.0 14.8 
Oytocin (Syntocinon®) in 1st or 
2nd stage 
18.4 35.9 24.3 
Birth 
SVD 76.1 25.9 59.2 
Instrumental vaginal delivery* 12.1 17.1 13.8 
Elective Caesarean section# 5.6 18.4 9.9 
Emergency Caesarean section 6.2 38.6 17.1 
Management of third stage of labour 
Physiological 9.2 3.4 7.2 
Oxytocin (Syntocinon®) IM 7.3 5.4 6.7 
Oxytocin (Syntocinon®) IV 13.4 58.1 28.5 
Ergometrine Maleate/Oxytocin 
(Syntometrine®) IM 
69.7 30.8 56.6 
Retained placenta 1.3 4.4 2.4 
Rupture of membranes, ROM; intramuscular, IM; intravenous IV. nw; Number of women 
represented by the reviewed notes allowing for the weighted sampling. *Forceps or 
ventouse; #Figures differ as some women planning elective Caesarean section had onset 
of labour, so Caesarean section classified as emergency. 
 
 
6.4.2 Previous Obstetric History 
Just over 4% of women had experienced PPH in at least one previous pregnancy, 
whilst traditionally identified as risk factor for excessive bleeding (Oyelese and 
Ananth, 2010; Ford et al., 2007), this was not associated with increased risk of 
PPH in the index pregnancy. Conversely previous CS was a potent risk factor for 
estimated blood loss exceeding 500 ml in subsequent pregnancies.  
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6.4.3 General health and medical factors and incidence of 
PPH. 
Pre-existing medical conditions were relatively rare, affecting 0.5% (epilepsy) to 
4.5% (uterine fibroids) of women.  It should be noted that whilst relatively rare, 
the commonest pre-existing conditions in the study population are associated 




The incidence of pre-existing epilepsy (0.5%), pre-gestational diabetes (2-5%) 
and lupus (0.2-1.0%) were comparable to those reported by others in antenatal 
populations (Diabetes UK, 2012; Mawhinney and Morrow, 2011; NICE 2008; 
Yasmeen et al., 2001).  Conversely essential hypertension (1%) and anaemia 
(0.8%) were lower than reported elsewhere (WHO, 2008; Sibai, 2002). 
General health and medical factors associated with increased estimated blood loss 
≥500 ml were: uterine fibroids, clotting or thrombotic disorders and assisted 
conception to achieve current pregnancy.  
 
 
6.4.4 Current pregnancy  
The incidence of multiple pregnancy was 2.6% compared with 1.6% for England 
and Wales in 2009 (ONS, 2010). Almost 50% of women attended ADU on at least 
one occasion, the most common reasons for attendance being abdominal pain 
(16.2%), suspected rupture of fetal membranes (ROM) (14.3%) and reduced 
fetal movements (13.3%). Just over 16% had at least one antenatal inpatient 
night. Placenta praevia complicated 0.6% of pregnancies, despite the incidence of 
previous Caesarean birth being 13.7%. 
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Pregnancy acquired risk factors that increased risk of PPH ≥500 ml included; 
multiple pregnancy, antenatal admissions, antenatal day unit attendances, pre-
eclampsia screen, gestational hypertension and pre-eclampsia. 
 
 
6.4.5 Labour and birth factors and incidence of PPH 
Induction of labour rate was 15.9%. When combined with the augmentation rate 
of 5.6%, this is similar to reported induction rates of around 20% 
(www.birthchoiceuk.com; www.hesonliine.nhs.uk). Almost a quarter of all women 
received Oxytocin (Syntocinon®) in the first and/or second stage of labour.  
 
 
Overall the CS rate was 27% (10% elective and 17% emergency), slightly higher 
than the national rate for England (24.8%) (www.birthchoiceuk.com). Conversely 
these national data reported a slightly lower rate of instrumental vaginal 
deliveries compared to the current study (12.5% versus 13.8%). The 
spontaneous vaginal delivery rate in these data was 59.2%, higher than the 
41.8% reported for England (Birthchoice, 2010, www.birthchoiceuk.com).  
 
 
The majority of women (91.4%) were given uterotonic drugs as part of active 
management of the third stage (AMTSL). The majority of women (56.4%) 
received Ergometrine Maleate/Oxytocin (Syntometrine®), with just over a third 
(35%) receiving Oxytocin (Syntocinon®) (28.3% IV; 6.7% IM). The impact of 
Oxytocin (Syntocinon®) IM failed to reach significance, despite being the 
recommended drug to prevent PPH. 
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Intrapartum factors that increased risk of PPH ≥500 ml included: induction of 
labour, elective CS, maternal temperature >37°C, ruptured fetal membranes >48 
hours before birth, dinoprostone pessary/gel, oxytocin (Syntocinon®) infusion in 
first and/or second stage, instrumental vaginal birth, elective CS, emergency CS, 
oxytocin (Syntocinon®) IV and retained placenta. Protective factors were: 
spontaneous onset of labour, spontaneous vaginal delivery (SVD) and 
prophylactic Ergometrine Maleate/Oxytocin (Syntometrine®) IM for management 
of the third stage. 
 
 
In summary, the women in this cohort were older, more ethnically diverse, 
heavier, more socially deprived and more likely to be expecting their first child 
than general UK figures for the study time period. However there were no higher 
levels of pre-existing medical conditions, previous Caesarean birth or previous 
PPH. Management of labour, birth and third stage was no different to other UK 
reports.  The impact of individual variables on estimated blood loss, less than and 
exceeding 500 ml, both confirms and disputes previous evidence, suggesting the 
emergence of some novel factors (assisted conception, temperature in labour) 
demonstrating the necessity to consider variables in combination, and the 
complexity of relationships between variables that influence PPH.  
 
 
6.5 Incidence of PPH at different thresholds 
 
Following adjustment for transcription errors, overall 33.7% of women in the 
sample had a PPH≥500 ml. Of these 9.4% ≥1000 ml; of these 3.9% ≥1500 ml 
and of these 0.8% ≥2500 ml. Table 4.2 shows incidence at various thresholds in 
order to facilitate comparison with other studies. 
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Table 6.2: Overall incidence of estimated blood loss by category and at different 
volume thresholds using ≥ as cutoff.  
 
Category Estimated Blood 
loss (ml) 
All (%) 95% CI 
No PPH <500 66.3 63.8 to 68.8 
PPH – All  ≥ 500 33.7 31.2 to 36.2 
PPH - Minor  500-999  24.3 22.0 to 26.6 
PPH - Moderate 1000-1499  5.5 4.8 to 6.1 
PPH - Severe  1500-1999 2.0 1.6 to 2.4 
2000-2499 1.1 0.74 to 1.5 
≥1500  3.9 3.3 to 4.6 
≥2500 0.82 0.63 to 1.0 
Postpartum haemorrhage, PPH. 
 
 
Table 6.2 shows the PPH rates for both Centres. Further investigation by Centre 
showed some variance at all levels (≥500 ml 36.7% versus 27.4%; ≥1000 ml 




Table 6.2a: Overall incidence of estimated blood loss at different thresholds in 




Centre 1 Centre 2 All 
Geometric mean 395 (414 to 377) 305 (328 to 284) 349 (363 to 336) 
Median (Quartiles) 400  
(IQR 250 to 600) 
300 
(IQR 200 to 500) 
350 
(IQR 200 to 545) 
No PPH 63.3%  
(60.1 to 66.4) 
72.1%  
(67.8 to 76.0) 
66.1% 
(63.5 to 68.6) 
≥ 500 ml 36.7 % 
(33.6 to 39.9) 
27.9%  
(24 to 32.2) 
33.9 
(31.4 to 36.5) 
≥ 1000 ml 10.2%  
(9.0 to 11.4) 
7.8% 
(6.4 to 9.4) 
9.4%  
(8.5 to 10.4) 
≥ 1500 ml 4.3% 
(3.5 to 5.2) 
3.3%  
(2.6 to 4.3) 
4.0% 
(3.4 to 4.6) 
≥ 2000 ml 2.2% 
(1.7 to 2.9) 
1.4% 
(1.0 to 1.9) 
2.0% 
(1.6 to 2.4) 
≥ 2500 ml 
  
0.8% 
(0.6 to 1.1) 
0.8% 
(0.6 to 1.2) 
0.8% 
(0.7 to 1.0) 
Postpartum haemorrhage, PPH. 
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Some authors report PPH as blood loss volumes exceeding thresholds. To assess 
incidence using these definitions, incidence of PPH in this cohort was calculated 
using >threshold volumes. Using these definitions the rates of PPH at all levels 
reduced; >500 ml= 25.6%; >1000 ml= 7.3%; >1500 ml= 3.1%; >2000 ml= 
1.3%; >2500 ml= 0.6% (Table 4.2b). There was no significant difference in 




Table 6.2b: Incidence of postpartum haemorrhage when estimated blood loss 




Centre 1 Centre 2 All  
Geometric mean 395 (414 to 377)  305 (328 to 284)               349 (363 to 336) 
Median (Quartiles) 400  
(IQR 250 to 600)  
300  
(IQR 200 to 500) 
350  




(69.3 to 74.8)  
79.3%  
(75.7 to 82.6) 
74.4%  
(72.2 to 76.6) 
> 500 ml 27.8%  
(25.2 to 30.7)  
20.7%  
(17.4 to 24.3) 
25.6%  
(23.4 to 27.8) 
> 1000 ml 7.9% (6.9 to 9.0)  6.1% (4.9 to 7.5)              7.3% (6.5 to 8.2) 
> 1500 ml 3.3% (2.6 to 4.1)  2.6% (2.0 to 3.4)              3.1% (2.6 to 3.7) 
> 2000 ml 1.4% (1.0 to 2.0)  1.0% (0.7 to 1.5)              1.3% (1.0 to 1.7) 




Further analysis to ensure rates of severest haemorrhage (≥2500 ml) were not 
skewed by complexity of cases (referred to previously in Centre 1), showed rates 
of 0.82% versus 0.83% shown in Tables 6.2c and 6.2d. This compared with 
0.56% (95% CI 0.49 to 0.62, n= 306/54910) in Scotland during the same period 








Frequency Percentage (%) Cumulative 95% CI 
<2500 6668 99.18 99.18 98.9 to 99.4 
2500+ 55 0.82 100.00 0.59 to 1.04 
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Frequency Percentage  Cumulative 95% CI 
<2500 3121 99.17 99.17 88.4 to 99.5 





6.6 Effects of mode of delivery on estimated 
blood loss. 
6.7  
Tables 6.3a, b show estimated blood loss associated with mode of birth, in each 
Centre. Following SVD Centre 1 recorded higher rates of PPH ≥500 ml (18% vs 
10%) and within this overall PPH rate higher estimated blood loss was reported   
at other thresholds (500-999 ml, 11% vs 6.9%; 1000-1499 ml, 2.7% vs 1.1%;  
≥1500 ml, 3.3% vs 1.3). Conversely in Centre 2 instrumental birth was 
associated with almost twice the rate of  PPH ≥500 ml than Centre 1 (44% vs 
22.2%).  
In Centre 1, emergency CS was associated with minimal blood loss <500 ml in 
almost 28% of cases, this was significantly less in Centre 2 where just under 10% 
























(78.7 to 85) 
11 
(9.3 to 14.8) 
2.7 
(2.0 to 3.5) 
3.3 




(47.4 to 64.2) 
30.2 
(23.0 to 38.6) 
8.3 
(5.9 to 11.3) 
5.3 
(3.8 to 7.3) 
Elective CS 36.1 
(25.4 to 48.2) 
52.4 
(41.5 to 63.1) 
8.0 
(5.7 to 11,1) 
3.5 




(20.9 to 35.9) 
53.3 
(46.3 to 60.2) 
12.8 
(10.3 to 15.7) 
6.2 
(4.7 to 8.2) 
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(87.1 to 93.4) 
6.9 
(4.5 to 10.4) 
1.1 
(0.5 to 2.0) 
1.3 




(49.7 to 75.8) 
28.6 
(17.9 to 42.3) 
3.7 
(2.0 to 6.6) 
3.9 
(2.2 to 7.0) 
Elective CS 39.8 
(25.8 to 55.6) 
48.1 
(34.3 to 62.1) 
8.3 
(5.3 to 12.7) 
3.9 




(3.3 to 25.7) 
57.2 
(45.5 to 68.2) 
19.9 
(13.5 to 28.4) 
13.1 
(8.8 to 19.1) 




Table 6.3c shows estimated blood loss according to mode of birth in the study 
population (both Centres combined). Overall PPH ≥500 ml occurred following SVD 
in almost 15% or women, following instrumental vaginal birth in almost 42% of 
cases, following elective CS with almost 63% and after emergency CS in more 
than 75% of cases. 
 
 

















(82.8 to 87.4) 
10.0  
(8.2 to 12.3) 
2.1 
(1.6 to 2.7) 
2.7 




(50.9 to 65.4) 
29. 8 
(23.6 to 36.8) 
7.0 
(5.3 to 9.3) 
5.0  
(3.8 to 6.5) 
Elective CS 37.4 
(28.7 to 47.0) 
50.8 
(42.2 to 59.4) 
8.1 
(6.2 to 10.5) 
3.7 




(18.0 to 30.9) 
54.1 
(48.1 to 60.1) 
14.3 
(11.8 to 17.2) 
7.7 
(6.1 to 9.6) 




Further comparison of estimation blood loss ≥ 1000 ml by mode of delivery 
showed the incidence following SVD was 4.75% (95%CI 0.37 to 5.7), after 
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vaginal instrumental delivery was 12.0% (95%CI 9.3 to 14.6), post elective CS 
was 11.8% (95%CI 8.9 to 14.5) and after emergency CS was 22% (95%CI 18.6 
to 25.4).  
 
 
Therefore, in the study cohort PPH ≥ 1000 ml following vaginal birth was 6.1% 




Table 6.4 shows the number of case notes reviewed in each category according to 
estimated blood loss category and mode of birth.  
 

















SVD 507 103 103 113 826 
Instrumental 
vaginal birth 
74 75 86 68 303 
Elective CS 34 84 80 36 234 
Emergency 
CS 
38 165 208 121 532 






6.7 Effects of day and time of birth on presence 
and absence of PPH 
 
Table 6.5a shows effects of day of the week and time of day of birth on incidence 
of PPH. These data are shown separately for women undergoing elective 
Caesarean birth due to the planned nature of the event (Table 6.5b). In those 
women with spontaneous, induced or augmented labour there was a marginal 
increase in babies born on Wednesday, Thursday and Friday. There were no 
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significant differences between no PPH and PPH ≥500 ml by day of the week or at 
any time of the day.  
 
 
Table 6.5a: Days of the week and time of birth no postpartum haemorrhage 
(PPH) versus PPH ≥500 ml in women without elective Caesarean section. 
 






n sampled 619 1042 1661* 
n represented 6216 2735 8951* 
Day of the week 
Sunday 816 (69.1) 365 (31.0) 1181 
Monday  782 (68.0) 371 (32.1) 1153 
Tuesday 712 (61.1) 453 (38.9) 1165 
Wednesday 946 (68.1) 444 (31.9) 1390 
Thursday 1025 (73.9) 361 (26.1) 1386 
Friday  1035 (73.5) 373 (26.5) 1408 
Saturday 900 (71.0) 368 (29.0) 1268 
Time of delivery 
00.00- 02.59 781 (70.2) 332 (29.8) 1113 
03.00- 05.59 
879 (73.1) 
324 (26.9) 1203 
06.00- 08.59 815 (73.3)  297 (26.7) 1112 
09.00- 11.59 748 (63.9) 422 (36.1) 1170 
12.00- 14.59 796 (69.9) 343 (30.1) 1139 
15.00- 17.59 777 (67.4) 376 (32.6) 1153 
18.00-20.59 666 (68.6) 305 (31.4) 971 
21.00- 23.59 754 (69.2) 336 (30.8) 1090 
*women undergoing elective Caesarean birth are excluded from this analysis 
Table 6.5b shows slightly more babies were born by elective CS on Wednesday, 
with significantly fewer on Friday and, unsurprisingly, on Saturday or Sunday. 
Table 6.5b shows the majority of these elective procedures occurred between 
09.00-17.59 hours, with women undergoing the procedure between 09.00-11.59 
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hours at greatest risk of PPH ≥500 ml (35.3% vs 0.1%). Interestingly 2% of 
these elective procedures occurred between 21.00- 08.59 hours, which would not 
generally be considered appropriate for elective procedures. 
 
Table 6.5b: Days of the week and time of birth, no postpartum haemorrhage 
(PPH) versus PPH ≥500 ml for women with elective Caesarean section. 
 





n sampled 35 201 236 
n represented 369 617 986 
Days of the week 
Sunday 0 (0%) 3 (100) 3 
Monday  48 (28.6) 120 (71.4) 168 
Tuesday 61 (30.8) 137 (69.2) 198 
Wednesday 92 (37.7) 152 (62.3) 244 
Thursday 84 (37.3) 141 (62.3) 225 
Friday 48 (49.5) 49 (50.5) 97  
Saturday 36 (70.6) 15 (29.4) 51 
Time of birth (h) 
00.00-0.2.59 0 (0) 1 (100) 1 
03.00- 05.59 0 (0) 6 (100) 6 
06.00- 08.59 0 (0) 6 (100) 6 
09.00- 11.59 188 (46.1) 220 (53.9) 408 
12.00- 14.59 121 (40.1) 181 (59.9) 302 
15.00- 17.59 36 (19.4) 150 (80.6) 186  
18.00- 20.59 24 (31.6) 52 (68.4) 76 
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6.8 Comparison with historic data 
 
Comparison with severe PPH (≥1500 ml) data collected in the units providing  
maternity care in the same geographical locations in 1997-1998 reveals a 19.7% 
increase in birth rate (8,329 to 10,213) and 3.4 (95% CI 2.7 to 4.3) risk ratio for 
PPH ≥1500 ml from 1.12% (95% CI 0.92 to 1.38) to 4.20% (93 cases versus 
391) and an 8.3 (95% CI 4.0 to 17.1) risk ratio for PPH ≥2500 ml (9 cases 




6.9 PPH incidence at thresholds commonly used in 
research and audit reports 
 
Tables 6.6a-d show the number of women sampled (n) and the number of women 
represented (nw) with % incidence of estimated blood loss at the various 
thresholds. Values within the variable were also investigated, for example, mean 
age for blood loss thresholds, number of antenatal day unit attendances (0-5+), 
parity (0-3+) and number of previous PPHs.  
 
 
6.9.1 Maternal demographic characteristics and estimated 
blood loss category. 
Table 6.6a shows there is a trend for increased age to be associated with 
increased estimated blood loss, but the effect is modified by extremes of age in 
each blood loss category. The majority of women in each ethnic group did not 
have a PPH (≥500 ml), the exception being Chinese women with 46.3% losing 
<500 ml, this may have been influenced by the small numbers of this ethnicity 
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within the cohort (0.6%). The % of women in each estimated blood loss category 





Table 6.6a: Population characteristics and estimated blood loss at different 
thresholds. 
 
Risk factor Estimated Blood Loss category (ml) All 
25-499 500-999 1000-1499 1500-1999 2000+ 
n sampled 653 427 477 167 171 1895 
n represented 6585 2419 542 198 193 9937 
Demography  














<20 77.7% 17.1% 2.4% 1.2% 1.7% 100% 
20-24 77.9% 14.9% 4.4% 1.5% 1.3% 100% 
25-29 66.6% 24.7% 5.0% 2.0% 1.7% 100% 
30-34 63.2% 26.7% 6.5% 1.8% 1.7% 100% 
35-39 63.3% 25.8% 5.4% 2.9% 2.6% 100% 
40+ 57.7% 32.1% 6.0% 1.8% 2.5% 100% 
Ethnicity       
White 68.5% 23.8% 4.5% 1.7% 1.6% 100% 
Black 59.9% 26.7% 8.0% 2.5% 2.8% 100% 
Asian 65.6% 24.5% 5.2% 3.0% 1.8% 100% 
Mixed/other 68.9% 21.5% 5.6% 2.0% 1.9% 100% 
Ethnicity detail 
White 68.5% 23.8% 4.5% 1.7% 1.6% 100% 
Black British 82.0% 9.8% 4.1% 2.6% 1.6% 100% 
Black Caribbean 67.4% 26.8% 3.7% 0.7% 1.4% 100% 
Black African 55.5% 28.7% 9.5% 3.0% 3.3% 100% 
Bangladeshi 78.8% 17.7% 1.8% 0.6% 1.2% 100% 
Indian 60.5% 27.8% 5.2% 4.9% 1.5% 100% 
Pakistani 65.0% 23.5% 6.7% 2.7% 2.2% 100% 
Other Asian 60.8% 30.4% 15.9% 4.8% 2.4% 100% 
Chinese 46.3% 30.5% 15.9% 4.9% 2.4% 100% 
Mixed 78.4% 16.9% 3.5% 1.2% 3.7% 100% 
Other/unknown 67.6% 22.5% 4.9% 1.3% 3.7% 100% 
ii) Local deprivation (Index of multiple deprivation & subscales; based on area of 
residence) 














Most deprived UK 
quintile (20%) 
65.9% 23.7% 6.1% 2.0% 2.2% 100% 
Less deprived UK 
quintile (80%) 
















Most deprived UK 
quintile (%) 
63.8%       25.7%       6.2%        2.1%       2.2% 100% 
Less deprived UK 
quintile (80%) 
70.3%       22.2% 4.3% 1.8% 1.5% 100% 
Crime & disorder 0.6 (0.7) 0.6 (0.7) 0.6 (0.6) 0.6 (0.7) 0.6 (0.7) 0.6 (0.7) 
Most deprived UK 
quintile (%) 
66.2%      24.9% 5.1% 2.0% 1.8% 100% 
Less deprived UK 
quintile (80%) 
66.4% 23.8% 5.8% 2.0% 2.0% 100% 
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Most deprived UK 
quintile 
77.5% 13.6% 5.0% 2.3% 1.7% 100% 
Less deprived UK 
quintiles (80%) 
65.2%       25.4% 5.5% 1.9% 2.0% 100% 
Employment 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.1 (01) 0.1 (0.1) 
Most deprived UK 
quintile (%) 
68.2%      21.2% 6.9% 1.5% 2.2% 100% 
Less deprived UK 
quintiles (80%) 




0.2 (0.7) 0.2 (0.7) 0.3 (0.6) 0.2 (0.6) 0.2 (0.7) 0.2 (0.7) 
Most deprived UK 
quintile 
66.5%      24.4% 5.5% 1.4% 2.2% 100% 
Less deprived UK 
quintile (80%) 
66.3       24.2% 5.5% 2.1% 1.9% 100% 
Income 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 
Most deprived UK 
quintile (%) 
66.2%  23.6% 6.2% 2.0% 1.9% 100% 
Less deprived UK 
quintile (80%) 















Most deprived UK 
quintile (%) 
64.4%       25.5% 6.0% 2.0% 2.1% 100% 
Less deprived UK 
quintile (80%) 





6.9.2 General health and pre-index pregnancy 
characteristics and estimated blood loss category 
Table 6.6b shows the general health and pre-index pregnancy characteristics 
association with estimated blood loss at all thresholds. Women with higher BMIs 
in the overweight (BMI 25.1 to 30 kg/m2) and obese (BMI 30.1 to 35 kg/m2) 
classifications were more likely to have excessive blood loss defined as estimated 
blood loss exceeding 500 ml than those with a low BMI (<19 kg/m2). There was 
no difference in estimated blood loss categories for women whose BMI was in the 
normal range (19.1-25 kg/m2). There were fewer cigarette smokers at first 
antenatal appointment in the higher estimated blood loss categories. 
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Most pre-existing maternal conditions in the study population were representative 
of the incidence in the general population, and were not associated with excessive 
blood loss. This was especially apparent in women with Lupus, although the 
numbers of women with this condition in the population were small despite 
Centre 1 being the regional referral hospital for this condition. The exceptions to 
these findings were the presence of uterine fibroids and female circumcision, 
whose association with PPH have been reported previously (WHO, 2012a; Cook et 
al., 2010). Additionally, women with pre-existing hypertension and 
clotting/thrombotic disorders were also likely to experience PPH ≥500 ml.  
Women on treatment for depression or receiving oral iron supplementation for 






Table 6.6b: Estimated blood loss following childbirth by general and pre-
pregnancy health 






n sampled 652 427 477 167 171 1895 
n represented 6585 2419 542 198 193 9937 









































BMI<19 71.9%       23.0% 3.8% 0.5% 0.7% 100% 
BMI 19-25 66.1%       25.6% 4.9% 1.5% 1.9% 100% 
BMI 25.1-30 66.2%      23.0% 6.4% 2.1% 2.2% 100% 
BMI 30.1- 35 62.9%  23.8% 6.1% 4.8% 2.4% 100% 
35.1+ 62.7%      22.1% 9.0% 3.2% 3.0 100% 
Current smoker 71.9% 23.7% 2.8% 0.6% 1.0% 100% 
Non-smoker  65.5% 24.4% 5.8% 2.2% 2.1% 100% 
Lupus 80.0%        0.0% 20.0% 0.0% 0.0% 100% 
No Lupus 66.2%       24.4% 5.4% 2.0% 2.0% 100% 
Pre-gestational 
Diabetes 
59.4%       29.7% 5.9% 3.0% 2.0% 100% 
No pre-existing 
diabetes 
66.3% 24.3% 5.5% 2.0% 1.9% 100% 
Epilepsy  
(on treatment) 
52.2% 39.1% 2.2% 6.5% 0.0% 100% 
No epilepsy 66.33%  24.3% 5.5% 2.0% 1.9% 100% 
Depression  
(on treatment) 
71.1% 24.2% 2.3% 1.2% 1.2% 100% 
  204 
No depression 66.1% 24.4% 5.5% 2.0% 1.9% 100% 
Anaemia (on iron 
at booking) 
71.4% 17.9% 5.9% 3.6% 1.2% 100% 
No anaemia at 
booking 
(Hb≥11 g/l) 
66.2% 24.4% 5.5% 2.0% 1.9% 100% 
Pre-existing 
hypertension 
48.0%      36.0% 13.0% 0.0% 3.0% 100% 
No pre-existing 
hypertension 
66.5%  24.2% 5.4% 2.0% 1.9% 100% 
Fibroids 55.1%  29.7% 10.0% 3.1% 2.2% 100% 
No fibroids 66.8%  24.1% 5.2% 1.9% 1.9% 100% 
FGM 62.5% 25.1% 5.2% 3.1% 4.1% 100% 








66.5% 24.2% 5.4% 2.0% 1.9% 100% 
Uterine anomaly 57.1%  28.6% 9.5% 0.0% 4.8% 100% 
No uterine 
anomaly 
66.3% 24.3% 5.5% 2.0% 1.9% 100% 
Previous obstetric history 
Previous PPH 56.4%  29.6% 4.9% 5.7% 3.5% 100% 
No previous PPH  66.7%  24.1% 5.5% 1.8% 1.9% 100% 
Number of 
previous PPH 
      
0 66.7% 24.1% 5.5% 1.8% 1.9% 100% 
1 58.2% 27.7% 5.1% 4.9% 3.6% 100% 
2 0.0% 66.7% 0.0% 33.3% 0.0% 100% 
3 0.0%  85.7% 0.0% 14.3% 0.0%            100% 
Previous CS 44.4%  41.8% 8.4% 2.4% 3.2% 100% 
No previous CS 69.8% 21.6% 5.0% 1.9% 1.7% 100% 
Para 0 61.1% 28.5% 6.3% 2.0% 2.0% 100% 
Para 1 71.3%  20.5% 4.9% 1.5% 1.8% 100% 
Para 2 71.7% 19.5% 4.2% 3.2% 1.5% 100% 
Para 3+ 72.8%  19.4% 3.7% 1.6% 2.4% 100% 
Multiparity 71.6%       20.1% 4.5% 2.0% 1.8% 100% 
Primiparity 61.1% 28.5% 6.3% 2.0% 2.1% 100% 




In those with a previous obstetric history, these data show women with a 
previous PPH or CS were more likely to experience PPH ≥500 ml concurring with 
others  (Sinha and Mishra, 2012; Ford et al., 2007). Primiparous women were 
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6.9.3 Index pregnancy events and health and impact on 
estimated blood loss category 
Table 6.6c shows that women experiencing multiple pregnancy, assisted 
conception to achieve current pregnancy, antenatal admission, antenatal day unit 
attendance (irrespective of reason for admission/attendance), non –specific 
symptoms of feeling generally unwell, pre-eclampsia screen, confirmed (and 
treated) UTI and bleeding per vagina (not requiring admission) were more likely 
to experience PPH ≥500 ml. There was no apparent trend for increased estimated 
blood loss relating to abdominal pain, external cephalic version, itching (symptom 
of obstetric cholestasis), suspected spontaneous rupture of fetal membranes 
(ROM), growth scan (suspected intrauterine growth restriction or macrosomia), 
chest pain/ shortness of breath, suspected UTI or feeling faint/dizzy.   
 
Table 6.6c: Percentage of women affected, according current pregnancy health 
and events, in detail, and estimated blood loss at different thresholds 
 






n sampled 653 427 477 167 171 1895 
n represented 6585 2419 542 198 193 9937 
v) Current pregnancy 
Singleton 
pregnancy 
66.8% 24.1% 5.4% 1.9% 1.9% 100% 
Multiple 
pregnancy 
47.6%  34.3% 8.7% 4.7% 4.7% 100% 
Number of fetuses 
= 2 (twins) 
49.2% 32.9% 8.9% 4.5% 4.5% 100% 
Number of fetuses 
= 3+ 
















66.3% 23.4% 5.2% 2.0% 1.8% 100% 
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Admissions 
<24/40 
73.3% 14.6% 7.3% 2.4% 2.4% 100% 
No admissions 
<24/40 
66.2%       24.5% 5.4% 2.0% 1.9% 100% 
Admissions 
>24/40 
57.4%  31,3% 6.5% 2.3% 2.5% 100% 
No admissions  
>24/40 
67.8%  23.2% 5.3% 2.0% 1.9% 100% 
Any ADU 
attendance 
63.4%  26.0% 5.8% 2.5% 2.3% 100% 
No ADU 
attendances 
69.1%       22.7% 5.2% 1.5% 1.6% 100% 
Number of ADU 
attendances: 
      
ADU attendance 1 65.2% 24.5% 5.5% 2.4% 2.5% 100% 
ADU attendance 2 58.5% 30.7% 6.4% 2.6% 1.8% 100% 
ADU attendance 3 62.0%  25.2% 6.7% 3.8% 2.2% 100% 
ADU attendance 4 84.5%  8.5% 4.2% 1.4% 1.4% 100% 
ADU attendance 5 0.0%  66.7% 11.1% 11.1% 11.1% 100% 
Abdominal pain 64.2% 26.8% 4.9% 1.9% 2.2% 100% 
No abdominal 
pain 
66.7%   23.9% 5.6% 2.0% 1.9% 100% 
Itching 63.8%  24.8% 6.7% 2.9% 1.9% 100% 
No itching  66.3%       24.3% 5.4% 2.0% 1.9% 100% 
Fainting/dizziness 63.5%  21.2% 9.4% 4.1% 1.8% 100% 
No 
fainting/dizziness 
66.3%       24.4% 5.4% 2.0% 1.9% 100% 
IM iron 0.0%      0.0% 100% 0.0% 0.0% 100% 
No IM iron 66.3%  24.4% 5.5% 2.0% 1.9% 100% 
ECV 57.9%       33.1% 5.5% 1.4% 2.1% 100% 
No ECV 66.4% 24.2% 5.5% 2.0% 1.9% 100% 
PE Screen 55.7%  31.3% 8.0% 2.2% 2.7% 100% 
No PET screen 67.2% 23.7% 5.2% 2.0% 1.9% 100% 
CTG (antenatal) 52.3%  37.5% 6.2% 1.2% 1.8% 100% 
No CTG 
(antenatal) 
66.7%  23.9% 5.4% 2.0% 1.9% 100% 
Growth scan 82.8%  6.9% 6.9% 1.2% 2.3% 100% 
No growth scan  66.1%  24.5% 5.4% 2.0% 1.9% 100% 
Reduced fetal 
movements  
63.6%  26.0% 5.6% 3.3% 1.7% 100% 
No reduced fetal 
movements 
66.7%  24.1% 5.4% 1.8% 2.0% 100% 
Possible ROM 64.0%  25.6% 55.4% 2.7% 2.4% 100% 
No attendance for 
suspected ROM 
66.64       24.2% 5.5% 1.9% 1.9% 100% 
Generally unwell 61.6%      20.1% 8.8% 6.4% 3.1% 100% 
No attendance for 
feeling generally 
unwell 
66.4%      24.5% 5.3% 1.8% 1.9% 100% 
Possible UTI 0.0%      50% 50% 0.0% 0.0% 100% 
No suspicion of 
UTI 
66.3%       24.3% 5.4% 2.0% 1.9% 100% 
Severe headaches 0.0%     100% 0.0% 0.0% 0.0%            0.1% 
No severe 
headaches 
66.3%       24.3% 5.5% 2.0% 1.9% 100% 
PV bleed - 
not requiring 
admission 
66.5%       22.3% 5.2% 3.4% 2.6% 100% 
No PV bleed- not 
requiring 
admission 
66.3%  24.4% 5.5% 1.9% 1.9% 100%   
  207 
Chest pain/  
shortness of 
breath 
74.4%  20.4% 1.4% 1.9% 1.9% 100% 
No chest pain or 
shortness of 
breath 
66.1%  24.4% 5.5% 2.0% 1.9% 100% 
Placenta praevia  
Placenta praevia 20.0%      31.7% 15.0% 5.0% 28.3% 100% 
No placenta 
Praevia 
66.5%       24.3% 5.4% 2.0% 1.8% 100% 
Major placenta 
praevia 
0.0%       41.9% 22.6% 0.0% 35.5% 100% 
No major placenta 
praevia 
66.5%      24.3% 5.4% 2.0% 1.8% 100% 
Minor placenta 
praevia 
42.9%       21.4% 7.1% 10.7% 17.9% 100% 
No minor placenta 
praevia 
66.3%      24.4% 5.5% 2.0% 1.9% 100% 
Anterior placenta 
praevia 
0.0%       0.0% 35.3% 5.9% 58.8% 100% 
No anterior  
placenta praevia 
66.3%  24.4% 5.4% 2.0% 1.9% 100% 
Posterior placenta 
praevia 
 28.6%       45.2% 7.1% 4.8% 14.3% 100% 
No posterior  
placenta praevia 
66.4%       24.3% 5.5% 2.0% 1.9% 100% 
APH 59.3%       23.9% 8.1% 2.6% 6.0% 100% 
No APH 66.5%       24.4% 5.4% 1.9% 1.8% 100% 
Gestation of APH  
< 24/40 
45.3%       47.2% 1.9% 1.9% 3.8% 100% 
Gestation of APH 
>24/40 
61.6%       20.1% 9.2% 2.7% 6.4% 100% 
UTI (confirmed) 64.0%      24.9% 6.0% 2.4% 2.7% 100% 
No UTI 66.4%      24.3% 5.4% 2.0% 1.9% 100% 
Number of UTI =1 64%       25.0% 5.9% 2.4% 2.8% 100% 
Number of UTI =2 66.2%  24.3% 6.8% 1.4% 1.4% 100% 
Number of UTI =3 0.0%  0.0% 0.0% 100% 0.0%            100% 
Gestational 
hypertension 
46.6%  40% 8.3% 1.4% 3.8% 100% 
No gestational  
hypertension 
66.8%  23.9% 5.4% 2.0% 1.9% 100% 
Pre-eclampsia 29.9%       51.5% 11.3% 2.5% 4.9% 100% 
No Pre-eclampsia 67%  23.9% 5.3% 2.0% 1.9% 100% 
Pre-eclampsia 
<34 weeks 
23.1%       48.1% 21.2% 3.9% 3.9% 100% 
No Pre-eclampsia 
<34 weeks’ 
66.5%      24.2% 5.4% 2.0% 1.9% 100% 
Pre-eclampsia 
34+ weeks’ 
32.2%  52.6% 7.9% 2.0% 5.3% 100% 
No pre-eclampsia 
34+ weeks’ 
66.8%       23.9% 5.4% 2.0% 1.9% 100% 
Anaemia  
Hb <10.5 g/ml) 
63.3%  24.7% 6.7% 3.2% 2.2% 100% 
No anaemia 
<10.5 g/ml 
66.7%       24.4% 5.3% 1.8% 1.9% 100% 
Anaemia (Hb 
<11.1 g/ml) 
30.3% 29.8% 32.7% 38.4% 26.9% 30.4% 
No anaemia  
<11.1 g/ml 
66.0%       23.9% 5.9% 2.5% 1.7% 100% 
Antenatal day unit, ADU; intramuscular, IM; external cephalic version, ECV; pre-eclampsia, 
PET; cardiotocograph, CTG; rupture of membranes, ROM; urinary tract infection, UTI; per 
vagina, PV; antepartum haemorrhage, APH. 
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The incidence of severe haemorrhage defined as EBL exceeding 1500 ml was 
higher in women with placenta praevia. Women who had an antepartum 
haemorrhage (APH) >24 weeks’ were more likely to experience greater estimated 
blood loss (Table 4.4c). Women with pre-eclampsia and anaemia (Hb <11.1 g/l in 
third trimester, but prior to onset of labour) were also more likely to experience 
PPH ≥500 ml. There were no trends for greater estimated blood loss in women 
who had vaginal bleeding in early pregnancy (prior to 24 weeks’ gestation).  
 
 
6.9.4 Intrapartum events and management and estimated 
blood loss category 
Table 6.6d shows that more women who had induced and augmented onset of 
labour experienced estimated blood loss over 500 ml. There appeared to be a 
linear trend between raised maternal temperature in labour and higher categories 
of estimated blood loss. This was the single most missing data point in the 
reviewed notes. Therefore this analysis was undertaken with all available data, 
and then repeated treating missing as ‘unknown’. In both analyses maternal 
pyrexia was associated with increased estimated blood loss (Table 6.6d). 
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Table 6.6d: Percentage of women affected, according intrapartum, birth and third 
stage management factors, and estimated blood loss at different thresholds. 






n sampled 653 427 477 167 171 1895 
n represented 6585 2419 542 198 193 9937 
Group 7: intrapartum and delivery 
Onset of labour 
spontaneous 
74.1%       18.6% 4.2% 1.6% 1.5% 100% 
Induced 59.1%   27.7% 7.9% 2.8% 2.5% 100% 
Augmented 58.4%       29.2% 5.4% 2.9% 4.1% 100% 
No labour onset 35.1%       50.1% 9.1% 2.9% 2.8% 100% 
Highest temperature 
in  
labour ≥37.0°C  
treating missing 
as unknown 









































as unknown  
66.7% 24.2% 5.4% 1.9% 1.9% 100% 
Duration of ruptured 
membranes (days) 
0.4 (0.7)  0.6 (0.7) 0.6 (0.8) 0.7 (0.9) 0.6 (0.7)       0.5 (0.7) 
Duration of ROM 
(days)= 0 
71.8%       20.2% 4.7% 1.8% 1.5% 100% 
Duration of ROM 
(days)= 1 
60.3%         27.0% 5.6% 2.7% 4.4% 100% 
Duration of ROM 
(days)= 2+ 
56.9%       31.5% 6.9% 2.8% 1.9% 100% 
Dinoprostone 58.7%       29.3% 6.8% 2.7% 2.5% 100% 
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No dnoprostone 67.6%      23.5% 5.2% 1.9% 1.8% 100% 
Dinoprostone  dose 0.2 (0.6) 0.3 (0.8) 0.4 (1.0) 0.5 (1.3) 0.3 (0.9) 0.2 (0.7) 
Dinoprostone = 1 60.7%  28.7% 6.3% 2.1% 2.3% 100% 
Dinprostone = 2+ 54.5%       30.5% 7.8% 4.1% 3.1% 100% 
Oxytocin 
(Syntocinon®) 
during 1st/2nd stage 




stage of labour 
71.5%       21.1% 4.2% 1.7% 1.6% 100% 
Mode of delivery- 
SVD 
85.2%       10.0% 2.1% 1.3% 1.4% 100% 
Operative vaginal 
delivery 
58.3%      29.8% 7.0% 2.5% 2.5% 100% 
ElCS 37.5%       50.8% 8.0% 1.9% 1.7% 100% 
EmCS 23.9%       54.1% 14.3% 4.1% 3.7% 100% 
Physiological 3rd 
stage 
84.1%       13.8% 0.7% 1.1% 0.3% 100% 
Active management 
of third stage of 
labour 




72.9  14.0% 7.4% 1.8% 3.9%           6.7% 
No Oxytocin 
(Syntocinon ®) IM 
(3rd stage) 
65.8%       25.1% 5.3% 2.0% 1.8% 100% 
Oxytocin 
(Syntocinon®) IV* 
31.1%       51.2% 11.5% 3.3% 3.0% 100% 
No Oxytocin 
(Syntocinon®) IV 



























79.0% 14.3% 3.6% 1.6% 1.5% 100% 
Retained placenta 37.0%  36.2% 14.5% 6.0% 6.4% 100% 
No retained 
placenta 





41.2% 17.7% 23.5% 17.7% 100% 
No evidence of 
chorioamnionitis 
66.4%       24.3% 5.4% 2.0% 1.9% 100% 
Rupture of membranes, ROM; international units IU; intramuscular, IM; intravenous, IV. * Routine 
prophylactic treatment as part of active management of third stage of labour. 
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All modes of delivery, apart from spontaneous vaginal birth, were associated with 
increased estimated blood loss categories. Eighty four per cent of women who 
had physiological management of the third stage of labour did not have excessive 
blood loss (<500 ml). All prophylactic uterotonics were associated with blood loss 
in all categories, with fewer women experiencing higher levels of estimated blood 
loss having received Ergometrine Maleate/Oxytocin (Syntometrine®) compared 
to those who received oxytocin (Syntocinon®); the exception being when 
oxytocin (Syntocinon®) is administered in a 40/50 IU infusion (Table 6.6d).  
 
 
6.9.5 Influence of place of birth and estimated blood loss 
category 
Forty percent of women giving birth in obstetric units experienced PPH ≥500 ml. 
The relationship between mode of delivery and place of birth should be 
considered in this result. The largest blood losses (2000+ ml) occurred in the 




Table 6.6e: Place of birth and incidence of blood loss at various levels 
 






n sampled 651 427 477 167 171 1893 
n represented 6583 2419 542 198 193 9935 
Place of birth 
Hospital  60.7%       28.1% 6.6% 2.3% 2.4% 100% 
Midwife-led unit 85.8%       11.5% 1.6% 0.7% 0.5% 100% 
Home 91.0%       4.9% 0.8% 3.3% 0.0% 100% 
Other* 91.4%        6.5% 0.0% 2.2% 0.0% 100% 
*Births not attended by midwives or doctors. All but one occurred outside hospital or midwife led unit, 
the majority were at home, but due to the unattended nature of the birth, these were analysed 
separately from planned or unplanned homebirths with a midwife present.  
 




The sample selection was appropriate and representative of the population from 
which it was drawn. There were, however, differences between this and the 
general UK population, particularly in terms of ethnicity and age. Incidence of 
pre-existing diseases was generally lower than reported elsewhere, the 
exceptions being ethnicity related (uterine fibroids and female genital mutilation).  
There were more primiparous women than reported elsewhere, which may reflect 
the inner city population served by Centre 1. 
 
 
Many factors previously identified as associated with PPH≥500 ml were confirmed, 
including: increasing maternal age (Cameron et al., 2006) primiparity (Gilbert et 
al., 1987), previous CS (Coulter-Smith et al., 1996), multiple pregnancy (Sebire 
et al., 2001), placenta praevia (Oyelese and Smullian, 2006), fibroids (Jolley, 
2009), female genital mutilation (Banks et al., 2006), induction of labour, elective 
and emergency CS, oxytocin (Syntocinon®) IV and retained placenta. The 
association with PPH ≥500 ml and Black African ethnicity, assisted conception 
techniques, gestational hypertension, pre-eclampsia and temperature in labour 
require further validation. Factors associated with EBL<500 ml included: 
multiparity, smoking at first antenatal contact, SVD, physiological management of 
the third stage of labour, prophylactic intramuscular Syntometrine® and, to a 
lesser degree, oxytocin (Syntocinon®).  
 
 
My study reports the highest rates of PPH at all thresholds, except >2500 ml, 
when the rate is comparable to contemporaneous data (Lennox C., 2011a). 
Intrapartum factors appeared to have the greatest impact on estimated blood 
loss, with all interventions conferring increased association with PPH. Some, such 
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CS, were associated with minor haemorrhage but not progression to more severe 
levels of estimated blood loss. The linear trend in increased estimated blood loss 
associated with maternal temperature is new and may be associated with 
evidence of chorioamnionitis, which was also associated with PPH. 
 
 
There was no difference in PPH incidence by day of the week or time of day for 
any mode of birth.  Giving birth in obstetric units was associated with higher 
levels of estimated blood loss, concurring with the findings of others (Hollowell et 
al., 2011). But complexity of cases and birth mode must be considered here. 
These results demonstrate the initial impact of factors whilst highlighting the 
complexity around risk factors for PPH at all levels. It is apparent that more 
analyses are required to further investigate the influences of individual and 
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Chapter 7: Results 2; Selection 
of variables prediction of PPH 
for use in regression models. 
Regression analysis facilitates statistical estimation of the relationships among 
variables. More precisely, it enables calculation of the impact of an independent 
variable on a dependent variable, in this case, estimated blood loss, whilst all 
other independent variables remain fixed (Field, 2009).  Multiple regression 
analysis is employed when there are several potential predictors, as in this case.  
Table 7.5 a, b and c identifies the influence of independent variables on estimated 
blood loss (mean ml) and independent predictors for PPH ≥500 ml in each of the 




7.2 Reference group selection 
 
A reference group is a group that other groups or individuals are compared to 
(Coggan, 2003). The purpose of a reference group is for comparison with the 
characteristics of another group or individual. Thus reference groups in this work 
were selected following discussion with the Stop Study Advisory Group and 
statistician. It was decided that groups considered “normal” (for example BMI 19-
24.9 kg/m2) or most common (for example, White ethnicity) would be the 
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Table 7.1: Reference groups and rationale for their use in this study 
Variable Reference group Reason for using this 
as reference group 
Age 20-24 years Reported as ideal time for 
childbirth. 
Ethnicity White Major ethnic group (60%) 
BMI 19- 24.9 kg/m2 “normal” BMI range. 
Parity 0 (primiparous women) Multiparity is reported to 
confer protection.  
Onset of labour spontaneous “normal” no intervention. 
Duration of ruptured 
membranes (ROM) 
1 hour Commonly ROM precedes 
labour, usually by at least 
an hour.  
ProsinE2® 0 (none) Spontaneous labour with 
no interventions 
considered normal. 
Mode of birth Spontaneous vaginal  
delivery (SVD) 






7.3 Factors and their influence on mean estimated 
blood loss 
 
Factors not significantly associated with increased mean estimated blood loss 
included: maternal age <20 years; maternal ethnicity- Black British, Black 
Caribbean, Bangladeshi, Indian, Pakistani, Asian (other than Chinese); all 
categories of BMI; all but one category assessing index of multiple deprivation; 
pre-existing maternal diseases- diabetes, epilepsy, depression, lupus, anaemia, 
essential hypertension female genital mutilation and gestation at booking.  
 
 
Table 7.2a shows pre-pregnancy factors that appear to be independently 
significantly associated with increased mean estimated blood loss. These included 
maternal age (67 ml for each 10 years, 95% CI 38 to 97 ml) in addition to a 
linear increase with age groups: 25-29 years 78 ml (23 to 133 ml), 30-34 years 
102 ml (48 to 157 ml), 35-39 years 115 ml (54 to 176 ml), ≥40 years 123 ml (31 
to 215 ml). Ethnicities associated with increased mean estimated blood loss: 
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Black African 128 ml, (64 to 192 ml), Chinese 237 ml (34 to 441 ml) and 
unknown 90 ml (1 to 180 ml). One aspect of the Index of multiple deprivation 
(IMD)- barriers to housing and services was associated with estimated increased 
mean blood loss of 61 ml (22 to 100 ml). Whilst the impact of BMI (1 to 10 ml) 
for each unit of BMI, would appear modest at first glance, the cumulative affect 
on the obese and morbidly obese should not be underestimated. 
 
 
The only significant pre-existing medical condition associated with increased 
mean estimated blood loss was uterine fibroids 116 ml (4 to 229 ml). Assisted 
conception techniques were also associated with increased mean estimated blood 
loss, 234 ml (108 to 360 ml). Previous PPH and CS were associated with 
increased mean estimated blood loss 164 ml (7 to 284 ml) and 194 (116 to 271 
ml) respectively.  
 
 
Variables associated with reduced mean estimated blood loss were associated 
with some ethnicities, most apparent in those of mixed race, -96ml (-174 to -19 
ml). Other variables associated with reduced mean estimated blood loss included 
current cigarette smoking, -82 ml (-141 to -21); BMI<19 kg/m2, -93 ml (-152 to 
-34 ml) and multiparity -80 ml (-118 to -42 ml); para 1, -73ml (-119 to -27 ml); 
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Table 7.2a: Changes in estimated blood loss in Group A: Pre-pregnancy and 
principal predictors of postpartum haemorrhage (PPH) ≥500 ml  
 ml (range) Odds Ratio (OR)  
(95% CI) 




Group A: Pre-pregnancy 
i) Age 
Age for each 10 years 67 (38 to 97) 1.46 (1.21 to 1.77) 
Age in years 
20- 24 years reference group 
<20 years -17  (-99 to 65) 1.01 (0.51 to 2.00) 
25 – 29 years 78 (22 to 133) 1.79 (1.20 to 2.68) 
30 – 34 years 103 (48 to 158) 2.03 (1.39 to 2.96) 
35 – 39 years 115 (54 to 176) 2.00 (1.33 to 3.01) 
≥40 years 123 (31 to 215) 2.54 (1.44 to 4.48) 
Ethnicity 
White (reference group)   
Black British -53 (-152 to 46) 0.46 (0.20 to 1.06) 
Black Caribbean  -48 (-125 to 29) 1.01 (0.57 to 1.78) 
Black African  128 (64 to 192) 1.68 (1.23 to 2.28) 
Bangladeshi -78 (-170 to 14) 0.56 (0.22 to 1.46) 
Indian  117 (-33 to 267) 1.40 (0.73 to 2.67) 
Pakistani 45 (-39 to 128) 1.13 (0.62 to 2.04) 
Chinese 237 (34 to 441) 2.54 (0.73 to 8.82) 
Other Asian  88 (-175 to 351) 1.35 (0.38 to 4.75) 
Mixed -96 (-174 to -19) 0.59 (0.26 to 1.33) 
Other/unknown 90 (1 to 180) 1.01 (0.60 to 1.71) 
ii) Local deprivation 
IMD*: most deprived 
quintile 
4 (-35 to 43) 1.00 (0.80 to 1.26) 
Barriers to housing & 
services 
61 (22 to 100) 1.29 (1.02 to 1.62) 
Crime & disorder -1 (-51 to 25) 1.00 (0.80 to 1.25) 
Education, skills & 
training 
-63 (-126 to 0) 0.57 (0.39 to 0.85) 
Employment -9 (-50 to 32) 0.88 (0.68 to 1.14) 
Health, deprivation & 
disability 
-5 (-51 to 41) 0.97 (0.72 to 1.30) 
Income 4 (-34 to 43) 0.99 (0.78 to 1.24) 
Living environment 29 (-9 to 68) 1.18 (0.94 to 1.48) 
iii) General and pre-existing health risk factors 
Current smoker -82 (-142 to -22) 0.74 (0.51 to 1.07) 
BMI per unit (kg/m2) 6 (1 to 10) 1.01 (0.99 to 1.04) 
BMI detail   
19.0 – 25.0 reference group   
<19 -93 (-152 to -34) 0.74 (0.45 to 1.23) 
25.1 – 30.0 24 (-25 to 74) 1.00 (0.75 to 1.33) 
30.1 – 35.0 51 (-21 to 124) 1.14 (0.79 to 1.66) 
≥35.1 97 (-26 to 220) 1.15 (0.67 to 1.97) 
Lupus -101 (-442 to 238) 0.48 (0.05 to 4.61) 
Diabetes  34 (-121 to 189) 1.31 (0.41 to 4.26) 
Epilepsy (on treatment) 46 (-120 to 212) 1.76 (0.33 to 9.46) 
Depression (on treatment) -49 (-128 to 29) 0.80 (0.39 to 1.62) 
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Anaemia  (iron at first 
appointment 
6 (-151 to 163) 0.76 (0.24 to 2.43) 
Essential hypertension 172 (-73 to 418) 2.09 (0.67 to 6.56) 
Uterine fibroids 116 (3 to 229) 1.60 (0.94 to 2.70) 
FGM 75 (-31 to 181) 1.15 (0.61 to 2.19) 
Clotting/ thrombotic 
disorders 
189 (-32 to 411) 3.14 (0.91 to 10.90) 
Uterine anomaly -26 (-365 to 312) 1.44 (0.13 to 15.66) 
Planned pregnancy 36 (-6 to 78) 1.06 (0.82 to 1.38) 
Assisted conception 234 (107 to 360) 3.80 (1.69 to 8.57) 
Gestation at booking -0 (-3 to 3) 1.00 (0.98 to 1.01) 
iv) Obstetric history 
Previous PPH 164 (7 to 320) 1.52 (0.86 to 2.68) 
>1 previous PPH 153 (22 to 284) 1.62 (0.99 to 2.64) 
Previous CS 195 (118 to 273) 2.80 (2.00 to 3.94) 
Parity (using 0 as reference 
range) 
  
1 -73 (-119 to -27) 0.64 (0.49 to 0.83) 
2 -96 (-150 to -41) 0.62 (0.44 to 0.89) 
3+ -77 (-161 to -7) 0.58 (0.37 to 0.91) 
Multiparity -80 (-118 to -42) 0.62 (0.50 to 0.78) 
For continuous measures (e.g. age, BMI) the change is given for each additional 10 years 
of age or 1kg/m2 of BMI.  For variables with more than 2 categories (e.g. ethnicity) a 
reference group is declared (White), and comparisons are made to this. * Index of multiple 
deprivation & subscales based on area of residence, UK, IMD; estimated blood loss, EBL; 




Independent factors arising during pregnancy and not significantly associated 
with increased mean estimated blood loss included: any antenatal admissions; 
elevated systolic or diastolic blood pressure at booking; abdominal pain; itching; 
fainting; external cephalic version; cardiotocography (CTG); growth scan; 
reduced fetal movements; possible spontaneous rupture of membranes (SROM); 
possible or confirmed urinary tract infection; antenatal day unit attendance for 
APH (no admission); chest pain/shortness of breath; anaemia (<11.0 g/l and 
<10.5 g/l); polyhydramnios; medications in pregnancy- anti allergy, anti 
eclampsia, antidepressants, antiemetics, asthma treatments, diabetic medication 
(oral and insulin), oral iron, steroids for maternal reasons, tocolytics and 
thyroxine. There was insufficient evidence to assess the effect of ursodeoxycholic 
acid (URSO) (given to women with obstetric cholestasis to ease pruritus). 
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Table 7.2b shows pregnancy events and health associated with increased mean 
estimated blood loss included: multiple pregnancy, 208 ml (90 to 326 ml), 
antenatal admissions >24 weeks gestation, 54 ml (0 to 107 ml); any antenatal 
day unit attendance 49 ml (11 to 87 ml); IM iron 512 ml (493 to 531 ml); pre-
eclampsia screen 81ml (12 to 150 ml); “generally unwell” (no diagnosis) 132 ml 
(13 to 251 ml); severe headaches 262 ml (243 to 281 ml).  
 
 
All placenta praevia was associated with increased mean estimated blood loss, 
1270 ml (410 to 2130 ml) anterior placenta praevia increased mean estimated 
blood loss by 2909 ml (1150 to 4669 ml). APH was associated with increased 
mean blood loss, 172 ml (15 to 329 ml) but “warning APH” (defined as recurrent, 
heavy, red) was associated with greater increased mean estimated blood loss 
1145 ml (325 to 1965 ml).  
 
 
Also associated with increased mean estimated blood loss was gestational 
hypertension 131 ml (11 to 252 ml), pre-eclampsia (all) 219 ml (113 to 326 ml), 
<34 weeks’ gestation 235 ml  (17 to 452 ml), >34 weeks’ gestation 212 ml (92 
to 333 ml). Medications in the last week of pregnancy associated with increased 
mean estimated blood loss included, antibiotics 52 ml (5 to 98 ml), 
antihypertensives 105 ml (927 to 182 ml), aspirin 129 ml (14 to 244 ml), blood 
thinners 174 ml (19 to 330 ml), steroids for fetal reasons 106 ml (12 to 201 ml) 
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Table 7.2b: Changes in estimated blood loss in group B: Current pregnancy, and 
principal predictors of postpartum haemorrhage ≥500 ml. 
 
 ml (range)    Odds Ratio (OR)  
(95% CI) 




Group B: Pregnancy 
v) Current pregnancy 
Multiple pregnancy 208 (90 to 326) 2.15 (1.05 to 4.41) 
Number of fetuses 215 (100 to 330) 2.18 (1.11 to 4.29) 
Antenatal admissions 
(any) 
42 (-10 to 94) 1.37 (1.01 to 1.87) 
Admissions >24/40 54 (0 to 107) 1.52 (1.10 to 2.09) 
sBP at booking  10 (-7 to 27) 1.04 (0.95 to 1.15) 
Booking sBP≥140 mmHg 234 (-42 to 510) 3.06 (0.87 to 10.75) 
Booking sBP ≥160 mmHg 788 (-415 to 1991) $ 
dBP at booking (for each 10 
mmHg) 
19 (-7 to 45) 1.07 (0.94 to 1.22) 
Booking dBP ≥90mmHg 115 (-145 to 374) 1.31 (0.45 to 3.83) 
Booking dBP ≥100mmHg 1345 (-334 to 3024) $ 
vi) Antenatal day Unit (ADU) 
Any ADU attendance 49 (11 to 87) 1.28 (1.02 to 1.60) 
>1 ADU attendance 27 (6 to 49) 1.15 (1.01 to 1.31) 
Abdominal pain 11 (-35 to 57) 1.10 (0.81 to 1.50) 
Itching 39 (-76 to 155) 1.13 (0.54 to 2.40) 
Fainting/ dizziness 39 (-89 to 167) 1.10 (0.48 to 2.51) 
IM iron 512 (493 to 531) * 
ECV 143 (-4 to 291) 1.40 (0.55 to 3.56) 
Pre-eclampsia screen 81 (12 to 150) 1.62 (1.07 to 2.43) 
CTG 43 (-54 to 140) 1.78 (0.94 to 3.36) 
Growth scan 33 (-190 to 256) 0.40 (0.12 to 1.31) 
Reduced fetal movements 4 (-54 to 62) 1.14 (0.82 to 1.59) 
Possible ROM 18 (-37 to 72) 1.12 (0.81 to 1.56) 
‘Generally unwell’ (no 
diagnosis) 
132 (13 to 251) 1.22 (0.66 to 2.23) 
Possible UTI 262 (-85 to 610) $ 
Severe headaches 262 (243 to 281) $ 
ADU for APH (no admission) 53 (-56 to 163) 0.99 (0.56 to 1.74) 
Chest pain/ shortness of 
breath 
-71 (-174 to 32) 0.67 (0.28 to 1.58) 
vii) Placenta praevia 
Placenta praevia 1270 (410 to 2130) 7.74 (1.02 to 58.41) 
Major placenta praevia 1931 (525 to 3336) NA 
Minor placenta praevia 477 (-41 to 996) 2.56 (0.30 to 21.59) 
Anterior placenta praevia 2909 (1150 to 4669) NA 
Posterior placenta 
praevia 
564 (61 to 1068) 4.81 (0.59 to 38.89) 
vii) APH and UTI 
APH 172 (15 to 329) 1.36 (0.78 to 2.37) 
“Warning” APH 1145 (325 to 1965) 7.26 (0.96 to 55.16) 
UTI 20 (-41 to 80) 1.08 (0.73 to 1.60) 
> 1 UTI 16 (-37 to 69) 1.07 (0.76 to 1.58) 
ix) Pre-eclampsia and anaemia 
Gestational hypertension 131 (11 to 252) 2.29 (1.15 to 4.54) 
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Pre-eclampsia (all) 219 (113 to 326) 4.63 (1.79 to 11.96) 
Pre-eclampsia <34/40 235  (17 to 452) 6.44 (0.81 to 51.41) 
Pre-eclampsia >34/40 212 (92 to 333) 4.12 (1.41 to 11.98) 
Anaemia<10.5 g/ml 40 (-20 to 101) 1.15 (0.83 to 1.60) 
Anaemia <11.1 g/ml 5 (-39 to 50) 1.00 (0.79 to 1.28) 
Polyhydramnios 75 (-178 to 328) 0.29 (0.03 to 2.90) 
x) Medications pre-delivery (in the week prior to birth) 
Allergy medications 141 (-63 to 346) 2.37 (0.78 to 7.16) 
Anti-eclampsia meds 165 (-114 to 444) 1.00 (0.19 to 5.25) 
Antibiotics 52 (5 to 98) 1.35 (1.02 to 1.80) 
Antidepressants/mood 
disorders 
12 (-107 to 131) 1.01 (0.48 to 2.09) 
Antiemetics -61 (-124 to 1) 0.74 (0.51 to 1.08) 
Antihypertensives 
(including for pre-eclampsia) 
105 (27 to 182) 1.76 (1.11 to 2.78) 
Aspirin 129 (14 to 244) 1.50 (0.81 to 2.81) 
Asthma medications 93 (-18 to 204) 1.71 (0.88 to 3.29) 
Blood thinners 174 (19 to 330) 1.58 (0.83 to 3.01) 
Medication for diabetes 100 (-44 to 244) 2.62 (1.04 to 6.57) 
Steroids for fetal reasons 106 (12 to 201) 1.17 (0.77 to 1.79) 
Oral iron 23 (-25 to 70) 1.08 (0.82 to 1.44) 
Steroids for maternal 
reasons 
53 (-65 to 170) 1.17 (0.59 to 2.33) 
Pain relief 154 (27 to 281) 1.62 (0.73 to 3.58) 
Threatened preterm birth 246 (-220 to 712) 1.77 (0.59 to 5.31) 
Thyroid disease 241 (-99 to 581) 1.55 (0.65 to 3.71) 
URSO $ $ 
Estimated blood loss, EBL; systolic blood pressure, sBP; diastolic blood pressure, dBP; 
antenatal day unit, ADU; imtramuscular, IM; external cephalic version, ECV; 
cardiotocograph, CTG; rupture of membranes, ROM; urinary tract infection, UTI; 
antepartum haemorrhage, APH; ursodeoxycholic acid, URSO; not applicable, NA; all 






The association between independent labour and birth factors with mean blood 
loss and PPH ≥500 ml are shown in Table 7.2c.  Independent labour and birth 
factors not significantly associated with increased mean estimated blood loss 
included gestational age at birth, administration of one dose of dinoprostone, 
duration of oxytocin (Syntocinon®) and unknown maternal temperature in labour. 
Third stage variables which failed to be significantly associated with increased 
mean estimated blood loss included oxytocin (Syntocinon®) IM, oxytocin 
(Syntocinon®) infusion increased and unknown interval to suturing of genital 
tract trauma. 
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Independent significantly associated labour and birth factors included maximum 
birth weight 50 ml  (15 to 85 ml), total birth weight 69 ml (38 to 101 ml), 
macrosomia >4 kg 128 ml (55 to 201 ml) and >4.5 kg 156 ml (31 to 281 ml). 
Induced and augmented labours were associated with 100 ml (50 to 150 ml) and 
113 ml (14 to 211 ml) respectively. Also associated with increased mean 
estimated blood loss were epidural analgesia 159 ml (117 to 202 ml), spinal 
anaesthesia 181 m (137 to 226 ml), temperature in labour >37.2°C suggested a 
linear trend with each increasing degree of temperature, and oxytocin 
(Syntocinon®) use in first and/or second stage of labour 137 ml (92 to 183 ml). 
 
 
Vaginal instrumental births (ventouse or forceps) were associated with increased 
mean estimated blood loss of 194 ml (132 to 255 ml), elective CS by 298 ml (238 
to 358 ml) and emergency CS by 409 ml (357 to 461 ml). Active management of 
the third stage utilising oxytocin (Syntocinon®) IV bolus, as prophylactic 
uterotonic, was associated with an increase in estimated mean blood loss by 317 




Intrapartum independent variables associated with reduced mean estimated 
blood loss were: physiological third stage of labour -177 ml (-223 to -130 ml) and 










  223 
 
Table 7.2c: Changes in estimated blood loss in group C: Labour and birth, and 
principal predictors of PPH ≥500 ml. 
 
 ml (range) Odds Ratio (OR)  
(95% CI) 




Group C: Labour and birth 
xi) Gestation at birth 
Gestational age at birth 0 (-9 to 9) 1.03 (0.98 to 1.09) 
xii) Birth weight 
Maximum birth weight* 
(kg) 
50 (15 to 85) 1.50 (1.22 to 1.85) 
Total birth weight (kg)* 69 (38 to 101) 1.55 (1.27 to 1.89) 
Macrosomia >4 kg 128 (55 to 201) 1.94 (1.33 to 2.82) 
Macrosomia >4.5kg 156 (31 to 281) 2.96 (1.19 to 7.36) 
xii) Onset of labour 
Spontaneous onset (reference group) 
Augmented 113 (14 to 211) 1.96 (1.19 to 3.24) 
Induced  100 (50 to 150) 1.90 (1.39 to 2.60) 
None (prelabour CS) 262 (202 to 323) 5.07 (3.41 to 7.53) 
Duration of ROM (days) 65 (28 to 102) 1.55 (1.20 to 1.99) 
Duration of ROM (hours)   
< 1 h (reference group) 
1-2 h  34 (-53 to 121) 1.16 (0.66 to 2.02) 
2-3 h 147 (45 to 249) 2.48 (1.40 to 4.40) 
3-6 h 78 (24 to 131) 1.76 (1.12 to 2.76) 
6-12 h 192 (135 to 250) 4.44 (2.91 to 6.78) 
12-24 h 253 (187 to 319) 6.33 (4.06 to 9.86) 
24+ h 198 (123 to 274) 4.23 (2.68 to 6.67) 
No ROM/ROM at CS 326 (259 to 392) 10.99 (6.70 to 18.04) 
Unknown ROM duration 280 (219 to 341) 6.39 (4.28 to 9.54) 
Dinoprostone 54 (5 to 104) 1.43 (1.04 to 1.96) 
Dinoprostone 0 (reference group) 
Dinoprostone x 1 27 (-29 to 84) 1.32 (0.91 to 1.92) 
Dinoprostone x 2+ 112 (26 to 199) 1.69 (1.00 to 2.87) 
xiv) Intrapartum 
Oxytocin (Syntocinon ®) 137 (92 to 183) 2.40 (1.84 to 3.14) 
Duration of oxytocin 
(Syntocinon®) 
10 (0 to 19) 1.06 (1.00 to 1.13) 
Spinal anaesthesia 181 (137 to 226) 4.10 (2.93 to 5.75) 
Epidural analgesia 159 (117 to 202) 2.91 (2.22 to 3.81) 
Temperature >37.2°C 190 (127 to 252) 2.65 (1.86 to 3.77) 
Temperature >37.5°C 282 (169 to 396) 4.60  (2.34 to 9.06) 
Temperature >37.8°C 413 (234 to 592) 7.94 (2.48 to 25.43) 
Temperature >38.0°C 724 (368 to 1080) 132.72 (17.53 to 
1004.68) 
Temperature unknown 41 (-2 to 84) 1.28 (1.00 to 1.65) 
Evidence of 
chorioamnionitis 
796 (261 to 1330) NA 
xv) Birth 
Mode of birth- SVD (reference group) 
Instrumental vaginal 
birth 
194 (132 to 255) 3.84 (2.71 to 5.44) 
Elective CS 298 (238 to 358) 8.95 (5.80 to 13.79) 
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Emergency CS 409 (357 to 461) 17.05 (11.47 to 25.34) 
xvi) third stage  
Physiological third stage -177 (-223 to -130) 0.47 (0.30 to 0.75) 
Oxytocin (Syntocinon® 
IM) 
18 (-71 to 106) 0.70 (0.44 to 1.11) 
Oxytocin (Syntocinon®) 
IV (bolus) 




-234 (-272 to -196) 0.19 (0.15 to 0.25) 
Oxytocin (Syntocinon®) 
IV increased 
36 (-23 to 94) 1.10 (0.71 to 1.69) 
Oxytocin (Syntocinon®) 
40/50 IU infusion 
commenced 
273 (232 to 313) 6.07 (4.64 to 7.92) 
Retained placenta 374 (154 to 594) 3.49 (1.55 to 7.82) 
Interval to suturing 113 (14 to 212) 0.97 (0.81 to 1.16) 
Unknown interval to 
suturing  
65 (-3 to 133) 1.69 (1.05 to 2.72) 
For variables with more than 2 categories (e.g. onset of labour) a reference group is 
declared (spontaneous), and comparisons are made to this. Not applicable NA; all women 
had EBL ≥500 ml; Caesarean section, CS; rupture of membranes, ROM; spontaneous 
vaginal delivery, SVD; intramuscular, IM; intravenous, IV. *maximum birth weight= 
weight of singleton baby, or heaviest baby in multiple pregnancy; total birth weight= 




7.4 Variables associated with PPH ≥500 ml  
 
With reference to Tables 7.2 a, b and c the odds ratios (OR) for PPH ≥500 ml 
were calculated. Effect size varied considerably, with the highest risk factors 
occurring closest to birth, as described below. 
 
7.4.1 Group A Pre-pregnancy associations with PPH ≥500 
ml 
 
Independent significant factors for increased mean estimated blood loss that 
failed to reach significance for PPH ≥500 ml were: Chinese ethnicity (OR 2.54, 
95% CI 0.73 to 8.82]) and unknown ethnicity (OR 1.01, 95% CI 0.60 to 1.71). 
Mixed ethnicity which was associated with reduced mean estimated blood loss 
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was also not significant when applied to PPH ≥500 ml (OR 0.59, 95% CI 0.26 to 
1.33) a similar effect was seen with smoking (OR 0.74, 95% CI 0.51 to 1.07), 
BMI (OR 1.01, 95% CI 0.99 to 1.04), uterine fibroids (OR 1.60, 95% CI 0.94 to 
2.70) and previous PPH (OR 1.52, 95% CI 0.86 to 2.68).  
 
Conversely IMD category ‘education skills and training’ whilst not significantly 
associated with increased mean estimated blood loss (OR -63 ml, 95% CI -126 to 
0 ml) was associated with reduced PPH≥500 ml (OR 0.57, 95% CI 0.39 to 0.85). 
Maternal age per 10 years was associated with increased risk of PPH ≥500 ml 
(OR 1.46, 95% CI 1.21 to 1.77). Further investigation showed a small 
incremental effect size with maternal age (25- 29 years OR 1.79, 95% CI 1.20 to 
2.68, to 40+ years OR 2.54, 95% CI 1.44 to 4.48). Other pre-pregnancy factors 
associated with a modest increased risk of PPH ≥500 ml were women of Black 
African ethnicity (OR 1.68, 95% CI 1.23 to 2.28) and in one component of the 
IMD (barriers to housing & services) (OR 1.29, 95% CI 1.02 to 1.62). 
 
Assisted conception (OR 3.80, 95% CI 1.69 to 8.57) and previous CS (both 
elective and emergency) (OR 2.80, 95% CI 2.00 to 3.94) conveyed moderate risk 
of PPH. Only multiparity (OR 0.62, 95% CI 0.50 to 0.78) was protective against 
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7.4.2 Group B Current pregnancy factors associated with 
PPH ≥ 500 ml 
Factors that failed to be significant for increased estimated mean blood loss, but 
are significantly associated with PPH ≥500 ml include: antenatal admissions (OR 
1.37 95% CI 1.01 to 1.87), ‘generally unwell’ (OR 1.22, 95% CI 0.66 to 2.23); 
pre-eclampsia <34 weeks’ (OR 6.44, 95% CI 0.81 to 51.41); APH (OR 1.36, 95% 
CI 0.78 to 2.37), ‘warning’ APH  (OR 7.26, 95% CI 0.96 to 55.16). Medications in 
the week preceding labour which also failed to be significantly associated with 
PPH ≥500 ml but were associated with increased mean estimated blood loss 
included; aspirin (OR 1.50, 95% CI 0.81 to 2.81), blood thinners (OR 1.58, 95% 
CI 0.83 to 3.01), steroids for fetal reasons (OR 1.17, 95% CI 0.77 to 1.79) and 
pain relief (OR 1.62, 95% CI 0.73 to 3.58). 
 
Current pregnancy factors with a small effect on PPH ≥500 ml (Table 5.2b) 
included: antenatal day unit attendance (any reason) (OR 1.28, 95% CI 1.02 to 
1.60); antenatal admission >24 weeks’ gestation (defined as at least 1 night 
antenatal inpatient stay: for any reason) (OR 1.52, 95% CI 1.10 to 2.09); pre-
eclampsia screen (serial BP/urinalysis/full blood screen/growth scan) (OR 1.62, 
95% CI 1.07 to 2.43). Medications in the week preceding birth associated with 
PPH were antibiotics (OR 1.35, 95% CI 1.02 to 1.80), antihypertensives (for 
gestational hypertension and pre-eclampsia) (OR 1.62, 95% CI 1.07 to 2.43). 
 
Factors with a moderate size effect on incidence of PPH ≥500 ml were multiple 
pregnancy (OR 2.15 95% CI 1.05 to 4.41); gestational hypertension (OR 2.29, 
95% CI 1.15 to 4.54) and diabetes medication in last week of pregnancy (both 
for pre-existing and gestational diabetes) (OR 2.62, 95% CI 1.04 to 6.59).  
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The largest size effects influenced by current pregnancy health and events were 
diagnosis of pre-eclampsia  (all) (OR 4.63, 95% CI 1.79 to 11.96) and after 34 
weeks’ gestation (OR 4.12, 95% CI 1.41 to 11.98) and placenta praevia, all 
degrees and positions (OR 7.74, 95% CI 1.02 to 58.41), women with anterior and 
major praevia all bled >500 ml).   
 
7.4.3 Group C Intrapartum, birth and third stage factors 
associated with PPH ≥500 ml 
Interval to suturing, although associated with increased mean estimated blood 
loss, was not significantly associated with PPH ≥500 ml (OR 0.97, 95% CI 0.81 to 
1.16). 
 
Labour and birth predictors of PPH ≥500 ml (Table 5.2c) in order of effect size 
were: maximum birthweight (weight of heaviest infant) (OR 1.50, 95% CI 1.22 to 
1.85) total birth weight (combined weights of infants in multiple pregnancies) (OR 
1.55, 95% CI 1.27 to 1.89); macrosomia (incrementally with birth weight >4 kg 
and >4.5 kg) (OR 1.94, 95% CI 1.33 to 2.82 and OR 2.96, 95% CI 1.19 to 7.36); 
induction of labour (OR 1.90, 95% CI 1.39 to 2.60); dinoprostone pessaries/gel 
(OR 1.43, 95% CI 1.04 to 1.96); two or more dinoprostone pessaries (or doses of 
gel) (OR 1.69, 95% CI 1.00 to 2.87); augmentation of the first and/or second 
stage of labour (OR 1.96, 95% CI 1.19 to 3.24) and duration of oxytocin 
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Moderate size effects were seen following the use of oxytocin (Syntocinon®) in 
the first and/or second stage of labour (OR 2.40, 95% CI 1.84 to 3.14); use of 
epidural analgesia (OR 2.91, 95% CI 2.22 to 3.81); duration of ROM, 2-3 hours 
(OR 2.48, 95% CI 1.40 to 4.40); instrumental vaginal birth (OR 3.84, 95% CI 
2.71 to 5.44) and retained placenta (OR 3.49, 95% CI 1.55 to 7.82). 
 
Large effect size was seen with; duration of ruptured membranes (ROM) 12-24 
hours (OR 6.33, 95% CI 4.06 to 9.86) spinal anaesthesia  (OR 4.10, 95% CI 2.93 
to 5.75); temperature in labour >37.5°C (OR 4.60, 95% CI 2.34 to 9.06), 
>37.8°C (OR 7.94, 95% CI 2.48 to 25.43), >38.0°C (OR 132.72, 95% CI 17.53 
to 1004.68).  
 
Evidence of chorioamnionitis was always associated with PPH ≥500 ml. 
 
Elective and emergency CS were both associated with PPH ≥500 ml  (OR 8.95, 
95% CI 5.80 to 13.79 and OR 17.05, 95% CI 11.47 to 25.34 respectively).  Third 
stage management associated with increased risk of PPH ≥500 ml included 
oxytocin (Syntocinon®) IV bolus (OR 8.56, 95% CI 6.42 to 11.41) and 40/50 IU 
infusion (OR 6.07, 95% CI 4.64 to 7.92). Conversely Ergometrine 
Maleate/Oxytocin (Syntometrine®) IM was associated with reduced risk of PPH 
≥500 ml (OR 0.19, 95% CI 0.15 to 0.25) as was physiological management of 
the third stage of labour (OR 0.47, 95% CI 0.30 to 0.75). 
 
 
  229 
7.5 Factors associated with PPH ≥1000 ml and 
≥1500 ml 
 
Further regression analyses were undertaken on a reduced dataset of all women 
who lost ≥500 ml (n= 1302) to ascertain the factors associated with PPH 
progression to ≥1000 ml and ≥1500 ml which could be considered more clinically 
important. In these analyses the association between individual variables and PPH 
≥1000 ml and ≥ 1500 ml are investigated. 
 
 
7.5.1 Pre-pregnancy factors associated with PPH ≥1000 
ml and ≥1500 ml 
Table 7.3a shows significant pre-pregnancy factors associated with PPH ≥1000 ml, 
although not progression to ≥1500 ml were: Black African ethnicity (OR 1.52, 
95% CI 1.09 to 2.12); BMI 25.1-30 (OR 1.44, 95% CI 1.04 to 2.00) and BMI 
≥35.1 (OR 2.02, 95% CI 1.11 to 3.68) and planned pregnancy (OR 1.36, 95% CI 
1.01 to 1.84). 
 
 
Pre-pregnancy factors associated with PPH ≥1000 ml and ≥1500 ml and shown in 
Table 7.3a included: IMD education, skills and training, (OR 1.92, 95% CI 1.13 to 
3.26 and OR 1.98, 95% CI 1.18 to 3.32); BMI per unit (OR 1.05, 95% CI 1.02 to 
1.08 and OR 1.04 95% CI 1.01 to 1.07) and BMI 30.1-35.0 (OR 1.66, 95% CI 
1.07 to 2.57 and OR 1.95, 95% CI 1.16 to 3.29). 
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Pre-pregnancy factors associated with PPH ≥1500 ml but not with lesser 
estimated blood loss were: previous PPH (OR 2.40, 95% CI 1.27 to 4.54) and >1 
previous PPH (OR 2.40, 95% CI 1.36 to 4.23), para 2 (those expecting their third 
child) (OR 1.73, 95% CI 1.04 to 2.88). Conversely essential hypertension was 
negatively associated with PPH ≥1500ml (OR 0.27, 95%CI 0.08 to 0.97). These 
data are also shown in Table 7.3a. 
 
 
Table 7.3a: Pre-pregnancy variables associated with postpartum haemorrhage 




Odds Ratio (OR) (95% CI) 
≥1000 ml (women 
with PPH ≥ 500 ml) 
≥1500 ml (women 
with PPH ≥500 ml) 
Group A: Pre-pregnancy 
i) Age 
Age for each 10 years 0.94 (0.75 to 1.17) 0.97 (0.76 to 1.25) 
Age at delivery in years 
20-24 years reference range   
<20 years 0.64 (0.27 to 1.52) 0.99 (0.41 to 2.40) 
25-29 years 0.76 (0.46 to 1.28) 0.92 (0.53 to 1.61) 
30-34 years 0.78 (0.48 to 1.29) 0.75 (0.43 to 1.30) 
35-39 years 0.84 (0.49 to 1.42) 1.06 (0.58 to 1.93) 
40+ years 0.64 (0.34 to 1.19) 0.70 (0.35 to 1.37 
Ethnicity 
White (reference group)   
Black British 2.31 (0.70 to 7.65) 2.01 (0.69 to 5.84) 
Black Caribbean 0.60 (0.32 to 1.11) 0.47 (0.21 to 1.03) 
Black African  1.52 (1.09 to 2.12) 1.13 (0.76 to 1.69) 
Bangladeshi 0.55 (0.17 to 1.82) 0.62 (0.15 to 2.52) 
Indian  1.21 (0.50 to 2.90) 1.44 (0.45 to 4.64) 
Pakistani 1.36 (0.67 to 2.76) 1.09 (0.45 to 2.64) 
Chinese 2.20 (0.76 to 6.31) 1.25 (0.46 to 3.41) 
Other Asian 0.80 (0.23 to 2.77) 0.73 (0.17 to 3.04) 
Mixed 0.83 (0.30 to 2.26) 0.52 (0.15 to 1.76) 
Other/unknown 1.23 (0.69 to 2.18) 1.27 (0.70 to 2.30) 
ii) Local deprivation 
IMD* most deprived 1.14 (0.87 to 1.49) 0.96 (0.69 to 1.34) 
Barriers to housing & 
services 
1.07 (0.82 to 1.40) 0.87 (0.64 to 1.20) 
Crime and disorder 0.85 (0.65 to 1.11) 0.88 (0.64 to 1.22) 
Education, skills & 
training 
1.92 (1.13 to 3.26) 1.98 (1.18 to 3.32) 
Employment 1.35 (1.00 to 1.83) 0.94 (0.68 to 1.29) 
Health, deprivation & 
disability 
0.90 (0.66 to1.24) 0.80 (0.56 to 1.15) 
Income 1.11 (0.85 to 1.46) 0.87 (0.63 to 1.20) 
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Living environment 0.95 (0.73 to 1.24) 0.76 (0.56 to 1.05) 
iii) General & medical risk factors 
Current smoker 0.47 (0.31 to 0.71) 0.48 (0.29 to 0.80) 
BMI per unit (kg/m2) 1.05 (1.02 to 1.08) 1.04 (1.01 to 1.07) 
BMI detail 
19.0 - 25.0 reference group   
<19.0 0.63 (0.35 to 1.13) 0.34 (0.15 to 0.81) 
25.1 - 30.0 1.44 (1.04 to 2.00) 1.33 (0.92 to 1.92) 
30.1 – 35.0 1.66 (1.07 to 2.57) 1.95 (1.16 to 3.29) 
35.1+ 2.02 (1.11 to 3.68) 1.62 (0.92 to 2.88) 
Lupus  $ $ 
Diabetes 0.89 (0.27 to 2.96) 0.91 (0.26 to 3.17) 
Epilepsy (on treatment) 0.54 (0.12 to 2.42) 1,04 (0.22 to 4.99) 
Depression (on treatment) 0.54 (0.24 to 1.22) 0.77 (0.31 to 1.89) 
Anaemia (iron at first 
appointment) 
1.46 (0.39 to 5.45) 1.31 (0.35 to 4.95) 
Essential hypertension 1.08 (0.42 to 2.80) 0.27 (0.08 to 0.97) 
Uterine fibroids 1.27 (0.76 to 2.14) 0.62 (0.35 to 1.11) 
FGM 1.21 (0.62 to 2.34) 1.72 (0.86 to 3.41) 
Clotting/ thrombotic 
disorders 
1.04 (0.36 to 3.05) 0.76 (0.19 to 3.00) 
Uterine anomaly 1.22 (0.13 to 11.76) 0.60 (0.05 to 6.67) 
Planned pregnancy 1.36 (1.01 to 1.84) 1.08 (0.73 to 1.60) 
Assisted conception 1.08 (0.58 to 2.01) 1.32 (0.57 to 3.07) 
Gestation at booking 1.00 (0.98 to 1.02) 0.98 (0.95 to 1.00) 
iv) Obstetric history 
Previous PPH 1.19 (0.67 to 2.11) 2.40 (1.27 to 4.54) 
>1 previous PPH 1.09 (0.68 to 1.73) 2.40 (1.36 to 4.23) 
Previous CS 0.77 (0.56 to 1.06) 0.76 (0.47 to 1.22) 
Parity (using 0 as reference group) 
1 1.13 (0.82 to 1.55) 1.11 (0.74 to 1.68) 
2 1.26 (0.82 to 1.92) 1.73 (1.04 to 2.88) 
3+ 1.05 (0.61 to 1.81) 1.50 (0.75 to 3.03) 
Multiparity 1.15 (0.88 to 1.50) 1.31 (0.93 to 1.86) 
For continuous measures (e.g. age, BMI) the change is given for each additional 10 years 
of age or 1 kg/m2 of BMI.  For variables with more than 2 categories (e.g. ethnicity) a 
reference group is declared (White), and comparisons are made to this. Index of multiple 
deprivation & subscales based on area of residence, UK, IMD; numbers too small, $; 
female genital mutilation, FGM; Caesarean section, CS. 
 
 
7.5.2 Current pregnancy health and events associated 
with PPH ≥1000 ml and PPH ≥1500 ml. 
All results are shown in Table 7.3b, and summarised here.  
There were no pregnancy related/acquired variables associated with PPH 
progression to ≥1000 ml although not to ≥1500 ml. 
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Current pregnancy health variables associated with progression to both ≥1000 ml 
and ≥1500 ml included attendance at ADU feeling “generally unwell” with no 
definitive diagnosis (OR 2.33, 95% CI 1.13 to 4.81 and OR 2.30, 95% CI 1.09 to 
4.88); placenta praevia (all)  (OR 3.80, 95% CI 1.21 to 11.93 and OR 4.86, 95% 
CI 1.99 to 11.87); APH (OR 1.82, 95% CI 1.03 to 3.23 and 1.96, 95% CI 1.15 to 
3.34); ‘warning’ APH (OR 3.39, 95% CI 1.07 to 10.74 and OR 4.10, 95% CI 1.65 
to 10.20).  
 
 
Pre-pregnancy factors associated with PPH ≥1500 ml but not with lesser 
estimated blood loss were:  major placenta praevia (OR 3.67, 95% CI 1.26 to 
10.71) minor placenta praevia (OR 6.66, 95% CI 1.25 to 35.89) all women with 
anterior placenta praevia lost at least 1500 ml (OR 12.30, 95% CI 4.49 to 
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Table 7.3b: Current pregnancy variables associated with postpartum 




Odds Ratio (OR) (95% CI) 
≥1000 ml (women 
with PPH ≥500 ml) 
≥1500 ml (women 
with PPH ≥500 ml) 
Group B: Pregnancy 
v) Current pregnancy 
Multiple pregnancy 1.30 (0.68 to 2.48) 1.47 (0.80 to 2.70) 
Number of fetuses 1.24 (0.68 to 2.24) 1.44 (0.82 to 2.53) 
Antenatal admissions 0.93 (0.66 to 1.31) 0.84 (0.58 to 1.23) 
Admissions>24/40 0.86 (0.61 to 1.21) 0.80 (0.54 to 1.18) 
sBP at booking (for each 
10mmHg) 
1.02 (0.92 to 1.14) 1.02 (0.90 to 1.15) 
Booking sBP ≥140 mmHg 1.41 (0.56 to 3.53) 1.05 (0.41 to 2.68) 
Booking sBP ≥160 mmHg 0.20 (0.02 to 2.21) 0.54 (0.05 to 5.96) 
dBP at booking (for each 
10mmHg) 
1.10 (0.95 to 1.27) 1.05 (0.89 to 1.24) 
Booking dBP ≥90 mmHg 1.72 (0.57 to 5.14) 1.57 (0.57 to 4.38) 
Booking dBP ≥100 mmHg 1.20 (0.12 to 11.62) 1.85 (0.20 to 16.71) 
vi) Antenatal day Unit (ADU) 
Any ADU attendance 1.09 (0.84 to 1.42) 1.25 (0.91 to 1.72) 
>1 ADU attendance 1.04 (0.90 to 1.20) 1.08 (0.92 to 1.27) 
Abdominal pain 0.82 (0.59 to 1.15) 0.91 (0.63 to 1.31) 
Itching 1.22 (0.57 to 2.62) 1.20 (0.55 to 2.63) 
Fainting/ dizziness 1.78 (0.72 to 4.37) 1.27 (0.54 to 3.00) 
IM iron $ $ 
ECV 0.65 (0.27 to 1.60) 0.90 (0.59 to1.37) 
Pre-eclampsia screen 1.05 (0.70 to 1.59) 0.79 (0.49 to 1.29) 
CTG 0.65 (0.37 to 1.14) 0.59 (0.30 to 1.16) 
Growth scan 3.68 (0.46 to29.16) 1.64 (0.35 to 7.81) 
Reduced fetal movements 1.03 (0.69 to 1.53) 1.14 (0.68 to 1.88) 
Possible ROM 1.06 (0.72 to 1.58) 1.23 (0.75 to 2.02) 
Generally unwell  
(no diagnosis) 
2.33 (1.13 to 4.81) 2.30 (1.09 to 4.88) 
Possible UTI 2.44 (0.15 to 39.22) $ 
Severe headaches $ $ 
ADU for APH (no admission) 1.30 (0.71 to 2.40) 1.60 (0.87 to 2.92) 
Chest pain/shortness of 
breath 
0.68 (0.25 to 1.85) 1.29 (0.46 to 3.59) 
vii) Placenta praevia 
Placenta praevia 3.80 (1.21 to 11.93) 4.86 (1.99 to 11.87) 
Major placenta praevia 3.41 (0.86 to 13.51) 3.67 (1.26 to 10.71) 
Minor placenta praevia 4.09 (0.52 to 32.09) 6.66 (1.25 to 35.89) 
Anterior placenta praevia NA 12.30 (4.49 to 33.72) 
Posterior placenta 
praevia 
1.41 (0.41 to 4.87) 2.41 (0.74 to 7.86) 
viii) APH and UTI 
APH 1.82 (1.03 to 3.23) 1.96 (1.15 to 3.34) 
“Warning” APH 3.39 (1.07 to 10.74) 4.10 (1.65 to 10.20) 
UTI 1.10 (0.71 to 1.71) 1.12 (0.69 to 1.82) 
>1 UTI 1.09 (0.75 to 1.60) 1.10 (0.72 to 1.68) 
ix) Pre-eclampsia and anaemia 
Gestational hypertension 0.83 (0.45 to 1.55) 0.74 (0.39 to 1.41) 
Pre-eclampsia (all) 0.88 (0.45 to 1.70) 0.76 (0.39 to 1.50) 
Pre-eclampsia <34/40 1.47 (0.40 to 5.36) 0.73 (0.21 to 2.51) 
  234 
Pre-eclampsia >34/40 0.69 (0.34 to 1.42) 0.78 (0.35 to 1.72) 
Anaemia <10.5 g/ml 1.29 (0.89 to 1.86) 1.27 (0.84 to 1.92) 
Anaemia <11.1 g/ml 1.11 (0.83 to 1.48) 1.05 (0.74 to 1.48) 
Polyhydramnios $ 6.57 (0.41 to 10.71) 
x) Medications pre-birth (in the week before birth) 
Allergy medications 0.96 (0.40 to 2.30) 1.16 (0.46 to 2.90) 
Anti- eclampsia 2.85 (0.35 to 23.30) 1.97 (0.37 to 10.67) 
Antibiotics 1.07 (0.78 to 1.45) 1.08 (0.76 to 1.53) 
Antidepressants/mood 
disorders 
1.63 (0.63 to 4.20) 1.22 (0.39 to 3.82) 
Antiemetics 1.17 (0.71 to 1.93) 0.89 (0.50 to 1.57) 
Antihypertensives 
(including for pre-eclampsia) 
0.95 (0.62 to 1.48) 0.79 (0.50 to 1.27) 
Aspirin 1.07 (0.57 to 2.02) 1.02 (0.55 to 1.91) 
Asthma medication 1.08 (0.52 to 2.23) 0.47 (0.22 to 1.00) 
Blood thinner 1.48 (0.74 to 2.56) 1.39 (0.75 to 2.58) 
Medications for diabetes 0.88 (0.42 to 1.83) 0.91 (0.42 to 2.00) 
Steroids for fetal reasons 1.45 (0.91 to 2.31) 2.06 (1.25 to 3.40) 
Oral iron 1.37 (0.99 to 1.88) 1.40 (0.99 to 2.00) 
Steroids for maternal 
reasons 
1.26 (0.55 to2.88) 1.67 (0.69 to 4.02) 
Pain relief 0.93 (0.45 to 1.92) 1.38 (0.65 to 2.91) 
Threatened preterm birth 0.68 (0.25 to 1.85) 0.65 (0.21 to 2.04) 
Thyroid disease 1.40 (0.55 to3.58) 2.04 (0.75 to 5.57) 
URSO $ $ 
Not applicable, NA; all women had estimated blood loss >1000 ml; numbers too small, $; 
systolic blood pressure, sBP; diastolic blood pressure, dBP; antenatal day unit, ADU; 
intramuscular, IM; external cephalic version, ECV; cardiotocograph, CTG; rupture of 
membranes, ROM; urinary tract infection, UTI; antepartum haemorrhage, APH.    
 
 
7.5.3 Intrapartum factors associated with PPH ≥1000 ml 
and ≥1500 ml 
Intrapartum factors associated with PPH progression to ≥1000 ml although not to 
≥1500 ml are shown in Table 7.3c and included: total birth weight (OR 1.25, 
95% CI 1.04 to 1.51); macrosomia >4 kg (OR 1.64, 95% CI 1.11 to 2.41). Active 
management of third stage of labour with oxytocin (Syntocinon®) IM (OR 2.40, 
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Intrapartum factors associated with progression to both ≥1000 ml and ≥1500 ml 
included: retained placenta (OR 1.92, 95% CI 1.04 to 3.54 and OR 1.76, 95% CI 
1.01 to 3.06); and interval to suturing of genital tract trauma (OR 1.33, 95% CI 
1.11 to 1.59 and OR 1.44, 95% CI 1.21 to1.72) (Table 7.3c). 
 
Negatively associated factors for PPH ≥1000 ml and ≥1500 ml, shown in Table 
7.3c, included: No labour onset (prelabour CS) (OR 0.68, 95% CI 0.49 to 0.94 
and 0.56, 95% CI 0.38 to 0.84); no duration of ROM at CS (OR 0.38, 95% CI 
0.22 to 0.63 and 0.21, 95% CI 0.12 to 0.37). Spinal anaesthesia (OR 0.51, 95% 
CI 0.38 to 0.68 and OR 0.37, 95% CI 0.25 to 0.54). Elective CS (OR 0.40, 95% 
CI 0.27 to 0.60 and 0.20, 0.13 to 0.33). Emergency CS (OR 0.71, 95% CI 0.50 to 
1.00 and 0.37, 0.25 to 0.55).  
 
Table 7.3c also shows third stage management negatively associated with PPH 
≥1000 ml and ≥1500 ml were: prophylactic oxytocin (Syntocinon®) IV bolus (OR 
0.69, 95% CI 0.52 to 0.90 and OR 0.44, 95% CI 0.32 to 0.60) and oxytocin 
(Syntocinon®) 40/50 IU infusion commenced (OR 0.62, 95% CI 0.48 to 0.81 and 
0.46, 95% CI 0.34 to 0.63). Duration of ROM, 6-12 hours (OR 0.45, 95% CI 0.27 
to 0.75); duration of ROM, 12-24 hours (OR 0.57, 95% CI 0.34 to 0.96); epidural 
analgesia (OR 0.71, 95% CI 0.52 to 0.97), instrumental vaginal birth (OR 0.45, 
95% CI 0.29 to 0.70); and unknown interval to suturing genital tract trauma (OR 
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Table 7.3c: Intrapartum variables associated with postpartum haemorrhage 
(PPH) to ≥1000 ml and ≥1500 ml. 
 
Variable 
Odds Ratio (OR) (95% CI) 
≥1000 ml (women 
with PPH ≥500 ml) 
≥1500 ml (women 
with PPH ≥ 500 ml) 
Group C: Labour and birth 
xi) gestation at birth 
Gestational age at birth 1.01 (0.95 to 1.07) 0.96 (0.91 to 1.02) 
xii) Birth weight 
Maximum birth weight 
(kg) 
1.25 (1.04 to 1.51) 1.16 (0.93 to 1.44) 
Total birth weight (kg) 1.25 (1.04 to 1.51) 1.06 (0.83 to 1.35) 
Macrosomia >4 kg 1.64 (1.11 to 2.41) 1.21 (0.76 to 1.95) 
Macrosomia  >4.5kg 1.21 (0.60 to 2.43) 0.81 (0.38 to 1.71) 
xiii) Onset of labour 
Spontaneous onset (reference group) 
Augmented 0.98 (0.55 to 1.76) 1.21 (057 to 2.58) 
Induced 1.10 (0.77 to 1.57) 0.89 (0.60 to 1.33) 
None (prelabour CS) 0.68 (0.49 to 0.94) 0.56 (0.38 to 0.84) 
Duration of ROM (days) 0.97 (0.79 to 1.20) 0.93 (0.70 to 1.23) 
Duration of ROM (hours) 
< 1h reference group   
1-2 h 1.00 (0.42 to 2.41) 1.55 (0.61 to 3.97) 
2-3 h 0.89 (0.39 to 2.05) 0.83 (0.30 to 2.31) 
3-6 h 0.80 (0.44 to 1.46) 0.68 (0.35 to 1.29) 
6-12 h 0.72 (0.43 to 1.22) 0.45 (0.27 to 0.75) 
12-24 h 0.73 (0.44 to 1.22) 0.57 (0.34 to 0.96) 
24+ h 0.81 (0.46 to 1.43) 0.80 (0.43 to 1.50) 
Length of ROM unknown 0.62 (0.38 to 1.01) 0.42 (0.25 to 0.68) 
No ROM/ROM at CS 0.38 (0.22 to 0.63) 0.21 (0.12 to 0.37) 
Dinoprostone 1.01 (0.72 to 1.43) 0.98 (0.66 to 1.45) 
Dinoprostone None reference group 
Dinoprostone x 1 0.92 (0.61 to 1.39) 0.85 (0.53 to 1.38) 
Dinoprostone x 2+ 1.20 (0.70 to 2.06) 1.23 (0.67 to 2.24) 
xiv) Intrapartum 
Oxytocin (Syntocinon®) 1.13 (0.86 to 1.49) 0.81 (0.58 to 1.14) 
Duration of oxytocin 
(Syntocinon®) (hours) 
1.02 (0.97 to 1.06) 1.03 (0.98 to 1.08) 
Spinal anaesthesia 0.51 (0.38 to 0.68) 0.37 (0.25 to 0.54) 
Epidural analgesia 0.95 (0.73 to 1.24) 0.71 (0.52 to 0.97) 
Temperature 
37.2°C 1.17 (0.83 to 1.64) 0.92 (0.62 to 1.38) 
37.5°C 1.23 (0.75 to 2.01) 1.12 (0.64 to 1.95) 
37.8°C 1.61 (0.82 to 3.15) 1.31 (0.62 to 2.78) 
38.0°C 2.14 (0.82 to 5.62) 2.49 (0.92 to 6.69) 
Temperature unrecorded 0.83 (0.63 to 1.10) 0.73 (0.53 to 1.01) 
Evidence of 
Chorioamnionitis 
3.50 (0.57 to 21.57) 4.65 (1.09 to 19.89) 
xv) Birth 
Mode of birth – SVD (Reference group 
Instrumental vaginal 
birth 
0.70 (0.47 to 1.06) 0.45 (0.29 to 0.70) 
Elective CS 0.40 (0.27 to 0.60) 0.20 (0.13 to 0.33) 
Emergency CS 0.71 (0.50 to 1.00) 0.37 (0.25 to 0.55) 
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xvi) Third stage of labour 
Physiological third stage 1.29 (0.71 to 2.36) 3.18 (1.75 to 5.77) 
Oxytocin (Syntocinon ®) 
IM 
2.40 (1.23 to 4.69) 1.83 (0.83 to 4.02) 
Oxytocin (Syntocinon®) 
IV (bolus) 




1.22 (0.91 to 1.63) 1.63 (1.15 to 2.29) 
Oxytocin (Syntocinon®) 
IV (increased) 
1.03 (0.64 to 1.68) 0.71 (0.42 to 1.18) 
Oxytocin (Syntocinon®) 
40/50 IU (infusion 
commenced) 
0.62 (0.48 to 0.81) 0.46 (0.34 to 0.63) 
Retained placenta 1.92 (1.04 to 3.54) 1.76 (1.01 to 3.06) 
Interval to suturing 
(genital tract trauma) 
1.33 (1.11 to 1.59) 1.44 (1.21 to 1.72) 
Interval to suturing not 
known 
0.78 (0.49 to 1.25) 0.56 (0.32 to 0.95) 
Caesarean section, CS; rupture of membranes, ROM; spontaneous vaginal delivery, SVD; 





7.6 Other indicators of severe blood loss 
 
7.6.1 Blood transfusion 
Overall 3.9% (95%CI 3.2 to 4.6) received a blood transfusion, the contribution of 
each Centre is shown in Table 7.4, the increased use in Centre 1 may represented 
the added complexity of the tertiary referral Centre. Despite both Centres having 
cell salvage available, only 1 woman, in Centre 2, received autologous transfusion. 
Twelve women received O rhesus negative blood, and 1 received ABO matched 
blood. Other blood products were utilised sparingly with minimal use of 
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Table 7.4: Blood transfusion rates in each Centre and combined 
 








Centre 1 308/6731 4.6% 3.5 to 5.6 
Centre 2 79/3206 2.4% 1.7 to 3.2 




7.6.2. Repair trauma and use of haemostatic suturing 
techniques 
Completion of genital tract trauma was effective at ameliorating blood loss prior 
to 1000 ml in 158 cases (132 in Centre 1 and 24 in Centre 2).  
 
 
In this cohort 9% of PPH ≥500 ml were treated by insertion of haemostatic 
suturing. Insertion of haemostatic sutures ameliorated blood loss before reaching 
1000 ml at CS in 199 women and following vaginal delivery for 24 women.  
Overall 155 women lost ≥1000 ml, required haemostatic sutures to arrest blood 
loss (134 following caesarean and 21 following vaginal birth, see Table 7.4).  
 
 
7.6. 3 Manual removal of placenta/ placental delivery 
Placental delivery, was undertaken in 3.5% of this cohort as an action to arrest 
bleeding (3.16%, 77/2430 in Centre 1; 4.0%, 26/649 in Centre 2). In these data 
most placentas were delivered within 2 hours. The longest delay in Centre 1 was 
4 hour 56 min, documented estimated blood loss 1300 ml, and in Centre 2 was 4 
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hour 5 min, documented estimated blood loss 1500 ml. Both cases were 
managed conservatively, as initial blood loss settled, but there was a subsequent 
substantial loss per vaginum, and manual removal was undertaken expediently.  
 
 
7.6.4 Vaginal packing and balloon tamponade 
Vaginal packing was employed in 24 women (1.2%) with EBL 500-999 ml in 
Centre 1 and none in Centre 2. In PPH ≥1000 ml, 6.9% of women were treated 
with a vaginal pack, 37 women in Centre 1 and 17 in Centre 2.  
Balloon tamponade was rarely employed in this cohort, and reserved for those 
who lost at least 1000 ml. In total 21 women received this treatment, 2.7% of 
those with PPH ≥1000 ml. 
 
 
7.6.5 Interventional radiology 
Despite the availability of interventional radiology on both sites, and cited as an 
effective treatment in both protocols, ligation of the uterine or internal iliac 
arteries was undertaken in 1 case (Centre 1). This concurs with the findings of 




There were 5 peripartum hysterectomies among 9935 births, a rate of 0.50 per 
1000 births, summary data regarding these are shown in Table 7.5.  
The majority (4/5) were undertaken in Centre 1, which may reflect the complex 
cases referred to this tertiary Centre. Eighty percent of these procedures were 
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undertaken in women with previous CS, confirming both the established 
association with uterine rupture and abnormal placentation reported previously 
(Al-Zirqi et al., 2010; Chattopadhyay et al., 1993). Eighty percent were also of 
Black African ethnicity, immigration history was not collected and therefore it is 
not possible to assess whether these women were born outside the UK, a factor 
noted as relevant in the most recent Confidential Enquiry into maternal death two 
women requiring peripartum hysterectomies registered late for antenatal care, 
another factor identified in the same report (CMACE, 2011). All but one of the 
women were over-weight or obese, and given the increasing numbers of women 
entering pregnancy with high BMIs, this underlines the importance of identifying 
effective strategies to improve pregnancy outcomes for heavier women (Oteng-




Table 7.5: Summary data for women requiring peripartum hysterectomy to 
control bleeding. 
 
ID and Centre Previous history Details Blood Loss 




Emergency CS for 
breech- not 
detected prior to 
full dilatation 
Admitted in spontaneous 
labour, screaming in pain. 
Sudden bradycardia. 
Emergency CS for uterine 
rupture. Transferred to 
HDU, continued bleeding, 
uterine atony. 
Transferred back to 
theatre EUA proceeded to 
hysterectomy. 



















Previous CS x3 
Late booker 
Placenta percreta 
suspected antenatally - 
radiology booked for 
elective CS, cross 
matched 6 units. Hb 9.1 
prior to delivery. 
CS in interventional 
radiology theatre. 
Interventional radiology 
inserted balloons to both 
uterine vessels prior to 
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partially separated - 




Proceeded to total 
abdominal hysterectomy, 
performed by consultant 
gynaecologist. Urologist 
present for hysterectomy.  





"Type IV placenta 
praevia, in labour - 
placenta encountered and 
baby delivered as breech 
through placenta in good 
condition. Placenta 
partially adherent and 
profuse bleeding seen 
originating from lower 
uterine segment. Anterior 
wall of uterus very thin 
probably due to placenta 
accreta. Rapid loss of 
blood - decision to 
perform hysterectomy 
taken." To ITU, but as no 
bed on HDU. 
Doctor 
estimated 





blood loss as 
6615 ml 





Late booker - unaware of 
pregnancy. 
Massive PPH at CS- 
atonic uterus, and 
bleeding from placental 
bed. Received 4 units 
RBC and 4 units FFP in 
theatre - medical 
attempts not effective, 
therefore hysterectomy 
performed. Further 2 
units blood transfused 
postnatally.  
Estimated 












notes as 3 l, 








No previous CS 
No previous PPH 
Arrived in labour ward in 
second stage. Proceeded 
rapidly to SVD. 2nd 
degree tear. 
Atonic uterus.  
8500 ml 
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7.6.7 Transfer to HDU/ITU 
Overall 86 (2.6%) women were transferred for high dependency or intensive care 
following PPH; 66 in Centre 1 and 20 in Centre 2.  
 
 
Due to variation in practice, with some units providing complex care, including 
mechanical ventilation in obstetric dependency units, whilst those without such 
facilities transfer women to general intensive care units, comparison with other 
data is problematic.  The Scottish Audit provides details of ITU admission where 
availability exists, but admissions are recorded as none in the absence of high 
dependency areas (Lennox, 2007). Reviews of admissions in Europe and Australia 
have also reported difficulties but suggest 0.7% of ITU admissions are associated 
with maternal morbidity and major obstetric haemorrhage is the most common 






The aim of the analyses in this chapter was to ascertain the impact of pre-
pregnancy, pregnancy acquired and intrapartum variables on mean estimated 
blood loss and PPH and different thresholds.  
 
 
Factors associated with PPH at different levels (≥500 ml; ≥1000 ml; ≥1500 ml) 
were inconsistent, with many being both causative and preventative at thresholds. 
Many previously identified factors that increase or attenuate risk of PPH have 
been confirmed, including: maternal age; BMI; ethnicity; primiparity; multiparity; 
maternal smoking; previous PPH; previous CS; placenta praevia; obstetric 
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cholestasis; induction and augmentation of labour; instrumental vaginal delivery; 
CS (elective and emergency); evidence of chorioamnionitis; interval to suturing. 
Additionally the complexity of different factors impact on estimated blood loss 
following birth has been highlighted.  Further statistical modeling is required to 
investigate the relative and cumulative impact of factors and the effect of 
interventions and actions that may attenuate blood loss. This is undertaken and 
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Chapter 8: Results 3; 
construction of statistical models 
to improve the prediction of 
postpartum haemorrhage ≥500 
ml, ≥1000 ml and ≥1500 ml 
 
Introduction 
Due to the inconsistent influence of the individual factors shown in previous 
analyses further investigation was required in order to assess the relative 
contribution of each factor, identification of those factors with greatest impact, 
and the cumulative effects of multiple factors that may increase and attenuate 
risk of PPH. Multiple regression modeling was employed to investigate the impact 
of sequentially introduced variables. 
 
Factors were selected from those employed in previous analyses (Chapters 6 and 
7) on the basis of statistical significance, 95% p values, rather than Odds Ratios 
(OR) and confidence intervals (CI). The rationale for this being, that although a 
high OR indicates a high risk with a particular exposure, when that exposure is 
rare, it is unlikely to be significant, with wide confidence intervals, and therefore 
the impact on the overall event rate is low (Coggan, 2003; Field, 2009).   
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Overall the number of factors needed to be reduced in order to a) ensure the 
behaviour of the model for the model fitting process, and b) maximise the 
practical usefulness of the model. The aim of the modeling was to identify a small 
number of statistically and clinically significant factors. Excessive numbers of 
factors would lead to reduced performance of the model in terms of it poorly 
discriminating those at risk. Factor selection was decided by clinical significance, 
defined as OR >2 (Coggan, 2003) or p=0.05 (Field, 2009). It has been proposed 
that when OR ≥2 but the confidence intervals cross one, caution should be 
exercised when claiming no clinical significance, as this can often be attributed to 




8.1 Risk factor modeling according to chronological 
sequence 
 
Multiple regression analysis was undertaken adding factors in chronological order 
to identify sequential risk factors for PPH acquired within the three groups A) pre-
pregnancy, B) during pregnancy, and C) labour and birth, and the 15 subgroups. 
This technique is similar to that described in hierarchical regression (blockwise 
entry), however the factors selected were from our own dataset and not those 
previously identified by others, as traditionally used in this technique (Field, 
2009). After the preliminary inclusion of all factors, those without clinical 
significance (OR<2 or confidence intervals crossing 1) (Coggan, 2003) or 
statistical significance (p=>0.05) were eliminated from the model (Field, 2009).  
 
 
This precluded the use of control variables, (irrespective of statistical significance) 
employed in some modeling techniques, concomitantly each factor was treated as 
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a predictor, with none considered as a control factor and consequently no 
adjusted results were produced (Field, 2009). 
 
8.2 Risk pathways for PPH ≥500 ml 
 
Table 8.1 shows the full regression model of the risk pathway for PPH ≥500 ml, 
resulting from 3 regression models selecting principal factors in groups A) pre-
pregnancy, B) pregnancy health and events and C) intrapartum, birth and third 




Group A) Pre-pregnancy risk factors reaching clinical or statistical significance 
included: maternal age (OR 1.45, 95% CI 1.19 to 1.76, p= <0.000); Black 
African ethnicity (OR 1.77, 95% CI 1.31 to 2.39, p= 0.000); BMI (OR 1.03, 95% 
CI 1.01 to 1.05, p=0.006); assisted conception (OR 2.93, 95% CI 1.30 to 6.59, 
p=0.010) and previous PPH (OR 2.34, 95% CI 1.30 to 6.59 p=0.003) with only 




With the addition of the factors in group B, pregnancy health and events, 
maternal age (OR 1.44, 95% CI 1.18 to 1.75, p=<0.000) remained, as did Black 
African ethnicity (OR 1.77, 95% CI 1.30 to 2.41, p=0.000) and BMI (OR 1.03, 
95% CI 1.00 to 1.05 p=0.016). Assisted conception remained in the model 
although now marginally insignificant (OR 2.28, 95%CI 0.99 to 5.29 p=0.054) 
and previous PPH (OR 2.45, 95% CI 1.38 to 4.35, p=0.002). Multiparity with no 
previous CS remained protective (OR 0.33, 95% CI 0.25 to 0.42, p=0.000). 
Added to these were multiple pregnancy (OR 2.27, 95% CI 1.04 to 4.96, 
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p=0.039), ‘warning’ APH (OR 8.95, 95% CI 1.02 to 78.7, p=0.048) and pre-
eclampsia (OR 3.16, 95% CI 1.12 to 8.93, p=0.030).  
 
 
All women with placenta praevia, regardless of degree and position, lost ≥500 ml, 
and therefore this variable was omitted from the prediction model for PPH  
≥500 ml as it provided 100% prediction (risk ratio 100%).  If included, the effect 
of this factor was so strong, the influence of other factors would not be apparent. 
We originally ran the model including placenta praevia, and it did, indeed, 
supersede all other factors. 
 
 
With the introduction of group C) Intrapartum, birth and third stage management 
variables age, assisted conception techniques, multiparity with no previous CS, 
multiple pregnancy and ‘warning’ APH failed to reach statistical significance. Only 
Black African ethnicity (OR 1.94, 95% CI 1.35 to 2.79, p=0.000) and previous 
PPH (OR 2.75, 95% CI 1.40 o 5.44, p=0.003) maintained statistical significance. 
Newly added significant factors were maximum birth weight (OR 2.19, 95% CI 
1.62 to 2.99, p=0.000); raised temperature in labour, per degree >37°C (OR 
2.62, 95% CI 1.24 to 5.52, p=0.001); instrumental vaginal delivery (OR 3.50, 
95% CI 2.21 to 5.24, p=0.000); elective CS (OR 24.4, 95% CI 5.53 to 108.0, 
p=0.000); emergency CS (OR 40.5, 95% CI 16.30 to 101.0, p=0.000); retained 
placenta (OR 21.3, 95% CI 8.31 to 54.70, p=0.000) interval to suturing (2.03, 
95% CI 1.65 to 2.50, p=0.000) and interval to suturing not known (OR 2.20, 
95% CI 1.32 to 3.69, p=0.003) .  
 
 
Conversely, Ergometrine Maleate/Oxytocin (Syntometrine®) IM (OR 0.55, 95% 
CI 0.33 to 0.91, p=0.019) and oxytocin (Syntocinon®) 40/50 IU infusion (OR 
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0.61, 95% CI 0.38 to 0.99, p=0.045) were protective for PPH ≥500ml. This 
information is shown diagrammatically in Figure 8.1. Whilst the majority of 
factors either clinically or statistically increasing risk of PPH ≥500ml occurred as a 
result of intrapartum or birth events, the only factor remaining significant from 
earlier inclusion were Black African ethnicity and previous PPH. There were 
several factors that, although initially statistically significant at inclusion, the 
subsequent addition of hierarchical factors rendered insignificant in the final 
model. These included: assisted conception techniques, maternal age and 
multiple pregnancy. 
Similarly multiparity with no previous CS was protective initially but was not 
statistically significant in the final model. 
 
 
Within the 16 subgroups several had no significant associations with PPH ≥500 ml, 
these were: Sub-group 2) local deprivation; 5) current pregnancy; 6) day unit 
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Table 8.1: Risk pathways for postpartum haemorrhage (PPH) ≥500 ml according to chronological variables grouped as pre-pregnancy, 
pregnancy, labour and birth. Full regression model; result of three multiple regression models selecting the principal significant variables. In each 
model, an additional group of predictors is added. Results adjusted for other members of the same group and for previous groups only. 
 
Risk factors included in final model  Pre-Pregnancy 
Variable subgroups 1-4 
(1895 women included) 
 
OR (95% CI), p 
During Pregnancy 
Variable subgroups 1-10 
(1868 women included; 27 excluded due to 
1 missing data and 26 perfectly predicted) 
OR (95% CI), p 
Labour and Birth 
Variable subgroups 1- 16 
(1724 women included; 171 excluded due to 135 
missing data, 36 perfectly predicted) 
OR (95% CI), p 
1) Sociodemographic 
Age, for each 10 years 1.45 (1.19 to 1.76), 0.000 1.44 (1.18 to 1.75), 0.000 0.93 (0.73 to 1.19), 0.57 
Black African 1.77 (1.31 to 2.39), 0.000 1.77 (1.30 to 2.41), 0.000 1.94 (1.35 to 2.79), 0.000 
2) Local Deprivation: index of multiple deprivation, most deprived UK quintile (%) 
Barriers to housing and services 1.06 (0.87 to 1.33), 0.61 1.05 (0.83 to 1.32), 0.69 1.04 (0.79 to 1.36), 0.80 
Education, skills and training 0.93 (0.64 to 1.36), 0.72 0.93 (0.64 to 1.36), 0.71 1.03 (0.57 to 1.62), 0.89 
3) General and medical risk factors 
Current smoker 0.76 (0.54 to 1.09), 0.14 0.77 (0.53 to 1.10), 0.15 0.82 (0.53 to 1.28), 0.38 
BMI (kg/m2) 1.03 (1.01 to 1.05), 0.006 1.03 (1.00 to 1.05), 0.016 1.01 (0.99 to 1.04), 0.32 
Assisted conception 2.93 (1.30 to 6.59), 0.010 2.28 (0.99 to 5.29), 0.054 2.10 (0.83 to 5.33), 0.19 
4) Previous obstetric history 
Previous PPH 2.34 (1.33 to 4.12), 0.003 2.45 (1.38 to 4.35), 0.002 2.75 (1.40 to 5.44), 0.003 
Multiparous previous Caesarean 1.32 (0.93 to 1.87), 0.19 1.30 (0.91 to 1.86), 0.14 0.96 (0.61 to 1.51), 0.86 
Multiparous no previous Caesarean 0.33 (0.26 to 0.42), 0.000 0.33 (0.25 to 0.42), 0.000 0.79 (0.56 to 1.11), 0.18 
5) Current pregnancy 
Multiple pregnancy  2.27 (1.04 to 4.96), 0.039 2.02 (0.82 to 5.00), 0.13 
Admissions >24 weeks  0.82 (0.57 to 1.18), 0.28 0.82 (0.53 to 1.29), 0.39 
6) Antenatal day unit (ADU) attendances 
Any ADU attendance  1.06 (0.84 to 1.34), 0.62 0.95 (0.72 to 1.26), 0.74 
Preeclampsia screen  1.06 (0.65 to 1.75), 0.81 1.04 (0.57 to 1.91), 0.89 
Generally unwell  1.22 (0.68 to 2.18), 0.50 1.33 (0.69 to 2.60), 0.40 
7) Placenta praevia: All 26 women with major or anterior placenta praevia PPH ≥500 ml 
8) Antepartum haemorrhage (APH) & urinary tract infection 
APH  1.11 (0.62 to 1.99), 0.74 1.27 (0.65 to 2.51), 0.48 
‘Warning APH’  8.95 (1.02 to 78.7), 0.048 1.92 (0.19 to 19.3), 0.58 
9) Pre-eclampsia (PET) and anaemia 
Gestational hypertension  1.83 (0.83 to 4.03), 0.13 2.22 (0.87 to 5.63), 0.093 
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Pre-eclampsia   3.16 (1.12 to 8.93), 0.030 3.21 (0.94 to 10.90), 0.062 
10) Medications in pregnancy pre-birth 
Antibiotics  1.35 (1.01 to 1.80), 0.043 1.14 (0.77 to 1.66), 0.52 
Antihypertensives (including for PET)  0.75 (0.44 to 1.29), 0.30 0.66 (0.33 to 1.32), 0.24 
Diabetic Rx  1.89 (0.79 to 4.56), 0.15 1.20 (0.43 to 3.37), 0.73 
Steroids for fetal reasons  0.90 (0.57 to 1.43), 0.65 1.23 (0.69 to 2.18), 0.49 
11) Gestation at birth  
Gestation at delivery (weeks)   0.98 (0.90 to 1.08), 0.70 
12) Birth weight 
Maximum birth weight (Kg)   2.19 (1.62 to 2.99), 0.000 
13) Onset of labour 
No labour onset   1.51 (0.47 to 4.90), 0.49 
Induction   0.75 (0.39 to 1.46), 0.40 
Augmentation   0.83 (0.42 to 1.64), 0.59 
ROM >2 hours before onset   0.95 (0.64 to 1.41), 0.79 
ROM >6 hours before onset    1.35 (0.90 to 2.02), 0.14 
ROM not recorded   1.03 (0.60 to 1.77), 0.91 
14) Intrapartum: all 10 women with evidence of chorioamnionitis PPH ≥ 500 ml 
Dinoprostone   1.04 (0.53 to 2.02), 0.91 
Oxytocin (Syntocinon)   1.44 (0.95 to 2.16), 0.085 
Spinal anaesthesia   0.87 (0.51 to 1.49), 0.60 
Epidural analgesia   1.08 (0.71 to 1.65), 0.71 
Raised temperature (per degree>37.0°C)    2.62 (1.24 to 5.52), 0.011 
Temperature not recorded   0.75 (0.50 to 1.11), 0.15 
15) Birth 
Instrumental vaginal   3.50 (2.21 to 5.24), 0.000 
Elective Caesarean   24.4 (5.53 to 108.00), 0.000 
Emergency Caesarean section   40.5 (16.30 to 101.00), 0.000 
16) Third stage 
Physiological    1.48 (0.80 to 2.77), 0.22 
Ergometrine Maleate/Oxytocin 
(Syntometrine) IM  
  0.55 (0.33 to 0.91), 0.019 
Oxytocin (Syntocinon) IV bolus    0.58 (0.27 to 1.25), 0.17 
Oxytocin (Syntocinon) 40/50 IU 
infusion started 
  0.61 (0.38 to 0.99), 0.045 
Retained placenta   21.3 (8.31 to 54.70), 0.000 
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Suture interval after vaginal birth (h)   2.03 (1.65 to 2.50), 0.000 
Suture interval not recorded   2.2 (1.32 to 3.69), 0.003 
 


















"Warning " APH 
 




During pregnancy and  
Intrapartum 
Black African  
Previous PPH 
Placenta praevia* 
Maximum birth weight 
Temp >370C 




Interval to suturing 
 
Syntometrine IM 




Figure 8.1: Diagram of multiple logistic regression and chronological regression analysis showing predictors of PPH ≥500 ml 
(risk factors in white, protective factors in black). Postpartum haemorrhage, PPH; body mass index, BMI; Caesarean section, CS; intramuscular, IM; 
antepartum haemorrhage, APH; perfect prediction * 
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8.3 Risk pathways for PPH ≥1000 ml 
 
The same process was undertaken to investigate the risk pathway for PPH  
≥1000 ml. Table 8.2 shows the full regression model, resulting from 3 regression 
models selecting principal variables in groups A) pre-pregnancy, B) pregnancy 
health and events and C) intrapartum, birth and third stage management, and 
removing all those that fail to reach clinical or statistical significance.  
 
 
Group A) Pre-pregnancy risk factors reaching clinical or statistical significance 
include: BMI (OR 1.05, 95% CI 1.03 to 1.07, p=0.000); Black African ethnicity 
(1.44, 95% CI 1.12 to 1.85, p=0.005); previous PPH (OR 1.83, 95% CI 1.16 to 
2.90, p=0.010). Attenuating factors were multiparity with no previous CS (OR 
0.64, 95% CI 0.50 to 0.81, p=0.000) and current smoker at first antenatal 
appointment (OR 0.59, 95% CI 0.42 to 0.85, p=0.004).  
 
 
With the addition of pregnancy health and events factors, Group B, the factors 
remaining significant included Black African ethnicity (OR 1.44, 95% CI 1.12 to 
1.88, p=0.005); BMI (1.05, 95% CI 1.03 to 1.07, p=0.000) and previous PPH 
(OR 1.89, 95% CI 1.18 to 3.02, p=0.008). Multiparity with no previous CS 
remained protective (OR 0.62, 95% CI 0.49 to 0.80, p=0.000), as did smoking at 
first antenatal visit (OR 0.59, 95% CI 0.41 to 0.85, p=0.005). Added to these 
were multiple pregnancy (OR 2.09, 95% CI 1.17 to 3.74, p=0.013), antenatal 
attendance feeling ‘generally unwell’ (OR 1.71, 95% CI 1.03 to 2.84, p=0.039) 
and ‘warning’ APH (OR 4.23, 95% CI 1.03 to 17.4, p=0.045).  
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All women with anterior placenta praevia bled ≥1000 ml, and therefore this factor 
was omitted from the prediction model for PPH ≥1000 ml as it provided 100% 
prediction (risk ratio 100%).  As with all degrees of placenta praevia for lesser 
bleeds, if included, the effect of this factor was so strong, relatively the influence 
of other factors would not be apparent; and as with the smaller bleeds we 
originally ran the model including anterior placenta praevia, and it did, indeed, 
supersede all other variables. 
 
 
With the introduction of intrapartum, birth and third stage management variables, 
Group C, no earlier acquired significant risk factors became insignificant and IMD 
education, skills and training was added (OR 1.51, 95% CI 1.02 to 2.23, 
p=0.038). Newly added intrapartum significant factors were maximum birth 
weight (OR 1.71, 95% CI 1.35 to 2.18, p=0.000); maternal temperature in 
labour per degree >37°C (OR 1.74, 95% CI 1.10 to 2.75, p=0.019); oxytocin 
(Syntocinon®) during first or second stage of labour (induction or augmentation) 
(OR 1.42, 95% CI 1.02 to 1.96, p=0.037) instrumental vaginal delivery (OR 2.53, 
95% CI 1.72 to 3.73, p=0.000); elective CS (OR 3.51, 95% CI 1.24 to 9.97, 
p=0.018); emergency CS (OR 7.05, 95% CI 3.5 to 14.2, p= 0.000); retained 
placenta (OR 7.51, 95% CI 4.08 to 13.8, p=0.000) interval to suturing (OR 1.74, 
95% CI p=0.000) and interval to suturing not known (OR 1.74, 95% CI 1.46 to 
2.08, p=0.000). Conversely, prophylactic intramuscular administration of 
uterotonic Ergometrine Maleate/Oxytocin (Syntometrine®)  (OR 0.58, 95% CI 
0.38 to 0.89, p=0.013) was protective for PPH ≥1000 ml. These results are 
diagrammatically represented in Figure 8.2. 
 
 
In this analysis risk factors in the initial model remained statistically significant for 
PPH ≥1000 ml, these were Black African ethnicity, BMI and previous PPH. Current 
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smoking at booking also remained protective against PPH ≥1000 ml, although the 
protection for multiparous women with no previous CS was no longer significant 
once intrapartum factors were added. 
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Table 8.2: Risk pathways for postpartum haemorrhage (PPH) ≥1000 ml including all women and according to chronological variables 
grouped as pre-pregnancy, during pregnancy, labour and birth. Full regression model: result of three multiple regression models selecting the 
principal significant variables.  In each model, a new additional group of predictors is used.  Results are adjusted for other members of the same group 
and for previous groups only. All women included. 
 
Risk factors included in final model  
(1785 included; 110 excluded due to missing data, 
15 excluded with anterior placenta praevia as all 
women bled ≥1000 ml) 
Pre-Pregnancy 
Variable subgroups 1-4 
OR (95% CI), p 
During Pregnancy 
Variable subgroups 1-10 
OR (95% CI), p 
Labour and Birth 
Variable subgroups 1- 16 
OR (95% CI), p 
1) Sociodemographic 
Age, for each 10 years 1.18 (0.99 to 1.40), 0.072 1.19 (0.99 to 1.42), 0.061 0.97 (0.79 to 1.18), 0.74 
Black African 1.44 (1.12 to 1.85), 0.005 1.45 (1.12 to 1.88), 0.005 1.50 (1.13 to 1.98), 0.005 
2) Local Deprivation: Index of multiple deprivation, most deprived UK quintile (%) 
Barriers to housing and services 1.07 (0.87 to 1.31), 0.54 1.05 (0.85 to 1.29), 0.66 1.01 (0.80 to 1.27), 0.94 
Education, skills and training 1.32 (0.93 to 1.88), 0.12 1.34 (0.94 to 1.93), 0.11 1.51 (1.02 to 2.23), 0.038 
3) General and medical risk factors 
Current smoker 0.59 (0.42 to 0.85), 0.004 0.59 (0.41 to 0.85), 0.005 0.63 (0.42 to 0.93), 0.021 
BMI (Kg/m2) 1.05 (1.03 to 1.07), 0.000 1.05 (1.03 to 1.07), 0.000 1.04 (1.02 to 1.06), 0.001 
Assisted conception 1.57 (0.93 to 2.65), 0.09 1.18 (0.67 to 2.07), 0.57 1.22 (0.67 to 2.23), 0.52 
4) Previous Obstetric history 
Previous PPH 1.83 (1.16 to 2.90), 0.010 1.89 (1.18 to 3.02), 0.008 1.88 (1.13 to 3.11), 0.015 
Multiparous previous Caesarean 0.91 (0.69 to 1.21), 0.52  0.88 (0.66 to 1.18), 0.40 0.96 (0.68 to 1.35), 0.80 
Multiparous no previous Caesarean 0.64 (0.50 to 0.81), 0.000 0.62 (0.49 to 0.80), 0.000 1.14 (0.84 to 1.55), 0.40 
5) Current Pregnancy 
Multiple pregnancy  2.09 (1.17 to 3.74), 0.013 2.33 (1.23 to 4.41), 0.009 
Admissions >24 weeks  0.77 (0.55 to 11.06), 0.11 0.86 (0.60 to 1.22), 0.40 
6) Antenatal Day Unit (ADU) attendances 
Any ADU attendance  1.13 (0.91 to 1.4), 0.28 1.04 (0.82 to 1.32), 0.73 
PET screen  1.19 (0.78 to 1.81), 0.43 1.23 (0.77 to 1.96), 0.39 
Generally unwell  1.71 (1.03 to 2.84), 0.039 2.03 (1.18 to 3.49), 0.011 
7) Placenta praevia 
Anterior  $ $ 
Major  0.43 (0.61 to 3.08), 0.40 0.54 (0.75 to 3.94), 0.55 
8) Antepartum haemorrhage (APH) & urinary tract infection (UTI) 
APH  1.44 (0.86 to 2.40), 0.16 1.66 (0.96 to 2.89), 0.071 
‘Warning APH’  4.23 (1.03 to 17.4), 0.045 2.31 (0.54 to 9.96), 0.26 
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9) Pre-eclampsia (PET) and anaemia 
Gestational hypertension  0.88 (0.46 to 1.66), 0.69 0.90 (0.45 to 1.80), 0.76 
Pre-eclampsia   1.13 (0.54 to 2.38), 0.74 0.90 (0.39 to 2.06), 0.80 
10) Medications in pregnancy pre-birth 
Antibiotics  1.22 (0.95 to 1.56), 0.12 0.96 (0.71 to 1.3), 0.79 
Antihypertensives (Incl. for PET)  0.99 (0.62 to 1.57), 0.95 0.95 (0.56 to 1.6), 0.84 
Diabetic treatments  1.18 (0.61 to 2.3), 0.62 0.99 (0.48 to 2.03), 0.97 
Steroids for fetal reasons  1.05 (0.71 to 1.58), 0.80 1.46 (0.93 to 2.3), 0.099 
11) Gestation at birth  
Gestation at delivery (weeks)   0.99 (0.92 to 1.07), 0.87 
12) Birth weight 
Maximum birth weight (kg)   1.71 (1.35 to 2.18), 0.000 
13) Onset of labour 
No labour onset   1.58 (0.73 to 3.44), 0.25 
Induction   1.11 (0.67 to 1.84), 0.69 
Augmentation   1.23 (0.73 to 2.08), 0.45 
ROM >2 hours before onset   1.02 (0.70 to 1.48), 0.93 
ROM >6 hours before onset    1.04 (0.73 to 1.48), 0.82 
ROM unknown   0.99 (0.63 to 1.56), 0.95 
14) Intrapartum  
Dinoprostone   0.82 (0.50 to 1.35), 0.43 
Oxytocin (Syntocinon®)   1.42 (1.02 to 1.96), 0.037 
Spinal anaesthesia   0.69 (0.47 to 1.00), 0.051 
Epidural analgesia   0.97 (0.69 to 1.36), 0.85 
Temperature per degree >37.0°C    1.74 (1.10 to 2.75), 0.019 
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Temperature not recorded   1.06 (0.74 to 1.51), 0.75 
Chorioamnionitis   3.54 (0.66 to 19.1), 0.14 
15) Birth 
Instrumental vaginal   2.53 (1.72 to 3.73), 0.000 
Elective Caesarean   3.51 (1.24 to 9.97), 0.018 
Emergency Caesarean section   7.05 (3.5 to 14.2), 0.000 
16) Third stage 
Physiological    1.36 (0.77 to 2.41), 0.29 
Ergometrine Maleate/Oxytocin 
(Syntometrine®) IM  
  0.58 (0.38 to 0.89), 0.013 
Oxytocin (Syntocinon®) IV bolus    0.59 (0.31 to 1.11), 0.099 
Oxytocin (Syntocinon®) 40/50 IU 
commenced 
  0.76 (0.54 to 1.06), 0.10 
Retained placenta   7.51 (4.08 to 13.8), 0.000 
Suture interval after vaginal birth (h)   1.74 (1.46 to 2.08), 0.000 
Suture interval not recorded   1.37 (0.87 to 2.16), 0.187 
Full regression model: result of three multiple regression models selecting the principal significant variables.  In each model, a new additional group of 
predictors is used.  Results are adjusted for other members of the same group and for previous groups only 
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Figure 8.2: Diagram of multiple logistic regression and chronological regression analysis showing predictors of PPH ≥1000 ml  (risk 
factors in white, protective factors in black).  Postpartum haemorrhage, PPH; body mass index, BMI; Caesarean section, CS; antepartum 
haemorrhage, APH; intramuscular, IM. 
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8.4 Risk pathways for PPH from ≥500 ml to ≥1500 
ml 
 
All women who bled at least 500 ml (n=1302) were included in further multiple 
regression models identifying the chronological factors for progression to PPH 
≥1500 ml. Table 8.3 shows that different variables in different sequential groups 
and subgroups are associated with progression to severe PPH.  
 
 
Clinically or statistically significant factors were: Group A) Pre-pregnancy; IMD 
category education, skills and training (OR 1.75, 95% CI 1.11 to 2.74, p=0.015); 
BMI (OR 1.03, 95% CI 1.00 to 1.05, p=0.022); previous PPH (OR 1.79, 95% CI 
1.06 to 3.02, p=0.030); multiparity with no previous CS (OR 1.65, 95% CI 1.20 
to 2.28, p=0.002). Cigarette smoking at first antenatal appointment was 
negatively associated with progression (OR 0.59, 95% CI 0.36 to 0.97, p=0.039). 
 
 
Group B, With the addition of current pregnancy health and events factors 
maintaining statistical significance were: IMD category ‘education, skills and 
training’ (OR 1.84, 95% CI 1.16 to 2.92, p=0.009); BMI (OR 1.03, 95% CI 1.00 
to 1.05, p=0.023); previous PPH (OR 1.93, 95% CI 1.13 to 3.31, p=0.016); 
multiparous with no previous CS (OR 1.55, 95% CI 1.12 to 2.16, p=0.009).  
Maternal smoking remained negatively associated (OR 0.56, 95% CI 0.33 to 0.93, 
p=0.026). Multiparity with previous CS became negatively associated with 
progression to ≥1500 ml  (OR 0.63, 95% CI 0.43 to 0.92, p=0.0018). Of the 
newly added variables, those significantly associated with PPH ≥1500 ml were: 
multiple pregnancy (OR 2.00, 95% CI 1.05 to 3.82, p=0.035) and steroids for 
fetal reasons (OR 2.00, 95% CI 1.24 to 3.22, p=0.004). 
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Group C) when intrapartum variables were added those variables maintaining 
statistical significance were: IMD category ‘education and skills’ (OR 1.82, 95% CI 
1.10 to 3.00,p=0.019); BMI (OR 1.04, 95% CI 1.01 to 1.06, p=0.008); previous 
PPH (OR 2.39, 95% CI 1.33 to 4.28, p=0.003); multiple pregnancy (OR 2.60, 
95% CI 1.27 to 5.38, p=0.009) and steroids for fetal reasons (OR 2.00, 95% CI 
1.17 to 3.41, p=0.011). Anterior placenta praevia became statistically significant 
(OR 5.55, 95% CI 1.29 to 23.9, p=0.022). Smoking became statistically 
insignificant in the final model. Newly added variables were: physiological 
management of the third stage of labour (OR 3.74, 95% CI 1.72 to 8.10, 
p=0.001) and negatively association variables were; unknown interval to suturing 
of genital tract trauma (OR 0.44, 95% CI 0.25 to 0.79, p=0.006); elective CS 
(OR 0.14, 95% CI 0.04 to 0.46, p=0.001) and emergency CS (OR 0.34, 95% CI 
1.72 to 8.10, p=0.013). These results are graphically represented in Figure 8.3
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Table 8.3: Risk pathways for postpartum haemorrhage (PPH) from ≥500 to ≥1500 ml according to chronological variables grouped as 
pre-pregnancy, during pregnancy, labour and birth. Full regression model: result of three multiple regression models selecting the principal 
significant variables.  In each model, a new additional group of predictors is used.  Results are adjusted for other members of the same group and for 
previous groups only. Women with estimated blood loss (EBL) <500 ml are excluded. 
 
 
Risk factors included in final model  
(1230 women included; 70 excluded due to missing 
data in addition to all women with EBL<500 ml) 
Pre-Pregnancy 
Variable subgroups 1-4 
OR (95% CI), p 
During Pregnancy 
Variable subgroups 1-10 
OR (95% CI), p 
Labour and Birth 
Variable subgroups 1- 16 
OR (95% CI), p 
1) Sociodemographic 
Age, for each 10 years 0.85 (0.67 to 1.07), 0.16 0.90 (0.68 to 1.09), 0.20 0.99 (0.77 to 1.29), 0.96 
Black African 0.86 (0.62 to 1.19), 0.36 0.84 (0.61 to 1.17), 0.31 0.91 (0.64 to 1.30), 0.61 
2) Local Deprivation: Index of multiple deprivation, most deprived UK quintile (%) 
Barriers to housing and services 0.79 (0.60 to 1.03), 0.076 0.78 (0.59 to 1.02), 0.069 0.75 (0.56 to 1.01), 0.055 
Education, skills and training 1.75 (1.11 to 2.74), 0.015 1.84 (1.16 to 2.92), 0.009 1.82 (1.10 to 3.00), 0.019 
3) General and medical risk factors 
Current smoker 0.59 (0.36 to 0.97), 0.039 0.56 (0.33 to 0.93), 0.026 0.67 (0.38 to 1.17), 0.16 
BMI (kg/m2) 1.03 (1.00 to 1.05), 0.022 1.03 (1.00 to 1.05), 0.023 1.04 (1.01 to 1.06), 0.008 
Assisted conception 1.41 (0.79 to 2.50), 0.025 1.02 (0.53 to 1.93), 0.096 1.18 (0.60 to 2.35), 0.64 
4) Previous Obstetric history 
Previous PPH 1.79 (1.06 to 3.02), 0.030 1.93 (1.13 to 3.31), 0.016 2.39 (1.33 to 4.28), 0.003 
Multiparous previous Caesarean 0.70 (0.49 to 1.01), 0.055 0.63 (0.43 to 0.92), 0.018 0.84 (0.54 to 1.30), 0.43 
Multiparous no previous Caesarean 1.65 (1.20 to 2.28), 0.002 1.55 (1.12 to 2.16), 0.009 1.17 (0.80 to 1.74), 0.42 
5) Current Pregnancy 
Multiple pregnancy  2.00 (1.05 to 3.82), 0.035 2.60 (1.27 to 5.38), 0.009 
Admissions >24 weeks  0.67 (0.44 to 1.02), 0.062 0.83 (0.53 to 1.32), 0.43 
6) Antenatal Day Unit (ADU) attendances 
Any ADU attendance  1.17 (0.89 to 1.56), 0.26 1.05 (0.77 to 1.43), 0.75 
PET screen  0.93 (0.55 to 1.57), 0.80 1.15 (0.66 to 2.01), 0.62 
Generally unwell  1.49 (0.82 to 2.70), 0.19 1.69 (0.90 to 3.20), 0.11 
7) Placenta praevia 
Anterior  3.37 (0.86 to 13.30), 0.082 5.55 (1.29 to 23.9), 0.022 
Major  0.72 (0.17 to 3.05), 0.660 0.97 (0.22 to 4.25), 0.97 
8) Antepartum haemorrhage (APH) & urinary tract infection (UTI) 
APH  1.26 (0.67 to 2.37), 0.48 1.25 (0.62 to 2.52), 0.53 
‘Warning APH’  1.70 (0.56 to 5.20), 0.35 1.99 (0.58 to 6.81), 0.27 
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9) Pre-eclampsia (PET) and anaemia 
Gestational hypertension  1.00 (0.47 to 2.16), 0.99 0.98 (0.43 to 2.22), 0.97 
Pre-eclampsia   1.03 (0.43 to 2.50), 0.95 0.87 (0.32 to 2.13), 0.69 
10) Medications in pregnancy pre-birth 
Antibiotics  1.02 (0.74 to 1.40), 0.91 0.95 (0.65 to 1.39), 0.79 
Antihypertensives (Incl. for PET)  0.99 (0.56 to 1.78), 0.92 0.91 (0.49 to 1.70), 0.77 
Diabetic treatments  0.98 (0.44 to 2.18), 0.96 1.23 (0.52 to 2.91), 0.64 
Steroids for fetal reasons  2.00 (1.24 to 3.22), 0.004 2.00 (1.17 to 3.41), 0.011 
11) Gestation at birth  
Gestation at delivery (weeks)   0.95 (0.86 to 1.04), 0.25 
12) Birth weight 
Maximum birth weight (kg)   1.17 (0.87 to 1.59), 0.30 
13) Onset of labour 
No labour onset   1.28 (0.54 to 3.03), 0.58 
Induction   1.07 (0.56 to 2.04), 0.83 
Augmentation   1.37 (0.73 to 2.58), 0.33 
ROM >2 hours before onset   1.01 (0.60 to 1.70), 0.96 
ROM >6 hours before onset    1.16 (0.73 to 1.85), 0.52 
ROM unknown   0.95 (0.52 to 1.73), 0.86 
14) Intrapartum  
Dinoprostone (Prostin E2®)   1.12 (0.60 to 2.11), 0.73 
Oxytocin (Syntocinon®)   0.75 (0.49 to 1.13), 0.17 
Spinal anaesthesia   0.73 (0.45 to 1.18), 0.20 
Epidural analgesia   1.20 (0.78 to 1.85), 0.41 
Temperature, per degree >37.0°C    1.21 (0.75 to 1.94), 0.44 
Temperature not recorded   1.40 (0.86 to 2.27), 0.17 
Chorioamnionitis   2.70 (0.70 to 10.5), 0.15 
15) Birth 
Instrumental vaginal   0.79 (0.49 to 1.29), 0.36 
Elective Caesarean   0.14 (0.04 to 0.46), 0.001 
Emergency Caesarean section   0.34 (0.15 to 0.80), 0.013 
16) Third stage 
Physiological    3.74 (1.72 to 8.10), 0.001 
Ergometrine Maleate/Oxytocin 
Syntometrine® IM  
  1.12 (0.66 to 1.91), 0.68 
Oxytoxin (Syntocinon®) IV bolus    1.35 (0.63 to 2.87), 0.44 
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Oxytocinon (Syntocinon®) 40/50 IU 
commenced 
  0.97 (0.65 to 1.44), 0.87 
Retained placenta   1.40 (0.77 to 2.54), 0.27 
Suture interval after vaginal birth (h)   1.16 (0.99 to 1.35), 0.058 
Suture interval not recorded   0.44 (0.25 to 0.79), 0.006 
Full regression model: result of three multiple regression models selecting the principal significant variables.  In each model, a new additional group of 
predictors is used.  Results are adjusted for other members of the same group and for previous groups only 











  265 
 
Pre-pregnancy  




multip no prev. CS 
 
Current smoker 
Pre-pregnancy and  
During pregnancy 
IMD (education, skills & training) 
BMI 
Previous PPH 
Multip no previous CS 
Multiple pregnancy 
Steroids for fetal reasons 
 
Current smoker 
multip prev. CS 
 
Pre-pregnancy ,  
During pregnancy and  
Intrapartum 





Anterior placenta praevia 
Steroids for fetal reasons  









Figure 8.3: Diagram of multiple logistic regression and chronological regression analysis showing predictors of PPH ≥500 ml to ≥1500 ml  
(Risk factors in white, protective factors in black). Index of multiple deprivation, IMD; postpartum haemorrhage, PPH; body mass index, BMI; Caesarean section, CS. 
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8.5 Summary 
These hierarchical regression models show that the factors associated with PPH 
≥500 ml and ≥1000 ml and progression to ≥1500 ml are different, and all three 
models provide additional information to that obtained in the previous research. 
 
 
Initial risk factors for PPH ≥500 ml appear to be superseded by intrapartum 
events, with only Black African ethnicity and previous PPH remaining statistlcally 
significant in the final model. Consequently there were no modifiable pre-
pregnancy risk factors that could ameliorate blood loss, but this information could 
prove valuable when women make decisions re place of birth, for example.  
Pregnancy health and events that are statistically significant when added to the 
model for PPH ≥500ml, with the exception of placenta praevia, were over ridden 
by intrapartum events.  
 
 
Intrapartum factors that may be modifiable are maximum birth weight, and this 
could be a surrogate marker for maternal obesity or diabetes, both of which are 
associated with increased fetal size (Poston, 2012; Heslehurst et al., 2010;). The 
association of maternal temperature in labour has hitherto not been reported. All 
medical interventions (induction/augmentation of labour, instrumental vaginal 
birth and elective or emergency CS) were associated with increased risk of PPH 
≥500 ml. In these data Ergometrine Maleate/Oxytocin (Syntometrine®) IM and 
Syntocinon® 40/50 IU prevented blood loss exceeding 500 ml.  
 
 
The risk pathway for PPH ≥1000 ml showed that pre-pregnancy factors Black 
African ethnicity, maternal BMI and previous PPH remained independently 
associated with estimated blood loss exceeding 1000 ml despite the hierarchical 
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addition of pregnancy and intrapartum acquired risk factors. Similarly the 
negative association with smoking at initial antenatal contact remained. The 
perfect predictive value of anterior placenta praevia is consistent, if unsurprising.  
The identification of attendance for “generally unwell” is novel. The association of 
IMD- education, skills and training achieved in the third regression model, 




The risk pathway for progression from 500 ml to severe PPH ≥1500 ml identified 
yet more risk factors pre-pregnancy IMD ‘education and skills’ was new. Factors 
associated with other levels of blood loss were: BMI, previous PPH and multiparity 
with no previous CS. Pregnancy health and events associated with severe blood 
loss included multiple pregnancy and anterior placenta praevia. The association 
with administration of fetal steroids is new, and requires additional investigation.  
 
 
The identification of both elective and emergency CS as negatively associated 
with severe PPH, suggests the presence of the multidisciplinary team to react 
promptly to emergencies, or causes of haemorrhage being essentially different in 
vaginal and abdominal births. These data suggest different physiological 




The findings of these, and earlier analyses, are discussed in Chapter 9. 
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Chapter 9: Discussion 
9.1 Introduction  
 
This thesis addresses several major unresolved issues related to the assessment 
of blood loss following childbirth. It highlights the limitations of visual assessment 
of blood loss following birth and focuses on further inaccuracies incurred within 
reporting and documentation of the incidence of PPH. Furthermore relevant 
contemporary risk factors are identified through a detailed analysis of PPH 
prospectively in two large hospital populations over one year (2008-2009). The 
incidences of PPH and severe PPH reported in this thesis are, to my knowledge, 
the highest reported from any high-income country (Kramer et al., 2013; 
Lutomski et al., 2012; Hogan et al., 2010; Callaghan et al., 2010; Knight et al., 
2009; Khan et al., 2006; Cameron et al., 2006). The novel application of a 
weighted sampling strategy in health science highlighted the potential for errors 
to be introduced between clinical notes and electronic summary data. Additionally 
digit and threshold preference and avoidance were demonstrated at all levels of 
blood loss. Day of the week and time of day of birth did not impact on PPH rates 
for any mode of birth. Established and novel risk factors for PPH at different 
thresholds (≥500 ml, ≥1000 ml, ≥1500 ml) have been quantified and rigorous 
and chronological assessment of contributory factors illuminated the complex 
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9.2 Incidence 
 
The main objective of this thesis was to determine the incidence of PPH in the 
selected cohort and identify the important risks factors leading to blood loss. 
Women giving birth in the UK are rarely compromised by losing 500 ml of blood, 
so it was appropriate to focus on more severe blood loss, where maternal 
morbidities were more likely to occur. Due to variable definitions of severe blood 
loss, analyses for different categories of blood loss were undertaken (≥500 ml; 
≥1000 ml; ≥1500 ml; ≥2500 ml). This was to facilitate comparison with the work 
of others and uniquely identify the factors associated with minor, moderate and 
severe PPH. The incidence of overall PPH (≥500 ml) in the current study was 
33.9%, which was significantly higher than that reported in the literature (1-
10%) at the time of starting the study (Ford et al., 2007b; Winter et al., 2007; 
Cameron et al., 2006; Wen et al., 2005) or indeed reported since (4-15%) (Euro-
Peristat Project, 2013 Bonnet et al., 2013; Lutomski et al., 2012; Callaghan et al., 
2010; Liu et al., 2010 Roberts et al., 2009).  It could be assumed the high rate 
reported here might, at least in part, be due to inclusion of estimated blood loss 
following all modes of birth. A recent report from Ireland, also considering all 
modes of birth and atonic PPH reported a rate of 25.5% (Lutomski et al., 2012). 
With inclusion of all other causes of PPH, it is plausible that these authors would 
have reported similar rates to the current study.  
 
 
Further comparison with Lutomski’s data demonstrated higher rates of PPH ≥500 
ml in the current study following spontaneous vaginal birth and instrumental 
vaginal birth; 14.8% vs. 4.3% and 41.8% versus 10.1%, respectively (Lutomski 
et al., 2012). Thus high PPH rates in the current study may not be solely 
attributable to rising CS rates as may be initially assumed.  
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In Australia and USA blood loss is considered excessive at higher volumes 
following CS (Ford et al., 2007b; Wen, 2005). In the UK, PPH is defined as blood 
loss exceeding 500ml, regardless of mode of birth. Mean blood loss following CS 
is indisputably higher than after vaginal birth and with increasing CS rates 
consideration of increasing the volume to describe excessive blood loss following 
this procedure may need reviewing.  
 
 
In the current study PPH rates were also higher at different thresholds, ≥1000 ml 
9.4%; ≥1500 ml 4.0%; ≥2000 ml 2.0%; ≥2500 ml 0.8%.  Almost 1:5 women 
lost at least 1000 ml following SVD (4.75% [95%CI 0.37 to 5.7]). When 
comparing all vaginal births (SVD, forceps, ventouse and assisted breech) with 
abdominal birth (elective and emergency CS) the rate of PPH ≥1000 ml was 6.1% 
(95%CI 5.2 to 7.1) versus 18.2% (95%CI 15.8 to 20.7) respectively. Figure 9.1 
shows pilot results from the Maternity Safety Thermometer (09/07/2014), a tool 
currently being developed to measure maternity care outcomes from the 
woman’s perspective. Survey data are collected and monthly reports developed. 
Most recently the rate of PPH ≥1000 ml was reported as 6.3%, although, when 
considering term births only, this increased to 7.7%, which is comparable to the 
current study (www.safetythermometer.nhs.uk).  
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Figure 9.1: The proportion of women with EBL ≥500 ml, by blood loss volume 
(Maternity Safety Thermometer Pilot Data Report 09/07/2014 p10).  
 
 
The Maternity safety Thermometer reports rates of PPH≥500 ml as 25.9% and 
≥2000 ml as 1.5%. Unlike the current study, these authors failed to demonstrate 
differences in blood loss according to mode of birth, probably because of the 
selected denominator used (all women). These findings are shown in Figure 9.2. 
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Figure 9.2: The proportion of women with EBL ≥1000 ml by mode of birth using 
all women surveyed each month as the denominator (Maternity Safety 
Thermometer Pilot Data Report 09/07/2014 p10) 
 
Recent reports of rising rates (Kramer et al., 2013; Driessen et al., 2011; Knight 
et al., 2009; Ford et al., 2007), up to 13% in high income countries (Mehrabadi 
et al., 2012; Rossen et al., 2010) and 15.2% across Europe (Euro-Peristat Project, 
2013) may be underestimates, as most studies use routinely collected, 
retrospective and ‘coded’ electronic data (Lutomski et al., 2012; Kramer et al., 
2011; Dreissen et al., 2011; Knight et al., 2009; Roberts et al., 2009; Ford et al., 
2007; Winter et al., 2007) with inherent errors (Feied et al., 2004) and variable 
data quality (Abrahams and Davey, 2002). Comparison with the Scottish Audit 
data, which uses risk reports from participating units, demonstrated that the 
most severe PPHs (>2500 ml) found in my study, although slightly higher, were 
comparable with this contemporaneous cohort (0.80% versus 0.55%) (Lennox 
and Marr, 2011) and recent data from the Maternity Safety Thermometer report 
incidence of blood loss exceeding 2000 ml of 1.5% also suggests the incidence of 
these highest levels of blood loss in my study are consistent with current trends. 
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The difference between incidences of PPH at a threshold (≥) compared to a 
volume above it (>), demonstrated digit preference that was apparent at all 
levels (≥500 ml, 33.9%; >500 ml 27.8%: ≥1000 ml 9.4%; >1000 ml 7.9%: 
≥1500 ml, 4.0%; >1500 ml, 3.3%: ≥2000 ml 2.0%; >2000 ml 1.4%: >2500 ml, 
0.8%; >2500 ml 0.6%). This was particularly apparent in PPH 500-999 ml, 
potentially influenced by Caesarean births with 500 ml blood loss documented. 
Neither Centre defined PPH as 750 ml or 1000 ml following CS (Fawcus and 
Moody, 2013: Magann et al., 2006). The same phenomenon (blood loss reported 
at a threshold) is apparent in the severest PPHs, when blood loss should be 
measured, not visually assessed. It could be assumed that clinicians round up 
total blood loss, therefore over estimating at this level, however, re- 
categorisation of blood loss following notes review, suggested this was not the 
case. Thus confirming a tendency to under estimate at all levels (Al Kadri et al., 
2011; Kavle et al., 2006). 
 
 
The considerably higher level of PPH in the current study population, therefore, is 
probably due, at least in part, to the rigorous data collection and validation 
methodology used. Although the limitations of visual assessment, most 
commonly used, are well documented and were not overcome in the current 
study, review of the documented blood loss is justified, as this represents the 
formal record of pregnancy, birth and the postnatal period (NMC, 2012).  
 
 
Table 9.1 summarises PPH rates from some recent studies, the majority are 
calculated using routinely collected clinical data. Furthermore Figure 9.3 
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demonstrates the temporal rise in severe PPH identified by Kramer and 
colleagues (2013) but contradicted by a Norwegian study that reported static 
incidence of severe PPH (Rossen et al., 2010). The Scottish Confidential Audit 
using data from 2010, 2011 and 2012 has reported a year on year increase in 
major obstetric haemorrhage since the current study was undertaken, 0.55%, 
0.58%, and 0.67% (Lennox and Marr, 2011; Lennox and Marr, 2012; Lennox and 
Marr, 2013) and a significant increase since the audit introduction in 2004 (Brace 
et al., 2004).    
 
Table 9.1: PPH rates reported in recent studies. 
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Figure 9.3: Temporal trend in total severe PPH, and clinical subtypes: atonic and 
non-atonic (from Kramer et al., 2013, p. 1.e3) 
There were no PPH related deaths in the study population, confirming that whilst 
PPH remains a major cause of maternal death in low resource settings (Hogan et 
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al., 2010) it is too rare an event to assess quality of care in high resource 
countries. Evidence of PPH related morbidities were similar to those reported 
elsewhere in Europe and the UK during the time frame of the study (Bouvier-Colle 
et al., 2012; Lutomski et al., 2012; Weeks, 2008; Knight et al., 2007). In the 
earlier work in the South of England, including the units involved in the current 
study, the overall incidence of severe obstetric morbidity was 12.0 per 1000 
births (95%CI 11.2 to 13.2) and for severe haemorrhage (>1500 ml) was 3.9 
(95%CI 3.3 to 4.5) (Waterstone et al., 2001). Thus, in comparison, the current 
study reports an increase in associated maternal morbidity.  
 
 
Overall 3.9% of the study population received a blood transfusion. This compares 
with 7.5% of women with PPH in France (Bonnet et al., 2012), 2.27% in Finland 
(Jakobsson et al., 2012), 16.5% in Ireland (Lutomski et al., 2012), 14.3% in 
Germany and 0.7% in Malta (Euro-Peristat Project, 2013). Reports have 
suggested that, despite guidelines to the contrary, women with low Hb and 
following PPH are not readily transfused (Bonnet et al., 2012). Confirming this, 
Lutomski and colleagues (2012) reported an overall increase in blood useage 
between 1999 and 2009 as shown in Figure 9.4. However this equates to 
transfusion rates of 0.5 to 1.3%. In the same time period PPH rates increased, 
however the number of women transfused for atonic PPH, has not increased 
proportionally (17.6% in 1999; 16.5% in 2009) as shown in Figure 9.5 (Lutomski 
et al., 2010). 
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Figure 9.4: Blood transfusion rates and blood transfusion rates as treatment for 







Figure 9.5 Blood transfusion rates for treatment of atonic PPH 1999-2009 in 
Ireland (Lutomski et al., 2012, p310)  
 
 
Both units had access to blood and blood products, yet 12 women received O 
rhesus D negative blood (universal donor), indicating that despite advances in the 
processes of cross matching and improved accessibility of cross matched blood, 
the availability of emergency obstetric blood remains an integral part of 
management of PPH. 
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Other blood products were utilised sparingly with minimal use of cryoprecipitate 
in both Centres and no fibrinogen used in Centre 2. Recent innovations in 
transfusion therapy suggest correction of coagulopathies may effectively reduce 
overall transfusion rates (Spahn and Rossaint, 2005; Moor et al., 2009; Moore 
and Chandrahan, 2010).  
 
 
The development of hypofibrinogenaemia and resultant impaired haemostasis has 
been identified as problematic in PPH (Fenger-Eriksen et al., 2008). Currently 
there are several randomised trials ongoing to investigate early treatment with 
fibrinogen, including the FIB-PPH trial (Denmark) NCT01359878 (Wikkelsoe et al., 
2012) and OBS2 (Wales) ISRCTN46295339  (Collins, et al., personal 
communication). In the current study the influence of coagulopathies could not 
be assessed.  
 
 
Autologous transfusion in obstetrics, although reported as early as the 1990s 
(O’Dwyer et al., 1993), was not widely employed at the time of this study 
(Geoghegan et al., 2009). There was no system available in Centre 1 and it was 
only used in one case of antenatally diagnosed placenta percreta in Centre 2.  It 
is plausible that, should the study be repeated, transfusion practices may have 
altered further with more women receiving autologous transfusions.  
 
 
The incidence of manual removal of placenta was in line with reports by others 
(Weeks, 2008). Delay in delivery of the placenta has been described as a 
modifiable risk factor in the prevention of PPH (Winter et al., 2007). Despite this, 
wide variation in practice and timing has been noted (Deneux-Tharaux et al., 
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2009). Overall, duration of the third stage is considered important to reduce PPH; 
despite variation in timing (EUPHRATES collaborative group, 2005) general 
consensus being failure to deliver the placenta within 30 minutes of the baby’s 
birth increases blood loss (Combs et al., 1991), with Magann and colleagues 
proposing 18 minutes as the optimal time (Magann et al., 2005). A further RCT, 
abandoned due to imbalance in the arms caused by placental delivery within 20 
minutes, suggested that a third stage exceeding 10 minutes was associated with 
PPH, but caution should be heeded as this time frame was not a pre-specified 
endpoint, and 89% (n= 1430) of the placentae delivered within 10 minutes 
(Magann et al., 2006). 
 
 
The long term effects of haemostatic sutures have been variably reported as 
influencing future fertility (Sentilhes et al., 2010a; Sentilhes et al., 2010b) and 
causing gynaecological problems (Ibrahim et al., 2013).  It is not possible to 
assess either the impact of previous haemostatic sutures or the influence of this 
treatment on subsequent pregnancies within the remit if this study. 
 
 
Despite being advocated as an effective treatment for PPH, particularly in low- 
resource settings, concurring with others, balloon tamponade was rarely used in 
our population  (Tindell et al., 2013). There is a paucity of evidence regarding the 
effectiveness of this technique, with early reports limited to case reports (Bakri, 
1992; Katesmark et al., 1994; De Loor and van Dam, 1996; Marcovici and 
Scoccia, 1999) and small retrospective (Keriakos and Mukhopadhyay, 2006) and 
prospective studies (Condous et al., 2003). More recently a population cohort 
study found that balloon tamponade was effective at achieving haemostasis and 
preventing employment of more invasive procedures  (Laas et al., 2012). A 
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prospective randomised controlled trial could fully evaluate the effectiveness of 




The peripartum hysterectomy rate was slightly higher than the incidence reported 
in an earlier UK national survey (0.40 per 1000) (Knight, 2007) but less than 
reported in a more recent UK (0.55 per 1000) and Australian cohort (0.85 per 
1000) (Knight, 2010; Awan et al., 2011). Other more recent reported rates from 
local review data include 0.42 per 1000 births in Portugal (Carvalho et al., 2012) 
and 0.92 per 1000 births in Greece (Christopoulos et al., 2011) A systematic 
review reporting a rate of 0.2 to 5 per 1000 births (Rossi et al., 2010) has been 
criticised for broad definitions, potentially inflating the rate (Knight et al., 2010).  
 
Lutomski and colleagues in Ireland and Parazzini and colleagues in Italy reported 
temporal increases in maternal morbidities, especially associated with PPH  
(Lutomski et al, 2012; Parazzini et al., 2013). The Scottish audit of severe 
maternal morbidity has similarly reported increased maternal morbidities 
associated with PPH since the inception of the Reports in 2004. These data 
comfirm the impact of PPH on short and long term associated morbidities for 
women and their families.   
  
The data management system enabled “real time” importation of electronic 
summary data from NHS databases, facilitating immediate identification of cases 
and rapid review of patient records. Additionally importation of uploaded clinical 
data incurred no impact for clinical staff, and evaded further errors incurred by 
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duplication (Hammond, 2003). To our knowledge, no similar system exists for 
monitoring and auditing PPH. Many studies, as mentioned previously, have relied 
on routinely entered and coded data and surrogate markers for PPH which was 
not validated. So comparison with these studies is not particularly informative. 
More useful, is the study by Roberts et al. (2009) which actually reviewed a 
series of 1200 randomly selected women in Australia and reported an incidence of 
PPH of 11.4% which the authors considered an under estimation. This is 
obviously still lower than the incidence in the current study, and could be 
explained by the use of the weighted sampling strategy. This much more robust 
approach identified women with all levels of blood loss for review, rather than the 
random selection employed in the Australian study, which may have omitted or 
under-represented some categories. Additionally, the PPH incidence in the 
Robert’s study was also further underestimated because the definition for PPH at 
CS in Australia was 750 ml rather than 500 ml (Roberts et al., 2009).  
 
9.3 Methodology employed 
 
The identification of cases from routinely data collection conveyed no burden to 
clinical staff. The weighted sampling strategy overcame many of the issues 
highlighted in the literature above, and addressed the limitations of case control 
studies, which are generally smaller and may focus on a restricted range of blood 
loss. Extraction of data from a complete cohort combined with a weighted 
strategy facilitated random identification of a large number of women with all 
categories of estimated blood loss. The weighted sample ensured that, whilst 
most cases reviewed were those of maximum interest (largest estimated blood 
loss) a representative sample of all other estimated blood loss volumes was also 
reviewed. The acquisition and review of all available records for selected women 
meant that blood loss was identified for all women in the sample, and all levels of 
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estimated blood loss. The additional identification of all women who received 
blood or blood products meant 35 women, with lower estimated blood loss 
volumes recorded and not randomly selected, underwent detailed review.  
 
Based on this, and using the error rates identified in routinely collected electronic 
summary data, employment of this methodology could be recommended as it 
provides an effective tool for contemporaneous monitoring of PPH locally, 
regionally and nationally and could be further modified and extrapolated to 
monitor other morbidities.  
 
9.4 Effect of time of birth 
 
There were no significant differences between PPH rates by day of the week or 
time of day for all modes of birth, including elective CS. This differs from 
evidence on other elective surgical procedures (Aylin et al., 2013) and may be 
the result of the ‘24/7’ Consultant presence on labour wards advocated in the 
Confidential Enquiry into Maternal Deaths and aspired to in both participating 
Centres (Lewis, 2007b). It was notable that some elective procedures were 
undertaken ‘out of hours’.  This could be due to labour ward staffing levels and 
policies, or errors in classification of urgency of CS (Wickham, 2010) and 
availability of specialist neonatal cots (Centre 1 is the regional referral Centre for 
babies with cardiac conditions). Further investigation showed some consultants 
delivered private patients in NHS facilities during weekends on call. Thus ensuring 
they were available for these patients and accounting for some ‘out of hours’ 
elective work. The safety of this practice remains questionable, with resultant 
implications for workforce workload.  
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9.5 Reporting errors 
 
This study also allowed for the comparison of NHS electronic summary data with 
documented blood loss in hand held maternity records.  This provided quantifiable 
data describing the errors generated during routine transcription from paper to 
electronic clinical databases. There is literature about errors related to blood loss 
estimation (Al Kadri et al., 2011; Buckland et al., 2007; Bose et al., 2006; 
Larsson et al., 2006; Glover, 2006), but currently, there has been little emphasis 
on the additional human error introduced by the need to replicate paper records 
electronically (Fawdry et al., 2011). In the current study, this process introduced 
a 0.19 to 2.03% error rate when transcribing basic data (e.g. maternal date of 
birth, time of birth of baby, mode of birth, birth weight and sex of baby), but 
worryingly introduced a 13.6% (14.9% in Centre 1 and 12.3% in Centre 2) error 
rate when entering blood loss information. The underlying reasons identified 
included failure to update electronic records when subsequent bleeding occurred 
in the first 24 h postpartum and incorrect addition of volumes recorded in hand 
held notes. These issues could easily be addressed by requiring ongoing addition 
of blood loss on each page of the handheld postnatal notes and inclusion of a 
data field regarding subsequent blood loss on the electronic discharge summary.     
 
Caution regarding errors introduced by data overload in maternity service has 
been highlighted previously by Fawdry et al. (2011) and the moving to electronic 
records has been strongly advocated by others in emergency medicine (Feied et 
al., 2004) and for other aspects of the health service (Freund et al., 2013). The 
abolition of hand held notes requiring transcription to NHS databases to a direct 
first entry electronic process could remove sources of transcription error and 
provide a mechanism for automated data monitoring. However the requisite 
internet access in addition to appropriate computer hard and software would 
require significant infrastructural and financial input. 
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The evidence of digit and threshold preference and avoidance in estimating blood 
loss is interesting and further investigation is required regarding the factors that 
influence midwives and other health care professionals when assessing blood loss. 
Understanding these factors could improve educational packages and ultimately 
improve the longevity of retention of improved assessment and be included in 
new strategies to improve patient care (Bingham, 2012).   
 
9.6 Prediction of those at risk of PPH 
 
Identification of women at risk, and resultant prediction, of PPH has long been 
attempted and is demonstrated by the numerous cited risk factors described in 
chapter 6. However, further complexity is introduced by the historical and 
ongoing diversity of definitions used. Some classifications are dependent on blood 
volumes lost, identified specifically (Lennox and Marr, 2013; Keriakos and 
Chaudhuri, 2012; RCOG, 2009; WHO, 1990b), alternatively when early 
postpartum blood loss is considered ‘excessive’ (NICE, 2007), or requirement for 
blood product replacement (any, >5 units, >10 units) (Holm et al., 2012; O’Brien 
et al., 2010; Macphail and Fitzgerald, 2001). All these are further compounded by 
application of different definitions according to mode of delivery (RCOG, 2009; 
Naeff et al., 1994).  Many identify risk factors for PPH at a specified level, be it 
any blood loss exceeding 500 ml (Biguzzi et al., 2012; Bibi et al., 2007) more 
severe haemorrhage (variably defined) (Al-Zirqi et al., 2008), or leading to 
associated severe morbidity, such as hysterectomy or ITU admission (Knight, 
2007). One study investigated PPH at both >500 ml and >1000 ml and relied on 
retrospective analyses of an electronic data register, but only included low risk 
women following vaginal birth. These authors noted that 2 women received blood 
products despite estimated blood loss <500 ml, and, essentially focusing on 
intrapartum risk factors, concluded retained placenta and third stage duration 
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>30 minutes were positively associated with PPH ≥500 ml and ≥ 1000 ml (Bais 
et al., 2004). However these authors had removed all pre-existing or pregnancy 
acquired risk factors with the exception of ethnicity, but they had categorized this 
as ‘West European’ and ‘non-West European’, so comparison with other reports is 
problematic.  
 
Another recent study failed to use any blood volume lost to define PPH and 
severe PPH, rather using the requirement for >1 unit transfusion and >3 unit 
transfusion (Mehrabadi et al., 2013). This would appear more indicative of blood 
product availability and transfusion and management protocols than severity of 
blood loss. Added to which thresholds for transfusions have altered in recent 
years (Wen et al., 2005) and the widespread availability of cell salvage also 
reduces total volume replacement requirements (Ashworth and Klein, 2010). 
Additionally new transfusion regimes developed in military medicine, require 
validation in obstetrics, but may further alter protocols (Saule and Hawkins, 
2012). Thus the employment of transfusion requirements should be considered 
an unreliable and inconsistent surrogate proxy for severity of PPH. 
None of these studies verified the information used with other data sources prior 
to analyses. Thus the proportion of missing or inaccurate data could not be 
assessed, which would have undoubtedly impacted on the results. Exceptions 
being UKOSS reports and the Scottish Audit of Severe Maternal Morbidity which 
rely on local clinicians completing minimal data reports and may be subject to 
ascertainment bias (UKOSS, 2013; Lennox and Marr, 2013). In both situations, 
no validation of the reports was undertaken. 
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However, the current study undertook detailed review of all available patient 
records, and triangulated reported details from different data sources, for 
example documented biochemical information in handheld notes with those 
available from the results system, cross checked with treatment charts and 
electronic summary data.  
 
 
The wealth of data collected in the current study allowed for the both univariate 
and multivariate regression analysis. This study was designed to assess the 
independent impact of sequentially attributed confounding factors, which was not 
possible in studies using coded data or reliant on admission and discharge data. 
Many risk factors identified as associated with PPH ≥500 ml were not necessarily 
associated with larger haemorrhages or vice versa. This highlighted the need to 
consider the complex interlinked contributing factors leading to PPH and how they 
contributed to the progression onto severe PPH. Risk assessment using 
chronological categories was preferable to stepwise regression, as, each variable 
within the category and each group of predictors were considered, whilst also 
adjusting for the influence of predictors identified from previous groups (potential 
confounders). By fitting new elements singly, factors not significantly related 
were removed. In this way, adjustments were made for potential confounders at 
each stage (Hernan et al., 2002). Investigating estimated blood loss at multiple 
levels, including equal to and more than (≥), and more than (>) thresholds, 
optimised comparison with other reports, which has not been achieved previously. 
Using this approach, significant pre-pregnancy risk factors were often superseded 
by other pregnancy acquired or intrapartum risk factors. Their impact varied 
according to size of PPH, included age, ethnicity, BMI, previous PPH and assisted 
conception.  
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9.6.1 Pre-existing factors predicting PPH 
The positive association between PPH and maternal age is variably reported 
(Lyndon et al., 2012; Montan, 2007; Cameron et al., 2006; Diejomaoh et al., 
2006). Older women are reported to have more medical (Dhanjal, 2009) and 
obstetric co-morbidities (Kenyon and Bewley, 2009) and poorer uterine 
contractility  (Smith et al., 2008). With increased numbers of older women 
embarking on pregnancy further work is required to more accurately ascertain 
the risk of PPH in this age group (Euro-Peristat Project, 2013).  
 
Other studies have identified specific ethnicities, namely Hispanic and Asian at 
increased risk of PPH (Bryant et al., 2012) no previous study has specifically 
identified Black African ethnicity as an independent predictor (Cabacungan et al., 
2012; Bryant et al., 2012; Kramer et al., 2011; Magann et al., 2005; Waterstone 
et al., 2001), possibly because of lack of adjustment for potential confounding 
variables (Calvert et al., 2012; Berg et al., 2010; Al-Zirqi et al., 2008; 
Sundararajan et al., 2007). The sequential addition of risk factors in the current 
study may account for uterine fibroids being associated with increased blood loss, 
but not PPH at any level. Women of African American ethnicity have been 
reported.to be more at risk of pregnancy related death, but not PPH (Harper et al., 
2007). In a UK cohort Knight and colleagues (2009) identified non-White women 
as more at risk severe maternal morbidities, including peripartum hysterectomy. 
Although overall Black Caribbean women were the most highly represented ethnic 
minority group, both Black Caribbean and black African women had more than 
double the risk of severe maternal morbidity than White women. This concurs 
with others regarding outcomes for non-indigenous women (Callagan et al., 
2008; Zwart et al., 2008). Some reports have suggested that migration history 
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may be important in assessing longer term health and risk factors of immigrants 
and the health of subsequent generations (Giuntellaelli, 2012; Jayaweera, 2011). 
These data are rarely collected, but may be beneficial in assessing long term 
health of multiethnic communities and to inform public health initiatives.  
 
The positive association between BMI and PPH concurs with findings for 
prospective cohort studies (Fyfe et al., 2012; Raja et al., 2012; Blomberg, 2011) 
although retrospective and routine data reports are equivocal (Paglia et al., 2012; 
Sebire et al., 2001a; Sebire et al., 2001b).  At first glance the impact of BMI 
appeared modest, but this 4% increase per BMI unit became substantial in higher 
obesity categories.  
 
The newly identified positive association with assisted conception could reflect 
multiple pregnancy or abnormal placentation (RCOG, 2011b; Kallen, 2008). 
Causes of infertility and assisted conception techniques have been ascribed 
varying risk profiles (Breheny et al., 2009). In the current study insufficient detail 
regarding gynaecological history or assisted conception treatment was collected 
to make comparisons, and further research in required in this area. 
 
With regard to previous obstetric history, these data did not highlight any 
association with either maternal age or previous caesarean and severe PPH. 
Contradicting the findings of others with regard to previous CS and association 
with blood loss exceeding 1500 ml  (Al-Zirqi et al., 2009).  Established pre-index 
pregnancy risk factors for severe PPH in the general population included maternal 
age, BMI, multiple pregnancy and previous caesarean (Blomberg, 2011; 
Arrowsmith et al., 2011; Fong et al., 2010; Waterstone et al., 2001, Sebire et al., 
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2001a; Sebire et al., 2001b; Coulter-Smith et al., 1996). In addition, these data 
quantified and confirmed the impact of previous PPH on blood loss in a 
subsequent pregnancy (Driessen et al., 2011; Ford et al., 2007). The positive 
association of grand multiparity with PPH (Driessen et al., 2011: Shahida et al., 
2011) could not be validated in the current study due to the low parity of the 
population, and limited number of women with >4 previous births. Grand and 
great-grand multiparity may become less important risk factors as family size 
diminishes (ONS, 2011).  
 
These data concur that multiparity is protective against PPH (≥500 ml) (Ford et 
al., 2007) using primiparous women as the reference group were at increased 
risk of PPH. Unexpectedly, this study identified that multiparity without previous 
CS and one subscale of the index of multiple deprivation (education, skills and 
training) for England (HM Government, 2012) were risk factors for progression to 
severe PPH (≥ 1500 ml). These are curious and require further research. 
In the present study, smoking was found to be protective against large 
haemorrhages (≥1500 ml) despite being previously associated with placental 
abruption (Kitsantas and Christopher, 2013; Tikkanen et al., 2011; Ananth et al., 
1996). Both may be a consequence of smoking induced impairment of 
placentation and endothelial function, abruption being due to poor placental 
adhesion and the protective effects against severe PPH due to failure of the spiral 
arteries and other vessels to adapt to pregnancy, restricting uterine blood supply 
and also associated with fetal intrauterine growth restriction (Zdravkovic et al., 
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9.6.2 Pregnancy- acquired factors predicting PPH 
Pregnancy acquired risk factors for PPH confirmed in the multivariate analyses 
included: multiple pregnancy (Callaghan et al., 2010; Magann et al., 2005), 
placenta praevia (Kramer et al., 2011; Onwere et al., 2011) pre-eclampsia  
(Eskild and Vatten, 2009) and macrosomia (Malabarey et al., 2011;Jolley, 2003). 
The novel association with prelabour antibiotic use could reflect chorioamnionitis, 
and requires further investigation in light of reported levels of antibiotic use in 
pregnancy (de Longe et al., 2013).  However, two randomised controlled trials of 
antibiotic use to prevent preterm birth, have not reported blood loss in their 
outcomes (Shennan et al., 2006; Kenyon et al., 2001). 
 
Similarly, this study confirmed that multiple pregnancy (Kramer et al., 2011) and 
anterior placenta praevia as predictors of progression to severe PPH ≥1500 ml 
(Kramer et al., 2011; Watanabe and Matsubara, 2010; Waterstone et al., 2001; 
Stones et al., 1993). The novel association of PPH with administration of steroids 
for fetal lung maturation could be linked to multiple pregnancy (a risk factor 
itself) and threatened preterm birth (Roberts and Dalziel, 2007), although 
gestation of delivery showed no effect.  
 
Data indicated that over 62% of women with Hb <8.5 g/l had PPH, 26% of whom 
progressed to severe PPH. This is of interest because NICE guidelines have 
recently identified this as a threshold for concern and advise treatment (NICE, 
2010).  The positive associations between third trimester anaemia and severe 
PPH using higher thresholds (as advised by the Government of South Australia, 
2012; and the RCOG, Arulkumaran et al., 2009) were not confirmed by these 
data.   
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In the current study there was no association with maternal antidepressant 
medication in the last week of pregnancy and PPH. This contradicts the findings of 
a large US study which recently reported a 1.4 to 1.5 fold increased risk of PPH in 
women taking serotonin and non-serotonin reuptake inhibitors for their 
depression (Palmsten et al., 2013). This may be partly explained by the small 
numbers of women on these medications immediately prior to giving birth in the 
current study. Palmsten and colleagues noted that there was no association with 
these medications and PPH in older women, and this may also be a reason why 
this result was not apparent in my study. Additionally these authors did not 
adjust for BMI, which is known to impact on depression (Heslehurst, 2010), or 
confirm drug compliance at time of birth. However, with increasing reports of 
antenatal depression further investigation is required regarding these results, in 
order for clinicians to ensure these women receive the best care possible, and for 
labour ward staff to be aware of this potential risk factor.  
 
9.6.3 Intrapartum factors predicting PPH 
Several important intrapartum risk factors for PPH identified, have been discussed 
previously in the literature including chorioamnionitis (Malabarey et al., 2011), 
instrumental and caesarean births (Unterscheider et al., 2011; Sheiner et al., 
2005) and retained placenta (Magann et al., 2005). The RCOG Green top 
guideline for PPH recommends monitoring of maternal temperature in labour 
(Arulkumaran et al., 2009) but does not specify temperatures of concern.  These 
results strongly suggest that any maternal temperature above 37.2 °C is a risk 
factor for PPH ≥500 ml and ≥1000 ml, and justifies inclusion as an alert trigger 
(coloured amber) in some versions of the modified obstetric early warning system 
(MEOWS) charts advocated by maternal mortality reports (Lewis, 2007). The 
  292 
linear relationship between blood loss and maternal temperature requires further 
investigation. 
 
Induction and augmentation of labour were not associated with haemorrhage 
≥500 ml in agreement with an earlier report (Stock et al., 2012) but at variance 
with others (Lutomski et al., 2012; Smith et al., 2008). Further recent evidence 
suggested that mode of induction of labour may be associated with PPH, defined 
as estimated blood loss ≥1000 ml and postnatal requirement for blood 
transfusion (Jozwiak et al., 2011). These authors reported induction of labour 
using a Foley catheter was associated with less PPH than induction with 
prostaglandins. This was an a priori secondary outcome in their open labelled, 
multicentre RCT in both multiparous and primiparous women. Contradicting the 
earlier findings of Pennell and colleagues who reported no difference in PPH rates 
comparing three modes of induction in nulliparous women with unfavourable 
cervixes (Pennel et al., 2009).  
Meta analysis of these two studies showed Foley catheter induction was less 
associated with PPH (OR 0.60 [95%CI 0.37 to 0.95]) (Jozwiak et al., 2011). 
However another meta-analysis of 5 studies investigating the association between 
induction of labour and CS, with PPH as a maternal secondary outcome, 
concluded that PPH and induction versus expectant management of onset of 
labour was not statistically significant (0.78 [95%CI 0.58 to 1.05]) (Wood et al., 
2014). 
 
 Further investigation regarding mode of induction of labour and PPH is required 
where blood loss is a powered for primary endpoint, as induction and 
augmentation rates appear to be rising, not least in a bid to reduce CS rates 
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(Wood et al., 2014).  Additionally innovative methods of should be explored.     
 
The positive association between elective and emergency CS and retained 
placenta on risk of PPH, as previously reported in the literature (Fong et al., 
2010) Arulkumaran et al., 2009; Weeks, 2008), were notable.  
 
The positive association of oxytocin (Syntocinon®) use in the first and second 
stage and PPH ≥1000 ml concurs with some previous research (Selo-Ojeme et al., 
2011: Rossen et al., 2010). This could be because oxytocin use prior to birth may 
adversely affect the uterine response to a bolus dose for the third stage. Due to 
varying oxytocin administration regimes to induce and augment labour, and 
variation in uterotonic agents employed for third stage management it is difficult 
to confirm or refute this. However when the effectiveness of pulsatile versus 
continuous, and high dose or low dose, oxytocin was investigated no difference in 
PPH rates was noted (Tribe et al., 2012; Mori et al., 2011). 
Elective and emergency section were both positively associated with PPH ≥500 ml, 
but negatively associated with progression to severe PPH (AORs 0.14, 95% CI 
0.04 to 0.46 and 0.34, 95% CI 0.15 to 0.80). This is likely to be due to prompt 
surgical and anaesthetic interventions, resource availability and effective protocol 
adherence  (Shields et al., 2011). Emergency CS has previously been positively 
associated with severe PPH (Holm et al., 2012; Al-Zirqi et al., 2009) and the 
RCOG state severe PPH is less likely following elective caesarean births  (Weston, 
2012; Alzirqi et al., 2009).  
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9.6.4 Third stage intrapartum factors predicting PPH 
Prophylactic Ergometrine Maleate/Oxytocin (Syntometrine®) IM and high dose 
oxytocin (Syntocinon®) IV infusion for management of the third stage were 
negatively associated with PPH, reinforcing concerns (Rogers, 2011) about 
current recommendations for oxytocin (Syntocinon®) IM (5-10 units) as 
appropriate to prevent PPH (NICE, 2007). A national survey suggested 
Ergometrine Maleate/Oxytocin Syntometrine® IM use remains widespread (Farrar 
et al., 2010), if this is indeed the case, it contradicts opinion that changes in 
uterotonic drugs for management of the third stage have contributed to rising 
PPH rates (Rogers, 2011). 
 
Whilst not positively associated with PPH, physiological management of the third 
stage was a risk factor for severe PPH ≥1500 ml, possibly related to delays in 
recognition or treatment, although in a large population study <0.5% postnatal 
transfers from home or free standing midwife led units were for maternal reasons, 
however, this was a low risk cohort (Rowe et al., 2012). This finding could also be 
associated with staff competence in practicing physiological management, given 
the high incidence of active management in the current study (92.3%).  In early 
randomised controlled trials initial results showed higher rates of PPH in the 
physiological arm of the studies, but this became less apparent as staff became 
familiar and competent with physiological management (Rogers et al., 1998; 
Prendiville et al., 1988).   
 
Systematic reviews of RCTs and quasi-RCTs have consistently shown that active 
management of the third stage reduces blood loss, but more recently 
physiological management has been considered a natural conclusion of a normal 
labour and not been associated with adverse outcomes in women with no risk 
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factors (Begley et al., 2011; Prendiville et al., 2003; Prendiville et al., 2000). The 
most recent review commented on the paucity of good quality data in the 7 trials 
included (n= 8247), however whilst confirming active management did reduce 
blood loss and was associated with fewer postnatal Hb <9 g/dl, it was not without 
consequences for mother and baby. Mothers were more likely to experience 
hypertension, nausea and vomiting and early cord clamping was associated with 
lower neonatal birthweight. This was attributed to reduced placental perfusion 
when the cord was prematurely clamped, which could have subsequent sequelae 
for the health of the child. There was a suggestion that controlled cord traction 
could lead to fragments of placental tissue being retained causing subsequent 
readmission. Furthermore the reviewers found no statistically significant 
difference in incidence of PPH > 1000ml in high resource countries where active 
management is widely practiced compare to low resource settings where 
expectant management is the norm (Begley et al., 2011). The rigorous review 
process of RCTs, quasi RCTs and systematic reviews reliably answer 
investigations comparing one type of treatment with another, or provide evidence 
for single specified end points. The value of findings from observational studies, 
such as the current work, is frequently questioned, but this study set out to 
identify current practices regarding the prediction and management and PPH, and 
therefore the research questions could not have been addressed by RCT or 
systematic review methodologies. Even within the constraints described, these 
observations require further investigation. 
 
Time to complete genital tract repair was confirmed as a risk for PPH 
(Ozdegirmenci et al., 2010) and where this is not recorded was a risk factor for 
progression to severe haemorrhage, contradicting the findings of others (Fong et 
al., 2010). 
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9.6.5 Summary of associated variables contribution to 
PPH at all levels 
Whilst some variables can be broadly categorised as caused by 1) surgical 
interventions, for example, assisted conception techniques, previous CS, CS;  
2) genital tract trauma, for example, instrumental vaginal birth, macrosomia, 
tears and episiotomies; or 3) suboptimal contractility, for example Black African 
ethnicity, maternal age, BMI and previous PPH. However it is unclear which of 
these categories some of the identified variables would influence, for example, 




These data further illuminate the complexity of PPH and the contribution and 
pathways of the condition. In the final models at each threshold the difference in 
associated variables indicates the potentially different pathways for different 
levels of blood loss. This means the concept of progression from minor to major 
haemorrhage may be intrinsically flawed. This has implications for the commonly 
held belief that a large haemorrhage may be the result of a poorly managed 
minor bleed, and reporting mechanisms therefore should be investigative and 




9.7 Associated morbidities  
 
9.7.1 Blood transfusion 
Inconsistent blood transfusion policies have been identified as problematic when 
used as a marker of severity of PPH (Wen et al., 2005). In the current study 
3.9% of women received a blood transfusion. This compares with 1.98% in 
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Finland (Jakobson et al., 2013), 2.3% and 1.03% in the USA (Alexander et al., 
2009; Ehrenthal et al., 2012) and 0.31% in Canada (Balki et al., 2008). Several 
authors report higher transfusion rates associated with CS compared with vaginal 
birth, although rates remain low 0.49% in Canada 0.63% in Australia and not 
significantly different between elective and emergency procedures (Balki et al., 
2008; Chua et al., 2009). Given increasing rates of CS in developed countries it is 
likely more women will require blood products, although antenatal treatment of 
haemoglobin levels below 9.5g/dl have been advocated as reducing transfusion 
requirement following CS and require further assessment (Ehrenthal et al., 2012).   
A retrospective analysis of maternal deaths caused by PPH in France (n=38) 
reported availability of blood products in 79% of cases, with 3 women not being 
transfused (Bonett et al., 2011). The availability of O rhesus negative blood is 
acknowledged as pivotal in the management of severe obstetric haemorrhage. In 
the current study, despite the availability of rapidly matched blood in both 
centres, 12 women (0.12%) required resuscitation with O rhesus negative blood, 
this compares with 278/34734 (0.80%) in a Canadian cohort (Bhella et al., 2012). 
The rarity of autologous blood transfusion in the current study means 
comparisons cannot be drawn with other investigations. Increasingly cell salvage 
is advocated as a useful treatment for women where massive blood loss is 
anticipated, patients are fully informed regarding the procedure and there is a 
multidisciplinary team cognisant with the technique (NICE, 2005). However it has 
been suggested that cell salvage is underused due to considerations regarding 
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9.7.2. Surgical treatments to ameliorate blood loss  
Expedient repair of genital tract trauma effectively ameliorated blood loss in 152 
women (1.52%) in the current study and is therefore identified as a potentially 
modifiable action to reduce PPH. However the impact of early repair was 
minimally effective at reducing blood loss due to trauma but did not influence 
haemoglogin or haematocrit levels in one RCT (Ozdegirmenci et al., 2010).  
 
 
In this cohort 9% of PPH ≥500 ml were treated by insertion of haemostatic 
suturing. Insertion of haemostatic sutures was first utilized by B-Lynch in 1997 
and since that time several modifications have been identified as an effective 
method of stopping bleeding, whilst preserving fertility. There are no RCTs in the 
literature comparing sutures, but many advocates of different variations (B-Lynch 
et al, 1997; Cho et al., 2000; Hayman et al., 2002; Nelson and Birch, 2006). It 
would appear haemostatic sutures, when properly applied, are effective and 
ameliorating blood loss. 
 
Other techniques advocated as effective treatment for intractable haemorrhage, 
such as vaginal packing and balloon tamponade, were minimally employed in the 
current cohort (n=24 women and m=21 respectively). There is a paucity of RCTs 
regarding balloon tamponade, and existing case series reports often group and 
assess all tamponade, thus the effectiveness of one device, over others, is not 
possible to assess (Georgiou, 2009). Those assessing individual devices, such as 
the Bakri balloon tend to me small and therefore, although they are reportedly 
effective in treating PPH, heterogeneity of the research design and differences in 
practice variation mean generalisability is uncertain (Aibar et al., 2013; Vitthala 
et al., 2009). Further prospective studies investigating and comparing tamponade 
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devices is required, in the current study it is possible balloon tamponade was an 
underused treatment.  
 
 
Interventional radiology, although available on both participating sites and 
advocated in protocols, was only used on one occasion in the current study. 
Underuse of this effective treatment has been reported elsewhere (Webster et al., 
2010). Familiarity with procedures and treatments has been advocated to ensure 
effective treatment, and the minimal use of interventional radiology could indicate 




9.7.3 Manual removal of placenta/ placental delivery 
Expedient management of the third stage has been advocated as reducing the 
risk of PPH, indeed Magann and colleagues (2005) considered prolonged third 
stage occurs 18 minutes after delivery of the baby, and the risk of PPH increased 
6-fold when the placenta was not delivered within 30 minutes (Magann et al., 
2005). Despite this current guidelines state the definition of prolonged third stage 
is made when the placenta has failed to be delivered 30 minutes after birth with 
active management of the third stage and an hour after expectant management 
(NICE, 2014). The degree of blood loss associated with a retained placenta is 
dependent on the type of placental retention: either trapped- separated from the 
uterine wall but not expelled due to cervical entrapment; adherens -caused by 
failure of myometrial contraction behind the placenta; or, a partial accreta where 
most of the placenta has separated, but a small piece is abnormally attached to 
the uterine wall (Weeks, 2008).  
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The longest delays in the current study were over 4 hours and associated 
estimated blood losses of 1300 ml and 1500 ml. When initial bleeding settled 
both cases were conservatively managed but both required prompt subsequent 
manual removal as bleeding increased. Whilst expectant management may be 
considered preferable for the women, without definitive diagnosis of cause of 
placental delay, it could be suggested failure to promptly deliver the placenta 
would constitute substandard care. 
 
   
9.7.4 Hysterectomy 
As previously described the rate of peripartum hysterectomy in the current study 
was comparable with the UK report using UKOSS  (0.50 versus 0.55 per 1000 
births).  There remains wide variability in peripartum hysterectomy rates between 
and within countries. The impact of delay in attendance is highlighted in reported 
rates of 10.52 per 1000 deliveries in a tertiary centre in Pakistan. This is 
particularly stark when compared to the UK and Canada (0.80 per 1000 
deliveries) (Knight, 2010; Glaze et al., 2008). In Turkey two recent reports 
demonstrate local differences in tertiary referral centre rates: 1.87 per 1000 
deliveries (Kara, 2012) and 0.63 per 1000 deliveries (Karayalcin et al., 2011). 
Karayalcin and colleagues, further identify the rate associated with CS as 2.0 per 
1000 deliveries compared with 0.12 per 1000 deliveries following vaginal birth. 
All authors concede an association with both previous and current CS in increased 
risk of peripartum hysterectomy.  
 
 
Peripartum hysterectomy is indisputably a major cause of maternal morbidity. 
One recent report suggested numbers are declining, identifying fewer cases of 
uterine rupture, but more cases of placenta accrete and percreta (Flood et al., 
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2009). In the UK, a nationwide survey reported an estimated incidence of 
placenta accreta, percreta or increta of 1.7 per 10,000 maternities (95%CI 1.4 to 
2.0) (Fitzpatrick et al., 2013). Half the cases were identified antenatally, and this 
was associated with lower blood loss at birth (1750 versus 3700 ml). Given 
recent advances in ultrasound and magnetic resonance imaging (MRI) further 
work regarding abnormal placentation could lead to more cases being identified 
leading to better informed women and well prepared staff, ultimately potentially 
improving outcomes for women. The management was variable, with Syntocinon 





Adoption of documented blood loss from clinical records, with no attempt to verify 
blood loss by more robust methods such as gravimetric, biochemical, drapes or 
other method could be considered a major limitation of the current study. 
However the aim of this work was to ascertain current practice, and risk factors, 
therefore confirmation of documented blood loss was out with the remit of the 
current study. Some of the data imported and reviewed identified women who 
had both measured and visually assessed volumes of blood loss. Where these 
were both provided, the total blood loss was used for analyses. Despite the 
presence of calibrated drapes in both Centres, they were rarely used.  When 
blood loss volume was documented as “measured”, as opposed to “estimated”, 
the method of measurement was seldom recorded. Thus in an ideal world more 
accurate means of assessing blood loss would be used, but the minimal use of 
calibrated drapes, suggests that, pragmatically, midwives and doctors rely on 
visual assessment. The aim of the STOP programme of work was to improve 
practice using routinely collected data and establish an audit cycle. Despite 
limitations of routinely collected data, the NHS Safety Thermometer for Maternity 
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is currently piloting blood loss as estimated from patient notes as an 
improvement indicator (www.safetythermometer.nhs.uk).   
 
9.8.1. Study population 
The demographics of the cohort could be considered as somewhat different from 
the general UK population. The inclusion of a tertiary referral and district general 
hospital increased generalisability in terms of social and ethnic diversity, but 
generalisability may be limited by not including a more rural population, or one 
less influenced by the proximity of London. Similarly the larger proportion of 
women living in areas of high deprivation (39% lowest quintile), and aged >30 
years in the current cohort compared to contemporaneous maternity data for 
England and Wales (60% versus 47%) (ONS, 2010) may reduce generalisability. 
Although obesity rates were similar to recent national figures (15.2% versus 
15.6%) (Heslehurst et al., 2010). Comparison with UK maternal ethnic 
distribution at the time of the study (ONS, 2011) was not feasible as these data 
are not in the public domain (HESonline, 2009). Additionally error rates between 
electronic and handheld data could not be assessed for ethnicity due to the 
diversity of information collected in each participating unit. This must be 
addressed if the influence of ethnicity is to be considered in health and social 
analyses. 
 
Historical comparison could have been influenced by the different methodology 
employed (case control versus weighted sample), changes in local service 
provision (one trust previously operating on two sites has now amalgamated 
maternity services to a single site, and the other is a new building in a new 
location), and shifting population demographics and profiles. Despite controlling 
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for known confounding variables, associations cannot necessarily be assumed to 
be causal. Gynaecological history, migration history, intended place of birth and 
degree of perineal trauma were not included. 
 
9.8.2 Missing data 
There was evidence of missing data related to blood loss, but this was resolved 
by our methodology. Overall, 7% (132/1896) of women had no recorded on NHS 
electronic summary data despite blood loss volumes being documented in their 
handheld notes. Of these, 27% (35 women) had a PPH ≥500 ml, 4% (5 women) 
of whom bled ≥1500 ml.  Inherent problems with summary data have long been 
noted (Cleary et al., 1994; Cartwright et al., 1987). Fully electronic patient 
records have been advocated as improving care (Tindale and Hardiker, 2012; 
Feied et al., 2004; Hammond et al., 2003) and would facilitate monitoring of 
severe maternal morbidity if data quality was improved and consistent (Bouvier-
Colle et al., 2012; Chantry et al., 2011). The completeness of written blood loss 
suggests that duplication of maternity records to electronic summary data, may 
be problematic in the participating units and further training may be required. 
Moving to a single entry electronic patient record system with automatic 
generation of summary data could improve discharge communication, ultimately 
improving postnatal care, but requires significant financial, development and 
training resource before such a system could be comprehensively introduced. 
 
Thirty five women were identified via blood transfusion records. Of these: nine 
had documented estimated blood loss <500 ml; 18 had documented estimated 
blood loss 500-999 ml; two had documented estimated blood loss 1000-1499 ml; 
six had documented estimated blood loss exceeding 1500 ml. Transfusion 
protocols and documented symptoms, suggest estimated blood loss 
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underestimation in all cases which may in part be due to incorrect or absent 
addition of blood loss volumes documented.  
 
In a few women, there was no information at all about blood loss, but these 
tended to be unattended or paramedic attended births. Paramedic and first aid 
training may require revision to include blood loss assessment after birth.  
Midwives arriving post-birth should also be reminded to comment on blood loss in 
addition to focusing on neonatal wellbeing.  
Blood loss assessment following water birth was problematic, albeit a small 
proportion of the study population (1.07%). Centre 2, estimated categorically, 
<500 ml or >500 ml, Centre 1 recorded volume as for any other birth. It was 
unclear how this blood volume estimation was achieved, an issue that has been 
identified by others (Otigbah et al., 2000).  The RCOG/RCM state only healthy 
women with uncomplicated pregnancies should consider water birth (Al Zirqi et 
al., 2006), this infers low risk of PPH but fails to address its’ unpredictability. No 
recommendations exist regarding estimation of blood loss assessment (Munro et 
al., 2008) with some suggesting visual assessment does not differ in water (Lim, 
1994).  
 
The largest source of missing data point was unfortunately ‘temperature in labour’ 
(27% of weighted sample), which proved significant in the final analyses. It 
would have been useful to have a complete data set although the association was 
so strong the lack data was not problematic.  Maternal temperature above 37°C 
was associated with PPH and therefore omission may mean clinicians are 
unnecessarily unprepared. 
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9.9 Implications for policy and practice 
 
As a result of this work there are several important implications for policy and 
practice:  
1. The methodology employed in this study should be recommended as tool 
for monitoring PPH at all levels and could include cross check fields with 
other electronic summary data, such as ITU admission, transfusion and 
hysterectomy, which could ultimately improve care for women 
experiencing this common obstetric complication. The use of electronic 
patient records for monitoring and other outcomes is a valuable tool for 
research and clinical audit and the error rates in this study (up to 2% 
changed following comparison with other forms of medical records) 
provide an indication of how EPR systems can be used in the future. In a 
Trust a weighted sampling strategy could be devised to minimise the 
volume of review work whilst providing adequate power for confidence in 
findings. It should also be possible to expand the database to monitor 
other morbidities, such as shoulder dystocia, eclampsia, stillbirth, and 
aspects of care. The implementation of the minimal maternity dataset 
(HSCIC, 2013) should facilitate this process, unifying definitions and 
terminology. Ultimately this monitoring system could improve patient 
care, being a useful adjunct to the Confidential Enquiry in to Maternal 
Deaths and CNST audits. 
2. The identification of errors in recording estimated, most commonly 
exaggerated by incorrect calculation or failure to update electronic patient 
records could be addressed by modifying handheld maternity records to 
include a pre-printed column on each postpartum page to document 
cumulative blood loss. Electronic discharge summary reports should 
include a requirement to input subsequent blood loss. 
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3. Blood loss assessment following water births also needs improvement. 
More accurate assessment and recording and addition of total blood loss, 
will improve patient care, enhance clinician confidence and provide better 
data for future audit and research.  
4. Dissemination of the risk factors identified in the pre-pregnancy, 
pregnancy acquired and intrapartum models will inform health care 
providers and women regarding an individual’s risk of PPH. This should 
result in improved patient care. For example specific consideration should 
be given to older and obese pregnant women, pregnancies achieved with 
ARTs, antenatal attendance feeling “generally unwell”, women who receive 
steroids for fetal lung maturation, maternal temperature in labour and 
time to genital tract repair. 
 
 
9.9 Future work 
 
This study has identified areas requiring further investigation and development, 
these include: 
1. Further expansion of the Internet based data management system needs 
to be explored in order to facilitate the adoption of approach into clinical 
use, so that PPH and other morbidities can be monitored locally, regionally 
and nationally.  
2. The usefulness of the weighted sampling strategy employed here should 
be assessed in relation to research other morbidities within health care. 
3. Further work is required to ascertain more accurately the true rates of 
blood loss at different levels in other geographical areas. The clinical 
utlility of the models will need validation. An algorithm to assess 
haemorrhage according to pre-existing, pregnancy acquired and 
intrapartum factors could be developed to better predict at what volume of 
blood loss a woman is likely to be compromised. As part of this process, 
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the mechanisms for informing women and health care professionals 
regarding risk of PPH should be investigated. Health care professionals will 
require additional education, which will necessitate the development of a 
training programme.  
4. The knowledge gained through the risk models will provide information to 
facilitate the development of targeted strategies to reduce PPH, and 
increased understanding of cumulative risk.  
5. Further investigation is required regarding several of the identified risk 
factors, especially the impact of Black African ethnicity.  
6. More work is required around blood loss assessment in water, and training 
packages need to be developed for paramedics and “first aiders” regarding 
estimating blood loss during birth.   New innovations developed in war 
medicine may improve the ability to assess blood loss more accurately. 
For example, haemostatic patch gauze and other dressings that absorb 
specific blood volumes, but not other body fluids. A randomised controlled 
trial investigating the effectiveness of these, versus traditional absorbent 
sheets and visual assessment of blood loss could be useful in targeting 
other readily available resources appropriately. Blood transfusion regimens 
have also been developed to improve prognosis and reduce overall blood 
product requirement in severe trauma. Investigation of the transferability 
of these initiatives to postpartum haemorrhage may reduce morbidities 
and improve care with concomitant advantages for women, their families 
and the NHS.  
7. Unification of terminology and definitions is required to improve 
communication and care. Investigation into the appropriateness of the 
term “haemorrhage” when applied to a volume not likely to cause 
compromise should be challenged. The validity of different volumes of 
estimated blood loss according to mode of birth and other factors, such as 
maternal BMI, should be explored.  
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9.10 Summary and Conclusions  
 
This study contributes to the body of literature regarding PPH. The derivation of 
clear models identifying independent risk factors for various levels of estimated 
blood loss should assist in the future management of this increasingly common 
emergency. It identifies novel risk factors and provides convincing supportive 
data for previously known risk factors. The main messages arising from this 
research are: i) Clinical estimation of blood loss and reporting of PPH data 
requires improvement, and much can be learned from the methodology used in 
this thesis; ii) Different risk factors predict different levels of PPH and as a result 
the concept of ‘progression’ may be misleading and a paradigm shift may be 
required based on the models developed as a result of this study, and iii) Many 
early variables positively associated with increased estimated blood loss are 
mediated by later events, many are not modifiable, but explanations are required 
when communicating with women and health care professionals. Simple 
measures, such as monitoring maternal temperature in labour and expedient 
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1 RATIONAL  
Can the prediction, prevention, identification and treatment of 






Bleeding can occur at any time during pregnancy. Serious haemorrhages can 
be antepartum, but most occur after delivery. The definition of postpartum 
haemorrhage (PPH) is: “the loss of 500mls or more of blood from the genital 
tract within 24 hours of the birth of a baby” (WHO,1989,1990; WHO ICD 10 
version 2007, O72.0;O 72.1). Chandraharan and Arulkumaran (2007)  further 
enhance the definition by suggesting PPH is blood loss of 1000 mls following 
caesarean section, and massive PPH refers to the loss of 30-40% (generally 
2000 ml) of the patient’s blood volume, resulting in alteration of 
haemodynamic parameters, leading to moderate to severe shock. 
 
Incidence: Many studies report an incidence if 5% (eg Magann et al, 2005), 
but an Australian study reported 12% of women experience PPH following 
vaginal delivery (Henry et al, 2005). Known risk factors for PPH include 
caesarean section (elective, increases risk 4 fold, and emergency 9 fold), 
maternal age and obesity (2 fold increase in the risk). As all these factors are 
increasing, it is likely therefore that more women will experience PPH in the 
future. 
 
Worldwide, PPH is a major cause of maternal mortality and morbidity. Lack of 
consensus regarding management of this common complication further 
compounds the consequences (Potts et al, 2006). Globally, the ability to 
identify and treat PPH is key to the effectiveness of maternity care   In a 
previous study in the Region, severe maternal morbidity occured in 12 per 
1000 deliveries. Sixty six percent of cases were secondary to massive PPH 
(>1.5 L) (Waterstone et al, 2001) and PPH is noted to have a high morbidity-
to-mortality ratio. 
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Substandard care contributes to maternal mortality and morbidity (Geller et al, 
2004; Pattinson et al, 2003) - cited in 60-67% of cases (1997-9:2000-2), with 
80% of maternal deaths attributed to PPH, increasing from 10 to 17 (DoH, 
2000; DoH, 2004). Professional factors and communication failure account for 
a large proportion of substandard care (Rowe et al, 2001). There is scope for 
reducing morbidity severity by evidence-based intervention as has been 
demonstrated in shoulder dystocia (Croft et al, 2006). Interdisciplinary 
learning facilitates multidisciplinary working (DoH, 2004). 
 
Evidence exists regarding the prevention and treatment of PPH, but no simple 
unified national guideline exists in England, unlike cardiopulmonary 
resuscitation (CPR), for example. The evidence base for current provision and 
quality of care is limited. Mandatory emergency training (which every Trust 
adheres to as part of the Clinical Negligence Scheme for Trusts, CNST) 
complies with local requirements, with no uniformity or collaboration regarding 
instruction (Rodgers, 2007). There is no consensus regarding guidelines and 
monitoring of PPH, so national practice remains variable, unreported, non-
standardised and incomparable. Discrepancies between actual and estimated 
blood loss volumes are cited as contributors to morbidity (Hall, 2004), with 
practice differing  in this assessment. Currently neither the Royal College of 
Obstetricans and Gynaecologists (RCOG) nor National Institute for Health 
and Clinical Excellence (NICE) have proposed guidelines for PPH 
management. 
Confidential Enquiry into Maternal and Child Health (CEMACH) 
recommendations have repeatedly included the following: unit protocols, 
‘skills drills’, blood bank responsiveness, experienced operators for placenta 
praevia and early senior involvement. CNST mandates that units have a 
protocol for haemorrhage and annual skills training. The rise in maternal 
deaths suggests that recommendations are not translated into practice, there 
are increasing risk factors for PPH, and potentially  declining working 
practices in struggling services. PPH is an emergency managed by a 
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multidisciplinary team assembling anew. Effective teamwork to agreed 
standards and protocols is vital.  
 
The Scottish Obstetric Guidelines and Audit Project (SOGAP) produced 
guidelines regarding the management of PPH in Scotland (1998; 2002). 
These appear to have been adopted throughout the country, with minimal 
local variation. The Scottish Confidential Audit of Severe Maternal Morbidity 
advocates ongoing audit (Penney et al, 2005). It currently collects PPH data 
across Scotland, reporting annually. However, contributing factors, such as 
location, case mix and ITU accessibility, are not adjusted for when comparing 
units. Even with these caveats, they have reported consistent reductions in 
substandard care. No such monitoring system exists elsewhere in the UK.  
The rate of massive PPH (>2.5l) has increased from 3.7/ 1000 (CI 3.4.-4.0) 
over the 2003-5 triennium to 5.0/1000 (CI 4.4-5.6) in 2006, but there appears 
to be an increase in well-managed cases (from 63% in 2004 to 79% in 2006) ( 
Penney & Adamson 2007) 
 
Guidelines improve care (Grilli and Lomas, 1994); effective implementation 
and active dissemination involves taking local circumstances into account 
(O’Brien et al, 2005). Evidence suggests there is a lag between dissemination 
and implementation of guidelines, dependent on clinician behaviour. A North 
American survey stated 98% of obstetricians were aware of guidelines, but 
only 60% changed practice (DoH, 2000). Non-adherence increases risks to 
patients and litigation and NHS costs (Ranson et al, 2003). 
 
The impact of these emergencies on health professionals has not been 
assessed or evaluated.  Staff express anxiety and increasing stress following 
such events.  Risk management procedures repeatedly identify delays in 
recognition, underestimation of blood loss, poor communication, inadequate 
teamwork, lack of senior involvement and non-adherence to guidelines as 
contributing factors. Other obstetric emergencies, eg shoulder dystocia, have 
been investigated and after system-wide policies have been implemented, 
complications have been reduced and staff confidence increased (Crofts et al, 
2006). There has been little formal evaluation regarding skills-drills training for 
  315 
emergency situations, with some suggestion that other methods may be more 
effective (Black and Brocklehurst, 2003). Effective ways of changing 
behaviour are audit and feedback of findings (Acker, 1991; O’Brien et al, 
2005). Passive approaches are ineffective, but may raise awareness and 
reinforce messages. Multifaceted interventions targeting different aspects of 
behaviour  are most effective (DoH, 2000). Future work should include 
qualitative process evaluations combined with randomised controlled trials 
(RCTs) to clarify how specific attributes of workshops influence professional 
practice (Thompson et al, 2001). Interactive educational workshops produce 
“moderately large changes” (O’Brien et al, 2005). 
 
Many maternity services are undergoing reconfiguration with challenges of 
recruitment, retention and training, whilst providing 24 hour cover. In the last 
decade maternity services have not been a high priority (excepting CNST). 
Current NHS policy to increase care in the community and midwife-led care 
means that maternity networks and care pathways must be developed and 
operate efficiently to ensure high standards of care and safety.   
 
NICE and RCOG recommendations have been ratified for many medical 
situations. None are in place regarding the management of PPH. UK Obstetric 
Surveillance System (UKOSS) recently investigated obstetric hysterectomy 
but this is the “tip of the tip of the iceberg”. This project aims to develop an 
effective audit tool for monitoring PPH in participating units. By collecting data 
regarding smaller PPHs all strategies will be examined and the most effective 
in preventing massive blood loss investigated. 
 
 
3 AIMS and OBJECTIVES 
To undertake a detailed review of the available literature regarding the 
prediction, prevention, recognition and management of peripartum 
haemorrhage. 
To investigate current practice regarding the management of peripartum 
haemorrhage from unit protocol and guidelines. 
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Using qualitative methodology: 
 Investigate the professional, personal and team factors that influence 
the management of haemorrhage. 
 Ascertain and examine multidisciplinary staff attitudes to the 
management of this complication. 
 Explore the experience of haemorrhage from the sufferer’s 
perspective. This will include their views of the professionals’ response 
to the emergency and the impact on them and their families. 
 
To develop a simple, unified protocol for the management of haemorrhage in 
the participating units, St Thomas’ Hospital (STH) and Queen Mary’s Hospital 
Sidcup (QMS) 
 
To establish an internet-based data collection system to continuously monitor 
all haemorrhage and the quality of care in analysis of cases of severe 
haemorrhage. This will facilitate effective monitoring and auditing in 
participating units. 
 
Following analysis of the information gained from the qualitative aspect of this 
study develop and test a training package to improve management of 
haemorrhage that will evolve and respond to identified needs, integrating 
theory and practice at STH and QMS. 
 
Dependant on the results above, investigate the potential impact of setting up 
a self help/support group for women who have experienced PPH 
 
 
4 DETAILED LITERATURE REVIEW 
 
Electronic databases and journals will be used to obtain all relevant data 
regarding the prediction, prevention, identification and treatment of PPH, 
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using general and specific search strategies, which will be exploded and 
focused. 
 
Current policy and guidelines 
Initially, the policies and practices at STH and QMS will be compared and 
contrasted to ascertain current practice in a teaching hospital and a DGH, 
thus increasing generaliseability of findings. 
Other maternity units will be approached regarding the guidelines they use for 
the management of PPH to investigate current availability of evidence based 
guidelines. 
 
Unified protocol development 
From the evidence found in the literature and from individual unit protocols a 
unified evidence-based protocol will be devised.   
 
 
5 DATA COLLECTION 
 
Internet based data collection /monitoring system 
An Internet database will be developed to record data regarding all blood loss 
and the diagnosis and management of all PPHs (≥ 500mls). This will be a 
secure Internet site accessed with personalised passwords. Minimal 
demographic details will be recorded, and no individual will be identifiable 
from the data saved. 
Several levels of access will be available: 
Public page data: information will be available regarding the project and also 
about PPH.  
Single unit : an individual will be only able to enter and see data relating to 
one maternity unit. 
Administrator: this level the user will be able to access information from all 
participating centres, and edit (i.e. for data cleaning purposes). A data 
tracking system will be in place to ensure a retrievable audit trail reporting 
when and by whom data was altered, and also what was changed. 
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View only: this level of access allows all data to be viewed but none to be 
edited or altered. 
 
The Internet data management system will be developed with MedSciNetTM 
Sweden. It is a Windows type interface with an Information tree - this means 
that additional information will only be collected when certain boxes are 
ticked. For example pre-existing medical condition, if marked no, no further 
information is required, if marked yes, additional internet “page” appears to 
record the information. 
 
The information collected will probably include: 
Maternal details: Gravida/Parity, Date of Birth, Ethnicity, Height, Weight (BMI 
will be calculated by the programme). 
Previous obstetric conditions and events (eg PPH, CS),  
Pre-existing maternal medical conditions (eg hypertension, diabetes, 
lupus),  
Medicines  
Pregnancy details: gestation at delivery, antenatal complications (e.g. pre-
eclampsia, placenta praevia, antepartum haemorrhage, obstetric cholestasis),  
Labour details: Place of delivery, onset of labour, mode of 
induction/augmentation, duration of 1st and 2nd stage of labour, mode of 
delivery, perineal/ vaginal trauma, management of 3rd stage 
Estimated blood loss (EBL): measured/estimated, at delivery and 
postnatally (and including large APH) 
Management of PPH: these datapoints are currently being developed and 
may include such things as staff involved, timing of arrival of senior staff etc. 
Paper copies of the database will be available as Appendix 2 of this manual, 
once development is complete. 
  
DATA PROTECTION 
All data will be collected and used within the context of the Data Protection 
Act (1998).  No details of any particular woman will be released to any other 
organisation. Participating centres are registered with the Data Protection 
Agency. 
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6 QUALITATIVE STUDY 
Face to face interviews (n dependant on data saturation) will be conducted 
with women who have EBL ≥ 500mls, and multidisciplinary team members 
involved in labour and delivery.  These will be undertaken by two of the 
research team, audio taped (with permission) and field notes taken. Some 
interviews will be conducted using women and staff from the same event. 
Initially criterion sampling will be employed for quality assurance (Patton, 
1990). Purposive sampling will ensure diversity of experience and data 
saturation (Patton, 1990). Using this mixed sampling combination will 
enhance triangulation. Staff sampling will involve the “cousin position” of 
diagonal (as opposed to vertical) sampling that minimises inhibition in 
organisational hierarchies (Wengraf, 2001). 
 
The interview will focus on women’s views of the management of the 
situation, what went well/badly, issues around communication between the 
multidisciplinary team and the women/partner, and their views of professional 
competence & teamwork. There is great interest in how patients can 
contribute to patient safety and these interviews can inform this work (Pandey, 
2007). Critical incident technique will be utilised in this aspect of the study  
 
ELIGIBILITY 
Staff:             Willing and able to give informed consent 
Multidisciplinary 
                     All grades 
                     Diverse length of service 
 
Women:        Willing and able to give informed consent 
PPH >500mls (in most recent delivery) 
PPH during study period 
  
RECRUITMENT PROCESS 
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 Eligible women and staff will be verbally asked to consider helping with 
this study. 
 Staff and eligible women will be asked to read an information sheet 
about the study (Appendix 1).  
 The study research midwife will contact staff/women and any queries 
or comments will be addressed. 
 If the potential participant verbally agrees to take part an appointment 
will be arranged, at a mutually convenient time and place, to undertake 
the interview. 
o This will be in an appropriate setting for the interviewee 
o Adequate time will be available for this interview to take place 
 At that interview, the researcher will answer any further queries. 
 Informed written consent will be obtained from participants (Consent 
Form: Appendix 2). 
 The interview will be recorded (with consent) and field notes taken. 
 
INTERVIEW 
The interviewee will be welcomed and explanation given regarding the taping 
of the interview and field notes being taken. 
Confidentiality will be maintained at all times. 
 Lightly structured depth narrative interview design, focusing on the 
elicitation and provocation of story-telling, will be utilised. 
 Open-ended questions will be asked to allow the informant maximum 
opportunity to express thoughts and feelings. 
 Subsequent queries will be developed from the information imparted. 
 Clarification of certain points will be ascertained, as required. 
Any issues raised will be dealt with after the interview or referred 
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Qualitative data will be analysed to examine emergent themes using the 
NVIVO7 software package. These data will be used to inform guidelines and 
develop training tools. 
Data entered into the database will be analysed using the STATA9.0 software 
package. These data will be used to develop an effective monitoring system 




7 QUANTATIVE ANALYSIS 
We will obtain routinely collected data about all blood loss in the women 
delivering in STH and QMS over a year. From this we will derive estimates of 
adjusted mean blood loss for different levels of obesity, parity, mode of 
delivery, age group and ethnicity. Additional factors such as placental location 
and previous PPH or caesarean will be investigated depending on the quality 
of data available. We will look at frequency distributions of blood loss and 
examine preferred values and digit preference/avoidance. We will examine 
blood loss by time of day, day of week and public holidays.  
 
We will examine the notes of a weighted sample of (1) women with blood loss 
<500mls (estimated 1%), (2) women with a PPH >500mls but <1,500mls 
(estimated 10%) and (3) all women with a massive haemorrhage (>1,500mls), 
in order to ensure data quality and to estimate the effects of all known risk 
factors (estimated total 300 sets of notes).  We will also examine other 
sources in the cases of major haemorrhage >1500mls, (for example, delivery 
register, theatre log, risk reporting, blood transfusion laboratory, ITU and 
pharmacy) to ensure full ascertainment of cases. 
 
We intend to use multiple logistic regression analysis to develop prediction 
models as with Waterstone et al (2001) for mean blood loss and proportion of 
women with severe blood loss (various cut offs can be used). These figures 
can be used to compare expected versus observed blood loss between 
centres. In addition we will be able to present new evidence of the relative 
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importance of various known and suspected risk factors. These figures will 




8 ETHICAL ISSUES 
The South East Multicentre Research Ethics Committee (MREC) has 
approved the study; Site Specific Information will be supplied to the Local 
Research Ethics Committee (LREC) for each participating centre. 
 
 
9 PROJECT FUNDING 
This project is funded by a grant from Guy’s & St Thomas’ Charity (Registered 
Charity Number 251983).  
 
 
10 NHS and CLINICAL INDEMNITY 
NHS indemnity will apply to women and clinical staff in respect of any injury or 
loss due to negligence by clinical staff during the study. This conforms with 
Department of Health guidelines, which state the NHS Trust Hospitals 
continue to have a duty of care to patients participating in research. 
 
 
11  POLICY FOR PUBLICATION & AUTHORSHIP 
Papers will be written collaboratively according to expertise and abiding by the 
international guidance for authorship or that of the appropriate journal. All 
contributions will be acknowledged.  The results will be presented, in 
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12 TIMESCALE 
The literature review, and subsequent protocol development will take 
approximately 1 year. The data monitoring system development and testing 
will start by the end of the first year. The complex intervention, in terms of 
training tools, will be developed in year 2. It is anticipated that by the end of 
year 2 the unified protocol will have been tested and accepted within 
participating units and the data monitoring system will provide an effective 
auditing tool for practice relating to PPH. 
 
 
13 STUDY MANAGEMENT 
The Principal Investigator, Dr Susan Bewley will share the overall 
responsibility of the study with the Clinical Trials Manager, Annette Briley. The 
day to day running of the trial will be undertaken by the Trial Management 
Team, Mrs Annette Briley and the study specific Research Midwife. Mr Paul 
Seed will provide statistical support. Laima Judosvainer will assist with IT. Mr 
Mark Waterstone will provide expert advice regarding maternal morbidity and 
oversee the study at QMS. Professor Jane Sandall will provide expertise 
regarding the qualitative aspects of the study. 
 
 
14 PROJECT ADVISORY COMMITTEE 
The Project Advisory Committee will meet regularly throughout the study to 
advise and monitor the programme of work (See GANTT Appendix 3). It has 
representation from maternity service users, clinicians and managers with 
expertise in postpartum haemorrhage, evaluation of complex interventions or 
educational/ training packages.  
Membership: 
Charles Wolfe, Professor of Public Health Medicine King’s College London 
(Chairman);  
Sue Eardley, Strategy Manager for Children and Maternity, Healthcare 
Commission 
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Sarah Gregson, Consultant Midwife, Maidstone and Tunbridge Wells, NHS 
Trust 
Laura Pettigrew, lay representative recommended by National Childbirth Trust 
and pscychologist with special interest in early parenting 
Graham Tydeman, Consultant Obstetrician, Fife NHS, Kirkcaldy, Scotland 
Rachel Tribe, Senior Lecturer, Maternal and Fetal Research Unit, King’s 
College, London 
The co-investigators will also be part of this committee 
 
The terms of reference of the Project Advisory Committee are: 
 To provide advice on the overall conduct of the project to the 
management team 
 To advise the project team on the research outputs 
 To provide advice on the engagement of key stakeholders and 
dissemination of findings 
 
Specific tasks are: 
 To approve the main project protocol. 
 To monitor and supervise the progress of the progress of the project 
towards its interim and overall objectives. 
 To review at regular intervals relevant information from other sources. 
 To advise and resolve problems brought to by the management team. 
 To advise on study reports and papers for publication. 
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Appendix 3: Imported data variables, and outcome 
variables definitions of categories, variables and 
terms, outcomes, exposures, risk factors, potential 
confounders, effect modifiers and diagnostic 
criteria listed in alphabetical order. 
Variable (and 
abbreviation) 
Definition used and 
data obtained 
Rationale for inclusion 
Importation and general data variables  
Centre The maternity services 
included in the study. 
Centre 1- tertiary 
referral centre; Centre 2 
-district general 
hospital. 
Identification of place of 
birth and management of 
PPH. 
Date of Import 
(date received) 
The date information 
was electronically 





identification of cases, and 
ensure ongoing reliability of 
system. 
Digit Avoidance Numbers avoided, 
usually due to 
documentation of those 
volumes requiring 
action, leading to lower 
numbers selected. 
To explore the potential of a 
phenomenon described in 
blood pressure monitoring 
(Shennan and Halligan, 
1996). 
Digit Preference Numbers preferred and 
therefore volumes 
rounded up or down to 
accommodate this 
preference. 
To explore the potential of a 
phenomenon described in 
blood pressure monitoring 
(Shennan and Halligan 
1996). 
Extraction comments Free text box on 
registration page- 
enables researchers to 
add any additional 
comments that might be 
relevant, but are not 
captured within the data 
Free text should be kept to 
a minimum, but 
occasionally relevant data is 
not captured elsewhere 
(ECRIN., 2007). 
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points. 
Estimated blood loss 
(EBL). Imported and 
confirmed 
An estimation of the 
total blood volume lost, 
usually achieved by 
visual assessment. 
Imported volume (in ml) 
and confirmed volume 
(in ml) 
Commonly used method of 
assessment in UK (Bose et 
al., 2006). Imported; refers 
to the volume recorded on 
the NHS electronic 
summary data. Confirmed; 
refers to the volume 
documented following 
review of clinical data 
available from multiple 
sources. 
Intramuscularly  (IM) Route of administration 





Route of administration 
of drug (or route of 
administration of drug 





number for all NHS 
patients treated in a 
specific unit. 
To aid identification and 
location of medical records 
for weighted sample. 
Postcode The unique post office 
code assigned to a 
group of residences in 
England. 
From this a super output 
area code is derived 
facilitating assessment of 
deprivation. 
Threshold avoidance An identified threshold 
is avoided, therefore 
typically lower volumes 
are recorded. 
Thresholds in blood loss 
are typically 500ml, 
1000ml, 1500ml, 
2000ml and 2500ml. 
Identification and 
description of blood loss 
reporting errors. 
Group A. Pre-pregnancy, pre-existing 
Assisted conception for 
this pregnancy 
Yes/no 
No details required 
Unknown impact on PPH.  
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Blood Pressure (BP) at 
booking 
The measurement of 
systolic and diastolic 
blood pressure at first 
antenatal appointment 
measured in millimetres 
of mercury (mmHg) 
Known association with 
hypertensive disorders of 
pregnancy 
Body Mass Index (BMI) Body weight divided by 
height squared in 
kg/m2. 
Described as causative of 
and protective against PPH 
at different levels (Paglia et 
al., 2012).. 
Depression Maternal history of 
depression, or current 
depression, if current, 
medications taken. 
Linked to PPH, especially 
certain medications (Tata et 
al., 2007). 
Ethnicity The racial/genetic 
background from which 
a person originates. 
Within this study 
ethnicity was defined 
pragmatically, as used 
in the NHS. Most 
commonly with women 
identifying themselves 
within an ethic group.  
Certain ethnic groups have 
been identified as at 
increased risk of PPH (RCOG 
guidelines; Al- Zirqi et al., 
2008; Magann et al., 2005). 
Epilepsy Maternal history of 
epilepsy yes/no, 
If yes medications for 
epilepsy, and changes 
made in early 
pregnancy. 
Association with epilepsy 
and treatments with 
adverse pregnancy 





All procedures that 
involve partial or total 
removal of the external 
female genitalia, or 
other injury to the 
female genital organs 
for non-medical 
reasons(www.who.int ). 
Most radical procedures 
have a known associated 
with PPH (Banks et al., 
2006). 
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Gestation at booking The number of weeks 
and days since last 
menstrual period when 
a woman first attends 
for antenatal care. 
Delayed attendance for care 
can be an indicator of social 
exclusion and poor outcome 
(Lewis, 2007). 
Gravida (G) The number of times a 
woman has been 
pregnant, including 
current pregnancy. 
Primiparity and grand 
multiparity are implicated as 
risk factors for PPH.  
Index of Multiple 
Deprivation (IMD) 
The level of social 
deprivation was 
estimated by matching 
every woman’s postcode 
to a small area (Local 
Super Output Area, 
LSOA) of some 2,000 
people, and then to the 
2010 Index of Multiple 
Deprivation (IMD) for 
that LSOA (McLenan et 
al., 2011).   
Association between levels 
of social deprivation and 
many health outcomes 
reported (Oakley et al., 
1994; Docherty et al., 
2012). 
Maternal date of birth 
(DOB)* 






Age automatically calculated 
from DOB, reducing errors. 
Age changes DOB does not. 
Maternal height Maternal height 
measured in 
centimetres (cm) at first 
antenatal appointment. 
Used to generate BMI, 
which ultimately is used for 
customised birthweight 
centiles. 
Maternal weight* Maternal weight 
measured in 
Kilogrammes (Kg) at 
first antenatal 
appointment. 
Used to generate BMI, 
which ultimately is used for 
customised birthweight 
centiles. 
Parity (P) The number of children 
born after 24 weeks’ 
Grand multiparity has been 
associated with PPH as has 
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gestation. primiparity 
(Dreissen et al., 2011). 
Planned pregnancy Did the woman plan to 
be pregnant at this 
time. Response, yes or 
no. 
Could be associated with 
delayed engagement with 
maternity services and poor 











If other, free text box 
for details. 
Conditions or treatments 






previous birth by 
Caesarean section 
(either elective or 
emergency) answer- 
yes/no 
If yes, how many? 
Impact of previous CS 
variably reported 
(Al-Zirqi., 2010, Homer et 
al., 2010) 
 Kramer et al,  2011). 
Previous PPH Documented or 
maternally reported 
history of blood loss 
>500ml following 
previous birth. 
Identified risk factor in 
current pregnancy (Ford et 
al, 2007). 
Smoking at antenatal 
booking appointment 
Options: yes/no  
Note: Self reported 
number of cigarettes 
smoked per day is 
notoriously unreliable 
and therefore was not 
recorded (Baker P.N., 
2009)(Baker et al, 
2009). 
Associated with abnormal 
placentation 
(Werler, 1997; Guirgis et 
al., 1997).  
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Systemic Lupus 
Erythematosus 
Maternal history of 
Lupus, yes/no, 
If yes, any medications 
for this? 
Known association with 
autoimmune diseases and 
pregnancy complications 
(Yasmeen et al., 2001). 
Group B: Pregnancy acquired 
Anaemia- last recorded 
Hb in pregnancy 
Recorded in g/ml 
Date of last blood test 
dd/mm/yyyy 
(variable levels reported 
as significant for risk of 
PPH, RCOG guidelines, 
NICE 2007) 
To enable assessment of 
antenatal anaemia and 
calculate change in Hb 
between this and postnatal 
results 
 
Antenatal Admissions Gestation age (weeks 
and days) and reason 
for admission (free 
text).  
Investigatation of links 
between antenatal 
complications and PPH 
Antenatal Anaemia Haemoglobin (Hb) 
<11g/l, <10.5g/l, 
<10g/l  antenatally, 
according to definition 
PPH linked with antenatal 
anaemia (RCOG guidelines; 
Pavord et al., 2011). 
Antenatal Day Unit 
(ADU) 
Did the women attend 
the antenatal day unit? 
Yes/no 
If yes how many 
occasions and reasons 
for attendance 
Maternity triage. Women 
attended for many reasons, 
some with identified risk 
factors (ie APH), and 
potentially novel predictors 
could be identified. 
Antepartum 
Haemorrhage (APH) 
Bleeding from the birth 
canal after the 24th 
week of pregnancy 




Date; gestation (weeks 
and days); duration 
(days); amount 
(options: spotting, light, 
like a period, 
heavy/clots, transfusion 
required); causes of 
APH (unknown, placenta 
praevia, placental 
Investigatation of the 
association between APH 
and PPH. 
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abruption, local genital 
tract, fetal bleeding, low 
lying placenta, other) 
Generally unwell Symptoms of lethargy, 
aches/discomfort, loss 
of appetite, not feeling 
“quite right”. But all 
investigations showed 
no deviation from the 
normal, no diagnosis 
was made or treatment 
given. 
Common reason for self 
referral for additional 
antenatal care. Initially 
considered as potential 
reason given for those 
experiencing domestic 
violence (RCM, 2006). 
External cephalic 
version, (ECV) 
The manipulation of the 
fetus, through the 
maternal abdomen, to a 
cephalic presentation 
(RCOG green top 20a). 
Abnormal presentation may 
indicate poor uterine 




Blood pressure higher 
than 140/90 on 2 
occasions at least 
4hours apart, without 
the presence of protein 
in the urine and 
diagnosed after 20 
weeks of gestation. 
Variably reported 
association with PPH.  
Intended method of 
infant feeding 
From the maternal 
records, planned 
method of infant 
feeding: breast, bottle, 
undecided. 
Ascertainment the antenatal 
intention of the woman 
regarding method of feeding 
her baby. 
Medication in pregnancy Drop down box, multiple 
entries possible. 
Options: oral iron; IM 





To investigate any 
relationships between 
medication taken in 
pregnancy and PPH. 
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steroids- maternal 
health; IM steroids- 
fetal ling maturation; 
AN blood transfusion; 
Antibiotics; salbutamol; 
B12 injections; Ventolin; 
Becotide; Piriton; 
Temazepam. 
Obstetric cholestasis Pruritis and liver 
dysfunction caused by 
oestrogen,  
Options: yes/no 




Some association with 
excessive blood loss at 
delivery (Kenyon et al., 
2002). 
Other infection in 
pregnancy 
Yes/no. To investigate any 
association between 
infection in pregnancy and 
PPH. 
Placenta praevia (PP) 
(Major, minor, anterior 
and posterior) 
The placenta attached 
to the lower uterine wall 
extending to or covering 
the internal cervical cs. 
Minor- the placenta 
reaches the lower 
uterine segment and 
partially covers the os. 
Major- the placenta is 
completely within the 
lower uterine segment 
and the internal os is 
occluded. 
Anterior – the placenta 
is either minor or major 
and attached to the 
anterior uterine wall. 
Posterior- the placenta 
Identified risk factor for PPH 
(Waterstone et al., 2001; 
Watanabe and Matsubara, 
2010). 
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is either major or minor 
and is attached to the 
posterior uterine wall.  
Placenta praevia yes/ 
no, 
If yes, 
diagnosis made on 
ultrasound scan (with 
location) or at delivery 
(with location). 
Pre-eclampsia (PET) New onset hypertension 




Pre-eclampsia can be 





eclampsia. Serial BP 
measurements, 
urinalysis, blood tests- 
full blood count (FBC), 
liver function(LFT) and 
renal function tests, +/-
growth scan. 
Common reason for referral 
to ADU. Data collected to 
ascertain association 
between suspected PET and 
PPH. 
Urinary tract infection 
(UTI) 
Diagnosed UTI 








1) Recurrent (at least 3 
episodes; 2) like a 
period or heavier; 3) 
placental  
 
Group C: Intrapartum, Labour acquired  
Actions indicating 
recognition of PPH 
Did attending clinicians 
undertake any action 
that might indicate 
response to excessive 
blood loss, such as: rub 
up contraction; nipple 
stimulation; head down 
All actions suggest concern 
regarding blood loss, even 
though PPH may not be 
documented.  
Management of PPH was 
also investigated within the 
STOP study but outwith this 
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tilt; oxygen; insert 
urinary catheter; 
suturing commenced; 





tranaexamic acid; IV 
fluid-crystalloid IV fluid- 
colloid; blood 
transfusion- emergency 
O Rh negative; blood 
transfusion type specific 
not cross matched; 
blood transfusion- cross 
matched; fresh frozen 
plasma given; platelets 
given; crypopreciptate 
given; Fibrinogen given; 
central venous pressure 





ligation of internal iliac 
arteries; iliac artery 
clamped; aortic artery 
compression; aortic 
artery clamped;  
haemostatic uterine 
suturing (i.e.,B-Lynch); 
manual removal of 
placenta; examination 
under anaesthetic; 
laparotomy; uterine teat 
repaired; drainage of 
thesis. 
 
This data point was included 
at two time points. This 
enabled information to be 
collected about both PPH 
immediately following 
delivery, and also at a later 
time point within the first 24 
hours following birth. Some 
women had data entered at 
each time point, where an 
initial bleed was arrested 








Date and time of first action 
enabled assessment of 
promptness of reaction to 
emergency. 





involved;  transfer to 
HDU/ITU. 
If any of these were 
entered, date and time 




Blood taken and sent, 
yes/no; if yes date and 
time sent dd/mm/yyyy: 
hh:mm 
Did the patient receive a 
transfusion? Yes/no 
Emergency O Rh Neg 
blood, yes/no 
Cross matched blood 
given, yes/no 
If yes, total number of 
units given 
Type specific unmatched 
blood given. Yes/no 
In total how many units 
did the woman receive? 
Was blood warming 
equipment used? 
yes/no/not documented 
Number of units of other 
blood products given: 
Fresh Frozen Plasma; 
Cryoprecipitate; 
Platelets; Fibrinogen: 
Factor VII; Autologous 
transfusion (ml) 
Confirmed the frequency of 
blood taken for cross match 
and investigated the use of 
blood and blood products in 
this cohort. 
Information regarding the 
use of emergency blood 
supplies and warming 
equipment was a surrogate 
indicator of urgency and 
concern. These data were 
interrogated when the 
management of PPH was 




Did the woman receive 
misoprostol, 
Misoprostol® has been 
identified as useful for IOL 
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Yes/no. and treatment of PPH 




If yes, total dose 
(number of pessaries). 





If yes, reason: to induce 
labour; to augment 1st 
stage of labour; to 
augment 2nd stage of 
labour. 
Total duration of 
oxytocin (Syntocinon®) 
administration hh:mm. 
Investigation of association 
between oxytocin 
administration and PPH. 
Admission to 
NICU/SCBU 
Was the baby admitted 
to the neonatal 
intensive care unit 
(NICU) or special care 
baby unit (SCBU)? 
Response yes or no. 
Identification of infants 
requiring additional support. 
Potentially indicative 
maternal problems, i.e. 
infection or severe PET or 
reason for delayed 
recognition of PPH.  
Apgar scores 
Routinely assessed at 1 
and 5 minutes of 
extrauterine life 
Assessment of early 
neonatal wellbeing. 
Assesses respiration 
(crying), pulse (heart 
rate), reflexes (response 
to stimuli) skin colour 
(body & extremities) 
and muscle tone. Score 
out of 10 (2 for each) 
assessed at 1 minute 
and 5 minutes after 
birth (Apgar V.A., 
1953). 
Indicates fetal compromise 
caused by intrapartum 
problems i.e. bleeding, 
infection, prematurity, but 
also linked to causes of PPH 
(Finster and Wood, 2005). 
Augmentation of labour  Labour is expedited 
where progress is slow. 
Associated with PPH 
(Williams et al., 1998). 
Baby’s sex Options: female; male; 
indeterminate 
Facilitated calculation of 
customised birth weight 
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centiles (www.grow.ac.uk) 
Birth outcome The status of the infant 
following birth: options 
were alive, 
intraurauterine fetal 
death (IUFD), death at 
delivery or death shortly 
after birth. 
Stillbirth associated with 
PPH (Magann et al., 2005). 
Birthweight Birthweight- the weight 
of the baby shortly after 
birth in grams (g). 
Maximum birthweight- 
largest infant. 
Total birth weight- 
additive weight of all 
fetuses 
Macrosomia has been 
associated with PPH, as 
have multiple pregnancies 
(NICE 2007; Magann et al., 
2005). 
Blood loss (BL) 
Blood loss measured/ 
estimated/both 
Blood loss total volume 
measured in millilitres 
(ml) 
Often visually assessed 
and therefore estimated 
(EBL). Measured when 
blood loss excessive, 
but often total blood 
loss is a combination of 
measured and 
estimated (both). 
Measurement of blood loss, 
routinely assessed visually 
(Bose et al., 2006) but 
other methods are more 
reliable with inherent 
limitations (Schorn 2010). 
Blood loss at birth; how 
was this ascertained? 
Total blood loss in ml. 
Tick boxes for 
measured, estimated or 
both 
Ascertainment of how blood 
loss at birth was assessed 
Blood loss subsequently Volume lost after 
completion of third 
stage of labour, but 
within the first 24 hours 
postnatally 
Tick boxes for 
measured, estimated or 
Ascertainment of how 
subsequent blood loss was 
assessed 
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both 
Blood loss reported on 
discharge letter 
Volume reported to 




Ascertainment of the 
accuracy of information 
provided to colleagues 
Blood loss total Total blood loss volume 
at birth and in the 24 
hours following 
Recorded/documented total 
blood volume loss in each 
reviewed case 
Caesarean section (CS) Surgical delivery of 
infant through the 
abdomen  
Identified risk factor for PPH 
(Kramer et al., 2011) 
Caesarean section 
performed by 
Grade of Doctor 
undertaking procedure. 
Drop down options: 
Consultant, Registrar, 
ST 
Adherence to local policies 
and national guidelines 
regarding senior staff 
present at emergencies 
(RCOG 2009) 
Causes of PPH If non-atonic, was the 
PPH caused by: vaginal 
tears; cervical tears; 
inverted uterus; 
amniotic fluid embolism; 
blood disorders; uterine 
tear; placenta praevia; 
adherent placenta; 
retained products of 
conception; 
intraperitoneal bleed at 
CS; brisk loss at CS; 
broad ligament tears at 
CS; extension of incision 
angles at CS; oozing at 
CS; placental abruption; 
ruptured uterus; sepsis; 
vulval haematoma; 
unknown 
Atonic uterus is cited as 
causative of 70% of PPH, 
therefore we decided to 
obtain details of all other 




Centile produced using 
the principles of the 
Customised centiles have 
the advantage of calculating 
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Gestation Related 
Optimal Weight (GROW) 
method of assessing 
appropriateness of 
birthweight. Takes into 
account maternal 
height, maternal weight, 
ethnicity, parity, 
gestation at birth (in 
days), sex of infant, 
birth weight 
(www.gestation.net)  
the appropriateness of birth 
weight of a baby according 
to maternal characteristics 
and gestational factors, 
Being more accurate than 
population centiles (Gardosi 
et al., 2011). 
Date and time of 
delivery of placenta 
dd/mm/yyyy, 24 hour 
clock hh:mm 
To assess time between 
birth of baby and placenta 
Date and time of 
ruptured membranes 
dd/mm/yyyy ; 24 hour 
clock hh:mm 
To investigate the impact of 
duration of ruptured 
membranes on PPH 
Date of Delivery The date on which a 
baby is born, expressed 
as day/month 
(numerical)/year 
To ensure birth occurred in 
study time frame and 
assess whether knowledge 




Date of Discharge The date the mother 
(and baby) is 
transferred home 
following the birth. 
Expressed as  
day/month 
(numerical)/year. 
To ascertain impact of 
intrapartum and early 
puerperium factors on 
duration of hospital stay. 
Date of last blood test dd/mm/yyyy To calculate the gestation of 
last blood test in pregnancy. 
Day of birth The day of the week the 
birth occurred, 
calculated by database 
from date information. 
To examine the influence of 
day of birth on PPH. 
Documentation of PPH Yes/no.  To identify whether the 
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in notes If yes, date and time 
dd/mm/yyyy 24h clock 
hh:mm 





Inflammation of the 
amnion and chorion 
caused by bacterial 
infection. Typically 
ascending infection from 
the vagina, is associated 
with prolonged labour 
and preterm birth.  
Known association between 
sepsis and PPH (NICE, 
2008; Malabarey et al., 
2011). 
Elective Caesarean 
section (elective S) 
Planned surgical 
delivery, timed to suit 
mother and/or staff. 
Category 4 according to 
RCOG guidelines 
(Wickham et al, 2010). 
To investigate associated 
with PPH (Al-Zirqi et al., 
2009).   
Emergency Caesarean 
section (emergency CS) 
Surgical delivery 
performed due to fetal 
and/or maternal 
compromise, which may 
be life threatening 
(Brennand JE, 2010) 
To investigate associated 
with PPH (Al-Zirqi et al., 
2009). 
Full blood count (FBC) Date and time of result 
dd/mm/yyyy; hh:mm 
Haemoglobin (Hb); 
Platelets; White Blood 
cell count (WBC). 
In cases where multiple  
investigations are 
undertaken additional 
forms can be generated. 
Investigation of the 
physiological response to 
blood loss and replacement, 
in addition to the 
management of the 
emergency. 
Gestation at delivery The number of weeks 
and days of pregnancy 
at which the baby is 
born. 
Pre and post term birth 
have been variably reported 
as associated with PPH 
(Ushma Kiran et al., 2005). 
Indication for induction Drop down options: IOL variably reported as 
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Poor obstetric history; 
Maternal request; SPD; 






distress; sickle cell 








impacting PPH (Stock et al., 
2012; Magann et al., 2005). 
Indication for IOL might 
elucidate association. 
Induction of labour Labour is medically 
initiated with 
prostaglandins, artificial 
rupture of membranes 
and/or intravenous 
oxytocin (syntocinon®). 
Variable description of the 
effects of induction on PPH 
(Stock et al., 2012; Magann 
et al., 2005; Malbarey et 
al., 2011)   
Inpatient stay 
Antenatal hospital nights 
Postnatal hospital nights 
Number of antenatal 
nights in hospital and 
number of postnatal 
nights in hospital. 
Facilitate assessment of 
costs of care. 
Interval to suturing of 
perineum 
The time between birth 
of baby and completion 
of suturing (hh:mm). 
To investigate the 
relationship between delay 




catheter in situ; prior to 
2nd stage; following 
delivery of baby; other. 
To assess the impact of a 
full bladder on uterine 
contractility. 
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Management of third 
stage of labour 










40/50iu in 500ml 
commenced. 
To ascertain current 
practice regarding the 
management of the third 
stage. 
Maternal age at delivery The age in years of the 
mother on the day she 
gave birth to her child 
(automatically 
calculated from 
maternal date of birth 
and baby’s date of 
birth). 
PPH has been variably 
associated with maternal 
age (Cameron et al., 2006; 
Montan et al., 2007). 
Maternal death Yes/no 
If yes, date and time 
dd/mm/yyyy; 24 hour 
clock hh:mm. 
To identify any woman in 
the cohort who died 
(regardless of cause). 
Medications taken in the 
last week of pregnancy 
Name of medication, 
daily dose 
For example, oral iron 2 
tabs daily. 
To investigate any 
relationships between 
medications taken in the 
week preceding birth.   
Method of infant feeding 
on discharge home 
How is baby feeding: 
exclusively breastfed; 
partially breastfed (has 
had at least 1 formula 
feed or water); mixed 
(has had several 
formula feeds in 
addition to breast milk); 
formula feeding (never 
put to breast). 
To compare intended with 
actual method of infant 
feeding, when discharged. 
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Mode of delivery The method by which a 








Each mode reported as 
influencing PPH rates 
(Sheiner et al., 2005). 
Multiple pregnancy More than one fetus in 
utero. Additional data 
points were provided for 
each baby for multiple 
births enabling more 
than one answer to be 
given. 
Associated with increased 
risk of PPH (Sebire et al., 
2001). 
Onset of labour Options: spontaneous; 
induced; augmented; no 
labour-prelabour 
elective Caesarean 
section; no labour- pre-
labour emergency 
Caesarean section; 
failed induction of 
labour –Caesarean 
section; stimulated 
prelabour rupture of 
membranes. 
Onset of labour may 
influence mode of delivery, 
uterine contractility and PPH 
(Schott & Anderson, 2006; 
Robson et al., 2001). 






anaesthetic (GA); GA 
following failed 
epidural/spinal. 
May influence uterine 
contractility and hormone 
production in addition to 
maternal mobility. 
Perineal trauma The state of the Genital tract trauma causes 
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sustained and repair 
required 
maternal perineum 
following the birth. 
Options: intact, 1st 
degree tear- not 
sutured; 1st degree tear 
-sutured; 2nd degree 
tear -not sutured; 2nd 
degree tear –sutured; 
3rd degree tear; 4th 
degree tear; cervical 
tear; episiotomy; not 
known. 
excessive blood loss being 
cited as one of the “4 Ts” 
(tissue, tone, trauma and 
thrombin). 
Perineum sutured by Grade of health care 
professional repaired 





Registrar: Doctor ST, if 
Doctor ST, grade. 
To explore any associations 
between experience of 
health professional and 
blood loss. 
Physiological third stage 
(or expectant 
management) 
Following delivery of the 
baby no uterotonic drug 
is given, no fundal 
guarding or controlled 
cord traction. The 
placenta and 
membranes are left to 
separate and are 
delivered by maternal 
effort. 
Used in low risk women with 
spontaneous labour and 
birth. Incidence and 
components vary 
(Prendeville et al., 1988).  
Place of birth The venue of birth. 
Options; home from 
home (centre 1); 
midwifery-led unit 
(centre 2); hospital 
birth centre (obstetric 
led units in both 
To determine local practices 
in interventions and 
management.  
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centres); home; other. 
Postnatal blood result 
data 
Details of 3rd day 
postnatal blood results: 
Hb; platelets, white cell 
count. 
To calculate fall in Hb from 
antenatal result. 
Preterm prelabour 
rupture of the 
membranes (PPROM) 
Breaking of the amniotic 
sac before labour and 
before 37 completed 
weeks of gestation. 
Can be associated with 
chorioamnionitis and 
therefore PPH. 
Reason for Caesarean 
section (CS) 
Drop down options: 
previous CS-elective; 
failure to progress; 
macrosomia; failed IOL; 
failed ECV; multiple 
pregnancy; pre-
eclampsia; placenta 












Unstable lie; Previous 




scar dehiscence; uterine 
rupture; cervical fibroid 
covering Os; brow 
presentation; NA (no 
CS); not documented. 
PPH could be attributed to 
CS but underlying reasons 
necessitating CS could 
cause the PPH. These data 
were collected to explore 
any such associations. 
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Resuscitation Did the baby require 
support to initiate and 
establish extra-uterine 
life? Yes/no.  
Identification of women 
where the condition of the 
baby could delay 3rd stage 
interventions. 
Retained placenta Yes/no 
If yes, management,  
options: oxytocin 
(syntocinon®) infusion; 
manual removal of 
placenta; hyperectomy. 
To assess the impact of 
retained placenta on PPH 
and the efficacy of 
conservative versus surgical 
management. 




Breaking of the amniotic 
sac. May occur 
spontaneously before or 
during labour (SROM) or 
medical staff rupture 
the membranes to 
induce or augment 
labour, referred to as 
artificial rupture of the 
membranes (ARM). 
Can occur spontaneously, 
but ARM achieves 
augmentation and induction 
of labour both associated 
with PPH (RCOG guidelines; 
RCM, 2012a). 
Sex of infant Boy, girl or 
indeterminate. 




A normal vaginal birth, 
without the assistance 
of a vacuum extractor 
or forceps. 
Reference range for all 
instrumental deliveries.  
Staff involved Tick box for all grades of 
staff involved: student 
midwife; staff midwife; 
labour ward co-
ordinator; medical 
student; doctor SHO; 
doctor SSHO; doctor 




consultant; on call 
Ascertainment of staff 
involvement at all levels in 
the management of this 
common obstetric 
complication. Lack of senior 
staff presence has been 
associated with adverse 
outcomes (Lewis 2004).  
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haematologist; blood 
transfusion service; 
porters; theatre staff. 
 Syntocinon® 
(Oxytocin) 
administration in the 
first or second stage of 
labour (prior to baby’s 
birth) 
Were uterotonics to 
introduce or increase 
contractility in the first 
and/or second stage of 
labour? yes/no 
If yes, duration of 
syntocinon 
administration. 
Oxytocin (Syntocinon®) in 
the first and second stage of 
labour, prior to the birth has 
been variably reported as 
influencing the effectiveness 
of uterotonics in the third 
stage (Grotegut et al., 
2011, Stock et al., 2012). 
Temperature in labour Maximum temperature 
in labour. Measured in 
degrees centigrade 
above 37, with normal 
temperatures coded as 
0. 
Associated with signs of 
infection & chorioamnionitis. 
Whilst T>37 is common, 
varying degrees above this 
level have been introduced  
as alert levels on MEOWS 
charts (CMACE, 2011) 
Time of birth The time of day birth 
occurs (24h clock), 
hh:mm. 
To ascertain whether time 
of birth influences incidence 
of PPH. 
Time suturing competed The time at which any 
repair to the genital 
tract is  finshed 
 
 
* Maternal age imported in black if 20-30 years; yellow if 31-35 years; pink 35-40 years; 
and red when aged more than 40 years. Maternal BMI (Kg/m2) was calculated and 
imported from height and weight entered on registration page in blue if <20 Kg/m2; black 
if 20-25 Kg/m2; orange in 25-29.9 Kg/m2 and red if >30 Kg/m2. Colour coding these data 
provided immediate visual warning for these previously identified risk factors (Dennedy et 
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